



US 20170283496A1

(19) **United States**

(12) **Patent Application Publication**
Pedersen et al.

(10) **Pub. No.: US 2017/0283496 A1**

(43) **Pub. Date: Oct. 5, 2017**

(54) **OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION**

Publication Classification

(71) Applicants: **Roche Innovation Center Copenhagen A/S**, Horsholm (DK); **F. Hoffmann-La Roche AG**, Basel (CH)

(51) **Int. Cl.**
C07K 16/28 (2006.01)
C12N 15/113 (2006.01)
A61K 39/395 (2006.01)
A61K 38/17 (2006.01)
A61K 39/39 (2006.01)

(52) **U.S. Cl.**
 CPC *C07K 16/28* (2013.01); *A61K 38/1709* (2013.01); *A61K 39/39* (2013.01); *A61K 39/39558* (2013.01); *C12N 15/1138* (2013.01); *A61K 45/06* (2013.01)

(72) Inventors: **Lykke Pedersen**, Horsholm (DK); **Hassan Javanbakht**, Basel (CH); **Malene Jackerott**, Horsholm (DK); **Soren Ottosen**, Horsholm (DK); **Souphalone Luangsay**, Basel (CH)

(57) **ABSTRACT**


The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.

(21) Appl. No.: **15/458,800**

(22) Filed: **Mar. 14, 2017**

(30) **Foreign Application Priority Data**

Mar. 14, 2016 (EP) 16160149.7






Figure 1






Figure 1 Cont'd






Figure 1 Cont'd




Figure 1 Cont.




Figure 2




Figure 3




FIG. 4
CMP ID NO 766_2




FIG. 5
CMP ID NO 767_2




FIG. 6
CMP ID NO 768_2




FIG. 7
CMP ID NO 769_2




FIG. 8
CMP ID NO 770_2




Figure 9




Figure 10





Figure 10 cont'd




Figure 11




Figure 12




Figure 13

OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION

RELATED APPLICATIONS

[0001] This application claims priority to European Application Number 16160149.7, which was filed Mar. 14, 2016, the entire contents of which are hereby incorporated by reference.

FIELD OF INVENTION

[0002] The present invention relates to oligonucleotides (oligomers) that are complementary to programmed death ligand-1 (PD-L1), leading to reduction of the expression of PD-L1 in the liver. The present invention also relates to a method of alleviating the T cell exhaustion caused by an infection of the liver or cancer in the liver. Relevant infections are chronic HBV, HCV and HDV and parasite infections like malaria and toxoplasmosis (e.g. caused by protozoa of the *Plasmodium*, in particular of the species *P. vivax*, *P. malariae* and *P. falciparum*).

BACKGROUND

[0003] The costimulatory pathway consisting of the programmed death-1 (PD-1) receptor and its ligand, PD-L1 (or B7-H1 or CD274) is known to contribute directly to T cell exhaustion resulting in lack of viral control during chronic infections of the liver. The PD-1 pathway also plays a role in autoimmunity as mice disrupted in this pathway develop autoimmune diseases.

[0004] It has been shown that antibodies that block the interaction between PD-1 and PD-L1 enhance T cell responses, in particular the response of CD8+ cytotoxic T cells (see Barber et al 2006 Nature Vol 439 p 682 and Maier et al 2007 J. Immunol. Vol 178 p 2714).

[0005] WO 2006/042237 describes a method of diagnosing cancer by assessing PD-L1 (B7-H1) expression in tumors and suggests delivering an agent, which interferes with the PD-1/PD-L1 interaction, to a patient. Interfering agents can be antibodies, antibody fragments, siRNA or antisense oligonucleotides. There are no specific examples of such interfering agents nor is there any mentioning of chronic liver infections.

[0006] RNA interference mediated inhibition of PD-L1 using double stranded RNA (dsRNA, RNAi or siRNA) molecules have also been disclosed in for example WO 2005/007855, WO 2007/084865 and U.S. Pat. No. 8,507,663. None of these describes targeted delivery to the liver.

[0007] Dolina et al. 2013 Molecular Therapy-Nucleic Acids, 2 e72 describes in vivo delivery of PD-L1 targeting siRNA molecules to Kupffer cells thereby enhancing NK and CD8+ T cell clearance in MCMV infected mice. This paper concludes that PD-L1 targeting siRNA molecules delivered to hepatocytes are not effective in relation to enhancing CD8+ T cell effector function.

[0008] The siRNA approach is significantly different from the single stranded antisense oligonucleotide approach since the biodistribution and the mode of actions is quite different. As described in Xu et al 2003 Biochem. Biophys. Res. Comm. Vol 306 page 712-717, antisense oligonucleotides and siRNAs have different preferences for target sites in the mRNA.

[0009] WO2016/138278 describes inhibition of immune checkpoints including PD-L1, using two or more single

stranded antisense oligonucleotides that are linked at their 5' ends. The application does not mention HBV or targeted delivery to the liver.

OBJECTIVE OF THE INVENTION

[0010] The present invention identifies novel oligonucleotides and oligonucleotide conjugates which reduce PD-L1 mRNA very efficiently in liver cells, both in parenchymal cells (e.g. hepatocytes) and in non-parenchymal cells such as Kupffer cells and liver sinusoidal endothelial cells (LSECs). By reducing or silencing PD-L1, the oligonucleotides and oligonucleotide conjugates decrease PD-1-mediated inhibition and thereby promote immunostimulation of exhausted T cells. Alleviation of the T cell exhaustion in a chronic pathogenic infection of the liver will result in regained immune control and reduced levels of viral antigens in the blood during a chronic pathogenic infection of the liver. Natural killer (NK) cells and natural killer T (NKT) cells may also be activated by the oligonucleotides and oligonucleotide conjugates of the present invention.

[0011] The oligonucleotide conjugates secure local reduction of PD-L1 in liver cells and therefore reduces the risk of autoimmune side effects, such as pneumonitis, non-viral hepatitis and colitis associated with systemic depletion of PD-L1.

SUMMARY OF INVENTION

[0012] The present invention relates to oligonucleotides or conjugates thereof targeting a nucleic acid capable of modulating the expression of PD-L1 and to treat or prevent diseases related to the functioning of the PD-L1. The oligonucleotides or oligonucleotide conjugates may in particular be used to treat diseases where the immune response against an infectious agent has been exhausted.

[0013] Accordingly, in a first aspect the invention provides oligonucleotides which comprise a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid. The oligonucleotide can be an antisense oligonucleotide, preferably with a gapmer design. Preferably, the oligonucleotide is capable of inhibiting the expression of PD-L1 by cleavage of a target nucleic acid. The cleavage is preferably achieved via nuclease recruitment.

[0014] In a further aspect, the oligonucleotide is conjugated to at least one asialoglycoprotein receptor targeting conjugate moiety, such as a conjugate moiety comprising at least one N-Acetylgalactosamine (GalNAc) moiety. The conjugation moiety and the oligonucleotide may be linked together by a linker, in particular a biocleavable linker.

[0015] In a further aspect, the invention provides pharmaceutical compositions comprising the oligonucleotides or oligonucleotide conjugates of the invention and pharmaceutically acceptable diluents, carriers, salts and/or adjuvants.

[0016] In a further aspect, the invention provides methods for in vivo or in vitro method for reduction of PD-L1 expression in a target cell which is expressing PD-L1, by administering an oligonucleotide or composition of the invention in an effective amount to said cell.

[0017] In a further aspect, the invention provides oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in restoration of immunity against a virus or parasite.

[0018] In a further aspect, the invention provides oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use as a medicament.

[0019] In a further aspect the invention provides methods for treating or preventing a disease, disorder or dysfunction by administering a therapeutically or prophylactically effective amount of the oligonucleotide of the invention to a subject suffering from or susceptible to the disease, disorder or dysfunction, in particular diseases selected from viral liver infections or parasite infections.

[0020] In a further aspect the oligonucleotide, oligonucleotide conjugates or pharmaceutical composition of the invention is used in the treatment or prevention of viral liver infections such as HBV, HCV and HDV or a parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver.

BRIEF DESCRIPTION OF FIGURES

[0021] FIG. 1: Illustrates exemplary antisense oligonucleotide conjugates, where the oligonucleotide either is represented as a wavy line (A-D) or as "oligonucleotide" (E-H) or as T₂ (I) and the asialoglycoprotein receptor targeting conjugate moieties are trivalent N-acetylgalactosamine moieties. Compounds A to D comprise a di-lysine brancher molecule a PEG3 spacer and three terminal GalNAc carbohydrate moieties. In compound A and B the oligonucleotide is attached directly to the asialoglycoprotein receptor targeting conjugate moiety without a linker. In compound C and D the oligonucleotide is attached directly to the asialoglycoprotein receptor targeting conjugate moiety via a C6 linker. Compounds E-I comprise a trebler brancher molecule and spacers of varying length and structure and three terminal GalNAc carbohydrate moieties.

[0022] FIG. 2: Graph showing EC50 (A) and PD-L1 knock down as % of saline (B) for the compounds tested in Example 2, in relation to their position on the target nucleic acid. The cell line in which the compound were tested are THP1(●) and Karpas (*).

[0023] FIG. 3: Structural formula of the trivalent GalNAc cluster (GN2). GN2 is useful as conjugation moiety in the present invention. The wavy line illustrates the site of conjugation of the cluster to e.g. a C6 amino linker or directly to the oligonucleotide.

[0024] FIG. 4: Structural formula of CMP ID NO 766_2.

[0025] FIG. 5: Structural formula of CMP ID NO 767_2.

[0026] FIG. 6: Structural formula of CMP ID NO 768_2.

[0027] FIG. 7: Structural formula of CMP ID NO 769_2.

[0028] FIG. 8: Structural formula of CMP ID NO 770_2.

[0029] FIG. 9: Western blot detecting PD-L1 protein expression in liver from poly(IC) induced animals following treatment with saline and the indicated CMP ID NO's. Each blot shows a naked oligonucleotide versus a GalNAc conjugated version of the same oligonucleotide, blot A) CMP ID NO 744_1 and 755_2, B) CMP ID NO 747_1 and 758_2, C) CMP ID NO 748_1 and 759_2, D) CMP ID NO 752_1 and 763_2 and E) CMP ID NO 753_1 and 764_2. The upper band is the vinculin loading control, the lower band is the PD-L1 protein. The first lane in each blot show saline treated mice without Poly(IC) induction. These mice express very little PD-L protein.

[0030] FIG. 10: Population of mononuclear cells in the liver after treatment with ● vehicle (group 10 and 1), ◆ DNA vaccine (group 11 and 2), ○ anti-PD-L1 antibody (group 12), ▲ naked PD-L1 ASO+DNA vaccine (group 7)

or Δ GalNAc conjugated PD-L1 ASO+DNA vaccine (group 8), for each group the individual animals are represented and the average is indicated by the vertical line for each group (see table 18). Statistical significance between the DNA vaccine group and the three treatment groups has been assessed and if present it is indicated by * between the groups (*=P<0.05, ***=P<0.001 and ****=P<0.0001). A) represents the number of T cells in the liver following treatment. B) represents the fraction of CD4+ T cells and C) represents the fraction of CD8+ T cells.

[0031] FIG. 11: Modulation of PD-L1 positive cells in the liver after treatment with ● vehicle (group 10 and 1), ◆ DNA vaccine (group 11 and 2), ○ anti-PD-L1 antibody (group 12), ▲ naked PD-L1 ASO+DNA vaccine (group 7) or Δ GalNAc conjugated PD-L1 ASO+DNA vaccine (group 8), for each group the individual animals are represented and the average is indicated by the vertical line for each group (see table 19). Statistical significance between the DNA vaccine group and the three treatment groups has been assessed and if present it is indicated by * between the groups (*=P<0.05 and ****=P<0.0001). A) represents the percentage of CD8+ T cells which express PD-L1 in the liver following treatment. B) represents the percentage of CD4+ T cells which express PD-L1 in the liver following treatment and C) represents the percentage of B cells which express PD-L1 in the liver following treatment.

[0032] FIG. 12: HBV antigen specific CD8+ cytokine secreting cells in the liver after treatment with ● vehicle (group 10 and 1), ◆ DNA vaccine (group 11 and 2), ○ anti-PD-L1 antibody (group 12), ▲ naked PD-L1 ASO+DNA vaccine (group 7) or Δ GalNAc conjugated PD-L1 ASO+DNA vaccine (group 8), for each group the individual animals are represented and the average is indicated by the vertical line for each group (see table 20). Statistical significance between the DNA vaccine group and the three treatment groups has been assessed and if present it is indicated by * between the groups (*=P<0.05). A) represents the percentage of IFN-γ secreting CD8+ T cells in the liver which are specific towards HBV PreS2+S antigen following treatment. B) represents the percentage of IFN-γ secreting CD8+ T cells in the liver which are specific towards HBV core antigen following treatment and C) represents the percentage of IFN-γ and TNF-α secreting CD8+ T cells in the liver which are specific towards HBV PreS2+S antigen following treatment.

[0033] FIG. 13: HBV-DNA, HBsAg and HBeAg in AAV/HBV mice following treatment with GalNAc conjugated PD-L1 antisense CMP NO: 759_2 (▽) compared to vehicle (■). The vertical line indicates the end of treatment.

DEFINITIONS

Oligonucleotide

[0034] The term "oligonucleotide" as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are commonly made in the laboratory by solid-phase chemical synthesis followed by purification. When referring to a sequence of the oligonucleotide, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides. The oligonucleotide of the invention is

man-made, and is chemically synthesized, and is typically purified or isolated. The oligonucleotide of the invention may comprise one or more modified nucleosides or nucleotides.

Antisense Oligonucleotides

[0035] The term “Antisense oligonucleotide” as used herein is defined as oligonucleotides capable of modulating expression of a target gene by hybridizing to a target nucleic acid, in particular to a contiguous sequence on a target nucleic acid. The antisense oligonucleotides are not essentially double stranded and are therefore not siRNAs. Preferably, the antisense oligonucleotides of the present invention are single stranded.

Contiguous Nucleotide Sequence

[0036] The term “contiguous nucleotide sequence” refers to the region of the oligonucleotide which is complementary to the target nucleic acid. The term is used interchangeably herein with the term “contiguous nucleobase sequence” and the term “oligonucleotide motif sequence”. In some embodiments all the nucleotides of the oligonucleotide constitute the contiguous nucleotide sequence. In some embodiments the oligonucleotide comprises the contiguous nucleotide sequence and may optionally comprise further nucleotide(s), for example a nucleotide linker region which may be used to attach a functional group to the contiguous nucleotide sequence. The nucleotide linker region may or may not be complementary to the target nucleic acid.

Nucleotides

[0037] Nucleotides are the building blocks of oligonucleotides and polynucleotides and for the purposes of the present invention include both naturally occurring and non-naturally occurring nucleotides. In nature, nucleotides, such as DNA and RNA nucleotides comprise a ribose sugar moiety, a nucleobase moiety and one or more phosphate groups (which is absent in nucleosides). Nucleosides and nucleotides may also interchangeably be referred to as “units” or “monomers”.

Modified Nucleoside

[0038] The term “modified nucleoside” or “nucleoside modification” as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the (nucleo)base moiety. In a preferred embodiment the modified nucleoside comprise a modified sugar moiety. The term modified nucleoside may also be used herein interchangeably with the term “nucleoside analogue” or modified “units” or modified “monomers”.

Modified Internucleoside Linkage

[0039] The term “modified internucleoside linkage” is defined as generally understood by the skilled person as linkages other than phosphodiester (PO) linkages, that covalently couples two nucleosides together. Nucleotides with modified internucleoside linkage are also termed “modified nucleotides”. In some embodiments, the modified internucleoside linkage increases the nuclease resistance of the oligonucleotide compared to a phosphodiester linkage. For naturally occurring oligonucleotides, the internucleoside

linkage includes phosphate groups creating a phosphodiester bond between adjacent nucleosides. Modified internucleoside linkages are particularly useful in stabilizing oligonucleotides for in vivo use, and may serve to protect against nuclease cleavage at regions of DNA or RNA nucleosides in the oligonucleotide of the invention, for example within the gap region of a gapmer oligonucleotide, as well as in regions of modified nucleosides.

[0040] In an embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from the natural phosphodiester to a linkage that is for example more resistant to nuclease attack. Nuclease resistance may be determined by incubating the oligonucleotide in blood serum or by using a nuclease resistance assay (e.g. snake venom phosphodiesterase (SVPD)), both are well known in the art. Internucleoside linkages which are capable of enhancing the nuclease resistance of an oligonucleotide are referred to as nuclease resistant internucleoside linkages. In some embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are modified. It will be recognized that, in some embodiments the nucleosides which link the oligonucleotide of the invention to a non-nucleotide functional group, such as a conjugate, may be phosphodiester. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are nuclease resistant internucleoside linkages.

[0041] Modified internucleoside linkages may be selected from the group comprising phosphorothioate, diphosphorothioate and boranophosphate. In some embodiments, the modified internucleoside linkages are compatible with the RNaseH recruitment of the oligonucleotide of the invention, for example phosphorothioate, diphosphorothioate or boranophosphate.

[0042] In some embodiments the internucleoside linkage comprises sulphur (S), such as a phosphorothioate internucleoside linkage.

[0043] A phosphorothioate internucleoside linkage is particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture. In some embodiments at least 50% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate, such as at least 60%, such as at least 70%, such as at least 80 or such as at least 90% of the internucleoside linkages in the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate. In some embodiments all of the internucleoside linkages of the oligonucleotide, or contiguous nucleotide sequence thereof, are phosphorothioate.

[0044] In some embodiments, the oligonucleotide comprises one or more neutral internucleoside linkage, particularly a internucleoside linkage selected from phosphotriester, methylphosphonate, MMI, amide-3, formacetal or thioformacetal.

[0045] Further internucleoside linkages are disclosed in WO2009/124238 (incorporated herein by reference). In an embodiment the internucleoside linkage is selected from linkers disclosed in WO2007/031091 (incorporated herein

by reference). Particularly, the internucleoside linkage may be selected from $-\text{O}-\text{P}(\text{O})_2-\text{O}-$, $-\text{O}-\text{P}(\text{O},\text{S})-\text{O}-$, $-\text{O}-\text{P}(\text{S})_2-\text{O}-$, $-\text{S}-\text{P}(\text{O})_2-\text{O}-$, $-\text{S}-\text{P}(\text{O},\text{S})-\text{O}-$, $-\text{S}-\text{P}(\text{S})_2-\text{O}-$, $-\text{O}-\text{P}(\text{O})_2-\text{S}-$, $-\text{O}-\text{P}(\text{O},\text{S})-\text{S}-$, $-\text{S}-\text{P}(\text{O})_2-\text{S}-$, $-\text{O}-\text{PO}(\text{R}^H)-\text{O}-$, $0-\text{PO}(\text{OCH}_3)-\text{O}-$, $-\text{O}-\text{PO}(\text{NR}^H)-\text{O}-$, $-\text{O}-\text{PO}(\text{OCH}_2\text{CH}_2\text{S}-\text{R})-\text{O}-$, $-\text{O}-\text{PO}(\text{BH}_3)-\text{O}-$, $-\text{O}-\text{PO}(\text{NHR}^H)-\text{O}-$, $-\text{O}-\text{P}(\text{O})_2-\text{NR}^H-$, $-\text{NR}^H-\text{P}(\text{O})_2-\text{O}-$, $-\text{NR}^H-\text{CO}-\text{O}-$, $-\text{NR}^H-\text{CO}-\text{NR}^H-$, and/or the internucleoside linker may be selected from the group consisting of: $-\text{O}-\text{CO}-\text{O}-$, $-\text{O}-\text{CO}-\text{NR}^H-$, $-\text{NR}^H-\text{CO}-\text{CH}_2-$, $-\text{O}-\text{CH}_2-\text{CO}-\text{NR}^H-$, $-\text{O}-\text{CH}_2-\text{CH}_2-\text{NR}^H-$, $-\text{CO}-\text{NR}^H-\text{CH}_2-$, $-\text{CH}_2-\text{NR}^H-\text{CO}-$, $-\text{O}-\text{CH}_2-\text{CH}_2-\text{S}-$, $-\text{S}-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{S}-\text{CH}_2-\text{CH}_2-\text{S}-$, $-\text{CH}_2-\text{SO}_2-\text{CH}_2-$, $-\text{CH}_2-\text{CO}-\text{NR}^H-$, $-\text{O}-\text{CH}_2-\text{CH}_2-\text{NR}^H-\text{CO}-$, $-\text{CH}_2-\text{NCH}_3-\text{O}-\text{CH}_2-$, where R^H is selected from hydrogen and C1-4-alkyl.

[0046] Nuclease resistant linkages, such as phosphothioate linkages, are particularly useful in oligonucleotide regions capable of recruiting nuclease when forming a duplex with the target nucleic acid, such as region G for gapmers, or the non-modified nucleoside region of headmers and tailmers. Phosphorothioate linkages may, however, also be useful in non-nuclease recruiting regions and/or affinity enhancing regions such as regions F and F' for gapmers, or the modified nucleoside region of headmers and tailmers.

[0047] Each of the design regions may however comprise internucleoside linkages other than phosphorothioate, such as phosphodiester linkages, in particularly in regions where modified nucleosides, such as LNA, protect the linkage against nuclease degradation. Inclusion of phosphodiester linkages, such as one or two linkages, particularly between or adjacent to modified nucleoside units (typically in the non-nuclease recruiting regions) can modify the bioavailability and/or bio-distribution of an oligonucleotide—see WO2008/113832, incorporated herein by reference.

[0048] In an embodiment all the internucleoside linkages in the oligonucleotide are phosphorothioate and/or borano-phosphate linkages. Preferably, all the internucleoside linkages in the oligonucleotide are phosphorothioate linkages.

Nucleobase

[0049] The term nucleobase includes the purine (e.g. adenine and guanine) and pyrimidine (e.g. uracil, thymine and cytosine) moiety present in nucleosides and nucleotides which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention the term nucleobase also encompasses modified nucleobases which may differ from naturally occurring nucleobases, but are functional during nucleic acid hybridization. In this context “nucleobase” refers to both naturally occurring nucleobases such as adenine, guanine, cytosine, thymidine, uracil, xanthine and hypoxanthine, as well as non-naturally occurring variants. Such variants are for example described in Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.

[0050] In some embodiments the nucleobase moiety is modified by changing the purine or pyrimidine into a modified purine or pyrimidine, such as substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methyl cytosine, 5-thiozolo-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil,

5-bromouracil 5-thiazolo-uracil, 2-thio-uracil, 2'thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.

[0051] The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are selected from A, T, G, C, and 5-methyl cytosine. Optionally, for LNA gapmers, 5-methyl cytosine LNA nucleosides may be used.

Modified Oligonucleotide

[0052] The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar-modified nucleosides and/or modified internucleoside linkages. The term “chimeric” oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.

Complementarity

[0053] The term “complementarity” describes the capacity for Watson-Crick base-pairing of nucleosides/nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T)/uracil (U). It will be understood that oligonucleotides may comprise nucleosides with modified nucleobases, for example 5-methyl cytosine is often used in place of cytosine, and as such the term complementarity encompasses Watson Crick base-pairing between non-modified and modified nucleobases (see for example Hirao et al (2012) Accounts of Chemical Research vol 45 page 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).

[0054] The term “% complementary” as used herein, refers to the number of nucleotides in percent of a contiguous nucleotide sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are complementary to (i.e. form Watson Crick base pairs with) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid). The percentage is calculated by counting the number of aligned bases that form pairs between the two sequences (when aligned with the target sequence 5'-3' and the oligonucleotide sequence from 3'-5'), dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100. In such a comparison a nucleobase/nucleotide which does not align (form a base pair) is termed a mismatch.

[0055] The term “fully complementary”, refers to 100% complementarity.

[0056] The following is an example of an oligonucleotide (SEQ ID NO: 5) that is fully complementary to the target nucleic acid (SEQ ID NO: 772).

(SEQ ID NO: 772)
5'gca gtagagccaatta3'

(SEQ ID NO: 5)
3'cg tcatctcggttaat5'

Identity

[0057] The term “Identity” as used herein, refers to the number of nucleotides in percent of a contiguous nucleotide

sequence in a nucleic acid molecule (e.g. oligonucleotide) which, at a given position, are identical to (i.e. in their ability to form Watson Crick base pairs with the complementary nucleoside) a contiguous nucleotide sequence, at a given position of a separate nucleic acid molecule (e.g. the target nucleic acid). The percentage is calculated by counting the number of aligned bases that are identical between the two sequences, including gaps, dividing by the total number of nucleotides in the oligonucleotide and multiplying by 100.

$$\text{Percent Identity} = (\text{Matches} \times 100) / \text{Length of aligned region (with gaps)}$$

Hybridization

[0058] The term “hybridizing” or “hybridizes” as used herein is to be understood as two nucleic acid strands (e.g. an oligonucleotide and a target nucleic acid) forming hydrogen bonds between base pairs on opposite strands thereby forming a duplex. The affinity of the binding between two nucleic acid strands is the strength of the hybridization. It is often described in terms of the melting temperature (T_m) defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. At physiological conditions T_m is not strictly proportional to the affinity (Mergny and Lacroix, 2003, Oligonucleotides 13:515-537). The standard state Gibbs free energy ΔG° is a more accurate representation of binding affinity and is related to the dissociation constant (K_d) of the reaction by $\Delta G^\circ = -RT \ln(K_d)$, where R is the gas constant and T is the absolute temperature. Therefore, a very low ΔG° of the reaction between an oligonucleotide and the target nucleic acid reflects a strong hybridization between the oligonucleotide and target nucleic acid. ΔG° is the energy associated with a reaction where aqueous concentrations are 1M, the pH is 7, and the temperature is 37° C. The hybridization of oligonucleotides to a target nucleic acid is a spontaneous reaction and for spontaneous reactions ΔG° is less than zero. ΔG° can be measured experimentally, for example, by use of the isothermal titration calorimetry (ITC) method as described in Hansen et al., 1965, *Chem. Comm.* 36-38 and Holdgate et al., 2005, *Drug Discov Today. The skilled person will know that commercial equipment is available for ΔG° measurements. ΔG° can also be estimated numerically by using the nearest neighbor model as described by SantaLucia, 1998, *Proc Natl Acad Sci USA.* 95: 1460-1465 using appropriately derived thermodynamic parameters described by Sugimoto et al., 1995, *Biochemistry* 34:11211-11216 and McTigue et al., 2004, *Biochemistry* 43:5388-5405. In order to have the possibility of modulating its intended nucleic acid target by hybridization, oligonucleotides of the present invention hybridize to a target nucleic acid with estimated ΔG° values below -10 kcal for oligonucleotides that are 10-30 nucleotides in length. In some embodiments the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG° . The oligonucleotides may hybridize to a target nucleic acid with estimated ΔG° values below the range of -10 kcal, such as below -15 kcal, such as below -20 kcal and such as below -25 kcal for oligonucleotides that are 8-30 nucleotides in length. In some embodiments the oligonucleotides hybridize to a target nucleic acid with an estimated ΔG° value of -10 to -60 kcal, such as -12 to -40, such as from -15 to -30 kcal or -16 to -27 kcal such as -18 to -25 kcal.*

Target Nucleic Acid

[0059] According to the present invention, the target nucleic acid is a nucleic acid which encodes mammalian PD-L1 and may for example be a gene, a RNA, a mRNA, and pre-mRNA, a mature mRNA or a cDNA sequence. The target may therefore be referred to as a PD-L1 target nucleic acid. The oligonucleotide of the invention may for example target exon regions of a mammalian PD-L1, or may for example target intron region in the PD-L1 pre-mRNA (see Table 1).

TABLE 1

human PD-L1 Exons and Introns					
Exonic regions in the human PD-L1 premRNA (SEQ ID NO 1)			Intronic regions in the human PD-L1 premRNA (SEQ ID NO 1)		
ID	start	end	ID	start	end
e1	1	94	i1	95	5597
e2	5598	5663	i2	5664	6576
e3	6577	6918	i3	6919	12331
e4	12332	12736	i4	12737	14996
e5	14997	15410	i5	15411	16267
e6	16268	16327	i6	16328	17337
e7	17338	20064			

[0060] Suitably, the target nucleic acid encodes a PD-L1 protein, in particular mammalian PD-L1, such as human PD-L1 (See for example tables 2 and 3, which provide reference to the mRNA and pre-mRNA sequences for human, monkey, and mouse PD-L1). In the context of the present invention pre-mRNA is also considered as a nucleic acid that encodes a protein.

[0061] In some embodiments, the target nucleic acid is selected from the group consisting of SEQ ID NO: 1, 2 and 3 or naturally occurring variants thereof (e.g. sequences encoding a mammalian PD-L1 protein).

[0062] If employing the oligonucleotide of the invention in research or diagnostics the target nucleic acid may be a cDNA or a synthetic nucleic acid derived from DNA or RNA.

[0063] For in vivo or in vitro application, the oligonucleotide of the invention is typically capable of inhibiting the expression of the PD-L1 target nucleic acid in a cell which is expressing the PD-L1 target nucleic acid. The contiguous sequence of nucleobases of the oligonucleotide of the invention is typically complementary to the PD-L1 target nucleic acid, as measured across the length of the oligonucleotide, optionally with the exception of one or two mismatches, and optionally excluding nucleotide based linker regions which may link the oligonucleotide to an optional functional group such as a conjugate, or other non-complementary terminal nucleotides (e.g. region D' or D''). The target nucleic acid may, in some embodiments, be a RNA or DNA, such as a messenger RNA, such as a mature mRNA or a pre-mRNA. In some embodiments the target nucleic acid is a RNA or DNA which encodes mammalian PD-L1 protein, such as human PD-L1, e.g. the human PD-L1 premRNA sequence, such as that disclosed as SEQ ID NO 1 or the human mRNA sequence with NCBI reference number NM_01414. Further information on exemplary target nucleic acids is provided in tables 2 and 3.

TABLE 2

Genome and assembly information for PD-L1 across species.						
Species	Chr.	Strand	Genomic coordinates			NCBI reference sequence* accession number for mRNA
			Start	End	Assembly	
Human	9	fwd	5450503	5470566	GRCh38:CM000671.2	NM_014143
Cynomolgus monkey	15		73560846	73581371	GCF_000364345.1	XM_005581779
Mouse	19	fwd	29367455	29388095	GRCm38:CM001012.2	NM_021893

Fwd = forward strand.

The genome coordinates provide the pre-mRNA sequence (genomic sequence).

The NCBI reference provides the mRNA sequence (cDNA sequence).

*The National Center for Biotechnology Information reference sequence database is a comprehensive, integrated, non-redundant, well-annotated set of reference sequences including genomic, transcript, and protein. It is hosted at www.ncbi.nlm.nih.gov/refseq.

TABLE 3

Sequence details for PD-L1 across species.			
Species	RNA type	Length (nt)	SEQ ID NO
Human	premRNA	20064	1
Monkey Cyno	premRNA GCF ref	20261	2
Monkey Cyno	premRNA Internal	20340	3
Mouse	premRNA	20641	4

Target Sequence

[0064] The term “target sequence” as used herein refers to a sequence of nucleotides present in the target nucleic acid which comprises the nucleobase sequence which is complementary to the oligonucleotide of the invention. In some embodiments, the target sequence consists of a region on the target nucleic acid which is complementary to the contiguous nucleotide sequence of the oligonucleotide of the invention. In some embodiments the target sequence is longer than the complementary sequence of a single oligonucleotide, and may, for example represent a preferred region of the target nucleic acid which may be targeted by several oligonucleotides of the invention.

[0065] The target sequence may be a sub-sequence of the target nucleic acid.

[0066] In some embodiments the sub-sequence is a sequence selected from the group consisting of a1-a149 (see tables 4). In some embodiments the sub-sequence is a sequence selected from the group consisting of a human PD-L1 mRNA exon, such as a PD-L1 human mRNA exon selected from the group consisting of e1, e2, e3, e4, e5, e6, and e7 (see table 1 above).

[0067] In some embodiments the sub-sequence is a sequence selected from the group consisting of a human PD-L1 mRNA intron, such as a PD-L1 human mRNA intron selected from the group consisting of i1, i2, i3, i4, i5 and i6 (see table 1 above).

[0068] The oligonucleotide of the invention comprises a contiguous nucleotide sequence which is complementary to or hybridizes to the target nucleic acid, such as a sub-sequence of the target nucleic acid, such as a target sequence described herein.

[0069] The oligonucleotide comprises a contiguous nucleotide sequence of at least 8 nucleotides which is complementary to or hybridizes to a target sequence present

in the target nucleic acid molecule. The contiguous nucleotide sequence (and therefore the target sequence) comprises of at least 8 contiguous nucleotides, such as 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides, such as from 12-25, such as from 14-18 contiguous nucleotides.

Target Cell

[0070] The term a “target cell” as used herein refers to a cell which is expressing the target nucleic acid. In some embodiments the target cell may be in vivo or in vitro. In some embodiments the target cell is a mammalian cell such as a rodent cell, such as a mouse cell or a rat cell, or a primate cell such as a monkey cell or a human cell.

[0071] In preferred embodiments the target cell expresses PD-L1 mRNA, such as the PD-L1 pre-mRNA or PD-L1 mature mRNA. The poly A tail of PD-L1 mRNA is typically disregarded for antisense oligonucleotide targeting.

Naturally Occurring Variant

[0072] The term “naturally occurring variant” refers to variants of PD-L1 gene or transcripts which originate from the same genetic loci as the target nucleic acid, but may differ for example, by virtue of degeneracy of the genetic code causing a multiplicity of codons encoding the same amino acid, or due to alternative splicing of pre-mRNA, or the presence of polymorphisms, such as single nucleotide polymorphisms, and allelic variants. Based on the presence of the sufficient complementary sequence to the oligonucleotide, the oligonucleotide of the invention may therefore target the target nucleic acid and naturally occurring variants thereof.

[0073] In some embodiments, the naturally occurring variants have at least 95% such as at least 98% or at least 99% homology to a mammalian PD-L1 target nucleic acid, such as a target nucleic acid selected from the group consisting of SEQ ID NO 1, 2 and 3.

[0074] Numerous single nucleotide polymorphisms are known in the PD-L1 gene, for example those disclosed in the following table (human premRNA start/reference sequence is SEQ ID NO 2)

Variant name	Variant alleles	minor allele	Minor allele frequency	Start on SEQ ID NO: 1
rs73397192	G/A	A	0.10	2591
rs12342381	A/G	G	0.12	308
rs16923173	G/A	A	0.13	14760
rs2890658	C/A	A	0.16	14628
rs2890657	G/C	C	0.21	2058
rs3780395	A/G	A	0.21	14050
rs147367592	AG/-	-	0.21	13425
rs7023227	T/C	T	0.22	6048
rs2297137	G/A	A	0.23	15230
rs1329946	G/A	A	0.23	2910
rs5896124	-/G	G	0.23	2420
rs61061063	T/C	C	0.23	11709
rs1411263	T/C	C	0.23	8601
rs59906468	A/G	G	0.23	15583
rs6476976	T/C	T	0.24	21012
rs35744625	C/A	A	0.24	3557
rs17804441	T/C	C	0.24	7231
rs148602745	C/T	T	0.25	22548
rs4742099	G/A	A	0.25	20311
rs10815228	T/C	C	0.25	21877
rs58817806	A/G	G	0.26	20769
rs822342	T/C	T	0.27	3471
rs10481593	G/A	A	0.27	7593
rs822339	A/G	A	0.28	2670
rs860290	A/C	A	0.28	2696
rs822340	A/G	A	0.28	2758
rs822341	T/C	T	0.28	2894
rs12002985	C/G	C	0.28	6085
rs822338	C/T	C	0.28	1055
rs866066	C/T	T	0.28	451
rs6651524	A/T	T	0.28	8073
rs6415794	A/T	A	0.28	8200
rs4143815	G/C	C	0.28	17755
rs111423622	G/A	A	0.28	24096
rs6651525	C/A	A	0.29	8345
rs4742098	A/G	G	0.29	19995
rs10975123	C/T	T	0.30	10877

-continued

Variant name	Variant alleles	minor allele	Minor allele frequency	Start on SEQ ID NO: 1
rs2282055	T/G	G	0.30	5230
rs4742100	A/C	C	0.30	20452
rs60520638	-/TC	TC	0.30	9502
rs17742278	T/C	C	0.30	6021
rs7048841	T/C	T	0.30	10299
rs10815229	T/G	G	0.31	22143
rs10122089	C/T	C	0.32	13278
rs1970000	C/A	C	0.32	14534
rs112071324	AGAGAG/-	AGAGAG	0.33	16701
rs2297136	G/A	G	0.33	17453
rs10815226	A/T	T	0.33	9203
rs10123377	A/G	A	0.36	10892
rs10123444	A/G	A	0.36	11139
rs7042084	G/T	G	0.36	7533
rs10114060	G/A	A	0.36	11227
rs7028894	G/A	G	0.36	10408
rs4742097	C/T	C	0.37	5130
rs1536926	G/T	G	0.37	13486
rs1411262	C/T	T	0.39	8917
rs7041009	G/A	A	0.45	12741

Modulation of Expression

[0075] The term “modulation of expression” as used herein is to be understood as an overall term for an oligonucleotide’s ability to alter the amount of PD-L1 when compared to the amount of PD-L1 before administration of the oligonucleotide. Alternatively modulation of expression may be determined by reference to a control experiment. It is generally understood that the control is an individual or target cell treated with a saline composition or an individual or target cell treated with a non-targeting oligonucleotide (mock). It may however also be an individual treated with the standard of care.

[0076] One type of modulation is an oligonucleotide’s ability to inhibit, down-regulate, reduce, suppress, remove, stop, block, prevent, lessen, lower, avoid or terminate expression of PD-L1, e.g. by degradation of mRNA or blockage of transcription. Another type of modulation is an oligonucleotide’s ability to restore, increase or enhance expression of PD-L1, e.g. by repair of splice sites or prevention of splicing or removal or blockage of inhibitory mechanisms such as microRNA repression.

High Affinity Modified Nucleosides

[0077] A high affinity modified nucleoside is a modified nucleotide which, when incorporated into the oligonucle-

otide enhances the affinity of the oligonucleotide for its complementary target, for example as measured by the melting temperature (T^m). A high affinity modified nucleoside of the present invention preferably result in an increase in melting temperature between +0.5 to +12° C., more preferably between +1.5 to +10° C. and most preferably between +3 to +8° C. per modified nucleoside. Numerous high affinity modified nucleosides are known in the art and include for example, many 2' substituted nucleosides as well as locked nucleic acids (LNA) (see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213).

Sugar Modifications

[0078] The oligomer of the invention may comprise one or more nucleosides which have a modified sugar moiety, i.e. a modification of the sugar moiety when compared to the ribose sugar moiety found in DNA and RNA.

[0079] Numerous nucleosides with modification of the ribose sugar moiety have been made, primarily with the aim of improving certain properties of oligonucleotides, such as affinity and/or nuclease resistance.


[0080] Such modifications include those where the ribose ring structure is modified, e.g. by replacement with a hexose ring (HNA), or a bicyclic ring, which typically have a biradicle bridge between the C2 and C4 carbons on the ribose ring (LNA), or an unlinked ribose ring which typically lacks a bond between the C2 and C3 carbons (e.g. UNA). Other sugar modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011/017521) or tricyclic nucleic acids (WO2013/154798). Modified nucleosides also include nucleosides where the sugar moiety is replaced with a non-sugar moiety, for example in the case of peptide nucleic acids (PNA), or morpholino nucleic acids.

[0081] Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen, or the 2'-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2', 3', 4' or 5' positions. Nucleosides with modified sugar moieties also include 2' modified nucleosides, such as 2' substituted nucleosides. Indeed, much focus has been spent on developing 2' substituted nucleosides, and numerous 2' substituted nucleosides have been found to have beneficial properties when incorporated into oligonucleotides, such as enhanced nucleoside resistance and enhanced affinity.

2' Modified Nucleosides.

[0082] A 2' sugar modified nucleoside is a nucleoside which has a substituent other than H or —OH at the 2' position (2' substituted nucleoside) or comprises a 2' linked biradicle, and includes 2' substituted nucleosides and LNA (2'-4' biradicle bridged) nucleosides. For example, the 2' modified sugar may provide enhanced binding affinity and/or increased nuclease resistance to the oligonucleotide. Examples of 2' substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-Fluoro-RNA, and 2'-F-ANA nucleoside. For further examples, please see e.g. Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3(2), 293-213, and Deleavey and Damha,


Chemistry and Biology 2012, 19, 937. Below are illustrations of some 2' substituted modified nucleosides.




Locked Nucleic Acid Nucleosides (LNA).

[0083] LNA nucleosides are modified nucleosides which comprise a linker group (referred to as a biradicle or a bridge) between C2' and C4' of the ribose sugar ring of a nucleotide. These nucleosides are also termed bridged nucleic acid or bicyclic nucleic acid (BNA) in the literature.

[0084] In some embodiments, the modified nucleoside or the LNA nucleosides of the oligomer of the invention has a general structure of the formula I or II:



-continued



Formula II

wherein W is selected from $-\text{O}-$, $-\text{S}-$, $-\text{N}(\text{R}^a)-$, $-\text{C}(\text{R}^a\text{R}^b)-$, such as, in some embodiments $-\text{O}-$; B designates a nucleobase or modified nucleobase moiety; Z designates an internucleoside linkage to an adjacent nucleoside, or a 5'-terminal group;

Z* designates an internucleoside linkage to an adjacent nucleoside, or a 3'-terminal group;

X designates a group selected from the list consisting of $-\text{C}(\text{R}^a\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{N}-$, $-\text{O}-$, $-\text{Si}(\text{R}^a)_2-$, $-\text{S}-$, $-\text{SO}_2-$, $-\text{N}(\text{R}^a)-$, and $>\text{C}=\text{Z}$

[0085] In some embodiments, X is selected from the group consisting of: $-\text{O}-$, $-\text{S}-$, $\text{NH}-$, NR^aR^b , $-\text{CH}_2-$, CR^aR^b , $-\text{C}(\text{=CH}_2)-$, and $-\text{C}(\text{=CR}^a\text{R}^b)-$

[0086] In some embodiments, X is $-\text{O}-$

Y designates a group selected from the group consisting of $-\text{C}(\text{R}^a\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{N}-$, $-\text{O}-$, $-\text{Si}(\text{R}^a)_2-$, $-\text{S}-$, $-\text{SO}_2-$, $-\text{N}(\text{R}^a)-$, and $>\text{C}=\text{Z}$

[0087] In some embodiments, Y is selected from the group consisting of: $-\text{CH}_2-$, $-\text{C}(\text{R}^a\text{R}^b)-$, $-\text{CH}_2\text{CH}_2-$, $-\text{C}(\text{R}^a\text{R}^b)-\text{C}(\text{R}^a\text{R}^b)-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{C}(\text{R}^a\text{R}^b)\text{C}(\text{R}^a\text{R}^b)\text{C}(\text{R}^a\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-$, and $-\text{C}(\text{R}^a)=\text{N}-$

[0088] In some embodiments, Y is selected from the group consisting of: $-\text{CH}_2-$, $-\text{CHR}^a-$, $-\text{CHCH}_3-$, CR^aR^b-

or $-\text{X}-\text{Y}-$ together designate a bivalent linker group (also referred to as a radicle) together designate a bivalent linker group consisting of 1, 2, 3 or 4 groups/atoms selected from the group consisting of $-\text{C}(\text{R}^a\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{C}(\text{R}^b)-$, $-\text{C}(\text{R}^a)=\text{N}-$, $-\text{O}-$, $-\text{Si}(\text{R}^a)_2-$, $-\text{S}-$, $-\text{SO}_2-$, $-\text{N}(\text{R}^a)-$, and $>\text{C}=\text{Z}$,

[0089] In some embodiments, $-\text{X}-\text{Y}-$ designates a biradicle selected from the groups consisting of: $-\text{X}-\text{CH}_2-$, $-\text{X}-\text{CR}^a\text{R}^b-$, $-\text{X}-\text{CHR}^a-$, $-\text{X}-\text{C}(\text{HCH}_3)-$, $-\text{O}-\text{Y}-$, $-\text{O}-\text{CH}_2-$, $-\text{S}-\text{CH}_2-$, $-\text{NH}-\text{CH}_2-$, $-\text{O}-\text{CHCH}_3-$, $-\text{CH}_2-\text{O}-\text{CH}_2-$, $-\text{O}-\text{CH}(\text{CH}_3\text{CH}_3)-$, $-\text{O}-\text{CH}_2-\text{CH}_2-$, $\text{OCH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{O}-\text{CH}_2\text{OCH}_2-$, $-\text{O}-\text{NCH}_2-$, $-\text{C}(\text{=CH}_2)-\text{CH}_2-$, $-\text{NR}^a-\text{CH}_2-$, $\text{N}-\text{O}-\text{CH}_2-$, $-\text{S}-\text{CR}^a\text{R}^b-$ and $-\text{S}-\text{CHR}^a-$.

[0090] In some embodiments $-\text{X}-\text{Y}-$ designates $-\text{O}-\text{CH}_2-$ or $-\text{O}-\text{CH}(\text{CH}_3)-$.

wherein Z is selected from $-\text{O}-$, $-\text{S}-$, and $-\text{N}(\text{R}^a)-$, and R^a and, when present R^b , each is independently selected from hydrogen, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, hydroxy, optionally substituted C_{1-6} -alkoxy, C_{2-6} -alkoxyalkyl, C_{2-6} -alkenyloxy, carboxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C_{1-6} -alkyl)amino, carbamoyl, mono- and di(C_{1-6} -alkyl)-

carbonyl, amino- C_{1-6} -alkyl-aminocarbonyl, mono- and di(C_{1-6} -alkyl)amino- C_{1-6} -alkyl-aminocarbonyl, C_{1-6} -alkyl-carbonylamino, carbamido, C_{1-6} -alkanoyloxy, sulphonylo, C_{1-6} -alkylsulphonyloxy, nitro, azido, sulphonyl, C_{1-6} -alkylthio, halogen, where aryl and heteroaryl may be optionally substituted and where two geminal substituents R^a and R^b together may designate optionally substituted methylene ($=\text{CH}_2$), wherein for all chiral centers, asymmetric groups may be found in either R or S orientation.

wherein R^1 , R^2 , R^3 , R^5 and R^{5*} are independently selected from the group consisting of: hydrogen, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkynyl, hydroxy, C_{1-6} -alkoxy, C_{2-6} -alkoxyalkyl, C_{2-6} -alkenyloxy, carboxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C_{1-6} -alkyl)amino, carbamoyl, mono- and di(C_{1-6} -alkyl)-amino-carbonyl, amino- C_{1-6} -alkyl-aminocarbonyl, mono- and di(C_{1-6} -alkyl)amino- C_{1-6} -alkyl-aminocarbonyl, C_{1-6} -alkyl-carbonylamino, carbamido, C_{1-6} -alkanoyloxy, sulphonylo, C_{1-6} -alkylsulphonyloxy, nitro, azido, sulphonyl, C_{1-6} -alkylthio, halogen, where aryl and heteroaryl may be optionally substituted, and where two geminal substituents together may designate oxo, thio, imino, or optionally substituted methylene.

[0091] In some embodiments R^1 , R^2 , R^3 , R^5 and R^{5*} are independently selected from C_{1-6} alkyl, such as methyl, and hydrogen.

[0092] In some embodiments R^1 , R^2 , R^3 , R^5 and R^{5*} are all hydrogen.

[0093] In some embodiments R^1 , R^2 , R^3 , are all hydrogen, and either R^5 and R^{5*} is also hydrogen and the other of R^5 and R^{5*} is other than hydrogen, such as C_{1-6} alkyl such as methyl.

[0094] In some embodiments, R^a is either hydrogen or methyl. In some embodiments, when present, R^b is either hydrogen or methyl.

[0095] In some embodiments, one or both of R^a and R^b is hydrogen

[0096] In some embodiments, one of R^a and R^b is hydrogen and the other is other than hydrogen

[0097] In some embodiments, one of R^a and R^b is methyl and the other is hydrogen

[0098] In some embodiments, both of R^a and R^b are methyl.

[0099] In some embodiments, the biradicle $-\text{X}-\text{Y}-$ is $-\text{O}-\text{CH}_2-$, W is O, and all of R^1 , R^2 , R^3 , R^5 and R^{5*} are all hydrogen. Such LNA nucleosides are disclosed in WO99/014226, WO00/66604, WO98/039352 and WO2004/046160 which are all hereby incorporated by reference, and include what are commonly known as beta-D-oxy LNA and alpha-L-oxy LNA nucleosides.

[0100] In some embodiments, the biradicle $-\text{X}-\text{Y}-$ is $-\text{S}-\text{CH}_2-$, W is O, and all of R^1 , R^2 , R^3 , R^5 and R^{5*} are all hydrogen. Such thio LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.

[0101] In some embodiments, the biradicle $-\text{X}-\text{Y}-$ is $-\text{NH}-\text{CH}_2-$, W is O, and all of R^1 , R^2 , R^3 , R^5 and R^{5*} are all hydrogen. Such amino LNA nucleosides are disclosed in WO99/014226 and WO2004/046160 which are hereby incorporated by reference.

[0102] In some embodiments, the biradicle $-X-Y-$ is $-O-CH_2-CH_2-$ or $-O-CH_2-CH_2-CH_2-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such LNA nucleosides are disclosed in WO00/047599 and Morita et al, Bioorganic & Med. Chem. Lett. 12 73-76, which are hereby incorporated by reference, and include what are commonly known as 2'-O-4'C-ethylene bridged nucleic acids (ENA).

[0103] In some embodiments, the biradicle $-X-Y-$ is $-O-CH_2-$, W is O, and all of $R^1, R^2, R^3,$ and one of R^5 and R^{5*} are hydrogen, and the other of R^5 and R^{5*} is other than hydrogen such as C_{1-6} alkyl, such as methyl. Such 5' substituted LNA nucleosides are disclosed in WO2007/134181 which is hereby incorporated by reference.

[0104] In some embodiments, the biradicle $-X-Y-$ is $-O-CR^aR^b-$, wherein one or both of R^a and R^b are other than hydrogen, such as methyl, W is O, and all of $R^1, R^2, R^3,$ and one of R^5 and R^{5*} are hydrogen, and the other of R^5 and R^{5*} is other than hydrogen such as C_{1-6} alkyl, such as methyl. Such bis modified LNA nucleosides are disclosed in WO2010/077578 which is hereby incorporated by reference.

[0105] In some embodiments, the biradicle $-X-Y-$ designate the bivalent linker group $-O-CH(CH_2OCH_3)-$ (2' O-methoxyethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81). In some embodiments, the biradicle $-X-Y-$ designate the bivalent linker group $-O-CH(CH_2CH_3)-$ (2' O-ethyl bicyclic nucleic acid—Seth at al., 2010, J. Org. Chem. Vol 75(5) pp. 1569-81). In some embodiments, the biradicle $-X-Y-$ is $-O-CHR^a-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such 6' substituted LNA nucleosides are disclosed in WO10036698 and WO07090071 which are both hereby incorporated by reference.

[0106] In some embodiments, the biradicle $-X-Y-$ is $-O-CH(CH_2OCH_3)-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such LNA nucleosides are also known as cyclic MOEs in the art (cMOE) and are disclosed in WO07090071.

[0107] In some embodiments, the biradicle $-X-Y-$ designate the bivalent linker group $-O-CH(CH_3)-$. —in either the R- or S-configuration. In some embodiments, the biradicle $-X-Y-$ together designate the bivalent linker group $-O-CH_2-O-CH_2-$ (Seth at al., 2010, J. Org. Chem). In some embodiments, the biradicle $-X-Y-$ is $-O-CH(CH_3)-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such 6' methyl LNA nucleosides are also known as cET nucleosides in the art, and may be either (S)cET or (R)cET stereoisomers, as disclosed in WO07090071 (beta-D) and WO2010/036698 (alpha-L) which are both hereby incorporated by reference).

[0108] In some embodiments, the biradicle $-X-Y-$ is $-O-CR^aR^b-$, wherein in neither R^a or R^b is hydrogen, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. In some embodiments, R^a and R^b are both methyl. Such 6' di-substituted LNA nucleosides are disclosed in WO 2009006478 which is hereby incorporated by reference.

[0109] In some embodiments, the biradicle $-X-Y-$ is $-S-CHR^a-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such 6' substituted thio LNA nucleosides are disclosed in WO11156202 which is hereby incorporated by reference. In some 6' substituted thio LNA embodiments R^a is methyl.

[0110] In some embodiments, the biradicle $-X-Y-$ is $-C(=CH_2)-C(R^aR^b)-$, such as $-C(=CH_2)-CH_2-$, or

$-C(=CH_2)-CH(CH_3)-$ W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. Such vinyl carbo LNA nucleosides are disclosed in WO08154401 and WO09067647 which are both hereby incorporated by reference.

[0111] In some embodiments the biradicle $-X-Y-$ is $-N(-OR^a)-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. In some embodiments R^a is C_{1-6} alkyl such as methyl. Such LNA nucleosides are also known as N substituted LNAs and are disclosed in WO2008/150729, which is hereby incorporated by reference. In some embodiments, the biradicle $-X-Y-$ together designate the bivalent linker group $-O-NR^a-CH_3-$ (Seth at al., 2010, J. Org. Chem). In some embodiments the biradicle $-X-Y-$ is $-N(R^a)-$, W is O, and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. In some embodiments R^a is C_{1-6} alkyl such as methyl.


[0112] In some embodiments, one or both of R^5 and R^{5*} is hydrogen and, when substituted the other of R^5 and R^{5*} is C_{1-6} alkyl such as methyl. In such an embodiment, $R^1, R^2, R^3,$ may all be hydrogen, and the biradicle $-X-Y-$ may be selected from $-O-CH_2-$ or $-O-C(HCR^a)-$, such as $-O-C(HCH_3)-$.




[0113] In some embodiments, the biradicle is $-CR^aR^b-O-CR^aR^b-$, such as CH_2-O-CH_2- , W is O and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. In some embodiments R^a is C_{1-6} alkyl such as methyl. Such LNA nucleosides are also known as conformationally restricted nucleotides (CRNs) and are disclosed in WO2013036868 which is hereby incorporated by reference.

[0114] In some embodiments, the biradicle is $-O-CR^aR^b-O-CR^aR^b-$, such as $O-CH_2-O-CH_2-$, W is O and all of R^1, R^2, R^3, R^5 and R^{5*} are all hydrogen. In some embodiments R^a is C_{1-6} alkyl such as methyl. Such LNA nucleosides are also known as COC nucleotides and are disclosed in Mitsuoka et al., Nucleic Acids Research 2009 37(4), 1225-1238, which is hereby incorporated by reference.

[0115] It will be recognized than, unless specified, the LNA nucleosides may be in the beta-D or alpha-L stereoisom.

[0116] Certain examples of LNA nucleosides are presented in Scheme 1.





[0117] As illustrated in the examples, in some embodiments of the invention the LNA nucleosides in the oligonucleotides are beta-D-oxy-LNA nucleosides.

Nuclease Mediated Degradation

[0118] Nuclease mediated degradation refers to an oligonucleotide capable of mediating degradation of a complementary nucleotide sequence when forming a duplex with such a sequence.

[0119] In some embodiments, the oligonucleotide may function via nuclease mediated degradation of the target nucleic acid, where the oligonucleotides of the invention are capable of recruiting a nuclease, particularly an endonuclease, preferably endoribonuclease (RNase), such as RNase H. Examples of oligonucleotide designs which operate via nuclease mediated mechanisms are oligonucleotides which typically comprise a region of at least 5 or 6 DNA nucleosides and are flanked on one side or both sides by affinity enhancing nucleosides, for example gapmers, headmers and tailmers.

RNase H Activity and Recruitment

[0120] The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when in a duplex with a complementary RNA molecule. WO01/23613 provides in vitro methods for determining RNaseH activity, which may be used to determine the ability to recruit RNaseH. Typically an oligonucleotide is deemed capable of recruiting RNase H if it, when provided with a complementary target nucleic acid sequence, has an initial rate, as measured in pmol/l/min, of at least 5%, such as at least 10% or more than 20% of the initial rate determined when using an oligonucleotide having the same base sequence as the modified oligonucleotide being tested, but containing only DNA monomers with phosphorothioate linkages between all monomers in the oligonucleotide, and using the methodology provided by Example 91-95 of WO01/23613 (hereby incorporated by reference).

Gapmer

[0121] The term gapmer as used herein refers to an antisense oligonucleotide which comprises a region of RNase H recruiting oligonucleotides (gap) which is flanked 5' and 3' by regions which comprise one or more affinity

enhancing modified nucleosides (flanks or wings). Various gapmer designs are described herein and are characterized by their ability to recruit RNaseH. Headmers and tailmers are oligonucleotides capable of recruiting RNase H where one of the flanks is missing, i.e. only one of the ends of the oligonucleotide comprises affinity enhancing modified nucleosides. For headmers the 3' flank is missing (i.e. the 5' flank comprises affinity enhancing modified nucleosides) and for tailmers the 5' flank is missing (i.e. the 3' flank comprises affinity enhancing modified nucleosides).

LNA Gapmer

[0122] The term LNA gapmer is a gapmer oligonucleotide wherein at least one of the affinity enhancing modified nucleosides is an LNA nucleoside.

Mixed Wing Gapmer

[0123] The term mixed wing gapmer or mixed flank gapmer refers to a LNA gapmer wherein at least one of the flank regions comprise at least one LNA nucleoside and at least one non-LNA modified nucleoside, such as at least one 2' substituted modified nucleoside, such as, for example, 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-Fluoro-RNA and 2'-F-ANA nucleoside(s). In some embodiments the mixed wing gapmer has one flank which comprises only LNA nucleosides (e.g. 5' or 3') and the other flank (3' or 5' respectfully) comprises 2' substituted modified nucleoside (s) and optionally LNA nucleosides.

Gapbreaker

[0124] The term "gapbreaker oligonucleotide" is used in relation to a gapmer capable of maintaining RNaseH recruitment even though the gap region is disrupted by a non-RNaseH recruiting nucleoside (a gap-breaker nucleoside, E) such that the gap region comprise less than 5 consecutive DNA nucleosides. Non-RNaseH recruiting nucleosides are for example nucleosides in the 3' endo conformation, such as LNA's where the bridge between C2' and C4' of the ribose sugar ring of a nucleoside is in the beta conformation, such as beta-D-oxy LNA or ScET nucleoside. The ability of gapbreaker oligonucleotide to recruit RNaseH is typically sequence or even compound specific—see Rukov et al. 2015 Nucl. Acids Res. Vol. 43 pp. 8476-8487, which discloses "gapbreaker" oligonucleotides which recruit RNaseH which in some instances provide a more specific cleavage of the target RNA.

[0125] In some embodiments, the oligonucleotide of the invention is a gapbreaker oligonucleotide. In some embodiments the gapbreaker oligonucleotide comprise a 5'-flank (F), a gap (G) and a 3'-flank (F'), wherein the gap is disrupted by a non-RNaseH recruiting nucleoside (a gap-breaker nucleoside, E) such that the gap contain at least 3 or 4 consecutive DNA nucleosides. In some embodiments the gapbreaker nucleoside (E) is an LNA nucleoside where the bridge between C2' and C4' of the ribose sugar ring of a nucleoside is in the beta conformation and is placed within the gap region such that the gap-breaker LNA nucleoside is flanked 5' and 3' by at least 3 (5') and 3 (3') or at least 3 (5') and 4 (3') or at least 4(5') and 3(3') DNA nucleosides, and wherein the oligonucleotide is capable of recruiting RNaseH.

[0126] The gapbreaker oligonucleotide can be represented by the following formulae:

F-G-E-G-F'; in particular $F_{1-7}G_{3-4}E_1G_{3-4}F'_{1-7}$

D'-F-G-F', in particular $D'_{1-3}F_{1-7}G_{3-4}E_1G_{3-4}F'_{1-7}$

F-G-F-D'', in particular $F_{1-7}G_{3-4}E_1G_{3-4}F'_{1-7}D''_{1-3}$

D'-F-G-F'-D'', in particular $D'_{1-3}F_{1-7}G_{3-4}E_1G_{3-4}F'_{1-7}D''_{1-3}$

Where region D' and D'' are as described in the section "Gapmer design".

[0127] In some embodiments the gapbreaker nucleoside (E) is a beta-D-oxy LNA or ScET or another beta-LNA nucleosides shown in Scheme 1).

Conjugate

[0128] The term conjugate as used herein refers to an oligonucleotide which is covalently linked to a non-nucleotide moiety (conjugate moiety or region C or third region), also termed a oligonucleotide conjugate.

[0129] Conjugation of the oligonucleotides of the invention to one or more non-nucleotide moieties may improve the pharmacology of the oligonucleotide, e.g. by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide. In some embodiments the conjugate moiety targets the oligonucleotide to the liver. At the same time the conjugate serve to reduce activity of the oligonucleotide in non-target cell types, tissues or organs, e.g. off target activity or activity in non-target cell types, tissues or organs. In one embodiment of the invention the oligonucleotide conjugate of the invention display improved inhibition of PD-L1 in the target cell when compared to an unconjugated oligonucleotide. In another embodiment the oligonucleotide conjugate of the invention has improved cellular distribution between liver and other organs, such as spleen or kidney (i.e. more conjugated oligonucleotide goes to the liver than the spleen or kidney) when compared to an unconjugated oligonucleotide. In another embodiment the oligonucleotide conjugate of the invention show improved cellular uptake into the liver of the conjugate oligonucleotide when compared to an unconjugated oligonucleotide.

[0130] WO 93/07883 and WO2013/033230 provides suitable conjugate moieties, which are hereby incorporated by reference. Further suitable conjugate moieties are those capable of binding to the asialoglycoprotein receptor (ASGPr). In particular tri-valent N-acetylgalactosamine conjugate moieties are suitable for binding to the ASGPr, see for example WO 2014/076196, WO 2014/207232 and WO 2014/179620 (hereby incorporated by reference). The conjugate moiety is essentially the part of the antisense oligonucleotides conjugates which is not composed of nucleic acids.

[0131] Oligonucleotide conjugates and their synthesis has also been reported in comprehensive reviews by Manoharan in Antisense Drug Technology, Principles, Strategies, and Applications, S. T. Croke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.

[0132] In an embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, pro-

teins, peptides, toxins (e.g. bacterial toxins), vitamins, viral proteins (e.g. capsids) or combinations thereof.

Linkers

[0133] A linkage or linker is a connection between two atoms that links one chemical group or segment of interest to another chemical group or segment of interest via one or more covalent bonds. Conjugate moieties can be attached to the oligonucleotide directly or through a linking moiety (e.g. linker or tether). Linkers serve to covalently connect a third region, e.g. a conjugate moiety (Region C), to a first region, e.g. an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A).

[0134] In some embodiments of the invention the conjugate or oligonucleotide conjugate of the invention may optionally, comprise a linker region (second region or region B and/or region Y) which is positioned between the oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region) and the conjugate moiety (region C or third region).

[0135] Region B refers to biocleavable linkers comprising or consisting of a physiologically labile bond that is cleavable under conditions normally encountered or analogous to those encountered within a mammalian body. Conditions under which physiologically labile linkers undergo chemical transformation (e.g., cleavage) include chemical conditions such as pH, temperature, oxidative or reductive conditions or agents, and salt concentration found in or analogous to those encountered in mammalian cells. Mammalian intracellular conditions also include the presence of enzymatic activity normally present in a mammalian cell such as from proteolytic enzymes or hydrolytic enzymes or nucleases. In one embodiment the biocleavable linker is susceptible to S1 nuclease cleavage. In a preferred embodiment the nuclease susceptible linker comprises between 1 and 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably between 2 and 6 nucleosides and most preferably between 2 and 4 linked nucleosides comprising at least two consecutive phosphodiester linkages, such as at least 3 or 4 or 5 consecutive phosphodiester linkages. Preferably the nucleosides are DNA or RNA. Phosphodiester containing biocleavable linkers are described in more detail in WO 2014/076195 (hereby incorporated by reference).

[0136] Region Y refers to linkers that are not necessarily biocleavable but primarily serve to covalently connect a conjugate moiety (region C or third region), to an oligonucleotide or contiguous nucleotide sequence complementary to the target nucleic acid (region A or first region). The region Y linkers may comprise a chain structure or an oligomer of repeating units such as ethylene glycol, amino acid units or amino alkyl groups. The oligonucleotide conjugates of the present invention can be constructed of the following regional elements A-C, A-B-C, A-B-Y-C, A-Y-B-C or A-Y-C. In some embodiments the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In a preferred embodiment the linker (region Y) is a C6 amino alkyl group.

Treatment

[0137] The term ‘treatment’ as used herein refers to both treatment of an existing disease (e.g. a disease or disorder as herein referred to), or prevention of a disease, i.e. prophylaxis.

It will therefore be recognized that treatment as referred to herein may, in some embodiments, be prophylactic.

Restoration of Immune Response Against Pathogens

[0138] The immune response is divided into the innate and adaptive immune response. The innate immune system provides an immediate, but non-specific response. The adaptive immune response is activated by innate immune response and is highly specific to a particular pathogen. Upon presentation of a pathogen-derived antigen on the surface of antigen-presenting cells, immune cells of the adaptive immune response (i.e. T and B lymphocytes) are activated through their antigen-specific receptors leading to a pathogenic-specific immune response and development of immunological memory. Chronic viral infections, such as HBV and HCV, are associated with T cell exhaustion characterized by unresponsiveness of the viral-specific T cells. T cell exhaustion is well studied, for a review see for example Yi et al 2010 Immunology 129, 474-481. Chronic viral infections are also associated with reduced function of NK cells that are innate immune cells. Enhancing viral immune response is important for clearance of chronic infection. Restoration of immune response against pathogens, mediated by T cells and NK cells, can be assessed by measurement of proliferation, cytokine secretion and cytolytic function (Dolina et al. 2013 Molecular Therapy-Nucleic Acids, 2 e72 and Example 6 herein).

DETAILED DESCRIPTION OF THE INVENTION

[0139] The present invention relates to the use of antisense oligonucleotides and conjugates thereof and pharmaceutical compositions comprising these to restore immune response against pathogens that have infected an animal, in particular a human. The antisense oligonucleotide conjugates of the present invention are particularly useful against pathogens that have infected the liver, in particular chronic liver infections like HBV. The conjugates allow targeted distribution of the oligonucleotides and prevents systemic knockdown of the target nucleic acid.

The Oligonucleotides of the Invention

[0140] The invention relates to oligonucleotides capable of modulating expression of PD-L1. The modulation is may be achieved by hybridizing to a target nucleic acid encoding PD-L1 or which is involved in the regulation of PD-L1. The target nucleic acid may be a mammalian PD-L1 sequence, such as a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3. The target nucleic acid may be a pre-mRNA, an mRNA or any RNA sequence expressed from a mammalian cell that supports the expression or regulation of PD-L1.

[0141] The oligonucleotide of the invention is an antisense oligonucleotide which targets PD-L1.

[0142] In one aspect of the invention the oligonucleotides of the invention are conjugated to a conjugate moiety, in particular an asialoglycoprotein receptor targeting conjugate moiety.

[0143] In some embodiments the antisense oligonucleotide of the invention is capable of modulating the expression of the target by inhibiting or down-regulating it. Preferably, such modulation produces an inhibition of

expression of at least 20% compared to the normal expression level of the target, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% inhibition compared to the normal expression level of the target. Preferably, such modulation produces an inhibition of expression of at least 20% compared to the expression level when the cell or organism is challenged by an infectious agent, or treated with an agent simulating the challenge by an infectious agent (eg poly I:C or LPS), more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% inhibition compared to the expression level when the cell or organism is challenged by an infectious agent, or treated with an agent simulating the challenge by an infectious agent (eg poly I:C or LPS). In some embodiments oligonucleotides of the invention may be capable of inhibiting expression levels of PD-L1 mRNA by at least 60% or 70% in vitro using KARPAS-299 or THP1 cells. In some embodiments compounds of the invention may be capable of inhibiting expression levels of PD-L1 protein by at least 50% in vitro using KARPAS-299 or THP1 cells. Suitably, the examples provide assays which may be used to measure PD-L1 RNA (e.g. example 1). The target modulation is triggered by the hybridization between a contiguous nucleotide sequence of the oligonucleotide and the target nucleic acid. In some embodiments the oligonucleotide of the invention comprises mismatches between the oligonucleotide and the target nucleic acid. Despite mismatches, hybridization to the target nucleic acid may still be sufficient to show a desired modulation of PD-L1 expression. Reduced binding affinity resulting from mismatches may advantageously be compensated by increased number of nucleotides in the oligonucleotide and/or an increased number of modified nucleosides capable of increasing the binding affinity to the target, such as 2' modified nucleosides, including LNA, present within the oligonucleotide sequence.

[0144] In some embodiments the antisense oligonucleotide of the invention is capable of restoring pathogen-specific T cells. In some embodiments, oligonucleotides of the invention are capable of increasing the pathogen-specific T cells by at least 40%, 50%, 60% or 70% when compared to untreated controls or controls treated with standard of care. In one embodiment the antisense oligonucleotide or conjugate of the invention is capable increasing HBV-specific T cells when compared to untreated controls or controls treated with standard of care. Suitably, the examples provide assays which may be used to measure the HBV-specific T cells (e.g. T cell proliferation, cytokine secretion and cytolytic activity). In another embodiment the antisense oligonucleotide or conjugate of the invention is capable increasing HCV-specific T cells when compared to untreated controls or controls treated with standard of care. In another embodiment the antisense oligonucleotide or conjugate of the invention is capable increasing HDV-specific T cells when compared to untreated controls or controls treated with standard of care.

[0145] In some embodiments the antisense oligonucleotide of the invention is capable reducing HBsAg levels in an animal or human. In some embodiments, oligonucleotides of the invention are capable of reducing the HBsAg levels by at least 40%, 50%, 60% or 70%, more preferably by at least 80%, 90% or 95% when compared to the level prior to treatment. Most preferably oligonucleotides of the invention are capable of achieving seroconversion of HBsAg in an animal or human infected with HBV.

[0146] An aspect of the present invention relates to an antisense oligonucleotide which comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid.

[0147] In some embodiments, the oligonucleotide comprises a contiguous sequence which is at least 90% complementary, such as at least 91%, such as at least 92%, such as at least 93%, such as at least 94%, such as at least 95%, such as at least 96%, such as at least 97%, such as at least 98%, or 100% complementary with a region of the target nucleic acid.

[0148] In a preferred embodiment the oligonucleotide of the invention, or contiguous nucleotide sequence thereof is fully complementary (100% complementary) to a region of the target nucleic acid, or in some embodiments may comprise one or two mismatches between the oligonucleotide and the target nucleic acid.

[0149] In some embodiments the oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as fully (or 100%) complementary, to a region target nucleic acid region present in SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present SEQ ID NO: 1 and SEQ ID NO: 2. In some embodiments the oligonucleotide sequence is 100% complementary to a corresponding target nucleic acid region present SEQ ID NO: 1 and SEQ ID NO: 3.

[0150] In some embodiments, the oligonucleotide or oligonucleotide conjugate comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid selected from the group consisting of position 371-3068, 5467-12107 and 15317-19511 on SEQ ID NO: 1. In a further embodiment the sub-sequence of the target nucleic acid is selected from the group consisting of position 371-510, 822-1090, 1992-3068, 5467-5606, 6470-12107, 15317-15720, 15317-18083, 18881-19494 and 1881-19494 on SEQ ID NO: 1. In a preferred embodiment the sub-sequence of the target nucleic acid is selected from the group consisting of position 7300-7333, 8028-8072, 9812-9859, 11787-11873 and 15690-15735 on SEQ ID NO: 1.

[0151] In some embodiments, the oligonucleotide or oligonucleotide conjugate comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementary, such as 100% complementarity, to a corresponding target nucleic acid region present in SEQ ID NO: 1, wherein the target nucleic acid region is selected from the group consisting of region a1 to a449 in table 4.

TABLE 4

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a1	51	82	32
a2	87	116	30
a3	118	133	16

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a4	173	206	34
a5	221	287	67
a6	304	350	47
a7	354	387	34
a8	389	423	35
a9	425	440	16
a10	452	468	17
a11	470	484	15
a12	486	500	15
a13	503	529	27
a14	540	574	35
a15	576	649	74
a16	652	698	47
a17	700	750	51
a18	744	758	15
a19	774	801	28
a20	805	820	16
a21	827	891	65
a22	915	943	29
a23	950	982	33
a24	984	1000	17
a25	1002	1054	53
a26	1060	1118	59
a27	1124	1205	82
a28	1207	1255	49
a29	1334	1349	16
a30	1399	1425	27
a31	1437	1458	22
a32	1460	1504	45
a33	1548	1567	20
a34	1569	1586	18
a35	1608	1662	55
a36	1677	1700	24
a37	1702	1721	20
a38	1723	1745	23
a39	1768	1794	27
a40	1820	1835	16
a41	1842	1874	33
a42	1889	1979	91
a43	1991	2011	21
a44	2013	2038	26
a45	2044	2073	30
a46	2075	2155	81
a47	2205	2228	24
a48	2253	2273	21
a49	2275	2303	29
a50	2302	2333	32
a51	2335	2366	32
a52	2368	2392	25
a53	2394	2431	38
a54	2441	2455	15
a55	2457	2494	38
a56	2531	2579	49
a57	2711	2732	22
a58	2734	2757	24
a59	2772	2786	15
a60	2788	2819	32
a61	2835	2851	17
a62	2851	2879	29
a63	2896	2912	17
a64	2915	2940	26
a65	2944	2973	30
a66	2973	2992	20
a67	2998	3016	19
a68	3018	3033	16
a69	3036	3051	16
a70	3114	3139	26
a71	3152	3173	22
a72	3181	3203	23

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a73	3250	3271	22
a74	3305	3335	31
a75	3346	3363	18
a76	3391	3446	56
a77	3448	3470	23
a78	3479	3497	19
a79	3538	3554	17
a80	3576	3597	22
a81	3603	3639	37
a82	3663	3679	17
a83	3727	3812	86
a84	3843	3869	27
a85	3874	3904	31
a86	3926	3955	30
a87	3974	3993	20
a88	3995	4042	48
a89	4053	4073	21
a90	4075	4123	49
a91	4133	4157	25
a92	4158	4188	31
a93	4218	4250	33
a94	4277	4336	60
a95	4353	4375	23
a96	4383	4398	16
a97	4405	4446	42
a98	4448	4464	17
a99	4466	4493	28
a100	4495	4558	64
a101	4571	4613	43
a102	4624	4683	60
a103	4743	4759	17
a104	4761	4785	25
a105	4811	4858	48
a106	4873	4932	60
a107	4934	4948	15
a108	4955	4974	20
a109	4979	5010	32
a110	5012	5052	41
a111	5055	5115	61
a112	5138	5166	29
a113	5168	5198	31
a114	5200	5222	23
a115	5224	5284	61
a116	5286	5302	17
a117	5317	5332	16
a118	5349	5436	88
a119	5460	5512	53
a120	5514	5534	21
a121	5548	5563	16
a122	5565	5579	15
a123	5581	5597	17
a124	5600	5639	40
a125	5644	5661	18
a126	5663	5735	73
a127	5737	5770	34
a128	5778	5801	24
a129	5852	5958	107
a130	6007	6041	35
a131	6049	6063	15
a132	6065	6084	20
a133	6086	6101	16
a134	6119	6186	68
a135	6189	6234	46
a136	6236	6278	43
a137	6291	6312	22
a138	6314	6373	60
a139	6404	6447	44
a140	6449	6482	34
a141	6533	6555	23

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a142	6562	6622	61
a143	6624	6674	51
a144	6679	6762	84
a145	6764	6780	17
a146	6782	6822	41
a147	6824	6856	33
a148	6858	6898	41
a149	6906	6954	49
a150	6969	6992	24
a151	6994	7020	27
a152	7033	7048	16
a153	7050	7066	17
a154	7078	7094	17
a155	7106	7122	17
a156	7123	7144	22
a157	7146	7166	21
a158	7173	7193	21
a159	7233	7291	59
a160	7300	7333	34
a161	7336	7351	16
a162	7353	7373	21
a163	7375	7412	38
a164	7414	7429	16
a165	7431	7451	21
a166	7453	7472	20
a167	7474	7497	24
a168	7517	7532	16
a169	7547	7601	55
a170	7603	7617	15
a171	7632	7647	16
a172	7649	7666	18
a173	7668	7729	62
a174	7731	7764	34
a175	7767	7817	51
a176	7838	7860	23
a177	7862	7876	15
a178	7880	7944	65
a179	7964	8012	49
a180	8028	8072	45
a181	8086	8100	15
a182	8102	8123	22
a183	8125	8149	25
a184	8151	8199	49
a185	8218	8235	18
a186	8237	8276	40
a187	8299	8344	46
a188	8346	8436	91
a189	8438	8470	33
a190	8472	8499	28
a191	8505	8529	25
a192	8538	8559	22
a193	8562	8579	18
a194	8581	8685	105
a195	8688	8729	42
a196	8730	8751	22
a197	8777	8800	24
a198	8825	8865	41
a199	8862	8894	33
a200	8896	8911	16
a201	8938	8982	45
a202	8996	9045	50
a203	9048	9070	23
a204	9072	9139	68
a205	9150	9168	19
a206	9170	9186	17
a207	9188	9202	15
a208	9204	9236	33
a209	9252	9283	32
a210	9300	9331	32

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a211	9339	9354	16
a212	9370	9398	29
a213	9400	9488	89
a214	9490	9537	48
a215	9611	9695	85
a216	9706	9721	16
a217	9723	9746	24
a218	9748	9765	18
a219	9767	9788	22
a220	9794	9808	15
a221	9812	9859	48
a222	9880	9913	34
a223	9923	9955	33
a224	9966	10007	42
a225	10009	10051	43
a226	10053	10088	36
a227	10098	10119	22
a228	10133	10163	31
a229	10214	10240	27
a230	10257	10272	16
a231	10281	10298	18
a232	10300	10318	19
a233	10339	10363	25
a234	10409	10426	18
a235	10447	10497	51
a236	10499	10529	31
a237	10531	10546	16
a238	10560	10580	21
a239	10582	10596	15
a240	10600	10621	22
a241	10623	10664	42
a242	10666	10685	20
a243	10717	10773	57
a244	10775	10792	18
a245	10794	10858	65
a246	10874	10888	15
a247	10893	10972	80
a248	10974	10994	21
a249	10996	11012	17
a250	11075	11097	23
a251	11099	11124	26
a252	11140	11157	18
a253	11159	11192	34
a254	11195	11226	32
a255	11235	11261	27
a256	11279	11337	59
a257	11344	11381	38
a258	11387	11411	25
a259	11427	11494	68
a260	11496	11510	15
a261	11512	11526	15
a262	11528	11551	24
a263	11570	11592	23
a264	11594	11634	41
a265	11664	11684	21
a266	11699	11719	21
a267	11721	11746	26
a268	11753	11771	19
a269	11787	11873	87
a270	11873	11905	33
a271	11927	11942	16
a272	11946	11973	28
a273	11975	11993	19
a274	12019	12114	96
a275	12116	12135	20
a276	12137	12158	22
a277	12165	12192	28
a278	12194	12216	23
a279	12218	12246	29

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a280	12262	12277	16
a281	12283	12319	37
a282	12334	12368	35
a283	12370	12395	26
a284	12397	12434	38
a285	12436	12509	74
a286	12511	12543	33
a287	12545	12565	21
a288	12567	12675	109
a289	12677	12706	30
a290	12708	12724	17
a291	12753	12768	16
a292	12785	12809	25
a293	12830	12859	30
a294	12864	12885	22
a295	12886	12916	31
a296	12922	12946	25
a297	12948	12970	23
a298	12983	13003	21
a299	13018	13051	34
a300	13070	13090	21
a301	13092	13115	24
a302	13117	13134	18
a303	13136	13169	34
a304	13229	13249	21
a305	13295	13328	34
a306	13330	13372	43
a307	13388	13406	19
a308	13408	13426	19
a309	13437	13453	17
a310	13455	13471	17
a311	13518	13547	30
a312	13565	13597	33
a313	13603	13620	18
a314	13630	13663	34
a315	13665	13679	15
a316	13706	13725	20
a317	13727	13774	48
a318	13784	13821	38
a319	13831	13878	48
a320	13881	13940	60
a321	13959	14013	55
a322	14015	14031	17
a323	14034	14049	16
a324	14064	14114	51
a325	14116	14226	111
a326	14229	14276	48
a327	14292	14306	15
a328	14313	14384	72
a329	14386	14408	23
a330	14462	14481	20
a331	14494	14519	26
a332	14557	14577	21
a333	14608	14628	21
a334	14646	14668	23
a335	14680	14767	88
a336	14765	14779	15
a337	14815	14844	30
a338	14848	14925	78
a339	14934	14976	43
a340	14978	15009	32
a341	15013	15057	45
a342	15064	15091	28
a343	15094	15140	47
a344	15149	15165	17
a345	15162	15182	21
a346	15184	15198	15
a347	15200	15221	22
a348	15232	15247	16

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a349	15250	15271	22
a350	15290	15334	45
a351	15336	15369	34
a352	15394	15416	23
a353	15433	15451	19
a354	15453	15491	39
a355	15496	15511	16
a356	15520	15553	34
a357	15555	15626	72
a358	15634	15652	19
a359	15655	15688	34
a360	15690	15735	46
a361	15734	15764	31
a362	15766	15787	22
a363	15803	15819	17
a364	15846	15899	54
a365	15901	15934	34
a366	15936	15962	27
a367	15964	15985	22
a368	15987	16023	37
a369	16025	16061	37
a370	16102	16122	21
a371	16134	16183	50
a372	16185	16281	97
a373	16283	16298	16
a374	16305	16323	19
a375	16325	16356	32
a376	16362	16404	43
a377	16406	16456	51
a378	16494	16523	30
a379	16536	16562	27
a380	16564	16580	17
a381	16582	16637	56
a382	16631	16649	19
a383	16655	16701	47
a384	16737	16781	45
a385	16783	16804	22
a386	16832	16907	76
a387	16934	16965	32
a388	16972	17035	64
a389	17039	17069	31
a390	17072	17109	38
a391	17135	17150	16
a392	17167	17209	43
a393	17211	17242	32
a394	17244	17299	56
a395	17304	17344	41
a396	17346	17400	55
a397	17447	17466	20
a398	17474	17539	66
a399	17561	17604	44
a400	17610	17663	54
a401	17681	17763	83
a402	17793	17810	18
a403	17812	17852	41
a404	17854	17928	75
a405	17941	18005	65
a406	18007	18035	29
a407	18041	18077	37
a408	18085	18146	62
a409	18163	18177	15
a410	18179	18207	29
a411	18209	18228	20
a412	18230	18266	37
a413	18268	18285	18
a414	18287	18351	65
a415	18365	18395	31
a416	18402	18432	31
a417	18434	18456	23

TABLE 4-continued

Regions of SEQ ID NO 1 which may be targeted using oligonucleotide of the invention			
Reg. a	Position in SEQ ID NO 1		Length
	from	to	
a418	18502	18530	29
a419	18545	18590	46
a420	18603	18621	19
a421	18623	18645	23
a422	18651	18708	58
a423	18710	18729	20
a424	18731	18758	28
a425	18760	18788	29
a426	18799	18859	61
a427	18861	18926	66
a428	18928	18980	53
a429	19001	19018	18
a430	19034	19054	21
a431	19070	19092	23
a432	19111	19154	44
a433	19191	19213	23
a434	19215	19240	26
a435	19255	19356	102
a436	19358	19446	89
a437	19450	19468	19
a438	19470	19512	43
a439	19514	19541	28
a440	19543	19568	26
a441	19570	19586	17
a442	19588	19619	32
a443	19683	19739	57
a444	19741	19777	37
a445	19779	19820	42
a446	19822	19836	15
a447	19838	19911	74
a448	19913	19966	54
a449	19968	20026	59

[0152] In some embodiment the oligonucleotide or contiguous nucleotide sequence is complementary to a region of the target nucleic acid, wherein the target nucleic acid region is selected from the group consisting of a7, a26, a43, a119, a142, a159, a160, a163, a169, a178, a179, a180, a189, a201, a202, a204, a214, a221, a224, a226, a243, a254, a258, 269, a274, a350, a360, a364, a365, a370, a372, a381, a383, a386, a389, a400, a427, a435 and a438.

[0153] In a preferred embodiment the oligonucleotide or contiguous nucleotide sequence is complementary to a region of the target nucleic acid, wherein the target nucleic acid region is selected from the group consisting of a160, a180, a221, a269 and a360.

[0154] In some embodiments, the oligonucleotide of the invention comprises or consists of 8 to 35 nucleotides in length, such as from 9 to 30, such as 10 to 22, such as from 11 to 20, such as from 12 to 18, such as from 13 to 17 or 14 to 16 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 16 to 20 nucleotides in length. It is to be understood that any range given herein includes the range endpoints. Accordingly, if an oligonucleotide is said to include from 10 to 30 nucleotides, both 10 and 30 nucleotides are included.

[0155] In some embodiments, the contiguous nucleotide sequence comprises or consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 contiguous nucleotides in length. In a preferred embodiment, the oligonucleotide comprises or consists of 16, 17, 18, 19 or 20 nucleotides in length.

[0156] In some embodiments, the oligonucleotide or contiguous nucleotide sequence comprises or consists of a sequence selected from the group consisting of sequences listed in table 5.

[0157] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NO: 5 to 743 (see motif sequences listed in table 5).

[0158] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NO: 5 to 743 and 771.

[0159] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to a sequence selected from the group consisting of SEQ ID NO: 6, 8, 9, 13, 41, 42, 58, 77, 92, 111, 128, 151, 164, 166, 169, 171, 222, 233, 245, 246, 250, 251, 252, 256, 272, 273, 287, 292, 303, 314, 318, 320, 324, 336, 342, 343, 344, 345, 346, 349, 359, 360, 374, 408, 409, 415, 417, 424, 429, 430, 458, 464, 466, 474, 490, 493, 512, 519, 519, 529, 533, 534, 547, 566, 567, 578, 582, 601, 619, 620, 636, 637, 638, 640, 645, 650, 651, 652, 653, 658, 659, 660, 665, 678, 679, 680, 682, 683, 684, 687, 694, 706, 716, 728, 733, 734, and 735.

[0160] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to SEQ ID NO: 287.

[0161] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to SEQ ID NO: 342.

[0162] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to SEQ ID NO: 640.

[0163] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to SEQ ID NO: 466.

[0164] In some embodiments, the antisense oligonucleotide or contiguous nucleotide sequence comprises or consists of 10 to 30 nucleotides in length with at least 90% identity, preferably 100% identity, to SEQ ID NO: 566.

[0165] In embodiments where the oligonucleotide is longer than the contiguous nucleotide sequence (which is complementary to the target nucleic acid), the motif sequences in table 5 form the contiguous nucleotide sequence part of the antisense oligonucleotides of the invention. In some embodiments the sequence of the oligonucleotide is equivalent to the contiguous nucleotide sequence (e.g. if no biocleavable linkers are added).

[0166] It is understood that the contiguous nucleobase sequences (motif sequence) can be modified to for example increase nuclease resistance and/or binding affinity to the target nucleic acid. Modifications are described in the definitions and in the "Oligonucleotide design" section. Table 5 lists preferred designs of each motif sequence.

Oligonucleotide Design

[0167] Oligonucleotide design refers to the pattern of nucleoside sugar modifications in the oligonucleotide sequence. The oligonucleotides of the invention comprise sugar-modified nucleosides and may also comprise DNA or RNA nucleosides. In some embodiments, the oligonucleotide comprises sugar-modified nucleosides and DNA nucleosides. Incorporation of modified nucleosides into the oligonucleotide of the invention may enhance the affinity of the oligonucleotide for the target nucleic acid. In that case, the modified nucleosides can be referred to as affinity enhancing modified nucleotides, the modified nucleosides may also be termed units.

[0168] In an embodiment, the oligonucleotide comprises at least 1 modified nucleoside, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 modified nucleosides. In an embodiment the oligonucleotide comprises from 1 to 10 modified nucleosides, such as from 2 to 8 modified nucleosides, such as from 3 to 7 modified nucleosides, such as from 4 to 6 modified nucleosides, such as 3, 4, 5, 6 or 7 modified nucleosides.

[0169] In an embodiment, the oligonucleotide comprises one or more sugar modified nucleosides, such as 2' sugar modified nucleosides. Preferably the oligonucleotide of the invention comprise the one or more 2' sugar modified nucleoside independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides. Even more preferably the one or more modified nucleoside is a locked nucleic acid (LNA).

[0170] In a further embodiment the oligonucleotide comprises at least one modified internucleoside linkage. In a preferred embodiment all the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate or boranophosphate internucleoside linkages. In some embodiments all the internucleotide linkages in the contiguous sequence of the oligonucleotide are phosphorothioate linkages.

[0171] In some embodiments, the oligonucleotide of the invention comprises at least one LNA nucleoside, such as 1, 2, 3, 4, 5, 6, 7, or 8 LNA nucleosides, such as from 2 to 6 LNA nucleosides, such as from 3 to 7 LNA nucleosides, 4 to 6 LNA nucleosides or 3, 4, 5, 6 or 7 LNA nucleosides. In some embodiments, at least 75% of the modified nucleosides in the oligonucleotide are LNA nucleosides, such as 80%, such as 85%, such as 90% of the modified nucleosides are LNA nucleosides. In a still further embodiment all the modified nucleosides in the oligonucleotide are LNA nucleosides. In a further embodiment, the oligonucleotide may comprise both beta-D-oxy-LNA, and one or more of the following LNA nucleosides: thio-LNA, amino-LNA, oxy-LNA, and/or ENA in either the beta-D or alpha-L configurations or combinations thereof. In a further embodiment, all LNA cytosine units are 5-methyl-cytosine. In a preferred embodiment the oligonucleotide or contiguous nucleotide sequence has at least 1 LNA nucleoside at the 5' end and at least 2 LNA nucleosides at the 3' end of the nucleotide sequence.

[0172] In some embodiments, the oligonucleotide of the invention comprises at least one modified nucleoside which is a 2'-MOE-RNA nucleoside, such as 2, 3, 4, 5, 6, 7, 8, 9 or

10 2'-MOE-RNA nucleosides. In some embodiments, at least one of said modified nucleoside is 2'-fluoro DNA, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 2'-fluoro-DNA nucleosides.

[0173] In some embodiments, the oligonucleotide of the invention comprises at least one LNA nucleoside and at least one 2' substituted modified nucleoside.

[0174] In some embodiments of the invention, the oligonucleotide comprise both 2' sugar modified nucleosides and DNA units. Preferably the oligonucleotide comprises both LNA and DNA nucleosides (units). Preferably, the combined total of LNA and DNA units is 8-30, such as 10-25, preferably 12-22, such as 12-18, even more preferably 11-16. In some embodiments of the invention, the nucleotide sequence of the oligonucleotide, such as the contiguous nucleotide sequence consists of at least one or two LNA nucleosides and the remaining nucleosides are DNA units. In some embodiments the oligonucleotide comprises only LNA nucleosides and naturally occurring nucleosides (such as RNA or DNA, most preferably DNA nucleosides), optionally with modified internucleoside linkages such as phosphorothioate.

[0175] In an embodiment of the invention the oligonucleotide of the invention is capable of recruiting RNase H.

[0176] The structural design of the oligonucleotide of the invention may be selected from gapmers, gapbreakers, headmers and tailmers.

Gapmer Design

[0177] In a preferred embodiment the oligonucleotide of the invention has a gapmer design or structure also referred herein merely as "Gapmer". In a gapmer structure the oligonucleotide comprises at least three distinct structural regions a 5'-flank, a gap and a 3'-flank, F-G-F' in '5->3' orientation. In this design, flanking regions F and F' (also termed wing regions) comprise a contiguous stretch of modified nucleosides, which are complementary to the PD-L1 target nucleic acid, while the gap region, G, comprises a contiguous stretch of nucleotides which are capable of recruiting a nuclease, preferably an endonuclease such as RNase, for example RNase H, when the oligonucleotide is in duplex with the target nucleic acid. Nucleosides which are capable of recruiting a nuclease, in particular RNase H, can be selected from the group consisting of DNA, alpha-L-oxy-LNA, 2'-Flouro-ANA and UNA. Regions F and F', flanking the 5' and 3' ends of region G, preferably comprise non-nuclease recruiting nucleosides (nucleosides with a 3' endo structure), more preferably one or more affinity enhancing modified nucleosides. In some embodiments, the 3' flank comprises at least one LNA nucleoside, preferably at least 2 LNA nucleosides. In some embodiments, the 5' flank comprises at least one LNA nucleoside. In some embodiments both the 5' and 3' flanking regions comprise a LNA nucleoside. In some embodiments all the nucleosides in the flanking regions are LNA nucleosides. In other embodiments, the flanking regions may comprise both LNA nucleosides and other nucleosides (mixed flanks), such as DNA nucleosides and/or non-LNA modified nucleosides, such as 2' substituted nucleosides. In this case the gap is defined as a contiguous sequence of at least 5 RNase H recruiting nucleosides (nucleosides with a 2' endo structure, preferably DNA) flanked at the 5' and 3' end by an affinity enhancing modified nucleoside, preferably LNA, such as beta-D-oxy-LNA. Consequently, the nucleosides of the 5' flanking region and the

3' flanking region which are adjacent to the gap region are modified nucleosides, preferably non-nuclease recruiting nucleosides.


Region F

[0178] Region F (5' flank or 5' wing) attached to the 5' end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an embodiment region F comprises or consists of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 5 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. The F region is defined by having at least one modified nucleoside at the 5' end and at the 3' end of the region.

[0179] In some embodiments, the modified nucleosides in region F have a 3' endo structure.

[0180] In an embodiment, one or more of the modified nucleosides in region F are 2' modified nucleosides. In one embodiment all the nucleosides in Region F are 2' modified nucleosides.

[0181] In another embodiment region F comprises DNA and/or RNA in addition to the 2' modified nucleosides. Flanks comprising DNA and/or RNA are characterized by having a 2' modified nucleoside in the 5' end and the 3' end (adjacent to the G region) of the F region. In one embodiment the region F comprise DNA nucleosides, such as from 1 to 3 contiguous DNA nucleosides, such as 1 to 3 or 1 to 2 contiguous DNA nucleosides. The DNA nucleosides in the flanks should preferably not be able to recruit RNase H. In some embodiments the 2' modified nucleosides and DNA and/or RNA nucleosides in the F region alternate with 1 to 3 2' modified nucleosides and 1 to 3 DNA and/or RNA nucleosides. Such flanks can also be termed alternating flanks. The length of the 5' flank (region F) in oligonucleotides with alternating flanks may be 4 to 10 nucleosides, such as 4 to 8, such as 4 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments only the 5' flank of the oligonucleotide is alternating. Specific examples of region F with alternating nucleosides are



[0182] Where 2' indicates a modified nucleoside and N' is a RNA or DNA. In some embodiments all the modified nucleosides in the alternating flanks are LNA and the N' is DNA. In a further embodiment one or more of the 2' modified nucleosides in region F are selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units.

[0183] In some embodiments the F region comprises both LNA and a 2' substituted modified nucleoside. These are often termed mixed wing or mixed flank oligonucleotides.

[0184] In one embodiment of the invention all the modified nucleosides in region F are LNA nucleosides. In a further embodiment all the nucleosides in Region F are LNA nucleosides. In a further embodiment the LNA nucleosides in region F are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET, and/or ENA, in either the beta-D or alpha-L configurations or

combinations thereof. In a preferred embodiment region F comprise at least 1 beta-D-oxy LNA unit, at the 5' end of the contiguous sequence.

Region G

[0185] Region G (gap region) preferably comprise, contain or consist of at least 4, such as at least 5, such as at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or at least 16 consecutive nucleosides capable of recruiting the aforementioned nuclease, in particular RNaseH. In a further embodiment region G comprise, contain or consist of from 5 to 12, or from 6 to 10 or from 7 to 9, such as 8 consecutive nucleotide units capable of recruiting aforementioned nuclease.

[0186] The nucleoside units in region G, which are capable of recruiting nuclease are in an embodiment selected from the group consisting of DNA, alpha-L-LNA, C4' alkylated DNA (as described in PCT/EP2009/050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both incorporated herein by reference), arabinose derived nucleosides like ANA and 2'F-ANA (Mangos et al. 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039 incorporated herein by reference). UNA is unlocked nucleic acid, typically where the bond between C2 and C3 of the ribose has been removed, forming an unlocked "sugar" residue.

[0187] In a still further embodiment at least one nucleoside unit in region G is a DNA nucleoside unit, such as from 1 to 18 DNA units, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 DNA units, preferably from 2 to 17 DNA units, such as from 3 to 16 DNA units, such as from 4 to DNA units, such as from 5 to 14 DNA units, such as from 6 to 13 DNA units, such as from 7 to 12 DNA units, such as from 8 to 11 DNA units, more preferably from units 8 to 17 DNA units, or from 9 to 16 DNA units, 10 to 15 DNA units or 11 to 13 DNA units, such as 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 DNA units. In some embodiments, region G consists of 100% DNA units.

[0188] In further embodiments the region G may consist of a mixture of DNA and other nucleosides capable of mediating RNase H cleavage. Region G may consist of at least 50% DNA, more preferably 60%, 70% or 80% DNA, and even more preferred 90% or 95% DNA.

[0189] In a still further embodiment at least one nucleoside unit in region G is an alpha-L-LNA nucleoside unit, such as at least one alpha-L-LNA, such as 2, 3, 4, 5, 6, 7, 8 or 9 alpha-L-LNA. In a further embodiment, region G comprises the least one alpha-L-LNA is alpha-L-oxy-LNA. In a further embodiment region G comprises a combination of DNA and alpha-L-LNA nucleoside units.

[0190] In some embodiments, nucleosides in region G have a 2' endo structure.

[0191] In some embodiments region G may comprise a gapbreaker oligonucleotide, leading to a gapbreaker oligonucleotide, which is capable of recruiting RNase H.

Region F'

[0192] Region F' (3' flank or 3' wing) attached to the 3' end of region G comprises, contains or consists of at least one modified nucleoside such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 modified nucleosides. In an



embodiment region F' comprise or consist of from 1 to 7 modified nucleosides, such as from 2 to 6 modified nucleosides, such as from 2 to 4 modified nucleosides, such as from 1 to 3 modified nucleosides, such as 1, 2, 3 or 4 modified nucleosides. The F' region is defined by having at least one modified nucleoside at the 5' end and at the 3' end of the region.

[0193] In some embodiments, the modified nucleosides in region F' have a 3' endo structure.

[0194] In an embodiment, one or more of the modified nucleosides in region F' are 2' modified nucleosides. In one embodiment all the nucleosides in Region F' are 2' modified nucleosides.

[0195] In an embodiment, one or more of the modified nucleosides in region F' are 2' modified nucleosides.

[0196] In one embodiment all the nucleosides in Region F' are 2' modified nucleosides. In another embodiment region F' comprises DNA or RNA in addition to the 2' modified nucleosides. Flanks comprising DNA or RNA are characterized by having a 2' modified nucleoside in the 5' end (adjacent to the G region) and the 3' end of the F' region. In one embodiment the region F' comprises DNA nucleosides, such as from 1 to 4 contiguous DNA nucleosides, such as 1 to 3 or 1 to 2 contiguous DNA nucleosides. The DNA nucleosides in the flanks should preferably not be able to recruit RNase H. In some embodiments the 2' modified nucleosides and DNA and/or RNA nucleosides in the F' region alternate with 1 to 3 2' modified nucleosides and 1 to 3 DNA and/or RNA nucleosides, such flanks can also be termed alternating flanks. The length of the 3' flank (region F') in oligonucleotides with alternating flanks may be 4 to 10 nucleosides, such as 4 to 8, such as 4 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments only the 3' flank of the oligonucleotide is alternating. Specific examples of region F' with alternating nucleosides are



[0197] Where 2' indicates a modified nucleoside and N' is a RNA or DNA. In some embodiments all the modified nucleosides in the alternating flanks are LNA and the N' is DNA. In a further embodiment modified nucleosides in region F' are selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabino nucleic acid (ANA) units and 2'-fluoro-ANA units.

[0198] In some embodiments the F' region comprises both LNA and a 2' substituted modified nucleoside. These are often termed mixed wing or mixed flank oligonucleotides.





[0199] In one embodiment of the invention all the modified nucleosides in region F' are LNA nucleosides. In a further embodiment all the nucleosides in Region F' are LNA nucleosides. In a further embodiment the LNA nucleosides in region F' are independently selected from the group consisting of oxy-LNA, thio-LNA, amino-LNA, cET and/or ENA, in either the beta-D or alpha-L configurations or combinations thereof. In a preferred embodiment region F' has at least 2 beta-D-oxy LNA unit, at the 3' end of the contiguous sequence.

Region D' and D''

[0200] Region D' and D'' can be attached to the 5' end of region F or the 3' end of region F', respectively. Region D' or D'' are optional.

[0201] Region D' or D'' may independently comprise 0 to 5, such as 1 to 5, such as 2 to 4, such as 0, 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. In this respect the oligonucleotide of the invention, may in some embodiments comprise a contiguous nucleotide sequence capable of modulating the target which is flanked at the 5' and/or 3' end by additional nucleotides. Such additional nucleotides may serve as a nuclease susceptible bio-cleavable linker (see definition of linkers). In some embodiments the additional 5' and/or 3' end nucleosides are linked with phosphodiester linkages, and may be DNA or RNA. In another embodiment, the additional 5' and/or 3' end nucleosides are modified nucleosides which may for example be included to enhance nuclease stability or for ease of synthesis. In one embodiment, the oligonucleotide of the invention, comprises a region D' and/or D'' at the 5' or 3' end of the contiguous nucleotide sequence. In a further embodiment the D' and/or D'' region is composed of 1 to 5 phosphodiester linked DNA or RNA nucleosides which are not complementary to the target nucleic acid.







[0202] The gapmer oligonucleotide of the present invention can be represented by the following formulae:



[0203] The preferred number and types of nucleosides in regions F, G and F', D' and D'' have been described above. The oligonucleotide conjugates of the present invention have a region C covalently attached to either the 5' or 3' end of the oligonucleotide, in particular the gapmer oligonucleotides presented above.

[0204] In one embodiment the oligonucleotide conjugate of the invention comprises a oligonucleotide with the formula 5'-D'-F-G-F'-3' or 5'-F-G-F'-D''-3', where region F and F' independently comprise 1-7 modified nucleosides, G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH and region D' or D'' comprise 1-5 phosphodiester linked nucleosides. Preferably region D' or D'' is present in the end of the oligonucleotide where conjugation to a conjugate moiety is contemplated.

[0205] Examples of oligonucleotides with alternating flanks can be represented by the following formulae:



[0206] Where a flank is indicated by F or F' it only contains 2' modified nucleosides, such as LNA nucleosides. The preferred number and types of nucleosides in the alternating regions, and region F, G and F', D' and D'' have been described above.

[0207] In some embodiments the oligonucleotide is a gapmer consisting of 16, 17, 18, 19, 20, 21, 22 nucleotides in length, wherein each of regions F and F' independently consists of 1, 2, 3 or 4 modified nucleoside units complementary to the PD-L1 target nucleic acid and region G consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 nucleoside units, capable of recruiting nuclease when in duplex with the PD-L1 target nucleic acid and region D' consists of 2 phosphodiester linked DNAs.

[0208] In a further embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' independently consists of 3, 4, 5 or 6 modified nucleoside units, such as nucleoside units containing a 2'-O-methoxyethyl-ribose sugar (2'-MOE) or nucleoside units containing a 2'-fluoro-deoxyribose sugar and/or LNA units, and region G consists of 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 nucleoside units, such as DNA units or other nuclease recruiting nucleosides such as alpha-L-LNA or a mixture of DNA and nuclease recruiting nucleosides.

[0209] In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' region consists of two LNA units each, and region G consists of 12, 13, 14 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 2-12-2, 2-13-2 and 2-14-2.

[0210] In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' independently consists of three LNA units, and region G consists of 8, 9, 10, 11, 12, 13 or 14 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 3-8-3, 3-9-3, 3-10-3, 3-11-3, 3-12-3, 3-13-3 and 3-14-3.

[0211] In a further specific embodiment, the oligonucleotide is a gapmer wherein each of regions F and F' consists of four LNA units each, and region G consists of 8 or 9, 10, 11 or 12 nucleoside units, preferably DNA units. Specific gapmer designs of this nature include 4-8-4, 4-9-4, 4-10-4, 4-11-4 and 4-12-4.

[0212] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 6 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-6-1, 1-6-2, 2-6-1, 1-6-3, 3-6-1, 1-6-4, 4-6-1, 2-6-2, 2-6-3, 3-6-2, 2-6-4, 4-6-2, 3-6-3, 3-6-4 and 4-6-3 gapmers.

[0213] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 7 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-7-1, 2-7-1, 1-7-2, 1-7-3, 3-7-1, 1-7-4, 4-7-1, 2-7-2, 2-7-3, 3-7-2, 2-7-4, 4-7-2, 3-7-3, 3-7-4, 4-7-3 and 4-7-4 gapmers.

[0214] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 8 nucleosides and independently 1 to 4 modified nucleosides in the wings including 1-8-1, 1-8-2, 1-8-3, 3-8-1, 1-8-4, 4-8-1, 2-8-1, 2-8-2, 2-8-3, 3-8-2, 2-8-4, 4-8-2, 3-8-3, 3-8-4, 4-8-3 and 4-8-4 gapmers.

[0215] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 9 nucleosides and independently 1 to 4 modified nucleosides in the wings including, 1-9-1, 2-9-1, 1-9-2, 1-9-3, 3-9-1, 1-9-4, 4-9-1, 2-9-2, 2-9-3, 3-9-2, 2-9-4, 4-9-2, 3-9-3, 3-9-4, 4-9-3 and 4-9-4 gapmers.

[0216] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 10 nucleosides including, 1-10-1, 2-10-1, 1-10-2, 1-10-

3, 3-10-1, 1-10-4, 4-10-1, 2-10-2, 2-10-3, 3-10-2, 2-10-4, 4-10-2, 3-10-3, 3-10-4, 4-10-3 and 4-10-4 gapmers.

[0217] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 11 nucleosides including, 1-11-1, 2-11-1, 1-11-2, 1-11-3, 3-11-1, 1-11-4, 4-11-1, 2-11-2, 2-11-3, 3-11-2, 2-11-4, 4-11-2, 3-11-3, 3-11-4, 4-11-3 and 4-11-4 gapmers.

[0218] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 12 nucleosides including, 1-12-1, 2-12-1, 1-12-2, 1-12-3, 3-12-1, 1-12-4, 4-12-1, 2-12-2, 2-12-3, 3-12-2, 2-12-4, 4-12-2, 3-12-3, 3-12-4, 4-12-3 and 4-12-4 gapmers.

[0219] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 13 nucleosides including, 1-13-1, 2-13-1, 1-13-2, 1-13-3, 3-13-1, 1-13-4, 4-13-1, 2-13-2, 2-13-3, 3-13-2, 2-13-4, 4-13-2, 3-13-3, 3-13-4, 4-13-3 and 4-13-4 gapmers.

[0220] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 14 nucleosides including, 1-14-1, 2-14-1, 1-14-2, 1-14-3, 3-14-1, 1-14-4, 4-14-1, 2-14-2, 2-14-3, 3-14-2, 2-14-4, 4-14-2, 3-14-3, 3-14-4, 4-14-3 and 4-14-4 gapmers.

[0221] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 15 nucleosides including, 1-15-1, 2-15-1, 1-15-2, 1-15-3, 3-15-1, 1-15-4, 4-15-1, 2-15-2, 2-15-3, 3-15-2, 2-15-4, 4-15-2 and 3-15-3 gapmers.

[0222] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 16 nucleosides including, 1-16-1, 2-16-1, 1-16-2, 1-16-3, 3-16-1, 1-16-4, 4-16-1, 2-16-2, 2-16-3, 3-16-2, 2-16-4, 4-16-2 and 3-16-3 gapmers.

[0223] Specific gapmer designs of this nature include F-G-F' designs selected from a group consisting of a gap with 17 nucleosides including, 1-17-1, 2-17-1, 1-17-2, 1-17-3, 3-17-1, 1-17-4, 4-17-1, 2-17-2, 2-17-3 and 3-17-2 gapmers.

[0224] In all instances the F-G-F' design may further include region D' and/or D'', which may have 1, 2 or 3 nucleoside units, such as DNA units, such as 2 phosphodiester linked DNA units. Preferably, the nucleosides in region F and F' are modified nucleosides, while nucleotides in region G are preferably unmodified nucleosides.

[0225] In each design, the preferred modified nucleoside is LNA.

[0226] In another embodiment all the internucleoside linkages in the gap in a gapmer are phosphorothioate and/or boranophosphate linkages. In another embodiment all the internucleoside linkages in the flanks (F and F' region) in a gapmer are phosphorothioate and/or boranophosphate linkages. In another preferred embodiment all the internucleoside linkages in the D' and D'' region in a gapmer are phosphodiester linkages.

[0227] For specific gapmers as disclosed herein, when the cytosine (C) residues are annotated as 5-methyl-cytosine, in various embodiments, one or more of the Cs present in the oligonucleotide may be unmodified C residues.

[0228] In a particular embodiment, the gapmer is a so-called shortmer as described in WO2008/113832 incorporated herein by reference.

[0229] Further gapmer designs are disclosed in WO2004/046160, WO2007/146511 and incorporated by reference.

[0230] For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO: 5₁ to 743₁ and 771₁.

[0231] For certain embodiments of the invention, the oligonucleotide is selected from the group of oligonucleotide compounds with CMP-ID-NO 6₁, 8₁, 9₁, 13₁, 41₁, 42₁, 58₁, 77₁, 92₁, 111₁, 128₁, 151₁, 164₁, 166₁, 169₁, 171₁, 222₁, 233₁, 245₁, 246₁, 250₁, 251₁, 252₁, 256₁, 272₁, 273₁, 287₁, 292₁, 303₁, 314₁, 318₁, 320₁, 324₁, 336₁, 342₁, 343₁, 344₁, 345₁, 346₁, 349₁, 359₁, 360₁, 374₁, 408₁, 409₁, 415₁, 417₁, 424₁, 429₁, 430₁, 458₁, 464₁, 466₁, 474₁, 490₁, 493₁, 512₁, 519₁, 519₁, 529₁, 533₁, 534₁, 547₁, 566₁, 567₁, 578₁, 582₁, 601₁, 619₁, 620₁, 636₁, 637₁, 638₁, 640₁, 645₁, 650₁, 651₁, 652₁, 653₁, 658₁, 659₁, 660₁, 665₁, 678₁, 679₁, 680₁, 682₁, 683₁, 684₁, 687₁, 694₁, 706₁, 716₁, 728₁, 733₁, 734₁, and 735₁.

[0232] In one preferred embodiment of the invention, the oligonucleotide is CMP-ID-NO: 287₁.

[0233] In another preferred embodiment of the invention, the oligonucleotide is CMP-ID-NO: 342₁.

[0234] In another preferred embodiment of the invention, the oligonucleotide is CMP-ID-NO: 640₁.

[0235] In another preferred embodiment of the invention, the oligonucleotide is CMP-ID-NO: 466₁.

[0236] In another preferred embodiment of the invention, the oligonucleotide is CMP-ID-NO: 566₁.

[0237] In a further embodiment of the invention the contiguous nucleotide sequence of the oligonucleotide motifs and oligonucleotide compounds of the invention comprise two to four additional phosphodiester linked nucleosides at the 5' end of the contiguous nucleotide sequence (e.g. region D'). In one embodiment the nucleosides serve as a biocleavable linker (see section on biocleavable linkers). In a preferred embodiment a ca (cytidine-adenosine) dinucleotide is linked to the 5' end of contiguous nucleotide sequence (i.e. any one of the motif sequences or oligonucleotide compounds listed in table 5) via a phosphodiester linkage. In a preferred embodiment the ca di nucleotide is not complementary to the target sequence at the position where the remainder of the contiguous nucleotide is complementary.

[0238] In some embodiments of the invention the oligonucleotide or contiguous nucleotide sequence is selected from the group consisting of the nucleotide motif sequences with SEQ ID NO: 766, 767, 768, 769 and 770.

[0239] In some embodiments of the invention the oligonucleotide is selected from the group consisting of the oligonucleotide compounds with CMP-ID-NO 766₁, 767₁, 768₁, 769₁ and 770₁.

Carbohydrate Conjugate Moieties

[0240] Carbohydrate conjugate moieties include but are not limited to galactose, lactose, n-acetylgalactosamine, mannose and mannose-6-phosphate. Carbohydrate conjugates may be used to enhance delivery or activity in a range of tissues, such as liver and/or muscle. See, for example, EP1495769, WO99/65925, Yang et al., *Bioconjug Chem* (2009) 20(2): 213-21. Zatspein & Oretskaya *Chem Biodivers.* (2004) 1(10): 1401-17.

[0241] In some embodiments the carbohydrate conjugate moiety is multivalent, such as, for example 2, 3 or 4 identical or non-identical carbohydrate moieties may be covalently

joined to the oligonucleotide, optionally via a linker or linkers. In some embodiments the invention provides a conjugate comprising the oligonucleotide of the invention and a carbohydrate conjugate moiety.

[0242] In some embodiments, the conjugate moiety is or may comprise mannose or mannose-6-phosphate. This is particularly useful for targeting muscle cells, see for example US 2012/122801.

[0243] Conjugate moieties capable of binding to the asialoglycoprotein receptor (ASGPr) are particularly useful for targeting hepatocytes in liver. In some embodiments the invention provides a oligonucleotide conjugate comprising the oligonucleotide of the invention and an asialoglycoprotein receptor targeting conjugate moiety. The asialoglycoprotein receptor targeting conjugate moiety comprises one or more carbohydrate moieties capable of binding to the asialoglycoprotein receptor (ASGPr binding carbohydrate moieties) with affinity equal to or greater than that of galactose. The affinities of numerous galactose derivatives for the asialoglycoprotein receptor have been studied (see for example: Jobst, S. T. and Drickamer, K. *J.B.C.* 1996, 271, 6686) or are readily determined using methods typical in the art.

[0244] One aspect of the present invention is an antisense oligonucleotide conjugate comprising a) an oligonucleotide (Region A) comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid; and b) at least one asialoglycoprotein receptor targeting conjugate moiety (Region C) covalently attached to the oligonucleotide in a). The oligonucleotide or a contiguous nucleotide sequence can be as described in any of the sections "oligonucleotides of the invention", "oligonucleotide design and "gapmer design".

[0245] In some embodiments asialoglycoprotein receptor targeting conjugate moiety comprises at least one ASPGr binding carbohydrate moiety selected from the group consisting of galactose, galactosamine, N-formyl-galactosamine, N-acetylgalactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine and N-isobutanoylgalactosamine. In some embodiments, the asialoglycoprotein receptor targeting conjugate moiety is mono-valent, di-valent, tri-valent or tetra-valent (i.e. containing 1, 2, 3 or 4 terminal carbohydrate moieties capable of binding to the asialoglycoprotein receptor). Preferably, the asialoglycoprotein receptor targeting conjugate moiety is di-valent, even more preferred it is trivalent. In a preferred embodiment the asialoglycoprotein receptor targeting conjugate moiety comprises 1 to 3 N-acetylgalactosamine (GalNAc) moieties (also termed a GalNAc conjugate). In some embodiments the oligonucleotide conjugate comprises a asialoglycoprotein receptor targeting conjugate moiety that is a tri-valent N-acetylgalactosamine (GalNAc) moiety. GalNAc conjugates have been used with phosphodiester, methylphosphonate and PNA antisense oligonucleotides (e.g. U.S. Pat. No. 5,994,517 and Hangeland et al., *Bioconjug Chem.* 1995 November-December; 6(6):695-701, Biessen et al 1999 *Biochem J.* 340, 783-792 and Maier et al 2003 *Bioconjug Chem* 14, 18-29) and siRNAs (e.g. WO 2009/126933, WO 2012/089352 & WO 2012/083046) and with LNA and 2'-MOE modified nucleosides WO 2014/076196 WO 2014/207232 and WO 2014/179620 (hereby incorporated by reference).

[0246] To generate the asialoglycoprotein receptor targeting conjugate moiety the ASPGr binding carbohydrate moiety

eties (preferably GalNAc) are attached to a brancher molecule through the C-I carbons of the saccharides. The ASPGr binding carbohydrate moieties are preferably linked to the brancher molecule via spacers. A preferred spacer is a flexible hydrophilic spacer (U.S. Pat. No. 5,885,968; Biesse et al. *J. Med. Chem.* 1995 Vol. 39 p. 1538-1546). A preferred flexible hydrophilic spacer is a PEG spacer. A preferred PEG spacer is a PEG3 spacer (three ethylene units). The brancher molecule can be any small molecule which permits attachment of two or three terminal ASPGr binding carbohydrate moieties and further permits attachment of the branch point to the oligonucleotide. An exemplary brancher molecule is a di-lysine. A di-lysine molecule contains three amine groups through which three ASPGr binding carbohydrate moieties may be attached and a carboxyl reactive group through which the di-lysine may be attached to the oligonucleotide. Alternative brancher molecules may be a doubler or trebler such as those supplied by Glen Research. In some embodiments the brancher may be selected from the group consisting of 1,3-bis-[5-(4,4'-dimethoxytrityloxy)pentylamido]propyl-2-[(2-cyanoethyl)-(N,N-diisopropyl)] phosphoramidite (Glen Research Catalogue Number: 10-1920-xx), tris-2,2,2-[3-(4,4'-dimethoxytrityloxy)propyloxymethyl]ethyl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (Glen Research Catalogue Number: 10-1922-xx), tris-2,2,2-[3-(4,4'-dimethoxytrityloxy)propyloxymethyl]methyleneoxypropyl-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite and 1-[5-(4,4'-dimethoxy-trityloxy)pentylamido]-3-[5-fluorenomethoxy-carbonyl-oxy-pentylamido]-propyl-2-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (Glen Research Catalogue Number: 10-1925-xx). WO 2014/179620 and PCT application No. PCT/EP2015/073331 describes the generation of various GalNAc conjugate moieties (hereby incorporated by reference). One or more linkers may be inserted between the brancher molecule and the oligonucleotide. In a preferred embodiment the linker is a biocleavable linker. The linker may be selected from the linkers described in the section "Linkers" and its subsections.

[0247] The asialoglycoprotein receptor targeting conjugate moiety, in particular the GalNAc conjugate moiety, may be attached to the 3'- or 5'-end of the oligonucleotide using methods known in the art. In preferred embodiments the asialoglycoprotein receptor targeting conjugate moiety is linked to the 5'-end of the oligonucleotide.

[0248] Pharmacokinetic modulators in relation to siRNAs delivery has been described in WO 2012/083046 (hereby incorporated by reference). In some embodiments the carbohydrate conjugate moiety comprises a pharmacokinetic modulator selected from the group consisting of a hydrophobic group having 16 or more carbon atoms, hydrophobic group having 16-20 carbon atoms, palmitoyl, hexadec-8-enoyl, oleyl, (9E,12E)-octadeca-9,12dienoyl, dioctanoyl, and C16-C20 acyl, and cholesterol. In a preferred embodiment the pharmacokinetic modulator containing carbohydrate conjugate moiety is a GalNAc conjugate.

[0249] Preferred carbohydrate conjugate moieties comprises one to three terminal ASPGr binding carbohydrate moieties, preferably N-acetylgalactosamine moiety(s). In some embodiments the carbohydrate conjugate moiety comprises three ASPGr binding carbohydrate moieties, preferably N-acetylgalactosamine moieties, linked via a spacer to a brancher molecule. The spacer molecule can be between 8 and 30 atoms long. A preferred carbohydrate conjugate

moiety comprises three terminal GalNAc moieties linked via a PEG spacer to a di-lysine brancher molecule. Preferably the PEG spacer is a 3PEG spacer. Suitable asialoglycoprotein receptor targeting conjugate moieties are shown in FIG. 1. A preferred asialoglycoprotein receptor targeting conjugate moiety is shown in FIG. 3.

[0250] Other GalNAc conjugate moieties can include, for example, small peptides with GalNAc moieties attached such as Tyr-Glu-Glu-(aminohexyl GalNAc)₃ (YEE(ahGalNAc)₃; a glycotriptide that binds to asialoglycoprotein receptor on hepatocytes, see, e.g., Duff, et al., *Methods Enzymol.* 2000, 313, 297); lysine-based galactose clusters (e.g., L3G4; Biessen, et al., *Cardiovasc. Med.*, 1999, 214); and cholane-based galactose clusters (e.g., carbohydrate recognition motif for asialoglycoprotein receptor).

[0251] In some embodiments of the invention the antisense oligonucleotide conjugate is selected from the group consisting of the following CPM ID NO: 766_2, 767_2, 768_2, 769_2 and 770_2.

[0252] In a preferred embodiment the antisense oligonucleotide conjugate corresponds to the compound represented in FIG. 4.

[0253] In another preferred embodiment the antisense oligonucleotide conjugate corresponds to the compound represented in FIG. 5.

[0254] In another preferred embodiment the antisense oligonucleotide conjugate corresponds to the compound represented in FIG. 6.

[0255] In another preferred embodiment the antisense oligonucleotide conjugate corresponds to the compound represented in FIG. 7.

[0256] In another preferred embodiment the antisense oligonucleotide conjugate corresponds to the compound represented in FIG. 8.

Linkers

Biocleavable Linkers (Region B)

[0257] The use of a conjugate is often associated with enhanced pharmacokinetic or pharmeodynamic dynamic properties. However, the presence of a conjugate moiety may interfere with the activity of the oligonucleotide against its intended target, for example via steric hindrance preventing hybridization or nuclease recruitment (e.g. RNaseH). The use of a physiologically labile bond (biocleavable linker) between the oligonucleotide (region A or first region) and the conjugate moiety (region C or third region), allows for the improved properties due to the presence of the conjugate moiety, whilst ensuring that once at the target tissue, the conjugate group does not prevent effective activity of the oligonucleotide.

[0258] Cleavage of the physiologically labile bond occurs spontaneously when a molecule containing the labile bond reaches an appropriate intra- and/or extra-cellular environment. For example, a pH labile bond may be cleaved when the molecule enters an acidified endosome. Thus, a pH labile bond may be considered to be an endosomal cleavable bond. Enzyme cleavable bonds may be cleaved when exposed to enzymes such as those present in an endosome or lysosome or in the cytoplasm. A disulfide bond may be cleaved when the molecule enters the more reducing environment of the cell cytoplasm. Thus, a disulfide may be considered to be a cytoplasmic cleavable bond. As used herein, a pH-labile bond is a labile bond that is selectively broken under acidic

conditions (pH<7). Such bonds may also be termed endosomally labile bonds, since cell endosomes and lysosomes have a pH less than 7.

[0259] For bioleavable linkers associated with a conjugate moiety for targeted delivery it is preferred that, the cleavage rate seen in the target tissue (for example muscle, liver, kidney or a tumor) is greater than that found in blood serum. Suitable methods for determining the level (%) of cleavage in target tissue versus serum or cleavage by S1 nuclease are described in the “Materials and methods” section. In some embodiments, the bioleavable linker (also referred to as the physiologically labile linker, or nuclease susceptible linker or region B), in a conjugate of the invention, is at least about 20% cleaved, such as at least about 30% cleaved, such as at least about 40% cleaved, such as at least about 50% cleaved, such as at least about 60% cleaved, such as at least about 70% cleaved, such as at least about 75% cleaved when compared against a standard.

[0260] In some embodiments, the oligonucleotide conjugate of the invention comprises three regions: i) a first region (region A), which comprises 10-25 contiguous nucleotides complementary to the target nucleic acid; ii) a second region (region B) which comprises a bioleavable linker and iii) a third region (region C) which comprises a conjugate moiety, such as an asialoglycoprotein receptor targeting conjugate moiety, wherein the third region is covalently linked to the second region which is covalently linked to the first region.

[0261] In one embodiment of the present invention the oligonucleotide conjugate comprises a bioleavable linker (Region B) between the contiguous nucleotide sequence (region A) and the asialoglycoprotein receptor targeting conjugate moiety (region C).

[0262] In some embodiments, the bioleavable linker may be situated either at the 5' end and/or the 3'-end of the contiguous nucleotides complementary to the target nucleic acid (region A). In a preferred embodiment the bioleavable linker is at the 5'-end.

[0263] In some embodiments, the cleavable linker is susceptible to nuclease(s) which may for example, be expressed in the target cell. In some embodiments the bioleavable linker is composed of 2 to 5 consecutive phosphodiester linkages. The linker may be a short region (e.g. 1-10 as detailed in the definition of linkers) phosphodiester linked nucleosides. In some embodiments, the nucleosides in the bioleavable linker region B is (optionally independently) selected from the group consisting of DNA and RNA or modifications thereof which do not interfere with nuclease cleavage. Modifications of DNA and RNA nucleosides which do not interfere with nuclease cleavage may be non-naturally occurring nucleobases. Certain sugar-modified nucleosides may also allow nuclease cleavage such as an alpha-L-oxy-LNA. In some embodiments, all the nucleosides of region B comprise (optionally independently) either a 2'-OH ribose sugar (RNA) or a 2'-H sugar—i.e. RNA or DNA. In a preferred embodiment, at least two consecutive nucleosides of region B are DNA or RNA nucleosides (such as at least 3 or 4 or 5 consecutive DNA or RNA nucleosides). In an even more preferred embodiment, the nucleosides of region B are DNA nucleosides. Preferably region B consists of between 1 to 5, or 1 to 4, such as 2, 3, 4 consecutive phosphodiester linked DNA nucleosides. In preferred embodiments region B is so short that it does not recruit RNaseH. In some embodiments, region B comprises no

more than 3 or no more than 4 consecutive phosphodiester linked DNA and/or RNA nucleosides (such as DNA nucleosides).

[0264] Where region B is composed of phosphodiester linked nucleosides, region A and B may together form the oligonucleotide that is linked to region C. In this context region A can be differentiated from region B in that Region A starts with at least one, preferably at least two, modified nucleosides with increased binding affinity to the target nucleic acid (e.g. LNA or nucleosides with a 2' substituted sugar moiety) and region A on its own is capable of modulation of the expression the target nucleic acid in a relevant cell line. Furthermore, if region A comprises DNA or RNA nucleosides these are linked with nuclease resistant internucleoside linkage, such phosphorothioate or boranophosphate. Region B on the other hand comprises phosphodiester linkages between DNA or RNA nucleosides. In some embodiments region B is not complementary to or comprises at least 50% mismatches to the target nucleic acid.

[0265] In some embodiments, region B is not complementary to the target nucleic acid sequence or to the contiguous nucleotides complementary to the target nucleic acid in region A.

[0266] In some embodiments, region B is complementary with the target nucleic acid sequence. In this respect region A and B together may form a single contiguous sequence which is complementary to the target sequence.

[0267] In some aspects of the invention the internucleoside linkage between the first (region A) and the second region (region B) may be considered part of the second region.

[0268] In some embodiments, the sequence of bases in region B is selected to provide an optimal endonuclease cleavage site, based upon the predominant endonuclease cleavage enzymes present in the target tissue or cell or sub-cellular compartment. In this respect, by isolating cell extracts from target tissues and non-target tissues, endonuclease cleavage sequences for use in region B may be selected based upon a preferential cleavage activity in the desired target cell (e.g. liver/hepatocytes) as compared to a non-target cell (e.g. kidney). In this respect, the potency of the compound for target down-regulation may be optimized for the desired tissue/cell.

[0269] In some embodiments region B comprises a dinucleotide of sequence AA, AT, AC, AG, TA, TT, TC, TG, CA, CT, CC, CG, GA, GT, GC, or GG, wherein C may be 5-methylcytosine, and/or T may be replaced with U. Preferably, the internucleoside linkage is a phosphodiester linkage. In some embodiments region B comprises a trinucleotide of sequence AAA, AAT, AAC, AAG, ATA, ATT, ATC, ATG, ACA, ACT, ACC, ACG, AGA, AGT, AGC, AGG, TAA, TAT, TAC, TAG, TTA, TTT, TTC, TAG, TCA, TCT, TCC, TCG, TGA, TGT, TGC, TGG, CAA, CAT, CAC, CAG, CTA, CTG, CTC, CTT, CCA, CCT, CCC, CCG, CGA, CGT, CGC, CGG, GAA, GAT, GAC, CAG, GTA, GTT, GTC, GTG, GCA, GCT, GCC, GCG, GGA, GGT, GGC, and GGG wherein C may be 5-methylcytosine and/or T may be replaced with U. Preferably, the internucleoside linkages are phosphodiester linkages. In some embodiments region B comprises a trinucleotide of sequence AAAX, AATX, AACX, AAGX, ATAX, ATTX, ATCX, ATGX, ACAX, ACTX, ACCX, ACGX, AGAX, AGTX, AGCX, AGGX, TAAX, TATX, TACX, TAGX, TTAX, TTTX, TTCX, TAGX, TCAX, TCTX, TCCX, TCGX, TGAX,

TGTX, TGCX, TGGX, CAAx, CATX, CACX, CAGX, CTAX, CTGX, CTCX, CTTX, CCAX, CCTX, CCCX, CCGX, CGAX, CGTX, CGCX, CGGX, GAAX, GATX, GACX, CAGX, GTAX, GTTX, GTCX, GTGX, GCAX, GCTX, GCCX, GCGX, GGAX, GGTX, GGCX, and GGGX, wherein X may be selected from the group consisting of A, T, U, G, C and analogues thereof, wherein C may be 5-methylcytosine and/or T may be replaced with U. Preferably, the internucleoside linkages are phosphodiester linkages. It will be recognized that when referring to (naturally occurring) nucleobases A, T, U, G, C, these may be substituted with nucleobase analogues which function as the equivalent natural nucleobase (e.g. base pair with the complementary nucleoside).

Other Linkers (Region Y)

[0270] The linker can have at least two functionalities, one for attaching to the oligonucleotide and the other for attaching to the conjugate moiety. Example linker functionalities can be electrophilic for reacting with nucleophilic groups on the oligonucleotide or conjugate moiety, or nucleophilic for reacting with electrophilic groups. In some embodiments, linker functionalities include amino, hydroxyl, carboxylic acid, thiol, phosphoramidate, phosphorothioate, phosphate, phosphite, unsaturations (e.g., double or triple bonds), and the like. Some example linkers (region Y) include 8-amino-3,6-dioxo-octanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), 6-amino-hexanoic acid (AHEx or AHA), 6-aminohexyloxy, 4-aminobutyric acid, 4-aminocyclohexylcarboxylic acid, succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amido-caproate) (LCSMCC), succinimidyl m-maleimido-benzoylate (MBS), succinimidyl N-e-maleimidocaproate (EMCS), succinimidyl 6-(beta-maleimidopropionamido) hexanoate (SMPH), succinimidyl N-(alpha-maleimido acetate) (AMAS), succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), beta-alanine (beta-ALA), phenylglycine (PHG), 4-aminocyclohexanoic acid (ACHC), beta-(cyclopropyl) alanine (beta-CYPR), amino dodecanoic acid (ADC), alylene diols, polyethylene glycols, amino acids, and the like. In some embodiments the linker (region Y) is an amino alkyl, such as a C2-C36 amino alkyl group, including, for example C6 to C12 amino alkyl groups. In a preferred embodiment the linker (region Y) is a C6 amino alkyl group. The amino alkyl group may be added to the oligonucleotide (region A or region A-B) as part of standard oligonucleotide synthesis, for example using a (e.g. protected) amino alkyl phosphoramidite. The linkage group between the amino alkyl and the oligonucleotide may for example be a phosphorothioate or a phosphodiester, or one of the other nucleoside linkage groups referred to herein. The amino alkyl group is covalently linked to the 5' or 3'-end of the oligonucleotide. Commercially available amino alkyl linkers are for example 3'-Amino-Modifier reagent for linkage at the 3'-end of the oligonucleotide and for linkage at the 5'-end of an oligonucleotide 5'-Amino-Modifier C6 is available. These reagents are available from Glen Research Corporation (Sterling, Va.). These compounds or similar ones were utilized by Krieg, et al, Antisense Research and Development 1991, 1, 161 to link fluorescein to the 5'-terminus of an oligonucleotide. A wide variety of further linker groups are known in the art and can be useful in the attachment of conjugate moieties to oligonucleotides. A review of many of the useful linker groups can be found in,

for example, Antisense Research and Applications, S. T. Crooke and B. Lebleu, Eds., CRC Press, Boca Raton, Fla., 1993, p. 303-350. Other compounds such as acridine have been attached to the 3'-terminal phosphate group of an oligonucleotide via a polymethylene linkage (Asseline, et al., Proc. Natl. Acad. Sci. USA 1984, 81, 3297). Any of the above groups can be used as a single linker (region Y) or in combination with one or more further linkers (region Y-Y' or region Y-B or B-Y).

[0271] Linkers and their use in preparation of conjugates of oligonucleotides are provided throughout the art such as in WO 96/11205 and WO 98/52614 and U.S. Pat. Nos. 4,948,882; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,580,731; 5,486,603; 5,608,046; 4,587,044; 4,667,025; 5,254,469; 5,245,022; 5,112,963; 5,391,723; 5,510,475; 5,512,667; 5,574,142; 5,684,142; 5,770,716; 6,096,875; 6,335,432; and 6,335,437, WO 2012/083046 each of which is incorporated by reference in its entirety.

Method of Manufacture

[0272] In a further aspect, the invention provides methods for manufacturing the oligonucleotides of the invention comprising reacting nucleotide units and thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide. Preferably, the method uses phosphoramidite chemistry (see for example Caruthers et al, 1987, Methods in Enzymology vol. 154, pages 287-313). In a further embodiment the method further comprises reacting the contiguous nucleotide sequence with a conjugating moiety (ligand). In a further aspect a method is provided for manufacturing the composition of the invention, comprising mixing the oligonucleotide or conjugated oligonucleotide of the invention with a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

Pharmaceutical Composition

[0273] In a further aspect, the invention provides pharmaceutical compositions comprising any of the aforementioned oligonucleotides and/or oligonucleotide conjugates and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant. A pharmaceutically acceptable diluent includes phosphate-buffered saline (PBS) and pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. In some embodiments the pharmaceutically acceptable diluent is sterile phosphate buffered saline. In some embodiments the oligonucleotide is used in the pharmaceutically acceptable diluent at a concentration of 50-300 μ M solution.

[0274] Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990). WO 2007/031091 provides further suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference). Suitable dosages, formulations, administration routes, compositions, dosage forms, combinations with other therapeutic agents, pro-drug formulations are also provided in WO2007/031091.

[0275] Oligonucleotides or oligonucleotide conjugates of the invention may be mixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and

methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

[0276] These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 7 and 8, such as 7 to 7.5. The resulting compositions in solid form may be packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules. The composition in solid form can also be packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment. In some embodiments, the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug. In particular with respect to oligonucleotide conjugates the conjugate moiety is cleaved of the oligonucleotide once the prodrug is delivered to the site of action, e.g. the target cell.

Applications

[0277] The oligonucleotides or oligonucleotide conjugates of the present invention may be utilized as research reagents for, for example, diagnostics, therapeutics and prophylaxis.

[0278] In research, such oligonucleotides or oligonucleotide conjugates may be used to specifically modulate the synthesis of PD-L1 protein in cells (e.g. in vitro cell cultures) and experimental animals thereby facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention. Typically the target modulation is achieved by degrading or inhibiting the mRNA producing the protein, thereby prevent protein formation or by degrading or inhibiting a modulator of the gene or mRNA producing the protein.

[0279] If employing the oligonucleotide of the invention in research or diagnostics the target nucleic acid may be a cDNA or a synthetic nucleic acid derived from DNA or RNA.

[0280] The present invention provides an in vivo or in vitro method for modulating PD-L1 expression in a target cell which is expressing PD-L1, said method comprising administering an oligonucleotide or oligonucleotide conjugate of the invention in an effective amount to said cell.

[0281] In some embodiments, the target cell, is a mammalian cell in particular a human cell. The target cell may be an in vitro cell culture or an in vivo cell forming part of a tissue in a mammal. In preferred embodiments the target cell is present in the liver. Liver target cell can be selected from parenchymal cells (e.g. hepatocytes) and non-parenchymal cells such as Kupffer cells, LSECs, stellate cells (or Ito cells), cholangiocytes and liver-associated leukocytes (including T cells and NK cells). In some embodiments the target cell is an antigen-presenting cell. Antigen-presenting cells displays foreign antigens complexed with major histocompatibility complex (MHC) class I or class II on their surfaces. In some embodiments the antigen-presenting cell expresses MHC class II (i.e. professional antigen-presenting cells such as dendritic cells, macrophages and B cells).

[0282] In diagnostics the oligonucleotides may be used to detect and quantitate PD-L1 expression in cell and tissues by northern blotting, in-situ hybridisation or similar techniques.

[0283] For therapeutics oligonucleotides or oligonucleotide conjugates of the present invention or pharmaceutical compositions thereof may be administered to an animal or a human, suspected of having a disease or disorder, which can be alleviated or treated by reduction of the expression of PD-L1, in particular by reduction of the expression of PD-L1 in liver target cells.

[0284] The invention provides methods for treating or preventing a disease, comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide, an oligonucleotide conjugate or a pharmaceutical composition of the invention to a subject suffering from or susceptible to the disease.

[0285] The invention also relates to an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention for use as a medicament.

[0286] The oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition according to the invention is typically administered in an effective amount.

[0287] The invention also provides for the use of the oligonucleotide or oligonucleotide conjugate or pharmaceutical composition of the invention as described for the manufacture of a medicament for the treatment of a disease or disorder as referred to herein. In one embodiment the disease is selected from a) viral liver infections such as HBV, HCV and HDV; b) parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis and c) liver cancer or metastases in the liver.

[0288] In one embodiment, the invention relates to oligonucleotides, oligonucleotide conjugates or pharmaceutical compositions for use in the treatment of diseases or disorders selected from viral or parasitic infections. In a further embodiment the disease is selected from a) viral liver infections such as HBV, HCV and HDV; b) parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis and c) liver cancer or metastases in the liver.

[0289] The disease or disorder, as referred to herein, is associated with immune exhaustion. In particular the disease or disorder is associated with exhaustion of virus-specific T-cell responses. In some embodiments disease or disorder may be alleviated or treated by reduction of PD-L1 expression.

[0290] The methods of the invention are preferably employed for treatment or prophylaxis against diseases associated with immune exhaustion.

[0291] In one embodiment of the invention the oligonucleotide, oligonucleotide conjugate or pharmaceutical compositions of the invention are used in restoration of immune response against a liver cancer or metastases in the liver.

[0292] In one embodiment of the invention the oligonucleotide, oligonucleotide conjugate or pharmaceutical compositions of the invention are used in restoration of immune response against a pathogen. In some embodiments the pathogen can be found in the liver. The pathogens can be a virus or a parasite, in particular those described herein. In a preferred embodiment the pathogen is HBV.

[0293] The invention further relates to use of an oligonucleotide, oligonucleotide conjugate or a pharmaceutical composition as defined herein for the manufacture of a

medicament for the restoration of immunity against a viral or parasite infection as mentioned herein.

[0294] Oligonucleotides or oligonucleotide conjugates or pharmaceutical compositions of the present invention can be used in the treatment of viral infections, in particular viral infections in the liver where the PD-1 pathway is affected (see for example Kapoor and Kottlilil 2014 Future Virol Vol. 9 pp. 565-585 and Salem and El-Badawy 2015 World J Hepatol Vol. 7 pp. 2449-2458). Viral liver infections can be selected from the group consisting of hepatitis viruses, in particular HBV, HCV and HDV, in particular chronic forms of these infections. In one embodiment the oligonucleotides or oligonucleotide conjugates or pharmaceutical compositions of the present invention are used to treat HBV, in particular chronic HBV. Indicators of chronic HBV infections are high levels of viral load (HBV DNA) and even higher levels of empty HBsAg particles (>100-fold in excess of virions) in the circulation.

[0295] Oligonucleotides or oligonucleotide conjugates of the present invention can also be used to treat viral liver infections that occur as co-infections with HIV. Other viral infections which can be treated with the oligonucleotides or oligonucleotide conjugates or pharmaceutical compositions of the present invention are lcmv (Lymphocytic Choriomeningitis Virus), and HIV as a mono infection, HSV-1 and -2, and other herpesviruses. These viruses are not hepatotropic, however they may be sensitive to PDL1 down regulation.

[0296] In some embodiments the restoration of immunity or immune response involves improvement of the T-cell and/or NK cell response and/or alleviation of the T-cell exhaustion, in particular the HBV-specific T-cell response, the HCV-specific T-cell response and or the HDV-specific T-cell response is restored. An improvement of the T cell response can for example be assessed as an increase in T cells in the liver, in particular an increase in CD8+ and/or CD4+ T cells when compared to a control (e.g. the level prior to treatment or the level in a vehicle treated subject) In a further embodiment it is the virus specific CD8+ T cells that are restored or increased when compared to control), in particular HBV specific CD8+ T cells or HCV specific CD8+ T cells or HDV specific CD8+ T cells are restored or increased when compared to control. In a preferred embodiment CD8+ T cells specific for HBV s antigen (HBsAg) and/or CD8+ T cells specific for HBV e antigen (HBeAg) and/or CD8+ T cells specific for HBV core antigen (HBcAg) are increased in subjects treated with an oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the present invention compared to control. Preferably the HBV antigen specific CD8+ T cells produce one or more cytokines, such as interferon-gamma (IFN- γ) or tumor necrosis factor alpha (TNF- α). The increase in CD8+ T cells described above is in particular observed in the liver. The increase described herein should be statistically significant when compared to a control. Preferably the increase is at least 20%, such as 25%, such as 50% such as 75% when compared to control. In another embodiment natural killer (NK) cells and/or natural killer T (NKT) cells are activated by the oligonucleotides or oligonucleotide conjugates of the present invention.

[0297] Oligonucleotides or oligonucleotide conjugates or pharmaceutical compositions of the present invention can be used in the treatment parasite infections, in particular parasite infections where the PD-1 pathway is affected (see for

example Bhadra et al. 2012 J Infect Dis vol 206 pp. 125-134; Bhadra et al. 2011 Proc Natl Acad Sci USA Vol. 108 pp. 9196-9201; Esch et al. J Immunol vol 191 pp 5542-5550; Freeman and Sharpe 2012 Nat Immunol Vol 13 pp. 113-115; Gutierrez et al. 2011 Infect Immun Vol 79 pp. 1873-1881; Joshi et al. 2009 PLoS Pathog Vol 5 e1000431; Liang et al. 2006 Eur J Immunol Vol. 36 pp 58-64; Wykes et al. 2014 Front Microbiol Vol 5 pp 249). Parasite infections can be selected from the group consisting of malaria, toxoplasmosis, leishmaniasis and trypanosomiasis. Malaria infection is caused by protozoa of the genus *Plasmodium*, in particular of the species *P. vivax*, *P. malariae* and *P. falciparum*. Toxoplasmosis is a parasitic disease caused by *Toxoplasma gondii*. Leishmaniasis is a disease caused by protozoan parasites of the genus *Leishmania*. Trypanosomiasis is caused by the protozoan of the genus *Trypanosoma*. Chaga disease which is the tropical form caused by the species *Trypanosoma cruzi*, and sleeping disease is caused by the species *Trypanosoma brucei*.

[0298] In some embodiments the restoration of immunity involves restoration of a parasite-specific T cell and NK cell response, in particular a *Plasmodium*-specific T-cell response, a *Toxoplasma gondii*-specific T-cell and NK cell response, a *Leishmania*-specific T-cell and NK cell response, a *Trypanosoma cruzi*-specific T-cell and NK cell response or a *Trypanosoma brucei*-specific T-cell and NK cell response. In a further embodiment it is the parasite-specific CD8+ T cell and NK cell response that is restored.

Administration

[0299] The oligonucleotides or pharmaceutical compositions of the present invention may be administered topical (such as, to the skin, inhalation, ophthalmic or otic) or enteral (such as, orally or through the gastrointestinal tract) or parenteral (such as, intravenous, subcutaneous, intramuscular, intracerebral, intracerebroventricular or intrathecal).

[0300] In a preferred embodiment the oligonucleotide or pharmaceutical compositions of the present invention are administered by a parenteral route including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, e.g. intracerebral or intraventricular, intravitreal administration. In one embodiment the active oligonucleotide or oligonucleotide conjugate is administered intravenously. In another embodiment the active oligonucleotide or oligonucleotide conjugate is administered subcutaneously.

[0301] In some embodiments, the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is administered at a dose of 0.1-15 mg/kg, such as from 0.1-10 mg/kg, such as from 0.2-10 mg/kg, such as from 0.25-10 mg/kg, such as from 0.1-5 mg/kg, such as from 0.2-5 mg/kg, such as from 0.25-5 mg/kg. The administration can be once a week, every 2nd week, every third week or even once a month.

Combination Therapies

[0302] In some embodiments the oligonucleotide, oligonucleotide conjugate or pharmaceutical composition of the invention is for use in a combination treatment with another therapeutic agent. The therapeutic agent can for example be the standard of care for the diseases or disorders described above.

[0303] For the treatment of chronic HBV infections a combination of antiviral drugs and immune system modulators is recommended as standard of care. The antiviral drugs effective against HBV are for example nucleos(t)ide analogs. There are five nucleos(t)ide analogs licensed for therapy of HBV namely lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude) these are effective in suppressing viral replication (HBV DNA) but have no effect on HBsAg levels. Other antiviral drugs include ribavirin and an HBV antibody therapy (monoclonal or polyclonal). The immune system modulators can for example be interferon alpha-2a and PEGylated interferon alpha-2a (Pegasys) or TLR7 agonists (e.g. GS-9620) or therapeutic vaccines. IFN- α treatment show only very modest effect in reducing viral load, but result in some HBsAg decline, albeit very inefficiently (<10% after 48 week therapy).

[0304] The oligonucleotide or oligonucleotide conjugates of the present invention may also be combined with other antiviral drugs effective against HBV such as the antisense oligonucleotides described in WO2012/145697 and WO 2014/179629 or the siRNA molecules described in WO 2005/014806, WO 2012/024170, WO 2012/2055362, WO 2013/003520 and WO 2013/159109.

[0305] When the oligonucleotides or oligonucleotide conjugates of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to an individual. Alternatively, pharmaceutical compositions according to the present invention may be comprised of a combination of an oligonucleotide or oligonucleotide conjugate of the present invention in association with a pharmaceutically acceptable excipient, as described herein, and another therapeutic or prophylactic agent known in the art.

Embodiments

[0306] The following embodiments of the present invention may be used in combination with any other embodiments described herein.

[0307] 1. An antisense oligonucleotide which comprises or consists of a contiguous nucleotide sequence of 10 to 30 nucleotides in length capable of reducing the expression of PD-L1.

[0308] 2. The oligonucleotide of embodiment 1, wherein the contiguous nucleotide sequence is at least 90% complementarity to a PD-L1 target nucleic acid.

[0309] 3. The oligonucleotide of embodiment 1 or 2, wherein the contiguous nucleotide sequence is complementary to a target nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3.

[0310] 4. The oligonucleotide of embodiment 1 to 3, wherein the contiguous nucleotide sequence is complementary to a region within position 1 and 15720 on SEQ ID NO: 1.

[0311] 5. The oligonucleotide of embodiment 1 to 4, wherein the oligonucleotide is capable of hybridizing to a target nucleic acid of selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3 with a ΔG° below -10 kcal.

[0312] 6. The oligonucleotide of embodiment 1 to 5, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the sub-sequence is selected from the group consisting of posi-

tion 371-3068, 5467-12107, 15317-15720, 15317-18083, 15317-19511 and 18881-19494 on SEQ ID NO: 1.

[0313] 7. The oligonucleotide of embodiment 6, wherein the sub-sequence is selected from the group consisting of position 7300-7333, 8028-8072, 9812-9859, 11787-11873 and 15690-15735 on SEQ ID NO: 1.

[0314] 8. The oligonucleotide of embodiment 2 to 7, wherein the target nucleic acid is RNA.

[0315] 9. The oligonucleotide of embodiment 8, wherein the RNA is mRNA.

[0316] 10. The oligonucleotide of embodiment 9, wherein the mRNA is pre-mRNA or mature mRNA.

[0317] 11. The oligonucleotide of embodiment 1-10, wherein the contiguous nucleotide sequence comprises or consists of at least 14 contiguous nucleotides, particularly 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 contiguous nucleotides.

[0318] 12. The oligonucleotide of embodiment 1-10, wherein the contiguous nucleotide sequence comprises or consists of from 16 to 20 nucleotides.

[0319] 13. The oligonucleotide of embodiment 1-10, wherein the oligonucleotide comprises or consists of 14 to 35 nucleotides in length.

[0320] 14. The oligonucleotide of embodiment 13, wherein the oligonucleotide comprises or consists of 18 to 22 nucleotides in length.

[0321] 15. The oligonucleotide of embodiment 1-14, wherein the oligonucleotide or contiguous nucleotide sequence is single stranded.

[0322] 16. The oligonucleotide of embodiment 1-15, wherein the contiguous nucleotide sequence is complementary to a sub-sequence of the target nucleic acid, wherein the subsequence is selected from the group consisting of A7, A26, A43, A119, A142, A159, A160, A163, A169, A178, A179, A180, A189, A201, A202, A204, A214, A221, A224, A226, A243, A254, A258, 269, A274, A350, A360, A364, A365, A370, A372, A381, A383, A386, A389, A400, A427, A435 and A438.

[0323] 17. The oligonucleotide of embodiment 16, wherein the subsequence is selected from the group consisting of A221, A360, A180, A160 and A269.

[0324] 18. The oligonucleotide of embodiment 1-17, wherein the oligonucleotide is not siRNA and is not self-complementary.

[0325] 19. The oligonucleotide of embodiment 1-18, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from SEQ ID NO: 5 to 743 or 771.

[0326] 20. The oligonucleotide of embodiment 1-19, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from SEQ ID NO: 6, 8, 9, 13, 41, 42, 58, 77, 92, 111, 128, 151, 164, 166, 169, 171, 222, 233, 245, 246, 250, 251, 252, 256, 272, 273, 287, 292, 303, 314, 318, 320, 324, 336, 342, 343, 344, 345, 346, 349, 359, 360, 374, 408, 409, 415, 417, 424, 429, 430, 458, 464, 466, 474, 490, 493, 512, 519, 519, 529, 533, 534, 547, 566, 567, 578, 582, 601, 619, 620, 636, 637, 638, 640, 645, 650, 651, 652, 653, 658, 659, 660, 665, 678, 679, 680, 682, 683, 684, 687, 694, 706, 716, 728, 733, 734, and 735.

[0327] 21. The oligonucleotide of embodiment 1-20, wherein the contiguous nucleotide sequence comprises or consists of a sequence selected from SEQ ID NO: 466, 640, 342, 287 and 566.

[0328] 22. The oligonucleotide of embodiment 1-21 wherein the contiguous nucleotide sequence has zero to three mismatches compared to the target nucleic acid it is complementary to.

[0329] 23. The oligonucleotide of embodiment 22, wherein the contiguous nucleotide sequence has one mismatch compared to the target nucleic acid.

[0330] 24. The oligonucleotide of embodiment 22, wherein the contiguous nucleotide sequence has two mismatches compared to the target nucleic acid.

[0331] 25. The oligonucleotide of embodiment 22, wherein the contiguous nucleotide sequence is fully complementary to the target nucleic acid sequence.

[0332] 26. The oligonucleotide of embodiment 1-25, comprising one or more modified nucleosides.

[0333] 27. The oligonucleotide of embodiment 26, wherein the one or more modified nucleoside is a high-affinity modified nucleosides.

[0334] 28. The oligonucleotide of embodiment 26 or 27, wherein the one or more modified nucleoside is a 2' sugar modified nucleoside.

[0335] 29. The oligonucleotide of embodiment 28, wherein the one or more 2' sugar modified nucleoside is independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, 2'-fluoro-ANA and LNA nucleosides.

[0336] 30. The oligonucleotide of embodiment 28, wherein the one or more modified nucleoside is a LNA nucleoside.

[0337] 31. The oligonucleotide of embodiment 30, wherein the modified LNA nucleoside is oxy-LNA.

[0338] 32. The oligonucleotide of embodiment 31, wherein the modified nucleoside is beta-D-oxy-LNA.

[0339] 33. The oligonucleotide of embodiment 30, wherein the modified nucleoside is thio-LNA.

[0340] 34. The oligonucleotide of embodiment 30, wherein the modified nucleoside is amino-LNA.

[0341] 35. The oligonucleotide of embodiment 30, wherein the modified nucleoside is cET.

[0342] 36. The oligonucleotide of embodiment 30, wherein the modified nucleoside is ENA.

[0343] 37. The oligonucleotide of embodiment 30, wherein the modified LNA nucleoside is selected from beta-D-oxy-LNA, alpha-L-oxy-LNA, beta-D-amino-LNA, alpha-L-amino-LNA, beta-D-thio-LNA, alpha-L-thio-LNA, (S)cET, (R)cET beta-D-ENA and alpha-L-ENA.

[0344] 38. The oligonucleotide of embodiment 30-37, wherein there in addition to the modified LNA nucleoside is at least one 2' substituted modified nucleoside.

[0345] 39. The oligonucleotide of embodiment 38, wherein the 2' substituted modified nucleoside is selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-DNA, 2'-fluoro-ANA.

[0346] 40. The oligonucleotide of any one of embodiments 1-39, wherein the oligonucleotide comprises at least one modified internucleoside linkage.

[0347] 41. The oligonucleotide of embodiment 40, wherein the modified internucleoside linkage is nuclease resistant.

[0348] 42. The oligonucleotide of embodiment 40 or 41, wherein at least 50% of the internucleoside linkages within

the contiguous nucleotide sequence are phosphorothioate internucleoside linkages or boranophosphate internucleoside linkages.

[0349] 43. The oligonucleotide of embodiment 40 or 41, wherein all the internucleoside linkages within the contiguous nucleotide sequence are phosphorothioate internucleoside linkages.

[0350] 44. The oligonucleotide of embodiment 1-43, wherein the oligonucleotide is capable of recruiting RNase H.

[0351] 45. The oligonucleotide of embodiment 44, wherein the oligonucleotide is a gapmer.

[0352] 46. The oligonucleotide of embodiment 44 or 45, wherein the oligonucleotide is a gapmer of formula 5'-F-G-F'-3', where region F and F' independently comprise or consist of 1-7 modified nucleosides and G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH.

[0353] 47. The oligonucleotide of embodiment 44 or 45, wherein the gapmer has formula 5'-D'-F-G-F'-3' or 5'-F-G-F'-D''-3', where region F and F' independently comprise 1-7 modified nucleosides, G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH and region D' or D'' comprise 1-5 phosphodiester linked nucleosides.

[0354] 48. The oligonucleotide of embodiment 47, wherein D' or D'' are optional.

[0355] 49. The oligonucleotide of embodiment 47, wherein region D' consist of two phosphodiester linked nucleosides.

[0356] 50. The oligonucleotide of embodiment 49, wherein the phosphodiester linked nucleosides are ca (cytidine-adenosine).

[0357] 51. The oligonucleotide of embodiment 46 or 47, wherein the modified nucleoside is a 2' sugar modified nucleoside independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.

[0358] 52. The oligonucleotide of embodiments 46 to 51, wherein one or more of the modified nucleosides in region F and F' is a LNA nucleoside.

[0359] 53. The oligonucleotide of embodiment 52, wherein all the modified nucleosides in region F and F' are LNA nucleosides.

[0360] 54. The oligonucleotide of embodiment 53, wherein region F and F' consist of LNA nucleosides.

[0361] 55. The oligonucleotide of embodiment 52-54, wherein all the modified nucleosides in region F and F' are oxy-LNA nucleosides.

[0362] 56. The oligonucleotide of embodiment 52, wherein at least one of region F or F' further comprises at least one 2' substituted modified nucleoside independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA and 2'-fluoro-DNA.

[0363] 57. The oligonucleotide of embodiment 46-56, wherein the RNaseH recruiting nucleosides in region G are independently selected from DNA, alpha-L-LNA, C4' alkylated DNA, ANA and 2'F-ANA and UNA.

[0364] 58. The oligonucleotide of embodiment 57, wherein the nucleosides in region G is DNA and/or alpha-L-LNA nucleosides.

- [0365]** 59. The oligonucleotide of embodiment 57 or 58, wherein region G consists of at least 75% DNA nucleosides.
- [0366]** 60. The oligonucleotide of embodiment 1-59, wherein the oligonucleotide is selected from any one of the CMP ID NO: 5₁ to 743₁ and 771₁ (table 5).
- [0367]** 61. The oligonucleotide of embodiment 1-60, wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 6₁, 8₁, 9₁, 13₁, 41₁, 42₁, 58₁, 77₁, 92₁, 111₁, 128₁, 151₁, 164₁, 166₁, 169₁, 171₁, 222₁, 233₁, 245₁, 246₁, 250₁, 251₁, 252₁, 256₁, 272₁, 273₁, 287₁, 292₁, 303₁, 314₁, 318₁, 320₁, 324₁, 336₁, 342₁, 343₁, 344₁, 345₁, 346₁, 349₁, 359₁, 360₁, 374₁, 408₁, 409₁, 415₁, 417₁, 424₁, 429₁, 430₁, 458₁, 464₁, 466₁, 474₁, 490₁, 493₁, 512₁, 519₁, 519₁, 529₁, 533₁, 534₁, 547₁, 566₁, 567₁, 578₁, 582₁, 601₁, 619₁, 620₁, 636₁, 637₁, 638₁, 640₁, 645₁, 650₁, 651₁, 652₁, 653₁, 658₁, 659₁, 660₁, 665₁, 678₁, 679₁, 680₁, 682₁, 683₁, 684₁, 687₁, 694₁, 706₁, 716₁, 728₁, 733₁, 734₁, and 735₁.
- [0368]** 62. The oligonucleotide of embodiment 1-61, wherein the oligonucleotide is selected from the group consisting of CMP ID NO: 287₁, 342₁, 466₁, 640₁, 566₁, 766₁, 767₁, 768₁, 769₁ and 770₁.
- [0369]** 63. An antisense oligonucleotide conjugate comprising
- [0370]** a. an oligonucleotide according to any one of claims 1-62 (Region A); and
 - [0371]** b. at least one at least one conjugate moiety (Region C) covalently attached to said oligonucleotide.
- [0372]** 64. The oligonucleotide conjugate of embodiment 63, wherein the conjugate moiety is selected from carbohydrates, cell surface receptor ligands, drug substances, hormones, lipophilic substances, polymers, proteins, peptides, toxins, vitamins, viral proteins or combinations thereof.
- [0373]** 65. The oligonucleotide conjugate of embodiment 63 or 64, wherein the conjugate moiety is a carbohydrate containing moiety.
- [0374]** 66. The oligonucleotide conjugate of embodiment 65, wherein the carbohydrate conjugate moiety comprises at least one asialoglycoprotein receptor targeting moiety covalently attached to an oligonucleotide according to any one of claims 1-62.
- [0375]** 67. The oligonucleotide conjugate of embodiment 66, wherein the asialoglycoprotein receptor targeting conjugate moiety comprises at least one carbohydrate moiety selected from group consisting of galactose, galactosamine, N-formyl-galactosamine, N-acetylgalactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine and N-isobutanoylgalactosamine.
- [0376]** 68. The oligonucleotide conjugate of embodiment 66 or 67, wherein the asialoglycoprotein receptor targeting conjugate moiety is mono-valent, di-valent, tri-valent or tetra-valent.
- [0377]** 69. The oligomer conjugate of embodiment 68, wherein the asialoglycoprotein receptor targeting conjugate moiety consists of two to four terminal GalNAc moieties, a PEG spacer linking each GalNAc moiety to a brancher molecule.
- [0378]** 70. The oligonucleotide conjugate of embodiment 66 to 69, wherein the asialoglycoprotein receptor targeting conjugate moiety is a tri-valent N-acetylgalactosamine (GalNAc) moiety.
- [0379]** 71. The oligonucleotide conjugate of embodiment 66 to 70, wherein the conjugate moiety is selected from one of the trivalent GalNAc moieties in FIG. 1.
- [0380]** 72. The oligonucleotide conjugate of embodiment 71, wherein the conjugate moiety is the trivalent GalNAc moiety in FIG. 3.
- [0381]** 73. The oligonucleotide conjugate of embodiment 63-72, where a linker is present between the oligonucleotide or contiguous oligonucleotide sequence and the conjugate moiety.
- [0382]** 74. The oligonucleotide conjugate of embodiment 73, wherein the linker is a physiologically labile linker (region B).
- [0383]** 75. The oligonucleotide conjugate of embodiment 74, wherein the physiologically labile linker is nuclease susceptible linker.
- [0384]** 76. The oligonucleotide conjugate of embodiment 74 or 75, wherein the physiologically labile linker is composed of 2 to 5 consecutive phosphodiester linkages.
- [0385]** 77. The oligonucleotide conjugate of embodiment 76, wherein the physiologically labile linker is equivalent to region D' or D'' presented in embodiment 47 to 50.
- [0386]** 78. The oligonucleotide conjugate of any one of embodiments 63-77, wherein the oligonucleotide conjugate is selected from CMP ID NO: 766₂, 767₂, 768₂, 769₂ and 770₂.
- [0387]** 79. The oligonucleotide conjugate of embodiment 78, wherein the oligonucleotide conjugate is selected from the oligonucleotide conjugated represented in FIGS. 4, 5, 6, 7 and 8.
- [0388]** 80. The oligonucleotide conjugate of embodiment 63-78, which display improved inhibition of PD-L1 in the target cell, or improved cellular distribution between liver and the spleen or improved cellular uptake into the liver of the conjugate oligonucleotide as compared to an unconjugated oligonucleotide.
- [0389]** 81. A pharmaceutical composition comprising the oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 and a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
- [0390]** 82. A method for manufacturing the oligonucleotide of embodiment 1-62, comprising reacting nucleotide units thereby forming covalently linked contiguous nucleotide units comprised in the oligonucleotide.
- [0391]** 83. The method of embodiment 82, further comprising reacting the contiguous nucleotide sequence with a non-nucleotide conjugation moiety.
- [0392]** 84. A method for manufacturing the composition of embodiment 81, comprising mixing the oligonucleotide with a pharmaceutically acceptable diluent, carrier, salt and/or adjuvant.
- [0393]** 85. An in vivo or in vitro method for modulating PD-L1 expression in a target cell which is expressing PD-L1, said method comprising administering an oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 or the pharmaceutical composition of embodiment 81 in an effective amount to said cell.
- [0394]** 86. A method for treating or preventing a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 or the pharmaceutical composition of embodiment 81 to a subject suffering from or susceptible to the disease.

[0395] 87. A method for restoration of immunity against a virus or parasite comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide conjugate of embodiment 63-80 or the oligonucleotide of embodiment 1-62 or the pharmaceutical composition of embodiment 81 to a subject infected with a virus or parasite.

[0396] 88. The method of embodiment 87, the restoration of immunity is an increase in the liver of CD8+ T cells specific to one or more HBV antigens when compared to a control.

[0397] 89. The oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 or the pharmaceutical composition of embodiment 81, for use as a medicament for treatment or prevention of a disease in a subject.

[0398] 90. Use of the oligonucleotide of oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 for the preparation of a medicament for treatment or prevention of a disease in a subject.

[0399] 91. The oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 or the pharmaceutical composition of embodiment 81, for use in restoration of immunity against a virus or parasite.

[0400] 92. The use of embodiment 91, wherein the restoration of immunity is an increase in the liver of CD8+ T cells specific to one or more HBV antigens when compared to a control.

[0401] 93. The use of embodiment 92, wherein the HBV antigen is the HBsAg.

[0402] 94. The method, the oligonucleotide or the use of embodiments 86-93, wherein the disease is associated with in vivo activity of PD-L1.

[0403] 95. The method, the oligonucleotide or the use of embodiments 86-94, wherein the disease is associated with increased expression of PD-L1 in an antigen presenting cell.

[0404] 96. The method, the oligonucleotide or the use of embodiments 95, wherein the PD-L1 is reduced by at least 30%, or at least or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95% compared to the expression without or before treatment with the oligonucleotide of embodiment 1-62 or a conjugate of embodiment 63-80 or the pharmaceutical composition of embodiment 81.

[0405] 97. The method, the oligonucleotide or the use of embodiments 86-95, wherein the disease is selected from a viral liver infection or a parasite infections.

[0406] 98. The method, the oligonucleotide or the use of embodiment 98, wherein the viral infection is HBV, HCV or HDV.

[0407] 99. The method, the oligonucleotide or the use of embodiment 86-95, wherein the disease is chronic HBV.

[0408] 100. The method, the oligonucleotide or the use of embodiment 98, wherein the parasite infection is malaria, toxoplasmosis, leishmaniasis or trypanosomiasis.

[0409] 101. The method, the oligonucleotide or the use of embodiments 86-100, wherein the subject is a mammal.

[0410] 102. The method, the oligonucleotide or the use of embodiment 101, wherein the mammal is human.

EXAMPLES

Materials and Methods

Motif Sequences and Oligonucleotide Compounds

[0411]

TABLE 5

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.

SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
5	taattggctctactgc	2-11-3	TAattggctctactGTC	5_1	236	-20
6	tcgcataagaatgact	4-10-2	TCGCataagaatgACT	6_1	371	-19
7	tgaacacacagtcgca	2-12-2	TGaacacacagtcgCA	7_1	382	-19
8	ctgaacacacagtcgc	3-10-3	CTGaacacacagtcCGC	8_1	383	-22
9	tctgaacacacagtcg	3-11-2	TCTgaacacacagtcCG	9_1	384	-19
10	ttctgaacacacagtc	3-11-2	TTctgaacacacagTC	10_1	385	-17
11	acaagtcattgttacta	2-11-3	ACaagtcattgttACTA	11_1	463	-16
12	acacaagtcattgttac	2-12-2	ACacaagtcattgtTAC	12_1	465	-14
13	cttacttagatgctgc	2-11-3	CTtacttagatgctGTC	13_1	495	-20
14	acttacttagatgctg	2-11-3	ACTtacttagatgctGTG	14_1	496	-18
15	gacttacttagatgct	3-11-2	GACTtacttagatgctCT	15_1	497	-19
16	agacttacttagatgct	2-11-3	AGacttacttagatGTC	16_1	498	-18
17	gcaggaagagacttac	3-10-3	GCAggaagagactTAC	17_1	506	-20
18	aataaattccgttcagg	4-9-4	AATAaattccgttCAGG	18_1	541	-22
19	gcaataaattccggtt	3-10-3	GCAaataaattccGTT	19_2	545	-18

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
19	gcaaataaattccggt	4-8-4	GCAAataaattcCGTT	19_1	545	-20
20	agcaataaattccgt	4-9-3	AGCAataaattcCGT	20_1	546	-20
21	cagagcaataaattcc	4-10-3	CAGAgcaataaattTCC	21_1	548	-21
22	tggaacagagcaataaat	4-11-3	TGGAcagagcaataAAT	22_1	551	-19
23	atggacagagcaata	4-8-4	ATGGacagagcaAATA	23_1	554	-20
24	cagaatggacagagca	2-11-3	CAgaatggacagagGCA	24_1	558	-21
25	ttctcagaatggacag	3-11-2	TTctcagaatggacAG	25_1	562	-17
26	ctgaactttgacatag	4-8-4	CTGAactttgacATAG	26_1	663	-20
27	aagacaaaccagactga	2-13-3	AAGacaaaccagactGTA	27_1	675	-21
28	tataagacaaaccagac	4-10-4	TATAagacaaaccAGAC	28_1	678	-22
29	ttataagacaaaccaga	4-10-4	TTATAagacaaaccCAGA	29_1	679	-23
30	tggtataagacaaacc	4-10-3	TGTTataagacaaacc	30_1	682	-22
31	tagaacaatggtacttt	4-9-4	TAGAacaatggtactTTT	31_1	708	-20
32	gtagaacaatggtact	4-10-2	GTAGAacaatggtact	32_1	710	-19
33	aggtagaacaatggtta	3-10-3	AGGTagaacaatgGTA	33_1	712	-19
34	aagaggtagaacaatgg	4-9-4	AAGAggtagaacaATGG	34_1	714	-21
35	gcattccacagtaaatt	2-12-2	GCattccacagtaaATT	35_1	749	-17
36	gaaggttatttaattc	2-11-3	GAaggttattttaattc	36_1	773	-13
37	ctaattcgaatgcagca	4-9-3	CTAattcgaatgcGCA	37_1	805	-22
38	taccaatctaactga	3-10-3	TACcaatctaactCGA	38_1	813	-20
39	tagttaccaatctaa	3-10-3	TAGttaccaatcTAA	39_1	817	-19
40	catttagttaccaat	3-10-3	CATtagttaccAAT	40_1	821	-18
41	tcatttagttaccacaa	3-10-3	TCatttagttaccCAA	41_1	822	-19
42	ttcatttagttaccaca	2-10-4	TTcatttagttaccCCA	42_1	823	-22
43	gaattaatttcatttagt	4-10-4	GAATtaatttcattTAGT	43_1	829	-19
44	cagtgaggaattaattt	4-9-4	CAGTgaggaattaATTT	44_1	837	-20
45	ccaacagtgaggaatt	4-8-4	CCAacagtgaggAATT	45_1	842	-21
46	ccaacagtgaggaat	3-10-3	CCAacagtgaggAAT	46_1	843	-22
47	tataccaacagtgagg	2-12-3	TAtaccaacagtgAGG	47_1	846	-21
48	ttataccaacagtgag	2-11-4	TTataccaacagTGAG	48_1	847	-21
49	tttataccaacagtgga	3-11-3	TTTataccaacagTGA	49_1	848	-21
50	cctttataccaacag	3-10-3	CCTttataccaacCAG	50_1	851	-23
51	taacctttatacccaa	4-8-4	TAACctttatacCCA	51_1	854	-22
52	aataacctttataccca	3-10-4	AATaacctttataCCA	52_1	855	-23
53	gtaaataacctttata	3-11-2	GTAaataacctttATA	53_1	859	-14

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
54	actgtaaataacctttat	4-10-4	ACTGtaaataacctTTAT	54_1	860	-20
55	atataatgcaatgag	3-11-2	ATAtatgcaatgAG	55_1	903	-14
56	agataatgcaatg	2-12-2	AGataatgcaatG	56_1	905	-12
57	gagataatgcaat	3-10-3	GAGataatgcaAAT	57_1	906	-15
58	ccagagataatgcaat	2-11-3	CCagagataatgcaTGC	58_1	909	-19
59	caatattccagagatat	4-9-4	CAATattccagagATAT	59_1	915	-20
60	gcaatattccagagata	4-10-3	GCAATattccagagATA	60_1	916	-22
61	agcaatattccagagat	3-11-3	AGCAatattccagaGAT	61_1	917	-22
62	cagcaatattccagag	3-9-4	CAGcaatattccAGAG	62_1	919	-22
63	aatcagcaatattccag	4-9-4	AATCagcaatattCCAG	63_1	921	-23
64	acaatcagcaatattcc	4-9-4	ACAatcagcaataTTCC	64_1	923	-21
65	actaagtagttacacttct	2-14-3	ACTaagtagttacactTCT	65_1	957	-20
66	ctaagtagttacacttc	4-11-2	CTAagtagttacactTC	66_1	958	-18
67	gactaagtagttacactt	3-12-3	GACTaagtagttacaCTT	67_1	959	-20
68	tgactaagtagttaca	3-9-4	TGActaagtagtTACA	68_1	962	-19
69	ctttgactaagtagtta	4-10-3	CTTTgactaagtagTTA	69_1	964	-19
70	ctctttgactaagtag	3-10-3	CTCtttgactaagTAG	70_1	967	-19
71	gctctttgactaagta	4-10-2	GCTCtttgactaagTA	71_1	968	-21
72	ccttaaatactgttgac	2-11-4	CCTtaaatactgtTGAC	72_1	1060	-20
73	cttaaatactgttgac	2-12-2	CTtaaatactgttgAC	73_1	1060	-13
74	tccttaaatactgttg	3-10-3	TCcttaaatactgTTG	74_1	1062	-18
75	tctccttaaatactggtt	4-11-2	TCTCcttaaatactgTT	75_1	1063	-19
76	tatcatagttctcctt	2-10-4	TAtcatagttctCCTT	76_1	1073	-21
77	agtatcatagttctcc	3-10-3	AGTatcatagttcTCC	77_1	1075	-22
78	gagtatcatagttctc	2-11-3	GAGtatcatagttCTC	78_1	1076	-18
79	agagtatcatagttct	2-10-4	AGagtatcatagTTCT	79_1	1077	-18
79	agagtatcatagttct	3-10-3	AGAgtatcatagTCT	79_2	1077	-19
80	cagagtatcatagttc	3-10-3	CAGagtatcatagTTC	80_1	1078	-18
81	ttcagagtatcatagt	4-10-2	TTCAgagtatcataGT	81_1	1080	-18
82	cttcagagtatcatag	3-9-4	CTTcagagtatcATAG	82_1	1081	-19
83	ttcttcagagtatcata	4-11-2	TTCTtcagagtatcaTA	83_1	1082	-19
84	tttcttcagagtatcat	3-10-4	TTTcttcagagtaTCAT	84_1	1083	-20
85	gagaaggctaagttt	4-9-3	GAGAAggctaagTTT	85_1	1099	-19
86	gacactcttgatcatt	2-10-4	GAcactcttgtaCATT	86_1	1213	-19
87	tgagacactcttgata	2-13-2	TGagacactcttgtaCA	87_1	1215	-18

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
88	tgagacactcttgTAC	2-11-3	TGagacactcttgTAC	88_1	1216	-18
89	ctttattaaactccat	2-10-4	CTttattaaactCCAT	89_1	1266	-18
90	accaaactttattaaa	4-10-2	ACCAaactttattAAA	90_1	1272	-14
91	aaacctctactaagtG	4-10-2	AAACctctactaagtTG	91_1	1288	-16
92	agattaagacagttga	2-11-3	AGattaagacagtTGA	92_1	1310	-16
93	aagtaggagcaagaggc	2-12-3	AAgtaggagcaagaGGC	93_1	1475	-22
94	aaagtaggagcaagagg	4-10-3	AAAGtaggagcaagAGG	94_1	1476	-20
95	gttaagcagccaggag	2-12-2	GTtaagcagccaggAG	95_1	1806	-20
96	agggtaggatgggtag	2-12-2	AGggtaggatgggtAG	96_1	1842	-20
97	aagggtaggatgggtgta	3-11-2	AAGggtaggatgggtTA	97_1	1843	-20
98	caagggtaggatgggt	2-12-2	CAagggtaggatggGT	98_2	1844	-20
98	caagggtaggatgggt	3-11-2	CAAgggtaggatggGT	98_1	1844	-21
99	ccaagggtaggatggg	2-12-2	CCaagggtaggatgGG	99_1	1845	-22
100	tccaagggtaggatgg	2-12-2	TCcaagggtaggatGG	100_1	1846	-20
101	cttccaagggtaggat	4-10-2	CTTCcaagggtaggAT	101_1	1848	-21
102	atcttccaagggtagga	3-12-2	ATCttccaagggtagGA	102_1	1849	-22
103	agaagtgatggctcatt	2-11-4	AGaagtgatggctCATT	103_1	1936	-21
104	aagaagtgatggctcat	3-10-4	AAGaagtgatggcTCAT	104_1	1937	-21
105	gaagaagtgatggctca	3-11-3	GAAgaagtgatggcTCA	105_1	1938	-21
106	atgaaatgtaaactggg	4-9-4	ATGAaatgtaaactGGG	106_1	1955	-21
107	caatgaaatgtaaactgg	4-10-4	CAATgaaatgtaaactGG	107_1	1956	-20
108	gcaatgaaatgtaaactg	4-10-4	GCAATgaaatgtaaactG	108_1	1957	-20
109	agcaatgaaatgtaaact	4-10-4	AGCAatgaaatgtaaact	109_1	1958	-20
110	gagcaatgaaatgtaaact	4-10-4	GAGCAatgaaatgtaaact	110_1	1959	-19
111	tgaattcccatatccga	2-12-3	TGaattcccatatcCGA	111_1	1992	-22
112	agaattatgaccatata	2-11-3	AGaattatgaccaTAT	112_1	2010	-15
113	aggtaagaattatgacc	3-10-4	AGGtaagaattatGACC	113_1	2014	-21
114	tcaggtaagaattatgac	4-10-4	TCAGgtaagaattatGAC	114_1	2015	-22
115	cttcaggtaagaattatg	4-10-4	CTTCaggtaagaattatG	115_1	2017	-21
116	tcttcaggtaagaatta	4-9-4	TCTTcaggtaagaATTA	116_1	2019	-20
117	cttcttcaggtaagaat	4-9-4	CTTcttcaggtaagaAT	117_1	2021	-21
118	tcttcttcaggtaagaa	4-10-3	TCTTcttcaggtaagAA	118_1	2022	-20
119	tcttcttcaggtaaga	3-10-3	TCTtcttcaggtaAGA	119_1	2023	-20
120	tggtctaagagaagaag	3-10-4	TGGtctaagagaGAAG	120_1	2046	-20
121	gttggtctaagagaag	4-9-3	GTTGgtctaagagaAAG	121_1	2049	-19

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
123	cagttggtctaagagaa	2-11-4	CAGttggtctaagAGAA	123_1	2050	-20
124	gcagttggtctaagagaa	3-13-2	GCAgttggtctaagagAA	124_1	2050	-22
122	agttggtctaagagaa	3-9-4	AGTtgggtctaagAGAA	122_1	2050	-20
126	gcagttggtctaagaga	2-13-2	GCagttggtctaagaGA	126_1	2051	-21
125	cagttggtctaagaga	4-10-2	CAGTtgggtctaagaGA	125_1	2051	-21
127	gcagttggtctaagag	2-11-3	GCagttggtctaagAG	127_1	2052	-21
128	ctcatatcagggcagt	2-10-4	CTcatatcagggCAGT	128_1	2063	-24
129	cacacatgttctttaac	4-11-2	CACAcatgttctttaAC	129_1	2087	-18
130	taaatacacacatgttct	3-11-4	TAAatacacacatgTTCT	130_1	2092	-19
131	gtaaatacacacatgttc	4-11-3	GTAAatacacacatgTTC	131_1	2093	-19
132	tgtaaatacacacatggt	4-10-4	TGTAaatacacacaTGTT	132_1	2094	-22
133	gatcatgtaaatacacac	4-10-4	GATCatgtaaatacACAC	133_1	2099	-20
134	agatcatgtaaatacaca	4-10-4	AGATcatgtaaataCACA	134_1	2100	-21
135	caaagatcatgtaaatacac	4-12-4	CAAagatcatgtaaatACAC	135_1	2101	-19
136	acaaagatcatgtaaataca	4-12-4	ACAAagatcatgtaaaTACA	136_1	2102	-20
137	gaatacaaatcatgtga	4-10-4	GAATacaaagatcaTGTA	137_1	2108	-20
138	agaatacaaatcatgtg	4-10-4	AGAatacaaatcatGTG	138_1	2109	-20
139	cagaatacaaatcatg	4-10-4	CAGAatacaaatCATG	139_1	2110	-21
140	gcagaatacaaatcatca	4-9-4	GCAGAatacaaatATCA	140_1	2112	-22
141	aggcagaatacaaatgat	4-11-2	AGGCagaatacaaatAT	141_1	2114	-19
142	aaggcagaatacaaaaga	4-10-3	AAGGCagaatacaaaAGA	142_1	2115	-19
143	attagtgagggacgaa	3-10-3	ATTagtgagggacGAA	143_1	2132	-18
144	cattagtgagggacga	2-11-3	CATTagtgagggacGA	144_1	2133	-20
145	gaggtgatggattag	2-11-3	GAGgtgatggatTAG	145_1	2218	-19
146	ttaggagtaataaagg	2-10-4	TTaggagtaataAAGG	146_1	2241	-14
147	ttaatgaatttggtg	3-11-2	TTAatgaatttggtTG	147_1	2263	-13
148	ctttaatgaatttggt	2-12-2	CTttaatgaatttgGT	148_1	2265	-14
149	catggattacaactaa	4-10-2	CATGgattacaactAA	149_1	2322	-16
150	tcatggattacaacta	2-11-3	TCatggattacaactA	150_1	2323	-16
151	gtcatggattacaact	3-11-2	GTCatggattacaact	151_1	2324	-18
152	cattaaatctagtc	2-10-4	CattaaatctagTCAT	152_1	2335	-16
153	gacattaaatctagtc	4-10-3	GACattaaatctagTCA	153_1	2336	-19
154	agggacattaaatcta	4-10-2	AGGGacattaaatcTA	154_1	2340	-18
155	caaagcattataacca	4-9-3	CAAagcattataaCCA	155_1	2372	-18
156	acttactaggcagaag	2-10-4	ActtactaggcagaAG	156_1	2415	-19

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
157	cagagttaactgtaca	4-10-2	CAGAgttaactgtaca	157_1	2545	-20
158	ccagagttaactgtac	4-10-2	CCAGagttaactgtac	158_1	2546	-20
159	gccagagttaactgta	2-12-2	GCcagagttaactgta	159_1	2547	-20
160	tgggccagagttaact	2-12-2	TGggccagagttaact	160_1	2550	-21
161	cagcatctatcagact	2-12-2	CAGcatctatcagaCT	161_1	2576	-19
162	tgaataacatgagtcac	3-11-4	TGAaataacatgagTCAT	162_1	2711	-19
163	gtgaataacatgagtc	3-10-4	GTGaaataacatgAGTC	163_1	2713	-19
164	tctgtttatgtcactg	4-10-2	TCTGtttatgtcacTG	164_1	2781	-20
165	gtctgtttatgtcact	4-10-2	GTCTgtttatgtcaCT	165_1	2782	-22
166	tggctgtttatgtca	2-10-4	TGGctgtttatGTCA	166_1	2784	-21
167	ttggtctgtttatgtc	4-10-2	TTGgtctgtttatgTC	167_1	2785	-20
168	tcaccattgtttaa	2-12-2	TCaccattgtttaa	168_1	2842	-15
169	ttcagcaaatattcgt	2-10-4	TTcagcaaatatTCGT	169_1	2995	-17
170	gtgtgttcagcaaat	3-10-4	GTgtgttcagcaaATAT	170_1	2999	-21
171	tctattgttaggtatc	3-10-3	TCTattgttaggtATC	171_1	3053	-18
172	attgccatcttactg	2-12-2	ATtgccatcttactTG	172_1	3118	-19
173	tattgccatcttact	3-11-2	TATtgccatcttactCT	173_1	3119	-21
174	aaatattgccatctt	2-11-3	AAatattgccatCTT	174_1	3122	-17
175	ataaccttatcataca	3-11-2	ATAaccttatcataCA	175_1	3174	-16
176	tataaccttatcatc	2-11-3	TATAaccttatcaTAC	176_1	3175	-14
177	ttataaccttatcata	3-11-2	TTATAaccttatcaATA	177_1	3176	-14
178	tttataaccttatcat	3-10-3	TTTataaccttatCAT	178_1	3177	-16
179	actgctattgctatct	2-11-3	ACTgctattgctaTCT	179_1	3375	-19
180	aggactgctattgcta	2-11-3	AGgactgctattgCTA	180_1	3378	-21
181	gaggactgctattgct	3-11-2	GAGgactgctattgCT	181_1	3379	-22
182	acgtagaataataaca	2-12-2	ACgtagaataataaCA	182_1	3561	-11
183	ccaagtgatataatgg	2-10-4	CCaagtgatataATGG	183_1	3613	-19
184	ttagcagaccaagtga	2-10-4	TTagcagaccaAGTGA	184_1	3621	-21
185	gtttagcagaccaagt	2-12-2	GTttagcagaccaAGT	185_1	3623	-19
186	tgacagtgattatatt	2-12-2	TGacagtgattataATT	186_1	3856	-13
187	tgtccaagatattgac	4-10-2	TGTCcaagatattgAC	187_1	3868	-18
188	gaatatcctagattgt	3-10-3	GAAatcctagatTGT	188_1	4066	-18
189	caaactgagaatatcc	2-11-3	CAaactgagaataTCC	189_1	4074	-16
190	gcaaactgagaatatc	3-11-2	GCAaactgagaataTC	190_1	4075	-16
191	tcctattacaatcgta	3-11-2	TCctattacaatcgTA	191_1	4214	-19

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
192	ttcctattacaatcgt	4-10-2	TTCctattacaatcGT	192_1	4215	-19
193	actaatgggaggattt	2-12-2	ACTaatgggaggatTT	193_1	4256	-15
194	tagttcagagaataag	2-12-2	TAgttcagagaataAG	194_1	4429	-13
195	taacatatagttcaga	2-11-3	TAacatatagttcAGA	195_1	4436	-15
196	ataacatatagttcag	3-11-2	ATAacatatagttcAG	196_1	4437	-14
197	cataacatatagttca	2-12-2	CAtaacatatagttCA	197_1	4438	-13
198	tcataacatatagttc	2-12-2	TCataacatatagttC	198_1	4439	-12
199	tagctcctaacaatca	4-10-2	TAGctcctaacaatCA	199_1	4507	-22
200	ctccaatctttgtata	4-10-2	CTCcaatctttgtATA	200_1	4602	-20
201	tctccaatctttgtat	4-10-2	TCTCcaatctttgtAT	201_1	4603	-19
202	tctatttcagccaatc	2-12-2	TctatttcagccaaTC	202_1	4708	-17
203	cggaagtcagagtgaa	3-10-3	CGGaagtcagagtGAA	203_1	4782	-19
204	ttaagcatgaggaaata	4-10-2	TTAAgcatgaggaaATA	204_1	4798	-16
205	tgattgagcacctctt	3-10-3	TGAttgagcacctCTT	205_1	4831	-22
206	gactaattatttcggt	3-11-2	GACTaattatttcgTT	206_1	4857	-15
207	tgactaattatttcggt	3-10-3	TGActaattatttcCGT	207_1	4858	-17
208	gtgactaattatttcg	3-10-3	GTGactaattattTCG	208_1	4859	-17
209	ctgcttgaaatgtgac	4-10-2	CTGcttgaaatgtGAC	209_1	4870	-20
210	cctgcttgaaatgtga	2-11-3	CctgcttgaaatgTGA	210_1	4871	-21
211	atcctgcttgaaatgt	2-10-4	ATcctgcttgaaATGT	211_1	4873	-20
212	attataaatctattct	3-10-3	ATTataaatctatTCT	212_1	5027	-13
213	gctaaatactttcatc	2-11-3	GctaaatactttcATC	213_1	5151	-16
214	cattgtaacataccta	2-10-4	CAttgtaacataCCTA	214_1	5251	-19
215	gcattgtaacatacct	2-12-2	GcattgtaacatacCT	215_1	5252	-18
216	taatattgcaccaa	2-12-2	TAatattgcaccaaAT	216_1	5295	-13
217	gataaatattgcaccaa	2-11-3	GAtaatattgcacCAA	217_1	5297	-16
218	agataaatattgcacca	2-12-2	AGataaatattgcacCA	218_1	5298	-16
219	gccagaagataaatat	2-10-4	GCcagaagataATAT	219_1	5305	-17
220	cacagccacataaaact	4-10-2	CACagccacataaaACT	220_1	5406	-21
221	ttgtaattgtggaaac	2-12-2	TTgtaattgtggaaAC	221_1	5463	-12
222	tgacttgaattgtgg	2-11-3	TGacttgaattgTGG	222_1	5467	-18
223	tctaactgaaatagtc	2-12-2	TCTaactgaaatagTC	223_1	5503	-13
224	gtggttctaactgaaa	3-11-2	GTGgttctaactgAAA	224_1	5508	-16
225	caatatgggacttggt	2-12-2	CAatatgggacttGGT	225_1	5522	-18
226	atgacaatatgggact	3-11-2	ATGacaatatgggACT	226_1	5526	-17

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
227	tatgacaatatgggac	4-10-2	TATGacaatatgggAC	227_1	5527	-17
228	atatgacaatatggga	4-10-2	ATATgacaatatggGA	228_1	5528	-17
229	cttcacttaataatta	2-11-3	CTtcacttaataaTTA	229_1	5552	-13
230	ctgcttcacttaataa	4-10-2	CTGcttcacttaatAA	230_1	5555	-18
231	aagactgcttcactta	2-11-3	AAgactgcttcacTTA	231_1	5559	-17
232	gaatgccctaattatg	4-10-2	GAATgccctaattaTG	232_1	5589	-19
233	tggaatgccctaatta	3-11-2	TGGaatgccctaataTA	233_1	5591	-19
234	gcaaatgccagtaggt	3-11-2	GCAaatgccagtagGT	234_1	5642	-23
235	ctaattggaaggatttg	3-11-2	CTAattggaaggattTG	235_1	5673	-15
236	aatatagaacctaattg	2-12-2	AAtatagaacctaTG	236_1	5683	-10
237	gaaagaatagaatggt	3-10-3	GAAagaatagaatGTT	237_1	5769	-12
238	atgggtaatatagattat	3-11-2	ATGggtaatatagattAT	238_1	5893	-15
239	gaaagagcacaggggtg	2-12-2	GAaagagcacagggTG	239_1	6103	-18
240	ctacatagaggggaatg	4-10-2	CTACatagaggggaATG	240_1	6202	-18
241	gcttcctacatagagg	2-10-4	GcttcctacataGAGG	241_1	6207	-24
242	tgcttcctacatagag	4-10-2	TGcttcctacatagAG	242_1	6208	-22
243	tgggcttgaatatgt	2-11-3	TGggcttgaataTGT	243_1	6417	-19
244	cattatatttaagaac	3-11-2	CATtatatttaagaAC	244_1	6457	-11
245	tcggttatgttatcat	2-10-4	TCggttatgttatCAT	245_1	6470	-19
246	cactttatctggtcgg	2-10-4	CActttatctggtTCGG	246_1	6482	-22
247	aaattggcacagcggt	3-10-3	AAAttggcacagcGTT	247_1	6505	-18
248	accgtgacagtaaatg	4-9-3	ACCGtgacagtaaATG	248_1	6577	-20
249	tgggaaccgtgacagta	2-13-2	TGggaaccgtgacagTA	249_1	6581	-22
250	ccacatagagtcctt	2-11-3	CCacatagagtcCTT	250_1	6597	-21
251	catattgctaccatac	2-11-3	CAtattgctaccaTAC	251_1	6617	-18
252	tcatattgctaccata	3-10-3	TCAtattgctaccATA	252_1	6618	-19
253	caattgtcatattgct	4-8-4	CAATtgtcatatTGCT	253_1	6624	-21
254	cattcaattgtcatattg	3-12-3	CATtcaattgtcataTTG	254_1	6626	-18
255	tttctactgggaatttg	4-9-4	TTTctactgggaaTTTG	255_1	6644	-20
256	caattagtgagccag	3-10-3	CAAttagtgagcCAG	256_1	6672	-21
257	gaataatgttcttatcc	4-10-3	GAAtaatgttcttaTCC	257_1	6704	-20
258	cacaaattgaataatgttct	4-13-3	CACAAattgaataatgtTCT	258_1	6709	-20
259	catgcacaaattgaataat	4-11-4	CATgcacaaattgaaTAAT	259_1	6714	-20
260	atcctgcaatttcacat	3-11-3	ATCctgcaatttcacAT	260_1	6832	-22
261	ccaccatagctgatca	2-12-2	CCaccatagctgatCA	261_1	6868	-22

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
262	accaccatagctgatca	2-12-3	ACcaccatagctgaTCA	262_1	6868	-23
263	caccaccatagctgatc	2-13-2	CACCaccatagctgaTC	263_1	6869	-21
264	tagtcggcaccaccat	2-12-2	TAgtcggcaccaccAT	264_1	6877	-22
265	cttgtagtgcggcaccac	1-14-2	CttgtagtgcggcaccAC	265_1	6880	-21
266	cttgtagtgcggcacca	1-13-2	CttgtagtgcggcacCA	266_1	6881	-21
267	cgcttgtagtgcggcac	2-12-2	CGcttgtagtgcggcAC	267_1	6883	-21
268	tcaataaagatcaggc	3-11-2	TCAataaagatcagGC	268_1	6942	-17
269	tggacttacaagaatg	2-12-2	TGgacttacaagaaTG	269_1	6986	-14
270	atggacttacaagaat	3-11-2	ATGgacttacaagaAT	270_1	6987	-15
271	gctcaagaaattggat	4-10-2	GCTCaagaaattggAT	271_1	7073	-19
272	tactgtagaacatggc	4-10-2	TACTgtagaacatgGC	272_1	7133	-21
273	gcaattcatttgatct	4-9-3	GCAAttcatttgaTCT	273_1	7239	-20
274	tgaagggaggaggacac	2-14-2	TGaaagggaggaggacAC	274_1	7259	-20
275	agtggtgaggaggaggag	2-13-2	AGtggtgaggaggaggAG	275_1	7265	-21
276	tagtggtgaggaggaggag	2-14-2	TAgtggtgaggaggaggAG	276_1	7265	-21
277	atagtggtgaggaggaggag	1-16-2	AtagtggtgaggaggaggAG	277_1	7265	-20
278	tagtggtgaggaggagga	2-13-2	TAgtggtgaggaggaggGA	278_1	7266	-21
279	atagtggtgaggaggagga	2-14-2	ATagtggtgaggaggaggGA	279_1	7266	-21
280	tagtggtgaggaggagg	3-11-2	TAGtggtgaggaggaggG	280_1	7267	-21
281	atagtggtgaggaggagg	3-12-2	ATAgtggtgaggaggaggG	281_1	7267	-22
282	gatagtggtgaggaggagg	2-14-2	GAtagtggtgaggaggaggG	282_1	7267	-21
283	atagtggtgaggaggagg	4-10-2	ATAGtggtgaggaggaggG	283_1	7268	-20
284	gatagtggtgaggaggagg	2-12-3	GAtagtggtgaggaggaggG	284_1	7268	-21
285	gagatagtggtgaggagg	2-10-4	GAgatagtggtgaggaggG	285_1	7271	-20
286	catgggagatagtgggt	4-10-2	CATgggagatagtggGT	286_1	7276	-22
287	acaaataatggttactct	4-10-4	ACAAataatggttactCTCT	287_1	7302	-20
288	acacacaaataatggtta	4-10-4	ACACacaaataatggTTTA	288_1	7306	-20
289	gagggacacacaaataat	3-11-4	GAGggacacacaaataAAT	289_1	7311	-21
290	atatagagaggctcaa	4-8-4	ATATagagaggctCAA	290_1	7390	-21
291	ttgatatagagaggct	2-10-4	TTgatatagagaggCT	291_1	7393	-20
292	gcatttgatagagaga	4-9-3	GCAtttgatagagAGA	292_1	7397	-20
293	tttgcatttgatagag	2-11-3	TTtgcatttgatagTAG	293_1	7400	-15
294	ctggaagaataggttc	3-11-2	CTGgaagaataggTC	294_1	7512	-17
295	actggaagaataggtt	4-10-2	ACTGgaagaataggTT	295_1	7513	-18
296	tactggaagaatagggt	4-10-2	TACTggaagaataggGT	296_1	7514	-18

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.

SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
297	tggettatacctgtact	4-10-2	TGGCttatcctgtaCT	297_1	7526	-25
298	atggcttatcctgtac	2-10-4	ATggcttatcctGTAC	298_1	7527	-22
299	tatggcttatcctgta	4-10-2	TATGgcttatcctgTA	299_1	7528	-22
300	gtatggcttatcctgt	3-10-3	GTAtggcttatccIGT	300_1	7529	-23
301	atgaatatatgccagct	2-11-4	ATgaatatatgccCAGT	301_1	7547	-22
302	gatgaatatatgccca	2-10-4	GATgaatatatgCCCA	302_1	7549	-22
303	caagatgaatatatgcc	3-10-4	CAAgatgaatataTGCC	303_1	7551	-21
304	gacaacatcagtataga	4-9-4	GACAacatcagtaTAGA	304_1	7572	-22
305	caagacaacatcagta	4-8-4	CAAGacaacatcAGTA	305_1	7576	-20
306	cactcctagttccttt	3-10-3	CACtCctagttccTTT	306_1	7601	-22
307	aacactcctagttcct	3-10-3	AACactcctagttCCT	307_1	7603	-22
308	taaacactcctagttcc	2-11-3	TAaacctcctagtTCC	308_1	7604	-20
309	ctaaacactcctagttc	2-12-2	CTaacactcctagtTC	309_1	7605	-18
310	tgataacataactgtg	2-12-2	TGataacataactGTG	310_1	7637	-13
311	ctgataacataactgt	2-10-4	CTgataacataaCTGT	311_1	7638	-18
312	tttgaactcaagtgac	4-10-2	TTTGaactcaagtgAC	312_1	7654	-16
313	tcctttacttagctag	4-9-3	TCCTttacttagcTAG	313_1	7684	-23
314	gagtttgattagctg	2-11-3	GAgtttgattagCTG	314_1	7764	-20
315	tgggatatgacagggga	2-11-3	TGgggatatgacagGGA	315_1	7838	-21
316	tgtgggatatgacaggg	4-10-2	TGTGgggatatgacaGG	316_1	7840	-22
317	atatggaagggatc	4-10-2	ATATggaagggatc	317_1	7875	-17
318	acaggatggaaggg	3-10-3	ACAggatggaaggG	318_1	7880	-21
319	atttcaacaggataggg	4-9-4	ATTTcaacaggatATGG	319_1	7885	-20
320	gagtaatttcaacagg	2-11-3	GAgtaatttcaacAGG	320_1	7891	-17
321	agggagtaatttcaaca	4-9-4	AGGGagtaatttcaACA	321_1	7893	-22
322	attagggagtaatttca	4-9-4	ATTAgggagtaatTTCA	322_1	7896	-21
323	cttactattagggagt	2-10-4	CTtactattaggGAGT	323_1	7903	-20
324	cagcttactattaggg	2-11-3	CAGcttactattaGGG	324_1	7906	-20
326	atttcagcttactattag	3-11-4	ATTTcagcttactATTAG	326_1	7908	-20
325	tcagcttactattaggg	3-10-3	TCAgcttactattAGG	325_1	7907	-20
327	ttcagcttactattag	2-10-4	TTcagcttactaTTAG	327_1	7908	-17
328	cagatttcagcttact	4-10-2	CAGAtttcagcttaCT	328_1	7913	-21
329	gactacaactagaggg	3-11-2	GACTacaactagagGG	329_1	7930	-19
330	agactacaactagaggg	4-10-2	AGACTacaactagaGG	330_1	7931	-19
331	aagactacaactagag	2-12-2	AAGactacaactagAG	331_1	7932	-13

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
332	atgatttaattctagtcAAA	4-12-4	ATGAtttaattctagTCAAA	332_1	7982	-20
333	tTTAattctagtcAAA	3-10-3	TTTAAattctagTcAAA	333_1	7982	-12
334	gatttAattctagtcA	4-8-4	GATTtAattctAgtCA	334_1	7984	-20
771	tGatttAattctagtcA	3-10-4	TGAttTtAattctAgtCA	771_1	7984	-20
335	atgatttAattctagtcA	4-11-3	ATGAttTtAattctagTCA	335_1	7984	-20
336	gatgatttAattctagtcA	4-13-2	GATGAttTtAattctagTCA	336_1	7984	-20
337	gatttAattctagtcA	2-10-4	GAttTtAattctAgtCA	337_1	7984	-18
338	gatgatttAattctagtc	4-11-3	GATGAttTtAattctAgtC	338_1	7985	-20
339	tGatttAattctagtc	2-12-2	TGAttTtAattctagTC	339_1	7985	-13
340	gagatgatttAattctA	4-9-4	GAGAtgatttAatTCTA	340_1	7988	-20
341	gagatgatttAattct	3-10-3	GAGAtgatttAatTCT	341_1	7989	-16
342	cagattgatggtagtt	4-10-2	CAGAttgatggtagTT	342_1	8030	-19
343	ctcagattgatggtag	2-10-4	CTcagattgatgGTAG	343_1	8032	-20
344	gttagccctcagattg	3-10-3	GTTAgccctcagaTTG	344_1	8039	-23
345	tGtattgttagccctc	2-10-4	TGtattgttagcCCTC	345_1	8045	-24
346	acttgtattgttagcc	2-10-4	ACTtgtattgtTAGCC	346_1	8048	-22
347	agccagtatcagggac	3-11-2	AGCcagtatcagggAC	347_1	8191	-23
348	ttgacaatagtggcat	2-10-4	TTgacaatagtGCAT	348_1	8213	-20
349	acaagtggtatcttct	3-10-3	ACAagtggtatctTCT	349_1	8228	-19
350	aatctactttacaagt	4-10-2	AATCtactttacaAGT	350_1	8238	-16
351	cacagtagatgcctgata	2-12-4	CAcagtagatgcctGATA	351_1	8351	-24
352	gaacacagtagatgcc	2-11-3	GAacacagtagatGCC	352_1	8356	-21
353	cttGgaacacagtagat	4-11-2	CTTGgaacacagtagAT	353_1	8359	-20
354	atAtcttGgaacacag	3-10-3	ATAtcttGgaacaCAG	354_1	8364	-18
355	tcttTtaatatcttGgaac	3-11-4	TCTtTtaatatcttGGAAC	355_1	8368	-19
356	tGatttcttTtaatatcttg	2-13-4	TGatttcttTtaatatCTTG	356_1	8372	-19
357	tGatgatttcttTtaatatc	2-13-4	TGatgatttcttTtaatTATC	357_1	8375	-18
358	aggctAagtcAtgatg	3-11-2	AGGctAagtcAtgaTG	358_1	8389	-19
359	ttgatgaggctAagtc	4-10-2	TTGAtgaggctAagTC	359_1	8395	-19
360	ccaggattatactctt	3-11-2	CCAggattatactAT	360_1	8439	-20
361	gccaggattatactct	2-10-4	GCCaggattataCTCT	361_1	8440	-23
362	ctGccaggattatact	3-11-2	CTGccaggattataCT	362_1	8442	-21
363	cAGAAacttatactttatg	4-13-2	CAGAAacttatactTTATG	363_1	8473	-19
364	aAGcAGAAacttatact	4-9-4	AAGcAGAAacttATACT	364_1	8478	-20
365	gAGcAGAAacttatact	3-11-4	GAGcAGAAacttATACT	365_1	8478	-20

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
366	tggaagcagaaacttatact	3-15-2	TGGaagcagaaacttataCT	366_1	8478	-21
367	tggaagcagaaacttatac	3-13-3	TGGaagcagaaacttaTAC	367_1	8479	-20
368	aagcagaaacttatac	2-11-3	AAGcagaaacttaTAC	368_1	8479	-13
369	tggaagcagaaacttata	3-11-4	TGGaagcagaaactTATA	369_1	8480	-21
370	aaggatattatggag	4-10-2	AAGGatattatggAG	370_1	8587	-18
371	tgccggaagatttcct	2-12-2	TGccggaagatttcCT	371_1	8641	-21
372	atggattgggagtaga	4-10-2	ATGGattgggagtaGA	372_1	8772	-21
373	agatggattgggagta	2-12-2	AGatggattgggagTA	373_1	8774	-18
374	aagatggattgggagt	3-11-2	AAGatggattgggaGT	374_1	8775	-18
375	acaagatggattggga	2-10-4	ACaagatggattGGGA	375_1	8777	-20
375	acaagatggattggga	2-12-2	ACaagatggattggGA	375_2	8777	-17
376	agaaggttcagacttt	3-9-4	AGAaggttcagaCTTT	376_1	8835	-20
377	gcagaaggttcagact	2-11-3	GCagaaggttcagACT	377_1	8837	-21
377	gcagaaggttcagact	3-11-2	GCAgaaggttcagaCT	377_2	8837	-22
378	tcagaaggttcagac	4-10-2	TGCAgaaggttcagAC	378_1	8838	-22
379	agtgcagaaggttcag	2-11-3	AGTgcagaaggttcAG	379_1	8840	-20
379	agtgcagaaggttcag	4-10-2	AGTGCagaaggttcAG	379_2	8840	-21
380	aagtgcagaaggttca	4-10-2	AAGTgcagaaggttCA	380_1	8841	-20
381	taagtgcagaaggttc	2-10-4	TAagtgcagaagGTTc	381_1	8842	-19
382	tctaagtgcagaaggt	2-10-4	TCtaagtgcagaAGGT	382_1	8844	-21
383	ctcaggagtcttacttc	3-12-2	CTCaggagtcttactTC	383_1	8948	-20
384	ctcaggagtcttactt	3-10-3	CTCaggagtcttaCTT	384_1	8949	-21
385	atggaggtgactcaggag	1-15-2	AtggaggtgactcaggAG	385_1	8957	-20
386	atggaggtgactcagga	2-13-2	ATggaggtgactcagGA	386_1	8958	-21
387	atggaggtgactcagg	2-11-3	ATggaggtgactcAGG	387_1	8959	-21
388	tatggaggtgactcagg	2-12-3	TAtggaggtgactcAGG	388_1	8959	-21
389	atatggaggtgactcagg	2-14-2	ATatggaggtgactcaGG	389_1	8959	-21
390	tatggaggtgactcag	4-10-2	TATGgaggtgactcAG	390_1	8960	-21
391	atatggaggtgactcag	2-11-4	ATatggaggtgactTCAG	391_1	8960	-22
392	catatggaggtgactcag	2-14-2	CAtatggaggtgactcAG	392_1	8960	-20
393	atatggaggtgactca	3-10-3	ATAtggaggtgactTCA	393_1	8961	-20
394	catatggaggtgactca	2-12-3	CAtatggaggtgactTCA	394_1	8961	-21
395	catatggaggtgactc	2-10-4	CAtatggaggtgactCTC	395_1	8962	-20
396	gcatatggaggtgactc	2-13-2	GCatatggaggtgactTC	396_1	8962	-21
397	tgcatatggaggtgactc	2-14-2	TGcatatggaggtgactTC	397_1	8962	-21

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
398	ttgcatatggaggtgactc	1-16-2	TtgcatatggaggtgacTC	398_1	8962	-20
399	tttgcataatggaggtgactc	1-17-2	TttgcataatggaggtgacTC	399_1	8962	-21
400	gcatatggaggtgact	2-12-2	GCatatggaggtgaCT	400_1	8963	-20
401	tgcatatggaggtgact	2-13-2	TGcatatggaggtgaCT	401_1	8963	-20
402	ttgcatatggaggtgact	3-13-2	TTGcatatggaggtgaCT	402_1	8963	-22
403	tttgcataatggaggtgact	1-16-2	TttgcataatggaggtgaCT	403_1	8963	-20
404	tgcatatggaggtgac	3-11-2	TGCatatggaggtgAC	404_1	8964	-20
405	ttgcatatggaggtgac	3-11-3	TTGcatatggaggtGAC	405_1	8964	-21
406	tttgcataatggaggtgac	4-12-2	TTTGCatatggaggtgAC	406_1	8964	-21
407	tttgcataatggaggtga	4-11-2	TTTGCatatggaggtGA	407_1	8965	-21
408	tttgcataatggaggtg	2-10-4	TTtgcataatggaGGTG	408_1	8966	-21
409	aagtgaagtccaacagc	2-11-4	AAgtgaagttcaaCAGC	409_1	8997	-20
410	tgggaagtgaagttca	2-10-4	TGggaagtgaagTCA	410_1	9002	-20
411	atgggaagtgaagttc	2-11-3	ATgggaagtgaagTTC	411_1	9003	-17
412	gatgggaagtgaagtt	4-9-3	GATGggaagtgaaGTT	412_1	9004	-21
413	ctgtgatgggaagtgaa	3-11-3	CTGtgatgggaagtGAA	413_1	9007	-20
414	attgagtgaatccaaa	3-10-3	ATTgagtgaatccAAA	414_1	9119	-14
415	aattgagtgaatccaa	2-10-4	AAttgagtgaatCCAA	415_1	9120	-16
416	gataaattgagtgaatcc	4-10-3	GATAaattgagtgaatTCC	416_1	9122	-20
417	gtgataaattgagtgaa	3-10-3	GTGataaattgagtGAA	417_1	9125	-16
418	aagaaaggtgcaataa	3-10-3	AAGaaaggtgcaaTAA	418_1	9155	-14
419	caagaaaggtgcaata	2-10-4	CAagaaaggtgcAATA	419_1	9156	-15
420	acaagaaaggtgcaat	4-10-2	ACAagaaaggtgcaAT	420_1	9157	-16
421	atttaaactcaciaaac	2-12-2	AtttaaactcaciaAAC	421_1	9171	-10
422	ctgttaggttcagcga	2-10-4	CTgttaggttcagCGA	422_1	9235	-24
423	tctgaatgaacatttcg	4-9-4	TCTgaatgaacatTTCG	423_1	9260	-20
424	ctcattgaaggttctg	2-10-4	CTcattgaaggtTCTG	424_1	9281	-20
425	ctaactctcattgaagg	3-11-2	CTAactctcattgaAGG	425_1	9286	-17
426	cctaactctcattgaag	2-12-2	CCTaactctcattgaAG	426_1	9287	-16
427	actttgatctttcagc	3-10-3	ACTttgatctttcAGC	427_1	9305	-20
428	actatgcaacactttg	2-12-2	ACTatgcaacactTTG	428_1	9315	-15
429	caaatagctttatcgg	3-10-3	CAAatagctttatCGG	429_1	9335	-17
430	ccaaatagctttatcgg	2-10-4	CCaaatagctttATCG	430_1	9336	-19
431	tccaaatagctttatc	4-10-2	TCCAAatagctttATC	431_1	9337	-18
432	gatccaaatagcttta	4-10-2	GATCCaaatagcttTA	432_1	9339	-18

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
433	atgatccaaatagctt	2-10-4	ATgatccaaatAGCTT	433_1	9341	-19
434	tatgatccaaatagct	4-10-2	TATGatccaaatagCT	434_1	9342	-18
435	taaacagggtgggaat	4-9-4	TAAAcagggtggGAAT	435_1	9408	-22
436	acttaaacagggtgg	2-10-4	ACTtaaacagggtCTGG	436_1	9412	-21
437	acacttaaacagggt	2-10-4	ACacttaaacaggGCT	437_1	9414	-22
438	gaacacttaaacagg	4-8-4	GAACacttaaacAGGG	438_1	9416	-20
439	agagaacacttaaacag	4-9-4	AGAGaacacttaaacAG	439_1	9418	-20
440	ctacagagaacactta	4-8-4	CTACagagaaacACTTA	440_1	9423	-20
441	atgctacagagaacact	3-10-4	ATGctacagagaacACT	441_1	9425	-22
442	ataaatgctacagagaaca	4-11-4	ATAAatgctacagagAACAA	442_1	9427	-20
443	agataaatgctacagaga	2-12-4	AGataaatgctacaGAGA	443_1	9430	-20
444	tagagataaatgctaca	4-9-4	TAGAgataaatgcTACA	444_1	9434	-21
445	tagatagagataaatgct	4-11-3	TAGAtagagataaatGCT	445_1	9437	-20
446	caatatactagatagaga	4-10-4	CAATatactagatAGAGA	446_1	9445	-21
447	tacacaatatactagatag	4-11-4	TACAcfaatatactagATAG	447_1	9448	-21
448	ctacacaatatactag	3-10-3	CTAcacaatatactTAG	448_1	9452	-16
449	gctacacaatatactta	4-8-4	GCTAcacaatataCTTA	449_1	9453	-21
450	atatgctacacaatatac	4-10-4	ATATgctacacaatATAC	450_1	9455	-20
451	tgatatgctacacaat	4-8-4	TGATatgctacacaCAAT	451_1	9459	-20
452	atgatatgatatgctac	4-9-4	ATGAtatgatatgCTAC	452_1	9464	-21
453	gaggagagagacaataaa	4-10-4	GAGGagagagacaatAAA	453_1	9495	-20
454	ctaggaggagagagaca	3-11-3	CTAggaggagagagACA	454_1	9500	-22
455	tattctaggaggagaga	4-10-3	TATTctaggaggagAGA	455_1	9504	-21
456	ttatattctaggaggag	4-10-3	TTATattctaggagGAG	456_1	9507	-21
457	gtttatattctaggag	3-9-4	GTTTatattctAGGAG	457_1	9510	-20
458	tggagtttatattctagg	2-12-4	TGgagtttatattctTAGG	458_1	9512	-22
459	cgtaccaccactctgc	2-11-3	CGtaccaccactcTGC	459_1	9590	-25
460	tgaggaaatcattcattc	4-10-4	TGAGgaaatcattcATTTC	460_1	9641	-22
461	tttgaggaaatcattcat	4-10-4	TTTGaggaaatcatTCAT	461_1	9643	-20
462	aggctaactcctatttg	4-10-2	AGGctaactcctattTG	462_1	9657	-22
463	tttaggctaactcctat	4-8-4	TTTAggctaactCTAT	463_1	9660	-22
464	tgctccagtgtaccct	3-11-2	TGctccagtgtaccCT	464_1	9755	-27
465	tagtagtactcgatag	2-10-4	TAgtagtactcgATAG	465_1	9813	-18
466	ctaattgtagtagtactc	3-12-3	CTAattgtagtagtaCTC	466_1	9818	-20
467	tgctaattgtagtagt	2-10-4	TGctaattgtagTAGT	467_1	9822	-19

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
468	agtgctaattgtagta	4-10-2	AGTGctaattgtagTA	468_1	9824	-19
469	gcaagtgctaattgta	4-10-2	GCAAgtgctaattgTA	469_1	9827	-20
470	gaggaaatgaactaattta	4-13-2	GAGGaaatgaactaattTA	470_1	9881	-18
471	caggaggaaatgaacta	4-11-2	CAGGaggaaatgaactTA	471_1	9886	-19
472	ccctagagtcatttcc	2-11-3	CCctagagtcattTCC	472_1	9902	-24
473	atcttacatgatgaagc	3-11-3	ATCttacatgatgaAGC	473_1	9925	-20
475	agacacactcagatttcag	2-15-2	AGacacactcagatttcAG	475_1	9967	-20
474	gacacactcagatttcag	3-13-2	GACacactcagatttcAG	474_1	9967	-20
476	aagacacactcagatttcag	3-15-2	AAGacacactcagatttcAG	476_1	9967	-21
477	agacacactcagatttca	2-13-3	AGacacactcagattTCA	477_1	9968	-20
478	aagacacactcagatttca	3-13-3	AAGacacactcagattTCA	478_1	9968	-21
479	aaagacacactcagatttca	2-14-4	AAagacacactcagattTCA	479_1	9968	-20
480	gaaagacacactcagatttc	3-14-3	GAAagacacactcagattTTC	480_1	9969	-20
481	aagacacactcagatttc	4-11-3	AAGacacactcagattTTC	481_1	9969	-21
482	aaagacacactcagatttc	4-11-4	AAAGacacactcagattTTC	482_1	9969	-20
483	tgaaagacacactcagattt	4-14-2	TGAAagacacactcagattTT	483_1	9970	-20
484	tgaaagacacactcagatt	2-13-4	TGaaagacacactcagattT	484_1	9971	-21
485	tgaaagacacactcagat	3-12-3	TGAAagacacactcagatT	485_1	9972	-20
486	attgaaagacacactca	4-10-3	ATTGaaagacacactCA	486_1	9975	-19
487	tcattgaaagacacact	2-11-4	TCattgaaagacactCACT	487_1	9977	-18
488	ttccatcattgaaaga	3-9-4	TTccatcattgaAAGA	488_1	9983	-18
489	ataataccacttatcat	4-9-4	ATAataccacttaTCAT	489_1	10010	-20
490	ttacttaatttctttgga	2-12-4	TTacttaatttctttTGGA	490_1	10055	-20
491	ttagaactagctttatca	3-12-3	TTagaactagctttatCA	491_1	10101	-20
492	gaggtaacaatatagg	3-10-3	GAGgtacaatatAGG	492_1	10171	-18
493	cttatgatacaactta	3-10-3	CTTatgatacaactTTA	493_1	10384	-15
494	tcttatgatacaactt	2-11-3	TCTtatgatacaactTT	494_1	10385	-15
495	ttcttatgatacaact	3-11-2	TTcttatgatacaactCT	495_1	10386	-15
496	cagtttcttatgatac	2-11-3	CagtttcttatgaTAC	496_1	10390	-16
497	gcagtttcttatgata	3-11-2	GCAgtttcttatgaATA	497_1	10391	-19
498	tacaaatgtctattaggtt	4-12-3	TACaaatgtctattagGTT	498_1	10457	-21
499	tgtacaaatgtctattag	4-11-3	TGTAc aaatgtctattAG	499_1	10460	-20
500	agcatcacaaattagta	3-11-2	AGCatcacaaattagTA	500_1	10535	-18
501	cta atgatagtgaagc	3-11-2	CTAatgatagtgaAGC	501_1	10548	-17
502	agctaatgatagtgaa	3-11-2	AGCTaatgatagtGAA	502_1	10550	-16

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
503	atgccttgacatatta	4-10-2	ATGCcttgacatATTA	503_1	10565	-20
504	ctcaagattattgacac	4-9-4	CTCAagattattgACAC	504_1	10623	-20
505	acctcaagattattga	2-10-4	ACctcaagattaTTGA	505_2	10626	-18
505	acctcaagattattga	3-9-4	ACctcaagattaTTGA	505_1	10626	-20
506	aacctcaagattattg	4-10-2	AACctcaagattatTG	506_1	10627	-17
507	cacaaacctcaagattatt	4-13-2	CACAaacctcaagattaTT	507_1	10628	-20
508	gtacttaattagacct	3-9-4	GTActtaattagACCT	508_1	10667	-21
509	agtacttaattagacc	4-9-3	AGTActtaattagACC	509_1	10668	-20
510	gtatgagggtggtaaac	4-10-2	GTATgagggtggtaaAC	510_1	10688	-18
511	aggaaacagcagaagtg	2-11-4	AGgaaacagcagaAGTG	511_1	10723	-21
512	gcacaacccagaggaa	2-12-2	GCacaacccagaggAA	512_1	10735	-20
513	caagcacacaaccagag	3-11-2	CAAgcacacaaccagAG	513_1	10738	-20
514	ttcaagcacacaaccag	3-10-3	TTCaagcacacaaccCAG	514_1	10740	-21
515	aattcaagcacacaacc	2-10-4	AAttcaagcacacaACCC	515_1	10742	-20
516	taataatcaagcacacaacc	4-13-2	TAATAatcaagcacacaCC	516_1	10743	-20
517	actaataattcaagcac	4-9-4	ACTAataattcaaGCAC	517_1	10747	-20
518	ataataactaataattcaagc	4-12-4	ATAataactaataattcAAGC	518_1	10749	-19
519	tagatttgtgaggttaa	2-10-4	TAgatttgtgagGTAA	519_1	11055	-18
520	agccttaattctccat	4-10-2	AGCCttaattctccAT	520_1	11091	-24
521	aatgatctagagcctta	4-9-4	AATGatctagagcCTTA	521_1	11100	-22
522	ctaatgatctagagcc	3-10-3	CTAatgatctagaGCC	522_1	11103	-22
523	actaatgatctagagc	3-9-4	ACTAatgatctaGAGC	523_1	11104	-21
524	cattaacatgttcttatt	3-11-4	CATtaacatgttctTATT	524_1	11165	-19
525	acaagtacattaacatgttc	4-12-4	ACAAGtacattaacatGTTC	525_1	11170	-22
526	ttacaagtacattaacatg	4-11-4	TTACAagtacattaacATG	526_1	11173	-20
527	gctttattcatgtttat	4-9-4	GCTTtattcatgtTTAT	527_1	11195	-22
528	gctttattcatgtttta	3-11-2	GCTTtattcatgtTTA	528_1	11196	-18
529	agagctttattcatgttt	3-13-2	AGAgctttattcatgtTT	529_1	11197	-20
530	ataagagctttattcatg	4-10-4	ATAAgagctttattCATG	530_1	11200	-21
531	cataagagctttattca	4-9-4	CATAagagcttTTCA	531_1	11202	-21
532	agcataagagctttat	4-8-4	AGCAtaagagctTTAT	532_1	11205	-22
533	tagattgttttagtgca	3-10-3	TAGattgtttagtGCA	533_1	11228	-20
534	gtagattgtttagtgc	2-10-4	GTagattgtttatGTGC	534_1	11229	-21
535	gacaattctagtagatt	4-9-4	GACAattctagtaGATT	535_1	11238	-21
536	ctgacaattctagtag	3-9-4	CTGacaattctaGTAG	536_1	11241	-20

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.

SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
537	gctgacaattctagta	4-10-2	GCTGacaattctagTA	537_1	11242	-21
538	aggattaagatacgta	2-12-2	AGgattaagatacgTA	538_1	11262	-15
539	caggattaagatacgt	2-11-3	CAggattaagataCGT	539_1	11263	-17
540	tcaggattaagatacg	3-11-2	TCAggattaagataCG	540_1	11264	-16
541	ttcaggattaagatac	2-10-4	TTcaggattaagATAC	541_1	11265	-15
542	aggaagaaagtgttgattc	4-10-4	AGGAagaaagtgtgATTC	542_1	11308	-21
543	tcaaggaagaaagtgttga	4-10-4	TCAaggaagaaagtTTGA	543_1	11311	-20
544	ctcaaggaagaaagtgtt	4-10-4	CTCAaggaagaaagtTTG	544_1	11312	-20
545	tgctcaaggaagaaagt	3-10-4	TGCTcaaggaagaAAGT	545_1	11315	-21
546	aattatgctcaaggaaga	4-11-3	AATTatgctcaaggaAGA	546_1	11319	-20
547	taggataccacattatga	4-12-2	TAGGataccacattatGA	547_1	11389	-22
548	cataatttattccattcctc	2-15-3	CAtaatttattccattcCTC	548_1	11449	-22
549	tgcataatttattccat	4-10-3	TGCAtaatttattcCAT	549_1	11454	-22
550	actgcataatttattcc	4-10-3	ACTGcataatttatTCC	550_1	11456	-21
551	ctaaactgcataatttatt	4-11-4	CTAAactgcataattTATT	551_1	11458	-20
552	ataactaaactgcata	2-10-4	ATAactaaactgCATA	552_1	11465	-16
553	ttattaataactaaactgc	3-12-4	TTAttaataactaaCTGC	553_1	11468	-19
554	tagtacattattaataaact	4-13-2	TAGTactattattaataaCT	554_1	11475	-18
555	cataactaaggacggt	4-10-2	CATAactaaggacgTT	555_1	11493	-17
556	tcataactaaggacgt	2-11-3	TCataactaaggacGT	556_1	11494	-16
557	cgtcataactaaggac	4-10-2	CGTCataactaaggAC	557_1	11496	-17
558	tcgtcataactaagga	2-12-2	TCgtcataactaagGA	558_1	11497	-16
559	atcgtcataactaagg	2-10-4	ATcgtcataactAAGG	559_1	11498	-17
560	gtagtagattcttact	2-11-3	GTagtagattcttactATT	560_1	11525	-15
561	ctctattgtagtagatc	3-10-3	CTCtattgtagtagATC	561_1	11532	-17
562	agtagtagagttactgt	3-10-3	AGTatagagttactTGT	562_1	11567	-19
563	ttcctggtgatacttt	4-10-2	TTCCtggtgatactTT	563_1	11644	-21
564	gttctggtgatactt	4-10-2	GTTCCtggtgatactTT	564_1	11645	-21
565	tgttcctggtgatact	2-12-2	TGttcctggtgataCT	565_1	11646	-20
566	ataaacatgaatctctcc	2-12-4	ATAaacatgaatctCTCC	566_1	11801	-20
567	ctttataaacatgaatctc	3-12-4	CTTtataaacatgaatCTC	567_1	11804	-19
568	ctgtctttataaacatg	3-10-4	CTGtctttataaaCATG	568_1	11810	-19
569	ttgttataaacatctgtctt	2-12-4	TTgttataaacatctGTCTT	569_1	11820	-18
570	ttaaatttattcttggata	3-12-4	TTAaatttattcttGGATA	570_1	11849	-19
571	cttaaatttattcttggga	2-12-4	CTtaaatttattctTGGA	571_1	11851	-19

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.

SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
572	cttcttaaatttattcttg	4-13-2	CTTCtaaatttattctTG	572_1	11853	-18
573	tatgtttctcagtaaag	4-9-4	TATGtttctcagtAAAG	573_1	11877	-19
574	gaattatctttaacca	3-10-4	GAAttatctttaaACCA	574_1	11947	-18
575	cccttaaatttctaca	3-11-2	CCcttaaatttctaca	575_1	11980	-20
576	acactgctcttgtacc	4-10-2	ACActgctcttgtACC	576_1	11995	-23
577	tgacaacactgctctt	3-10-3	TGacaacactgctCTT	577_1	12000	-21
578	tacatttattgggctc	4-10-2	TACAtttattgggcTC	578_1	12081	-19
579	gtacatttattgggct	2-10-4	GTacatttattGGCT	579_1	12082	-23
580	ttggtacatttattgg	3-10-3	TTGgtacatttTGG	580_1	12085	-18
581	catgttggtacatttat	4-10-3	CATGttggtacattTAT	581_1	12088	-21
582	aatcatggttggtacat	4-10-2	AATCatggttggtacAT	582_1	12092	-16
583	aaatcatggttggtaca	2-12-2	AAatcatggttggtaca	583_1	12093	-14
584	gacaagtttggtataa	3-11-2	GACAagtttggtataa	584_1	12132	-14
585	aatgttcagatgcctc	2-10-4	AAtgttcagatGCCTC	585_1	12197	-21
586	gcttaatgttcagatg	2-12-2	GcttaatgttcagaTG	586_1	12201	-17
587	cgtacatagcttgatg	4-10-2	CGTAcatagcttgATG	587_1	12267	-20
588	gtgaggaattaggata	3-11-2	GTGaggaattaggata	588_1	12753	-17
589	gtaacaatatggtttg	3-11-2	GTAacaatatggtttG	589_1	12780	-15
590	gaaatattgtagacta	2-11-3	GAaatattgtagacta	590_1	13151	-14
591	ttgaaatattgtagac	3-11-2	TTGaaatattgtagac	591_1	13153	-12
592	aagtctagtaatttgc	2-10-4	AAgtctagtaattTGC	592_1	13217	-17
593	gctcagtagattataa	4-10-2	GCTCagtagattataa	593_1	13259	-17
594	catacactgttgctaa	3-10-3	CATAcactgttgctTAA	594_1	13296	-19
595	atggtctcaaatcatt	3-10-3	ATGgtctcaaatcATT	595_1	13314	-17
596	caatggtctcaaatca	4-10-2	CAATggtctcaaatCA	596_1	13316	-18
597	ttcctattgattgact	4-10-2	TTcctattgattgact	597_1	13568	-20
598	tttctgttcacaacac	4-10-2	TTTctgttcacaacAC	598_1	13600	-17
599	aggaaccactaatct	2-11-3	AGgaaccactaaTCT	599_1	13702	-20
600	taaatggcaggaaccc	3-11-2	TAAatggcaggaacCC	600_1	13710	-19
601	gtaaatggcaggaacc	4-10-2	GTAAatggcaggaacCC	601_1	13711	-20
602	ttgtaaatggcagga	2-11-3	TTgtaaatggcagGAA	602_1	13713	-16
603	ttatgagttaggcatg	2-10-4	TTatgagttaggCATG	603_1	13835	-19
604	ccaggtgaaactttaa	3-11-2	CCAggtgaaacttTAA	604_1	13935	-17
605	cccttagtcagctcct	3-10-3	CCcttagtcagctCCT	605_1	13997	-30
606	acccttagtcagctcc	2-10-4	ACccttagtcagctTCC	606_1	13998	-27

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
607	cacccttagtcagctc	2-11-3	CACccttagtcagCTC	607_1	13999	-24
608	tctcttactaggctcc	3-10-3	TCTcttactaggcTCC	608_1	14091	-24
609	cctatctgtcatcatg	2-11-3	CCt atctgtcatcATG	609_1	14178	-20
610	tcctatctgtcatcat	3-11-2	TCct atctgtcatcAT	610_1	14179	-20
611	gagaagtgtgagaagc	3-11-2	GAGAagtgtgagaaGC	611_1	14808	-19
612	catccttgaagtttag	4-10-2	CATCcttgaagtttAG	612_1	14908	-19
613	taataagatggctccc	3-10-3	TAAaagatggctCCC	613_1	15046	-21
614	caaggcataataagat	3-11-2	CAAggcataataagAT	614_1	15053	-14
615	ccaaggcataataaga	2-10-4	CCaaggcataatAAGA	615_1	15054	-18
616	tgatccaattctcacc	2-12-2	TGatccaattctcaCC	616_1	15151	-19
617	atgatccaattctcac	3-10-3	ATGatccaattctCAC	617_1	15152	-19
618	cgcttcatcttcaccc	3-11-2	CGcttcatcttcacCC	618_1	15260	-26
619	tatgacactgcatctt	2-10-4	TAtgacactgcaTCTT	619_1	15317	-19
620	gtatgacactgcatct	3-10-3	GTAtgacactgcaTCT	620_1	15318	-21
621	tgatgacactgcatc	2-10-4	TGatgacactgCATC	621_1	15319	-20
622	ttctcttctgtaagtc	4-10-2	TTCTcttctgtaagTC	622_1	15363	-19
623	ttctacagaggaacta	2-10-4	TtctacagaggaACTA	623_1	15467	-17
624	actacagttctacaga	3-10-3	ACTacagttctacAGA	624_1	15474	-19
625	ttcccacaggtaaatg	4-10-2	TTCCcacaggtaaaTG	625_1	15561	-21
626	attatttgaatatactcatt	4-12-4	ATTAtttgaatatactCATT	626_1	15594	-20
627	tgggaggaaattatttg	4-10-3	TGGGaggaaattatTTG	627_1	15606	-20
628	tgactcatcttaaatg	4-10-2	TGACTcatcttaaaTG	628_1	15621	-17
629	ctgactcatcttaaat	3-11-2	CTGactcatcttaaAT	629_1	15622	-16
630	tttactctgactcatc	3-10-3	TTTactctgactcATC	630_1	15628	-17
631	tattggaggaattatt	3-11-2	TATtgaggaattaTT	631_1	15642	-14
632	gtattggaggaattat	3-11-2	GTAttggaggaattAT	632_1	15643	-16
633	tggtatacttctctaagtat	2-15-3	TGgtatacttctctaagTAT	633_1	15655	-22
634	gatctcttggataact	4-10-2	GATCtcttggataACT	634_1	15666	-20
635	cagacaactctatacc	2-12-2	CAGacaactctataCC	635_1	15689	-18
636	aacatcagacaactcta	4-9-4	AACatcagacaacTCTA	636_1	15693	-21
637	taacatcagacaactc	4-10-2	TAAcatcagacaacTC	637_1	15695	-16
638	tttaacatcagacaactc	4-10-4	TTTAacatcagacaACTC	638_1	15695	-20
639	atttaacatcagacaa	2-12-2	ATttaacatcagacAA	639_1	15698	-11
640	cctatttAACatcagac	2-11-4	CctatttAACatcAGAC	640_1	15700	-20
641	tcctatttAACatca	3-10-3	TCCtatttAACaTCA	641_1	15703	-21

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
642	tcaacgactattggaat	4-9-4	TCAAcgactattgGAAT	642_1	15737	-20
643	cttatattctggctat	4-9-3	CTTAtattctggcTAT	643_1	15850	-20
644	atccttatattctggc	4-10-2	ATCCttatattctgGC	644_1	15853	-23
645	gatccttatattctgg	2-10-4	GATccttatattCTGG	645_1	15854	-21
646	tgatccttatattctg	3-10-3	TGATccttatattCTG	646_1	15855	-19
647	attgaaacttgatcct	4-8-4	ATTGaaacttgaTCCT	647_1	15864	-21
648	actgtcattgaaactt	2-10-4	ACTgtcattgaaACTT	648_1	15870	-16
649	tcttactgtcattgaa	3-11-2	TCTtactgtcattgAA	649_1	15874	-16
650	aggatccttactgtcatt	2-11-4	AGgatccttactgtCATT	650_1	15877	-21
651	gcaaatcaactccatc	3-10-3	GCAaatcaactccATC	651_1	15896	-20
652	gtgcaaatcaactcca	3-10-3	GTGcaaatcaactCCA	652_1	15898	-22
653	caattatttctttgtgc	4-10-3	CAATtatttctttGTGC	653_1	15910	-21
654	tggcaacaattatttctt	3-11-4	TGGcaacaattattTCTT	654_1	15915	-21
655	gctggcaacaattatt	3-9-4	GCTggcaacaatTATT	655_1	15919	-21
656	atccatttctactgcc	4-10-2	ATCCatttctactgCC	656_1	15973	-24
657	taatattctattgatttcta	4-11-4	TAAtatctattgattTCTA	657_1	15988	-20
658	tcaatagtgtagggca	2-12-2	TCaatagtgtagggCA	658_1	16093	-18
659	ttcaatagtgtagggc	3-11-2	TTCaatagtgtaggGC	659_1	16094	-19
660	aggttaattaattcaatag	4-11-4	AGGTtaattaattcaATAG	660_1	16102	-21
661	catttgtaatccctag	3-10-3	CATttgtaatcccTAG	661_2	16163	-20
661	catttgtaatccctag	3-9-4	CATttgtaatccCTAG	661_1	16163	-22
662	acatttgtaatcccta	3-10-3	ACAtttgtaatccCTA	662_1	16164	-20
663	aacatttgtaatccct	2-10-4	AACatttgtaatCCCT	663_2	16165	-21
663	aacatttgtaatccct	3-9-4	AACatttgtaatCCCT	663_1	16165	-22
664	taaatttcaagttctg	2-11-3	TAAatttcaagttCTG	664_1	16184	-14
665	gtttaaatttcaagttct	3-11-4	GTTtaaatttcaagTTCT	665_1	16185	-19
666	ccaagtttaaatttcaag	4-10-4	CCAagtttaaatttCAAG	666_1	16189	-21
667	acccaagtttaaatttc	4-9-4	ACCCaagtttaaaTTTC	667_1	16192	-22
668	catacagtgacccaagttt	2-14-3	CATacagtgacccaagTTT	668_1	16199	-23
669	acatcccatacagtga	2-11-3	ACatcccatacagTGA	669_1	16208	-21
670	agcacagctctacatc	2-10-4	AGcacagctctacATC	670_1	16219	-22
671	atatagcacagctcta	3-9-4	ATAtagcacagcTCTA	671_1	16223	-21
672	tccatatagcacagct	3-11-2	TCCatatagcacagCT	672_1	16226	-22
673	atttccatatagcaca	3-9-4	ATTtccatatagCACA	673_1	16229	-20
674	tttatttccatatagca	4-9-4	TTTAtttccatatAGCA	674_1	16231	-22

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
675	tttatttccatatagc	3-10-3	TTTatttccatatAGC	675_1	16232	-18
676	aaggagaggagattatg	4-9-4	AAGGagaggagatTATG	676_1	16409	-21
677	agttcttgtgtagct	3-11-2	AGTtcttgtgtagCT	677_1	16456	-21
678	gagttcttgtgtagc	2-12-2	GAGttcttgtgtagc	678_1	16457	-20
679	attaattatccatccac	3-10-4	ATTAattatccatCCAC	679_1	16590	-21
680	atcaattaattatccatc	3-11-4	ATCaattaattatcCATC	680_1	16593	-19
681	agaatcaattaattatcc	3-12-3	AGAatcaattaattatTCC	681_1	16596	-18
682	tgagataccgtgcatg	2-12-2	TGagataccgtgcatG	682_1	16656	-18
683	aatgagataccgtgca	2-10-4	AATgagataccgtGCA	683_1	16658	-21
684	ctgtggtaggcta	3-11-2	CTGtggtaggctaAT	684_1	16834	-19
685	aagagtaagggctctgtggtt	1-17-2	AagagtaagggctctgtggTT	685_1	16842	-21
686	gatgggtaagagtaa	4-9-3	GATGggtaagagTAA	686_1	16854	-19
687	agcagatgggtaaga	3-11-2	AGCagatgggtaaGA	687_1	16858	-20
688	tgtaaacattttagc	2-10-4	TGtaaacattttagTAGC	688_1	16886	-19
689	cctgcttataaatgta	3-11-2	CCTgcttataaatGTA	689_1	16898	-19
690	tgccctgcttataaat	4-10-2	TGCCctgcttataaAT	690_1	16901	-23
691	tcttcttagttcaata	2-12-2	TcttcttagttcaaTA	691_1	16935	-15
692	tggtttctaactacat	2-10-4	TGgtttctaactACAT	692_1	16980	-18
693	agtttggtttctaacta	2-12-3	AGtttggtttctaactA	693_1	16983	-19
694	gaatgaaacttgcctg	3-10-3	GAAtgaaacttgcCTG	694_1	17047	-18
695	attatccttacatgat	3-10-3	ATTatccttacatGAT	695_1	17173	-17
696	gtaccaattatcctt	2-11-3	GTaccaattatcCTT	696_1	17180	-21
697	tgtaccaattatcct	3-10-3	TGTaccaattatCCT	697_1	17181	-24
698	ttgtaccaattatcc	2-11-3	TTgtaccaattaTCC	698_1	17182	-20
699	tttgtaccaattatc	3-11-2	TTTgtaccaattaTC	699_1	17183	-17
700	agcagcagggtatatt	4-10-2	AGCagcagggtataATT	700_1	17197	-22
701	tgggaagtggctctggg	3-10-3	TGGgaagtggctctGGG	701_1	17292	-25
702	ctggagagtgataata	3-11-2	CTGgagagtgataaTA	702_1	17322	-17
703	aatgctggattacgtc	4-10-2	AATGctggattacgTC	703_1	17354	-19
704	caatgctggattacgt	2-11-3	CAatgctggattaCGT	704_1	17355	-19
705	ttgttcagaagtatcc	2-10-4	TTgttcagaagtATCC	705_1	17625	-19
706	gatgatttgcctggag	2-10-4	GATgatttgcctGGAG	706_1	17646	-21
707	gaaatcattcacaacc	3-10-3	GAAatcattcacaACC	707_1	17860	-17
708	ttgtaacatctactac	3-10-3	TTGtaacatctacTAC	708_1	17891	-16
709	cattaagcagcaagtt	3-11-2	CATtaagcagcaagTT	709_1	17923	-17

TABLE 5-continued

list of oligonucleotide motif sequences (indicated by SEQ ID NO) targeting the human PD-L1 transcript (SEQ ID NO: 1), designs of these, as well as specific antisense oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.

SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start ID NO: 1	dG
710	ttactagatgtgagca	3-11-2	TTActagatgtgagCA	710_1	17942	-18
711	tttactagatgtgagc	2-11-3	TtactagatgtgAGC	711_1	17943	-18
712	gaccaagcaccttaca	3-11-2	GACcaagcaccttaCA	712_1	17971	-22
713	agaccaagcaccttac	3-10-3	AGAccaagcacctTAC	713_1	17972	-22
714	atgggttaaataaagg	2-10-4	ATgggttaaataAAGG	714_1	18052	-15
715	tcaaccagagtattaa	2-12-2	TCaaccagagtattAA	715_1	18067	-13
716	gtcaaccagagtatta	3-11-2	GTCaaccagagtatTA	716_1	18068	-18
717	attgtaaagctgatata	2-11-3	ATtgtaaagctgaTAT	717_1	18135	-14
718	cacataattgtaaacg	2-10-4	CAcataattgtaAAGC	718_1	18141	-16
719	gaggtctgctatttac	2-11-3	GAggtctgctattTAC	719_1	18274	-19
720	tgtagattcaatgcct	2-11-3	TGtagattcaatgCCT	720_1	18404	-20
721	cctcattatactatga	2-11-3	CCtcattatactaTGA	721_1	18456	-19
722	ccttatgctatgacac	2-12-2	CCttatgctatgacAC	722_1	18509	-18
723	tccttatgctatgaca	4-10-2	TCCTtatgctatgaCA	723_1	18510	-22
724	aagatgtttaagtata	3-10-3	AAGatgtttaagtATA	724_1	18598	-13
725	ctgattattaagatgt	2-10-4	CTgattattaagATGT	725_1	18607	-17
726	tggaaggatgaatt	2-12-2	TGgaaaggatgaaTT	726_1	18808	-13
727	acttgaatggcttgga	2-12-2	ACttgaatggcttgGA	727_1	18880	-18
728	aacttgaatggcttgg	3-10-3	AACTtgaatggctTGG	728_1	18881	-19
729	caatgtgttactatTT	4-10-2	CAATgtgttactatTT	729_1	19004	-16
730	acaatgtgttactatt	3-10-3	ACAatgtgttactATT	730_1	19005	-15
731	catctgctatataaga	4-10-2	CATCtgcataataaGA	731_1	19063	-18
732	cctagagcaaaactt	4-10-2	CCTAgagcaaaactTT	732_1	19223	-20
733	cagagttaataataag	3-10-3	CAGagttaataatAAG	733_1	19327	-13
734	gttcaagcacaacgaa	4-10-2	GTTCaagcacaacgAA	734_1	19493	-18
735	agggttcaagcacaac	2-11-3	AGggttcaagcacAAC	735_1	19496	-18
736	tggttgagacactggt	2-12-2	TGgttgagacactgTT	736_1	19677	-17
737	aaggaggagttaggac	3-11-2	AAGgaggagttaggAC	737_1	19821	-18
738	ctatgccatttacgat	4-10-2	CTATgccatttacgAT	738_1	19884	-21
739	tcaaatgcagaattag	2-12-2	TCaaatgcagaattAG	739_1	19913	-12
740	agtgacaatcaaagtc	2-10-4	AGtgacaatcaaATGC	740_1	19921	-18
741	aagtgacaatcaaagtc	2-11-3	AAgtgacaatcaaATG	741_1	19922	-12
742	gtgtaccaagtaacaa	3-11-2	GTGtaccaagtaacAA	742_1	19978	-16
743	tgggatgttaaacTGA	3-10-3	TGGgatgttaaacTGA	743_1	20037	-20

Motif sequences represent the contiguous sequence of nucleobases present in the oligonucleotide.

[0412] Designs refer to the gapmer design, F-G-F', where each number represents the number of consecutive modified nucleosides, e.g. 2' modified nucleosides (first number=5' flank), followed by the number of DNA nucleosides (second number=gap region), followed by the number of modified nucleosides, e.g. 2' modified nucleosides (third number=3' flank), optionally preceded by or followed by further

repeated regions of DNA and LNA, which are not necessarily part of the contiguous sequence that is complementary to the target nucleic acid.

[0413] Oligonucleotide compounds represent specific designs of a motif sequence. Capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, all internucleoside linkages are phosphorothioate internucleoside linkages.

TABLE 6

Oligonucleotides targeting mouse PD-L1 transcript (SEQ ID NO: 4) designs of these, as well as specific oligonucleotide compounds (indicated by CMP ID NO) designed based on the motif sequence.						
SEQ ID NO	Motif sequence	Design	Oligonucleotide Compound	CMP ID NO	Start on SEQ ID NO: 4	dG
744	agtttacattttctgc	3-10-3	AGTttacattttcTGC	744_1	4189	-20
745	tatgtgaagaggagag	3-10-3	TATgtgaagaggagAG	745_1	7797	-19
746	cacctttaaacccca	3-10-3	CACctttaaaccCCA	746_1	9221	-23
747	tcctttataatcacac	3-10-3	TCctttataatcaCAC	747_1	10386	-19
748	acggtattttcacagg	3-10-3	ACGgtattttcacAGG	748_1	12389	-21
749	gacactacaatgagga	3-10-3	GACactacaatgaGGA	749_1	15088	-20
750	tggtttttaggactgt	3-10-3	TGGtttttaggacTGT	750_1	16410	-21
751	cgacaaattctatcct	3-10-3	CGacaaattctatCCT	751_1	18688	-20
752	tgatatacaatgctac	3-10-3	TGAtatacaatgcTAC	752_1	18735	-16
753	tcgttgggtaaatTTA	3-10-3	TCGttgggtaaatTTA	753_1	19495	-17
754	tgctttataaatggtg	3-10-3	TGctttataaatgGTG	754_1	19880	-19

Motif sequences represent the contiguous sequence of nucleobases present in the oligonucleotide.

[0414] Designs refer to the gapmer design, F-G-F', where each number represents the number of consecutive modified nucleosides, e.g. 2' modified nucleosides (first number=5' flank), followed by the number of DNA nucleosides (second number=gap region), followed by the number of modified nucleosides, e.g. 2' modified nucleosides (third number=3' flank), optionally preceded by or followed by further repeated regions of DNA and LNA, which are not necessarily part of the contiguous sequence that is complementary to the target nucleic acid.

[0415] Oligonucleotide compounds represent specific designs of a motif sequence. Capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, all internucleoside linkages are phosphorothioate internucleoside linkages.

TABLE 7

Oligonucleotide motif sequences and antisense compounds with 5' ca biocleavable linker.			
SEQ ID NO	motif sequence	oligonucleotide compound with ca linker	CMP ID NO
755	caagtttacattttctgc	c ₀ a ₀ AGTttacattttcTGC	755_1
756	catatgtgaagaggagag	c ₀ a ₀ TATgtgaagaggagAG	756_1
757	cacctttaaacccca	c ₀ a ₀ CACctttaaaccCCA	757_1

TABLE 7-continued

Oligonucleotide motif sequences and antisense compounds with 5' ca biocleavable linker.			
SEQ ID NO	motif sequence	oligonucleotide compound with ca linker	CMP ID NO
758	catcctttataatcacac	c ₆ a ₀ TCctttataatcaCAC	758_1
759	caacggatattttcacagg	c ₆ a ₀ ACGgtattttcacAGG	759_1
760	cagacactacaatgagga	c ₆ a ₀ GACactacaatgaGGA	760_1
761	catggtttttaggactgt	c ₆ a ₀ TGGtttttaggacTGT	761_1
762	cacgacaaattctatcct	c ₆ a ₀ CGAcaaattctatCCT	762_1
763	catgatatacaatgctac	c ₆ a ₀ TGAtatacaatgcTAC	763_1
764	catcgttgggtaaatTTA	c ₆ a ₀ TCGttgggtaaatTTA	764_1
765	catgctttataaatggtg	c ₆ a ₀ TGctttataaatgGTG	765_1
766	caacaaataatggttactct	c ₆ a ₀ ACAaataatggttaCTCT	766_1
767	cacagattgatggtagtt	c ₆ a ₀ CAGattgatggtagTT	767_1
768	cacctatttaacatcagac	c ₆ a ₀ CctatttaacatcAGAC	768_1
769	cactaattgtagtagtactc	c ₆ a ₀ CTAattgtagtagtaCTC	769_1
770	caataaacatgaatctctcc	c ₆ a ₀ ATAaacatgaatctCTCC	770_1

[0416] Capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, subscript o represent a phosphodiester internucleoside linkage and unless otherwise indicated other internucleoside linkages are phosphorothioate internucleoside linkages.

TABLE 8

GalNAc conjugated antisense oligonucleotide compounds.	
antisense oligonucleotide conjugate	CMP ID NO
GN2-C6 ₀ c ₆ a ₀ AGTttacattttcTGC	755_2
GN2-C6 ₀ c ₆ a ₀ TATgtgaagaggagAG	756_2
GN2-C6 ₀ c ₆ a ₀ CACctttaaaaccCCA	757_2
GN2-C6 ₀ c ₆ a ₀ TCctttataatcaCAC	758_2
GN2-C6 ₀ c ₆ a ₀ ACGgtattttcacAGG	759_2
GN2-C6 ₀ c ₆ a ₀ GACactacaatgaGGA	760_2
GN2-C6 ₀ c ₆ a ₀ TGGtttttaggacTGT	761_2
GN2-C6 ₀ c ₆ a ₀ CGAcaaattctatCCT	762_2
GN2-C6 ₀ c ₆ a ₀ TGAtatacaatgcTAC	763_2
GN2-C6 ₀ c ₆ a ₀ TCGttgggtaaatTTA	764_2
GN2-C6 ₀ c ₆ a ₀ TGctttataaatgGTG	765_2
GN2-C6 ₀ c ₆ a ₀ ACAaataatggttaCTCT	766_2
GN2-C6 ₀ c ₆ a ₀ CAGattgatggtagTT	767_2
GN2-C6 ₀ c ₆ a ₀ CctatttaacatcAGAC	768_2

TABLE 8-continued

GalNAc conjugated antisense oligonucleotide compounds.	
antisense oligonucleotide conjugate	CMP ID NO
GN2-C6 ₀ c ₆ a ₀ CTAattgtagtagtaCTC	769_2
GN2-C6 ₀ c ₆ a ₀ ATAaacatgaatctCTCC	770_2

[0417] GN2 represents the trivalent GalNAc cluster shown in FIG. 3, C6 represents an amino alkyl group with 6 carbons, capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, subscript o represent a phosphodiester nucleoside linkage and unless otherwise indicated internucleoside linkages are phosphorothioate internucleoside linkages. Chemical drawings representing some of the molecules are shown in FIGS. 4 to 8.

AAV/HBV Mouse Models

Pasteur Model:

[0418] HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout (here referred to as HLA-A2/DR1) mice were created and bred at the Institut Pasteur. These mice represent an in vivo experimental model for human immune function studies without any interference with mouse MHC response (Pajot et al 2004 Eur J Immunol. 34(11):3060-9.

[0419] Adeno-associated virus (AAV) vector, AAV serotype 2/8 carrying a replication competent HBV DNA genome was used in these studies. The AAV-HBV vector (batch GVPN #6163) was diluted in sterile Phosphate buffered Saline (PBS) to reach a titer of 5×10^{11} vg/mL. Mice were injected intravenously (i.v.) with 100 μ L of this diluted solution (dose/mouse: 5×10^{10} vg) in a tail vein. Complete

viral particles containing HBV DNA were detected in the blood of HBV-carrier mice. HBcAg was detected for up to one year in the liver together with HBV circulating proteins HBeAg and HBsAg in the blood. In all AAV2/8-HBV-transduced mice, HBsAg, HBeAg, and HBV DNA persisted in serum for at least one year (Dion et al 2013 J Virol 87:5554-5563).

Shanghai Model:

[0420] In this model, mice infected with a recombinant adeno-associated virus (AAV) carrying the HBV genome (AAV/HBV) maintains stable viremia and antigenemia for more than 30 weeks (Dan Yang, et al. 2014 Cellular & Molecular Immunology 11, 71-78).

[0421] Male C57BL/6 mice (4-6 weeks old), specific pathogen free, were purchased from SLAC (Shanghai Laboratory Animal Center of Chinese Academy of Sciences) and housed in an animal care facility in individually ventilated cages. Guidelines were followed for the care and use of animals as indicated by WuXi IACUC (Institutional Animal Care and Use Committee, WUXI IACUC protocol number R20131126-Mouse). Mice were allowed to acclimate to the new environment for 3 days and are grouped according to the experimental design.

[0422] Recombinant AAV-HBV was diluted in PBS, 200 μ L per injection. This recombinant virus carries 1.3 copies of the HBV genome (genotype D, serotype ayw).

[0423] On day 0, all mice were injected through tail vein with 200 μ L AAV-HBV. On days 6, 13 and 20 after AAV injection, all mice in were submandibularly bled (0.1 ml blood/mouse) for serum collection. On day 22 post injection, mice with stable viremia were ready for oligonucleotide treatment. The oligonucleotides can be unconjugated or GalNAc conjugated.

DNA Vaccine

[0424] Plasmid DNA were endotoxin-free and manufactured by Plasmid-Factory (Germany). pCMV-S2.S ayw encodes the preS2 and S domains of the HBsAg (genotype D), and its expression is controlled by the cytomegalovirus immediate early gene promoter (Michel et al 1995 Proc Natl Acad Sci USA 92:5307-5311). pCMV-HBc encodes the HBV capsid carrying the hepatitis core (HBc) Ag (Dion et al 2013 J Virol 87:5554-5563).

[0425] Treatment with DNA vaccine was conducted as described here. Five days prior to vaccination cardiotoxine (CaTx, Latoxan refL81-02, 50 μ L/muscle) was injected into the muscle of the mice. CaTx depolarizes the muscular fibers to induce cell degeneration, 5 days post injection, new muscular fibers will appear and will receive the DNA vaccine for a better efficacy for transfection. The pCMV-S2.S ayw and pCMVCore at 1 mg/ml each were mixed in equal amount and each mouse received a total of 100 μ g by bilateral intramuscular injection into cardiotoxin-treated tibialis anterior muscles as previously described in Michel et al 1995 Proc Natl Acad Sci USA 92:5307-5311, under anesthesia (100 μ L of 12.5 mg/mL ketamine, 1.25 mg/mL xylazine).

Anti-PD-L1 Antibody

[0426] This is a mouse anti mouse PD-L1 IgG1 antibody clone 6E11 internally produced at Genentech. It is a surrogate antibody that cross blocks Atezolizumab and has similar in vitro blocking activity Atezolizumab produced internally at Roche. The antibody was administered by intraperitoneal (i.p.) injection at a dose of 12.5 μ g/g.

Oligonucleotide Synthesis

[0427] Oligonucleotide synthesis is generally known in the art. Below is a protocol which may be applied. The oligonucleotides of the present invention may have been produced by slightly varying methods in terms of apparatus, support and concentrations used.

[0428] Oligonucleotides are synthesized on uridine universal supports using the phosphoramidite approach on an Oligomaker 48 at 1 μ mol scale. At the end of the synthesis, the oligonucleotides are cleaved from the solid support using aqueous ammonia for 5-16 hours at 60° C. The oligonucleotides are purified by reverse phase HPLC (RP-HPLC) or by solid phase extractions and characterized by UPLC, and the molecular mass is further confirmed by ESI-MS.

Elongation of the Oligonucleotide:

[0429] The coupling of β -cyanoethyl-phosphoramidites (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf), or LNA-T) is performed by using a solution of 0.1 M of the 5'-O-DMT-protected amidite in acetonitrile and DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as activator. For the final cycle a phosphoramidite with desired modifications can be used, e.g. a C6 linker for attaching a conjugate group or a conjugate group as such. Thiolation for introduction of phosphorothioate linkages is carried out by using xanthane hydride (0.01 M in acetonitrile/pyridine 9:1). Phosphordiesther linkages can be introduced using 0.02 M iodine in THF/Pyridine/water 7:2:1. The rest of the reagents are the ones typically used for oligonucleotide synthesis.

[0430] For post solid phase synthesis conjugation a commercially available C6 amino linker phosphoramidite can be used in the last cycle of the solid phase synthesis and after deprotection and cleavage from the solid support the amino-linked deprotected oligonucleotide is isolated. The conjugates are introduced via activation of the functional group using standard synthesis methods.

[0431] Alternatively, the conjugate moiety can be added to the oligonucleotide while still on the solid support by using a GalNAc- or GalNAc-cluster phosphoramidite as described in PCT/EP2015/073331 or in EP appl. NO. 15194811.4.

Purification by RP-HPLC:

[0432] The crude compounds are purified by preparative RP-HPLC on a Phenomenex Jupiter O18 10 μ 150 \times 10 mm column. 0.1 M ammonium acetate pH 8 and acetonitrile is used as buffers at a flow rate of 5 mL/min. The collected fractions are lyophilized to give the purified compound typically as a white solid.

ABBREVIATIONS

- [0433]** DCI: 4,5-Dicyanoimidazole
- [0434]** DCM: Dichloromethane
- [0435]** DMF: Dimethylformamide
- [0436]** DMT: 4,4'-Dimethoxytrityl
- [0437]** THF: Tetrahydrofuran
- [0438]** Bz: Benzoyl
- [0439]** Ibu: Isobutyryl
- [0440]** RP-HPLC: Reverse phase high performance liquid chromatography

T_m Assay

[0441] Oligonucleotide and RNA target (phosphate linked, PO) duplexes are diluted to 3 mM in 500 ml RNase-free water and mixed with 500 ml 2 \times T_m-buffer (200 mM NaCl, 0.2 mM EDTA, 20 mM Naphosphate, pH 7.0). The solution

is heated to 95° C. for 3 min and then allowed to anneal in room temperature for 30 min. The duplex melting temperatures (T_m) is measured on a Lambda UV/VIS Spectrophotometer equipped with a Peltier temperature programmer PTP6 using PE Templab software (Perkin Elmer). The temperature is ramped up from 20° C. to 95° C. and then down to 25° C., recording absorption at 260 nm. First derivative and the local maximums of both the melting and annealing are used to assess the duplex T_m .

Tissue Specific In Vitro Linker Cleavage Assay

[0442] FAM-labeled oligonucleotides with the biocleavable linker to be tested (e.g. a DNA phosphodiester linker (PO linker)) are subjected to in vitro cleavage using homogenates of the relevant tissues (e.g. liver or kidney) and Serum.

[0443] The tissue and serum samples are collected from a suitable animal (e.g. mice, monkey, pig or rat) and homogenized in a homogenisation buffer (0.5% Igepal CA-630, 25 mM Tris pH 8.0, 100 mM NaCl, pH 8.0 (adjusted with 1 N NaOH)). The tissue homogenates and Serum are spiked with oligonucleotide to concentrations of 200 µg/g tissue. The samples are incubated for 24 hours at 37° C. and thereafter the samples are extracted with phenol-chloroform. The solutions are subjected to AIE HPLC analyses on a Dionex Ultimate 3000 using an Dionex DNAPac p-100 column and a gradient ranging from 10 mM-1 M sodium perchlorate at pH 7.5. The content of cleaved and non-cleaved oligonucleotide are determined against a standard using both a fluorescence detector at 615 nm and a uv detector at 260 nm.

S1 Nuclease Cleavage Assay

[0444] FAM-labelled oligonucleotides with S1 nuclease susceptible linkers (e.g. a DNA phosphodiester linker (PO linker)) are subjected to in vitro cleavage in S1 nuclease extract or Serum.

[0445] 100 µM of the oligonucleotides are subjected to in vitro cleavage by S1 nuclease in nuclease buffer (60 U pr. 100 µL) for 20 and 120 minutes. The enzymatic activity is stopped by adding EDTA to the buffer solution. The solutions are subjected to AIE HPLC analyses on a Dionex Ultimate 3000 using an Dionex DNAPac p-100 column and a gradient ranging from 10 mM-1 M sodium perchlorate at pH 7.5. The content of cleaved and non-cleaved oligonucleotide is determined against a standard using both a fluorescence detector at 615 nm and a uv detector at 260 nm.

Preparation of Liver Mononuclear Cells

[0446] Liver cells from AAV/HBV mice were prepared as described below and according to a method described by Tupin et al 2006 *Methods Enzymol* 417:185-201 with minor modifications. After mouse euthanasia, the liver was perfused with 10 ml of sterile PBS via hepatic portal vein using syringe with G25 needle. When organ is pale, the organ was harvested in Hank's Balanced Salt Solution (HBSS) (GIBCO® HBSS, 24020)+5% de complemented fetal calf serum (FCS). The harvested liver was gently pressed through 100 µm cell-strainer (BD Falcon, 352360) and cells were suspended in 30 ml of HBSS+5% FCS. Cell suspension was centrifuged at 50 g for 5 min. Supernatants were then centrifuged at 289 g for 10 min at 4° C. After centrifugation, supernatants were discarded and pellets were re-suspended in 15 mL at room temperature in a 35% isotonic

Percoll solution (GE Healthcare Percoll #17-0891-01 diluted into RPMI 1640 (GIBCO, 31870)) and transferred to a 15 ml tube. Cells were further centrifuged at 1360 g for 25 min at room temperature. The supernatant was discarded by aspiration and the pellet containing mononuclear cells was washed twice with HBSS+5% FCS.

[0447] Cells were cultured in complete medium (a-minimal essential medium (Gibco, 22571) supplemented with 10% FCS (Hyclone, # SH30066, lot APG21570), 100 U/mL penicillin+100 µg/mL streptomycin+0.3 mg/mL L-glutamine (Gibco, 10378), 1× non-essential amino acids (Gibco, 11140), 10 mM Hepes (Gibco, 15630), 1 mM sodium pyruvate (Gibco, 11360) and 50 µM β-mercaptoethanol (LKB, 1830)).

Surface Labeling of Cells

[0448] Cells were seeded in U-bottom 96-well plates and washed with PBS FACS (PBS containing 1% bovine serum albumin and 0.01% sodium azide). Cells were incubated with 5 µL of PBS FACS containing a rat anti-mouse CD16/CD32 antibody and a viability marker LD fixable yellow, Thermofisher, L34959 for 10 min in the dark at 4° C. Then, cells were stained for 20 min in the dark at 4° C. with 25 µL of PBS FACS containing monoclonal antibodies (Mab) against NK P46 BV421 (Rat Mab anti mouse NK P46, Biologend, 137612) and F4/80 (rat Mab anti-mouse F4/80 FITC, BD Biologend, 123108) and two supplemental surface markers: PD1 (rat Mab anti-mouse PD1 PE, BD Biosciences, 551892) and PDL1 (rat Mab anti-mouse PDL1 BV711, Biologend, 124319) were also added.

Intracellular Cytokine Staining (ICS) Assay

[0449] ICS assays were performed on both splenocytes and liver mononuclear cells. Cells were seeded in Ubottom 96-well plates. Plates with cells were incubated overnight at 37° C. either in complete medium alone as negative control or with the peptides described in Table 9 at a concentration of 2 µg/ml. Brefeldin A at 2 µg/mL (Sigma, B6542) was added after one hour of incubation.

[0450] After the overnight culture, cells were washed with PBS FACS and incubated with 5 µL of PBS FACS containing rat anti-mouse CD16/CD32 antibody and a viability marker LD fixable yellow, Thermofisher, L34959 for 10 min in the dark at 4° C. Then, cells were stained for 20 min in the dark at 4° C. with 25 µL of PBS FACS containing Mab. The mix was composed of monoclonal antibodies against CD3 (hamster Mab anti-mouse CD3-PerCP, BD Biosciences, 553067), CD8 (rat Mab anti-mouse CD8-APC-H7, BD Biosciences, 560182), CD4 (rat Mab anti-mouse CD4-PE-Cy7, BD Biosciences, 552775), and NK cells (Rat Mab anti mouse NK P46 BV421, Biologend, 137612). Cells were fixed after several washes and permeabilized for 20 min in the dark at room temperature with Cytofix/Cytoperm, washed with Perm/Wash solution (BD Biosciences, 554714) at 4° C.

[0451] Intracellular cytokine staining with antibodies against IFNγ (rat Mab anti-mouse IFNγ-APC, clone XMG1.2, BD Biosciences, 554413) and tumor necrosis factor alpha (TNFα) (rat Mab anti-mouse TNFα-FITC, clone MP6-XT22; 1/250 (BD Biosciences 554418) was performed for 30 min in the dark at 4° C. Before analysis by flow cytometry using the MACSQuant Analyzer, cells were

washed with Perm/Wash and re-suspended in PBS FACS containing 1% Formaldehyde.

[0452] Live CD3+CD8+CD4- and cells CD3+CD8-CD4+ were gated and presented on dot-plot. Two regions were defined to gate for positive cells for each cytokine. Numbers of events found in these gates were divided by total number of events in parental population to yield percentages of responding T cells. For each mouse, the percentage obtained in medium alone was considered as background and subtracted from the percentage obtained with peptide stimulations.

[0453] Threshold of positivity was defined according to experiment background i.e. the mean percentage of stained cells obtained for each group in medium alone condition plus two standard deviations. Only percentage of cytokine represented at least 5 events were considered as positive.

Oligonucleotide Efficacy

[0456] THP-1 cells (3.104 in RPMI-GLutamax, 10% FBS, 1% Pen-Strep (Thermo Fisher Scientific) were added to the oligonucleotides (4-5 ul) into 96-well round bottom plates and cultured for 6 days in a final volume of 100 µl/well. Oligonucleotides were screened at one single concentration (20 µM) and in dose-range concentrations from 25 µM to 0.004 µM (1:3 dilution in water). Total mRNA was extracted using the MagNA Pure 96 Cellular RNA Large Volume Kit on the MagNA Pure 96 System (Roche Diagnostics) according to the manufacturer's instructions.

[0457] For gene expression analysis, RT-qPCR was performed using the TaqMan RNA-to-ct 1-Step kit (Thermo Fisher Scientific) on the QuantStudio machine (Applied Biosystems) with pre-designed Taqman primers targeting

TABLE 9

HLA-A2/DR1 restricted epitopes contained in the HBV Core protein and the Envelope domains of the HBsAg (S2 + S).					
Protein	Start Position	End Position	Sequence	HLA restriction	References
Core	18	27	FLPSDFFPSV (SEQ ID NO: 773)	A2	Bertoletti et al Gastroenterology 1997; 112: 193-199
	111	125	GRETVLEYLVSGVW (SEQ ID NO: 774)	DR1	(Bertoletti et al Gastroenterology 1997; 112: 193-199)
Envelope (S2 + S)	114	128	TTFHQTLQDPRVRGL (SEQ ID NO: 775)	DR1	Pajot et al Microbes Infect 2006; 8: 2783-2790.
	179	194	QAGFFLLTRILTIPQS (SEQ ID NO: 776)	A2 + DR1	Pajot et al Microbes Infect 2006; 8: 2783-2790.
	183	191	FLLTRILTI (SEQ ID NO: 777)	A2	Sette et al J Immunol 1994; 153: 5586-5592.
	200	214	TSLNFLGGTTVCLGQ (SEQ ID NO: 778)	A2 + DR1	Pajot et al Microbes Infect 2006; 8: 2783-2790.
	204	212	FLGGTTVCL (SEQ ID NO: 779)	A2	Rehermann et al J Exp Med 1995; 181: 1047-1058.
	335	343	WLSLLVPFV (SEQ ID NO: 780)	A2	Nayersina et al J Immunol 1993; 150: 4659-4671.
	337	357	SLLVPFVQWFVGLSPTVWLSV (SEQ ID NO: 781)	A2 + DR1	Loirat et al J Immunol 2000; 165: 4748-4755
	348	357	GLSPTVWLSV (SEQ ID NO: 782)	A2	Loirat et al J Immunol 2000; 165: 4748-4755
370	379	SILSPFLPLL (SEQ ID NO: 783)	A2	Mizukoshi et al J Immunol 2004; 173: 5863-5871.	

Example 1 Testing In Vitro Efficacy

[0454] A gene walk was performed across the human PD-L1 transcript primarily using 16 to 20mer gapmers. Efficacy testing was performed in an in vitro experiment in the human leukemia monocytic cell line THP1 and in the human non-Hodgkin's K lymphoma cell line (KARPAS-299).

Cell Lines

[0455] THP1 and Karpas-299 cell line were originally purchased from European Collection of Authenticated Cell Cultures (ECACC) and maintained as recommended by the supplier in a humidified incubator at 37° C. with 5% CO₂.

human PDL1 and ACTB used as endogenous control (Thermo Fisher Scientific). The relative PD-L1 mRNA expression level was calculated using 2-(Delta Delta C(T)) method and the percentage of inhibition as the % compared to the control sample (non-treated cells).

[0458] Karpas-299 cells were cultured in RPMI 1640, 2 mM Glutamine and 20% FBS (Sigma). The cells were plated at 10000 cell/well in 96 wells plates incubated for 24 hours before addition of oligonucleotides dissolved in PBS. Final concentration of oligonucleotides was in a single dose of 5 µM, in a final culture volume was 100 µl/well or added in a dose response ranging from 50 µM, 15.8 µM, 5.0 µM, 1.58 µM, 0.5 µM, 0.158 µM, 0.05 µM, to 0.0158 µM in 100 µL culture volume. The cells were harvested 3 days after

addition of oligonucleotide compounds and RNA was extracted using the PureLink Pro 96 RNA Purification kit (Ambion), according to the manufacturer's instructions. cDNA was synthesized using M-MLT Reverse Transcriptase, random decamers RETROscript, RNase inhibitor (Ambion) and 100 mM dNTP set (Invitrogen, PCR Grade) according to the manufacturer's instruction. For gene

expressions analysis, qPCR was performed using TaqMan Fast Advanced Master Mix (2x) (Ambion) in a duplex set up with TaqMan primer assays for the PD-L1 (Applied Biosystems; Hs01125299_m1) and TBP (Applied Biosystems; 4325803). The relative PD-L1 mRNA expression level is shown in table 10 as % of control sample (PBS-treated cells).

TABLE 10

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
4_1	50	1	32	11	TAattggctctacTGC	236
5_1	25	5	9	6	TCGCataagaatgaCT	371
6_1	29	2	15	5	TGaacacacagtcgCA	382
7_1	27	7	3	1	CTGaacacacagtcGC	383
8_1	23	4	11	3	TCTgaacacacagtcCG	384
9_1	32	3	19	6	TTCTgaacacacagtcTC	385
10_1	57	5	39	16	ACAagtcagttactTA	463
11_1	75	5	37	12	ACacaagtcagttactAC	465
12_1	22	2	10	3	CTtacttagatgcTGC	495
13_1	33	4	23	11	ACTtacttagatgcCTG	496
14_1	33	7	21	6	GACTtacttagatgcCT	497
15_1	41	6	18	10	AGacttacttagaTGC	498
16_1	96	14	40	7	GCAggaagagactTAC	506
17_1	22	2	9	3	AATAaattccggttCAGG	541
18_1	34	6	21	9	GCAAataaattccGTT	545
18_2	51	4	27	11	GCAAataaattccGTT	545
19_1	38	5	23	7	AGCAataaattccGT	546
20_1	73	8	56	15	CAGAgcaataaattTCC	548
21_1	83	8	65	10	TGGAcagagcaataAAT	551
22_1	86	6	80	8	ATGGacagagcaAATA	554
23_1	44	4	30	2	CAaatggacagaGCA	558
24_1	63	10	40	11	TTCTcagaatggacAG	562
25_1	31	1	39	5	CTGAactttgacATAG	663
26_1	60	4	56	19	AAGacaaaccagacTGA	675
27_1	36	4	34	10	TATAagacaaaccAGAC	678
28_1	40	4	28	13	TTATAagacaaaccCAGA	679
29_1	30	2	18	6	TGTTataagacaaaCCC	682
30_1	77	3	67	10	TAGAacaatggtaCTTT	708
31_1	81	17	20	14	GTAGaacaatggtaCT	710

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299
cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
32_1	29	5	14	8	AGGtagaacaatGGTA	712
33_1	32	1	43	20	AAGAggtagaacaATGG	714
34_1	70	4	35	13	GCatccacagtaaaTT	749
35_1	83	2	66	21	GAaggttatttaaTTC	773
36_1	18	2	15	5	CTAAtcgaatgcaGCA	805
37_1	64	7	35	10	TACccaatctaataCGA	813
38_1	69	1	49	13	TAGttaccaatcTAA	817
39_1	49	5	26	9	CATttagttaccCAAT	821
40_1	23	7	8	2	TCAtttagttaccCAA	822
41_1	24	6	12	3	TTcatttagttaCCCA	823
42_1	51	7	40	5	GAATtaatttcattTAGT	829
43_1	71	9	45	3	CAGTgaggaattaATTT	837
44_1	60	5	45	17	CCAAcagtgaggAATT	842
45_1	63	1	37	15	CCCAacagtgaggAAT	843
46_1	31	3	29	12	TAtaccaacagtGAGG	846
47_1	44	3	27	0	TTataccaacagTGAG	847
48_1	38	3	26	6	TTTataccaacagTGA	848
49_1	20	4	7	1	CCTttatacccaaCAG	851
50_1	22	3	6	2	TAACctttatacCCAA	854
51_1	28	1	29	16	AATAacctttataCCCA	855
52_1	80	11	48	10	GTAaataacctttaATA	859
53_1	54	4	37	14	ACTGtaaataacctTTAT	860
54_1	81	4	53	15	ATAtatatgcaatGAG	903
55_1	86	12	70	15	AGatatatatgcaATG	905
56_1	56	8	27	7	GAGatatatatgcAAT	906
57_1	28	7	13	5	CCagagatatataTGC	909
58_1	88	13	69	23	CAATattccagagATAT	915
59_1	29	3	14	6	GCAAtattccagagATA	916
60_1	25	3	14	3	AGCAatattccagaGAT	917
61_1	29	4	17	2	CAGcaatattccAGAG	919
62_1	27	3	14	3	AATCagcaatattCCAG	921
63_1	23	6	12	6	ACAAtcagcaataTTCC	923
64_1	53	9	43	15	ACTaagtagttacactTCT	957

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
65_1	32	5	14	6	CTAAgtagttacactTC	958
66_1	35	4	31	6	GACTaagtagttacaCTT	959
67_1	64	10	55	14	TGActaagtagtTACA	962
68_1	62	11	57	16	CTTTgactaagtagTTA	964
69_1	42	9	59	13	CTCtttgactaagTAG	967
70_1	81	6	56	12	GCTCtttgactaagTA	968
71_1	27	3	39	9	CCttaaactactgtTGAC	1060
72_1	75	5	36	7	CTtaaactactgttgAC	1060
73_1	35	6	43	13	TCcTtaaactactgTTG	1062
74_1	57	4	79	25	TCTCcttaaactactgTT	1063
75_1	53	6	28	6	TAtcatagttctCCTT	1073
76_1	26	4	9	2	AGTatcatagttcTCC	1075
77_1	74	5	39	12	GAgatcatagttcTTC	1076
78_1	49	5	35	6	AGagtatcatagTTCT	1077
78_2	74	6	36	8	AGAgatcatagTCT	1077
79_1	19	2	19	13	CAGagtatcatagTTC	1078
80_1	23	2	26	2	TTCAgagtacataGT	1080
81_1	35	3	36	11	CTTcagagtatcATAG	1081
82_1	24	6	20	7	TTCTtcagagtatcaTA	1082
83_1	20	2	16	2	TTTcttcagagtaTCAT	1083
84_1	33	4	37	10	GAGAAaggctaagTTT	1099
85_1	42	2	35	18	GAcactcttgtaCATT	1213
86_1	50	4	54	8	TGagacactcttgtaCA	1215
87_1	50	8	28	8	TGagacactcttgTAC	1216
88_1	61	4	33	6	CTttattaaactCCAT	1266
89_1	71	8	43	12	ACCAaactttattaAA	1272
90_1	62	5	42	9	AAACctctactaagTG	1288
91_1	22	3	12	5	AGattaagacagtTGA	1310
92_1	46	3	ND	ND	AAgtaggagcaagaGGC	1475
93_1	42	4	60	24	AAAGtaggagcaagAGG	1476
94_1	86	15	46	10	GTtaagcagccaggAG	1806
95_1	66	6	82	27	AGggtaggatgggtAG	1842
96_1	83	19	62	36	AAGggtaggatgggTA	1843
97_1	60	9	69	5	CAAgggtaggatggGT	1844

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
97_2	76	13	34	7	CAagggtaggatggGT	1844
98_1	65	8	76	28	CCaagggtaggatgGG	1845
99_1	61	2	75	17	TCcaagggtaggatGG	1846
100_1	83	4	82	13	CTTCcaagggtaggAT	1848
101_1	45	3	52	14	ATCttccaagggtagGA	1849
102_1	29	2	17	7	AGaagtgatggctCATT	1936
103_1	26	3	22	1	AAGaagtgatggcTCAT	1937
104_1	34	6	22	2	GAAgaagtgatggcTCA	1938
105_1	41	5	21	5	ATGAaatgtaaacTGGG	1955
106_1	40	8	29	6	CAATgaaatgtaaaCTGG	1956
107_1	24	3	16	4	GCAATgaaatgtaaACTG	1957
108_1	30	4	20	6	AGCAatgaaatgtaAACT	1958
109_1	44	4	34	14	GAGCaatgaaatgtAAAC	1959
110_1	18	1	13	3	TGaattcccatatcCGA	1992
111_1	69	8	35	8	AGaattatgaccaTAT	2010
112_1	77	7	38	10	AGGtaagaattatGACC	2014
113_1	97	10	56	13	TCAGgtaagaattaTGAC	2015
114_1	69	8	54	21	CTTCaggtagaatTATG	2017
115_1	91	7	115	42	TCTTcaggtagaATTA	2019
116_1	88	6	104	36	CTTcttcaggtaaGAAT	2021
117_1	85	6	118	17	TCTTcttcaggtaaGAA	2022
118_1	105	14	102	9	TCTtcttcaggtaaAGA	2023
119_1	37	2	76	18	TGGtctaagagaaGAAG	2046
120_1	46	6	81	11	GTTGgtctaagagAAG	2049
121_1	74	11	64	4	AGTtgggtctaagAGAA	2050
122_1	74	9	55	21	CAGttgggtctaagAGAA	2050
123_1	65	9	95	21	GCAgttgggtctaagagAA	2050
124_1	63	7	ND	ND	CAGTtgggtctaagaGA	2051
125_1	65	6	ND	ND	GCagttgggtctaagaGA	2051
126_1	67	14	104	34	GCagttgggtctaagAGAG	2052
127_1	22	6	10	3	CTcatatcagggCAGT	2063
128_1	50	4	46	9	CACAcattgttctttaAC	2087
129_1	22	4	12	12	TAAatacacacatgTTCT	2092

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
130_1	24	2	43	28	GTAAatacacacatgTTC	2093
131_1	33	3	20	12	TGTAaatacacacaTGTT	2094
132_1	73	17	57	21	GATCatgtaaatacACAC	2099
133_1	47	5	28	14	AGATcatgtaaataCACA	2100
134_1	35	6	26	11	CAAAGatcatgtaaatACAC	2101
135_1	30	2	14	3	ACAAgatcatgtaaatTACA	2102
136_1	52	6	24	18	GAATacaaagatcaTGTA	2108
137_1	33	5	20	6	AGAAatacaaagatcATGT	2109
138_1	37	1	22	15	CAGAatacaaagatCATG	2110
139_1	85	6	53	8	GCAGAatacaaagATCA	2112
140_1	79	4	40	6	AGGCagaatacaaagAT	2114
141_1	56	2	53	20	AAGGcagaatacaaAGA	2115
142_1	28	5	20	5	ATTagtgaggacGAA	2132
143_1	26	2	22	10	CAttagtgagggaCGA	2133
144_1	29	6	16	4	GAgggtgatggatTAG	2218
145_1	45	6	22	5	TTaggagtaataAAGG	2241
146_1	65	7	44	9	TTAatgaatttggtTG	2263
147_1	84	8	43	10	CTttaatgaatttgGT	2265
148_1	32	0	15	3	CATGgattacaactAA	2322
149_1	33	2	20	4	TCatggattacaactTA	2323
150_1	29	1	11	3	GTCatggattacaactCT	2324
151_1	64	2	40	9	CAttaaatctagTCAT	2335
152_1	97	8	63	22	GACAttaaatctagTCA	2336
153_1	92	7	ND	ND	AGGGacattaaatcTA	2340
154_1	35	4	25	15	CAAAGcattataaCCA	2372
155_1	34	3	24	6	ACTtactaggcaGAAG	2415
156_1	102	6	113	18	CAGAgttaactgtaca	2545
157_1	102	10	103	15	CCAGagttaactgtAC	2546
158_1	88	7	95	18	GCcagagttaactgtTA	2547
159_1	78	10	ND	ND	TGggccagagttactCT	2550
160_1	59	5	26	5	CAGcatctatcagaCT	2576
161_1	78	8	42	10	TGAaataacatgagTCAT	2711
162_1	31	6	ND	ND	GTGaaataacatgAGTC	2713
163_1	18	2	11	3	TCTGtttatgtcacTG	2781

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
164_1	56	5	29	9	GTCTgtttatgtcaCT	2782
165_1	37	8	12	5	TGgtctgtttatGTCA	2784
166_1	39	1	19	3	TGGTctgtttatgTC	2785
167_1	41	3	35	14	TCacccattgtttaAA	2842
168_1	18	3	14	4	TTcagcaaatatTCGT	2995
169_1	36	8	13	2	GTGtgttcagcaaATAT	2999
170_1	18	2	11	4	TCTattgttaggtATC	3053
171_1	67	4	26	12	ATtgcccatcttacTG	3118
172_1	71	2	33	9	TATtgcccatcttaCT	3119
173_1	47	4	20	5	AAatattgcccatCTT	3122
174_1	74	4	34	7	ATAaccttatcataCA	3174
175_1	98	19	44	12	TAtaaccttatcaTAC	3175
176_1	100	10	64	11	TTAtaaccttatcaTATA	3176
177_1	72	38	28	5	TTTataaccttatCAT	3177
178_1	47	6	34	6	ACTgctattgctaTCT	3375
179_1	41	3	23	6	AGgactgctattgCTA	3378
180_1	32	6	27	7	GAGgactgctattgCT	3379
181_1	83	1	46	20	ACgtagaataataaCA	3561
182_1	94	4	52	9	CCaagtgatataATGG	3613
183_1	49	2	16	3	TTagcagaccaaGTGA	3621
184_1	96	3	26	5	GTttagcagaccaaGT	3623
185_1	78	3	46	10	TGacagtgattataTT	3856
186_1	88	5	45	21	TGTCcaagatattgAC	3868
187_1	46	6	23	6	GAAatcctagatTGT	4066
188_1	79	3	45	14	CAaactgagaataTCC	4074
189_1	63	5	27	8	GCAaactgagaataTC	4075
190_1	77	9	37	11	TCCTattacaatcgTA	4214
191_1	74	10	36	9	TTCCtattacaatcGT	4215
192_1	91	8	51	28	ACTaatgggaggatTT	4256
193_1	95	14	67	24	TAgttcagagaataAG	4429
194_1	86	5	47	16	TAacatatagttcAGA	4436
195_1	87	4	81	20	ATAacatatagttcAG	4437
196_1	101	6	67	20	CAtaacatatagttCA	4438

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
197_1	91	6	60	13	TCataacatatagtTC	4439
198_1	61	3	31	10	TAGCtcctaacaatCA	4507
199_1	79	12	49	11	CTCCaatctttgtaTA	4602
200_1	74	2	58	13	TCTCcaatctttgtAT	4603
201_1	53	3	33	10	TCtatttcagccaaTC	4708
202_1	25	4	30	9	CGGaagtcagagtGAA	4782
203_1	32	5	21	7	TTAagcatgaggaaTA	4798
204_1	34	10	26	11	TGAttgagcacctCTT	4831
205_1	81	12	62	12	GACTaattatttcgTT	4857
206_1	57	7	37	7	TGActaattatttcCGT	4858
207_1	26	5	21	6	GTGactaattattTCG	4859
208_1	48	3	33	13	CTGcttgaaatgtgAC	4870
209_1	32	1	34	13	CCtgcttgaaatgTGA	4871
210_1	60	5	50	19	ATcctgcttgaaATGT	4873
211_1	111	8	110	26	ATTataaatctatTCT	5027
212_1	107	1	67	12	GCTaataactttcATC	5151
213_1	26	3	19	6	CAttgtaacataCCTA	5251
214_1	33	2	20	4	GCattgtaacatacCT	5252
215_1	89	8	53	16	TAatattgcaccaaAT	5295
216_1	25	2	29	9	GAtaatattgcacCAA	5297
217_1	27	1	27	6	AGataaatattgcacCA	5298
218_1	79	6	45	11	GCCaagaagataATAT	5305
219_1	159	16	68	14	CACAgccacataaaaCT	5406
220_1	90	2	72	12	TTgtaattgtggaaAC	5463
221_1	10	2	11	5	TGacttgaattgtGG	5467
222_1	82	1	67	18	TCtaactgaaatagTC	5503
223_1	30	1	32	9	GTGgttctaactgaAA	5508
224_1	53	7	53	15	CAatatgggacttgGT	5522
225_1	44	1	33	10	ATGacaatatgggaCT	5526
226_1	49	1	41	14	TATGacaatatgggAC	5527
227_1	77	1	54	15	ATATgacaatatggGA	5528
228_1	100	3	98	29	CTtcacttaataaTTA	5552
229_1	90	12	80	19	CTGcttcacttaataAA	5555
230_1	91	0	79	23	AAGactgcttcacTTA	5559

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299
cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
231_1	49	8	77	34	GAATgcctaattaTG	5589
232_1	17	7	88	33	TGGaatgcctaataTA	5591
233_1	40	5	35	10	GCAaatgccagtagGT	5642
234_1	81	6	72	25	CTAatggaaggattTG	5673
235_1	97	17	87	25	AAatagaacctaaTG	5683
236_1	98	4	83	21	GAAagaatagaatGTT	5769
237_1	93	2	102	26	ATGggtaatagattAT	5893
238_1	110	24	44	14	GAAagagcacagggTG	6103
239_1	66	5	36	10	CTACatagagggaaTG	6202
240_1	70	4	34	8	GCttcctacataGAGG	6207
241_1	64	NA	33	6	TGCTtcctacatagAG	6208
242_1	30	NA	19	7	TGggcttgaaataTGT	6417
243_1	88	6	69	15	CATtatatttaagaAC	6457
244_1	8	2	5	2	TCggttatgttaTCAT	6470
245_1	18	9	12	4	CActttatctggTCGG	6482
246_1	37	2	19	5	AAAAttggcacagcGTT	6505
247_1	46	12	29	8	ACCGtgacagtaaATG	6577
248_1	31	2	25	2	TGggaaccgtgacagTA	6581
249_1	17	2	23	9	CCacatataggtcCTT	6597
250_1	15	6	23	7	CAtattgctaccaTAC	6617
251_1	4	2	9	2	TCAtattgctaccATA	6618
252_1	65	12	85	14	CAATtgtcatatTGCT	6624
253_1	20	2	51	7	CATtcaattgtcataTTG	6626
254_1	48	8	91	41	TTTCTactgggaaTTG	6644
255_1	11	5	23	8	CAAttagtgcagcCAG	6672
256_1	43	7	62	13	GAATaatgttcttaTCC	6704
257_1	28	2	36	19	CACAaattgaataatgtTCT	6709
258_1	64	4	78	22	CATGcacaattgaaTAAT	6714
259_1	53	8	104	73	ATCctgcaatttcaCAT	6832
260_1	54	5	59	14	CCaccatagctgatCA	6868
261_1	42	8	52	22	ACcaccatagctgaTCA	6868
262_1	68	5	118	66	CAccaccatagctgaTC	6869
263_1	40	2	73	20	TAgtcggcaccaccAT	6877

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
264_1	64	6	72	35	CttgtagtggcaccAC	6880
265_1	56	4	82	35	CttgtagtggcacCA	6881
266_1	41	5	46	21	CGctttagtggcCAC	6883
267_1	51	4	33	14	TCAataaagatcagGC	6942
268_1	61	2	49	10	TGgacttacaagaaTG	6986
269_1	45	7	40	9	ATGgacttacaagaAT	6987
270_1	51	12	36	12	GCTCaagaaattggAT	7073
271_1	17	0	14	5	TACTgtagaacatgGC	7133
272_1	15	3	11	3	GCAAttcatttgaTCT	7239
273_1	64	11	ND	ND	TGaagggaggaggacAC	7259
274_1	52	6	50	28	AGtggtgaagggaggAG	7265
275_1	79	7	ND	ND	TAgtggtgaagggaggAG	7265
276_1	81	6	ND	ND	AtagtggtgaagggaggAG	7265
277_1	70	9	ND	ND	TAgtggtgaagggaggGA	7266
278_1	84	9	ND	ND	ATagtggtgaagggaggGA	7266
279_1	40	6	64	53	TAGtggtgaagggaggAG	7267
280_1	42	10	ND	ND	ATAgtggtgaagggaggAG	7267
281_1	63	7	ND	ND	GAtagtggtgaagggaggAG	7267
282_1	27	7	38	11	ATAGtggtgaagggaggAG	7268
283_1	60	22	ND	ND	GAtagtggtgaagggaggAG	7268
284_1	23	3	97	54	GAgatagtggtgAAGG	7271
285_1	51	6	72	19	CATGggagatagtgGT	7276
286_1	7	1	21	9	ACAaataatggttaCTCT	7302
287_1	66	8	48	20	ACACacaaataatgGTTA	7306
288_1	67	6	58	20	GAGggacacacaaaTAAT	7311
289_1	46	2	50	21	ATATagagaggcTCAA	7390
290_1	22	6	ND	ND	TTgatatagagaGGCT	7393
291_1	11	2	17	3	GCAtttgatatagAGA	7397
292_1	70	18	44	8	TTtgcatattgataTAG	7400
293_1	30	1	30	9	CTGgaagaataggtTC	7512
294_1	53	5	42	10	ACTGgaagaataggtTT	7513
295_1	56	2	41	15	TACTggaagaatagGT	7514
296_1	80	8	53	13	TGGCttatcctgtaCT	7526
297_1	73	6	52	14	ATggcttatcctGTAC	7527

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
298_1	75	7	89	25	TATGgcttatcctgTA	7528
299_1	52	5	50	11	GTAtggcttatccTGT	7529
300_1	27	3	31	6	ATgaatatatgccCAGT	7547
301_1	41	8	33	9	GATgaatatatgCCCA	7549
302_1	8	2	ND	ND	CAAgatgaatataTGCC	7551
303_1	32	5	37	14	GACAacatcagtaTAGA	7572
304_1	28	5	30	23	CAAGacaacatcAGTA	7576
305_1	47	5	41	9	CACtctcctagttccTTT	7601
306_1	39	6	33	7	AACactcctagttCCT	7603
307_1	68	3	42	14	TAacactcctagTCC	7604
308_1	115	5	69	22	CTaacactcctagTTC	7605
309_1	97	16	57	14	TGataacataactgTG	7637
310_1	36	1	23	10	CTgataacataaCTGT	7638
311_1	38	5	24	5	TTTGaactcaagtGAC	7654
312_1	42	3	39	5	TCCtTtacttagCTAG	7684
313_1	15	2	14	3	GAgtttgattagCTG	7764
314_1	49	28	ND	ND	TGggatgatgacagGGA	7838
315_1	34	6	ND	ND	TGTGggatgatgacaGG	7840
316_1	47	3	37	8	ATATggaaggataTC	7875
317_1	11	3	ND	ND	ACAggatatggaaGGG	7880
318_1	48	4	ND	ND	ATTTcaacaggatATGG	7885
319_1	18	2	16	4	GAgtaattcaacAGG	7891
320_1	74	6	44	5	AGGGagtaattcAACA	7893
321_1	38	5	56	28	ATTAgggagtaattTCA	7896
322_1	66	9	32	11	CTtactattaggGAGT	7903
323_1	13	1	15	5	CAGcttactattaGGG	7906
324_1	26	4	20	9	TCAGcttactattAGG	7907
325_1	43	4	17	2	ATTTcagcttactaTTAG	7908
326_1	54	5	57	16	TTcagcttactaTTAG	7908
327_1	28	3	8	2	CAGAtttcagcttaCT	7913
328_1	43	4	37	16	GACTacaactagagGG	7930
329_1	45	12	36	10	AGACTacaactagaGG	7931
330_1	99	8	94	32	AAGactacaactagAG	7932

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
331_1	59	4	52	19	ATGAtttaattctagTCAAA	7982
332_1	100	2	84	23	TTAattctagTCAAA	7982
333_1	91	9	60	19	GATTtaattctagTCA	7984
771_1	74	6	50	5	TGAtttaattctagTCA	7984
334_1	73	5	54	12	ATGAtttaattctagTCA	7984
335_1	15	1	26	3	GATGatttaattctagTCA	7984
336_1	71	22	49	16	GAtttaattctagTCA	7984
337_1	43	5	30	11	GATGatttaattctagTCT	7985
338_1	98	5	90	27	TGatttaattctagTCT	7985
339_1	87	21	86	2	GAGAtgatttaattTCTA	7988
340_1	92	5	85	27	GAGAtgatttaattTCT	7989
341_1	7	1	7	1	CAGAttgatggtagTT	8030
342_1	7	2	24	11	CTcagattgatgGTAG	8032
343_1	3	1	14	9	GTTagccctcagaTTG	8039
344_1	14	5	20	7	TGtattgttagcCCTC	8045
345_1	10	2	11	5	ACttgtattgttAGCC	8048
346_1	52	4	52	17	AGCcagatcagggAC	8191
347_1	33	3	18	8	TTgacaatagtgGCAT	8213
348_1	7	2	13	5	ACAagtggatatctTCT	8228
349_1	63	8	44	15	AATCtactttacaaGT	8238
350_1	36	2	ND	ND	CACagtagatgcctGATA	8351
351_1	24	2	30	9	GAacacagtagatGCC	8356
352_1	23	4	103	14	CTTGgaacacagtagAT	8359
353_1	20	2	45	2	ATAtcttggaaacAG	8364
354_1	25	3	24	6	TCTttaatatcttgGAAC	8368
355_1	39	2	41	10	TGatttctttaatatCTTG	8372
356_1	54	5	88	43	TGatgatttctttaTATC	8375
357_1	31	4	45	27	AGGctaagtcatgaTG	8389
358_1	18	3	43	20	TTGAtgaggctaagTC	8395
359_1	6	2	11	2	CCAggattatactaT	8439
360_1	43	5	40	14	GCcaggattataCTCT	8440
361_1	56	8	73	13	CTGccaggattataCT	8442
362_1	23	1	33	7	CAGAAaacttatactttaTG	8473
363_1	49	8	45	14	AAGCagaaacttaTACT	8478

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
364_1	39	6	37	4	GAAGcagaaacttaTACT	8478
365_1	26	4	45	13	TGGAagcagaaacttataCT	8478
366_1	21	4	44	5	TGGAagcagaaacttaTAC	8479
367_1	97	4	70	22	AAGcagaaacttaTAC	8479
368_1	34	3	32	11	TGGAagcagaaactTATA	8480
369_1	71	7	46	19	AAGGgatattatggAG	8587
370_1	51	9	79	38	TGccggaagatttcCT	8641
371_1	45	6	52	25	ATGgattgggagtaGA	8772
372_1	27	7	30	8	AGatggattgggagTA	8774
373_1	13	3	28	6	AAGatggattgggaGT	8775
374_1	42	10	44	11	ACaagatggattGGGA	8777
374_2	41	3	45	14	ACaagatggattggGA	8777
375_1	83	9	88	32	AGAaggttcagaCTTT	8835
376_1	40	5	33	3	GCAgaaggttcagaCT	8837
376_2	28	5	20	4	GCagaaggttcagACT	8837
377_1	70	2	43	8	TGCAgaaggttcagAC	8838
378_1	23	3	55	17	AGTgcagaaggttcAG	8840
378_2	51	6	41	8	AGTGCagaaggttcAG	8840
379_1	34	6	35	7	AAGTgcagaaggttcCA	8841
380_1	44	11	24	6	TAagtgcagaagGTTC	8842
381_1	37	5	45	9	TCtaagtgcagaAGGT	8844
382_1	75	5	147	26	CTCaggagtctactTC	8948
383_1	90	10	141	55	CTCaggagtctactCTT	8949
384_1	73	8	234	116	AtggaggtgactcaggAG	8957
385_1	33	4	42	7	ATggaggtgactcagGA	8958
386_1	24	3	29	14	ATggaggtgactcAGG	8959
387_1	37	2	65	15	TAtggaggtgactcAGG	8959
388_1	50	10	81	19	ATatggaggtgactcaGG	8959
389_1	42	5	61	10	TATGgaggtgactcAG	8960
390_1	36	2	76	50	ATatggaggtgactCAG	8960
391_1	52	6	64	6	CAtatggaggtgactcAG	8960
392_1	63	5	57	6	ATAtggaggtgactCA	8961
393_1	53	7	64	12	CAtatggaggtgactCA	8961

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
394_1	51	5	56	24	CAtatggaggtgACTC	8962
395_1	23	3	41	34	GCatatggaggtgacTC	8962
396_1	34	3	54	10	TGcatatggaggtgacTC	8962
397_1	54	5	71	24	TtgcataatggaggtgacTC	8962
398_1	61	11	59	13	TttgcatatggaggtgacTC	8962
399_1	25	2	30	6	GCatatggaggtgacT	8963
400_1	34	4	25	9	TGcatatggaggtgacT	8963
401_1	25	4	31	20	TTGcatatggaggtgacT	8963
402_1	51	6	37	11	TttgcatatggaggtgacT	8963
403_1	26	1	33	5	TGCatatggaggtgac	8964
404_1	25	2	69	19	TTGcatatggaggtgac	8964
405_1	26	4	24	4	TTTGcatatggaggtgac	8964
406_1	19	3	20	7	TTTGcatatggaggtgac	8965
407_1	16	5	46	16	Tttgcatatggaggtgac	8966
408_1	9	2	9	6	AAgtgaagttcaacAGC	8997
409_1	26	8	109	52	TGggaagtgaagTCA	9002
410_1	31	5	24	5	ATggaagtgaagTTC	9003
411_1	49	9	19	10	GATGggaagtgaagTTC	9004
412_1	28	10	17	9	CTGtgatgggaagtGAA	9007
413_1	54	4	34	8	ATTgagtgaatccAAA	9119
414_1	11	1	14	2	AAttgagtgaatCCAA	9120
415_1	58	6	14	2	GATAatgagtgaatTCC	9122
416_1	5	1	16	3	GTGataatgagtGAA	9125
417_1	73	5	61	14	AAGaaaggtgcaatTAA	9155
418_1	86	6	64	13	CAagaaaggtgcAATA	9156
419_1	75	19	64	14	ACAAGaaaggtgcaAT	9157
420_1	75	8	50	13	ATttaaactcaciaAC	9171
421_1	21	8	23	6	CTgttaggttcaGCGA	9235
422_1	54	10	30	5	TCTGaatgaacatTTCG	9260
423_1	11	4	15	5	CTcattgaaggtTCTG	9281
424_1	87	3	52	8	CTAatctcattgaaGG	9286
425_1	95	1	85	13	CCtaatctcattgaAG	9287
426_1	31	7	22	7	ACTttgatctttcAGC	9305
427_1	64	7	49	16	ACtatgcaacacttTG	9315

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
428_1	18	6	21	3	CAAatagctttatCGG	9335
429_1	19	6	17	4	CCaaatagctttATCG	9336
430_1	35	4	27	8	TCCAaatagctttaTC	9337
431_1	75	8	43	7	GATCcaaatagcttTA	9339
432_1	67	11	32	8	ATgatccaaataGCTT	9341
433_1	53	5	43	6	TATGatccaaatagCT	9342
434_1	97	9	66	29	TAAAcagggtggGAAT	9408
435_1	58	12	44	17	ACttaaacagggtGG	9412
436_1	58	10	30	12	ACacttaaacagGGCT	9414
437_1	87	38	41	3	GAACacttaaacAGGG	9416
438_1	70	4	59	33	AGAGaacacttaACAG	9418
439_1	83	17	28	9	CTACagagaacaCTTA	9423
440_1	49	12	27	4	ATGctacagagaaCACT	9425
441_1	53	10	24	13	ATAAatgctacagagAACAA	9427
442_1	23	6	20	10	AGataaatgctacaGAGA	9430
443_1	48	6	27	7	TAGAgataaatgctTACA	9434
444_1	51	3	32	8	TAGAtagagataaatGCT	9437
445_1	38	5	ND	ND	CAATatactagataGAGA	9445
446_1	52	3	31	1	TACAcaatatactagATAG	9448
447_1	65	6	48	11	CTAcacaatatactTAG	9452
448_1	67	9	29	2	GCTAcacaatataCTA	9453
449_1	103	17	65	15	ATATgctacacaatATAC	9455
450_1	71	13	129	22	TGATatgctacaCAAT	9459
451_1	19	4	9	1	ATGAtatgatatgCTAC	9464
452_1	75	10	45	21	GAGGagagagacaaTAAA	9495
453_1	68	6	43	10	CTAggaggagagACA	9500
454_1	72	7	79	25	TATTctaggaggagAGA	9504
455_1	31	3	29	9	TTATattctaggagGAG	9507
456_1	38	5	62	17	GTTtatattctaGGAG	9510
457_1	15	6	15	8	TGgagtttatattcTAGG	9512
458_1	34	3	21	3	CGtaccaccactcTGC	9590
459_1	41	5	55	22	TGAGgaaatcattcATTC	9641
460_1	81	8	47	22	TTGaggaatcatTCAT	9643

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
461_1	76	8	39	5	AGGCTaatcctattTG	9657
462_1	93	12	216	12	TTTAGgctaateCTAT	9660
463_1	15	6	30	9	TGCTccagtgaccCT	9755
464_1	27	3	25	6	TAgtagtactcgATAG	9813
465_1	9	2	7	3	CTAattgtagtagtaCTC	9818
466_1	52	3	32	6	TGctaattgtagTAGT	9822
467_1	68	11	36	16	AGTGctaattgtagTA	9824
468_1	35	6	32	3	GCAAgtgctaattgTA	9827
469_1	91	9	ND	ND	GAGGaaatgaactaattTA	9881
470_1	92	5	ND	ND	CAGGaggaatgaacTA	9886
471_1	67	5	42	6	CCctagagtcattTCC	9902
472_1	35	5	20	8	ATCttacatgatgaAGC	9925
473_1	13	1	20	5	GACacactcagatttcAG	9967
474_1	24	4	20	2	AGacacactcagatttcAG	9967
475_1	25	4	24	7	AAGacacactcagatttcAG	9967
476_1	26	6	19	4	AGacacactcagattTCA	9968
477_1	28	4	32	13	AAGacacactcagattTCA	9968
478_1	31	8	37	6	AAagacacactcagatTTC	9968
479_1	63	7	51	26	GAAagacacactcagatTTC	9969
480_1	37	10	ND	ND	AAGAcacactcagatTTC	9969
481_1	41	4	ND	ND	AAAGacacactcagaTTTC	9969
482_1	19	5	48	14	TGAAagacacactcagatTT	9970
483_1	60	8	68	10	TGaaagacacactcaGATT	9971
484_1	42	8	63	22	TGAAagacacactcaGAT	9972
485_1	48	9	41	20	ATTGaaagacacacTCA	9975
486_1	27	6	27	12	TCattgaaagacaCACT	9977
487_1	88	13	121	33	TTCCatcattgaAAGA	9983
488_1	80	12	ND	ND	ATAAtaccacttaTCAT	10010
489_1	13	4	27	15	TTacttaatttcttTGGA	10055
490_1	32	5	60	24	TTAgaactagctttaTCA	10101
491_1	58	10	55	17	GAGgtacaaatatAGG	10171
492_1	4	1	12	3	CTTatgatacaacTTA	10384
493_1	37	6	35	5	TCttatgatacaacTT	10385
494_1	30	0	27	6	TTCTtatgatacaacCT	10386

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
495_1	27	8	18	3	CAGtttcttatgaTAC	10390
496_1	25	10	25	6	GCAgtttcttatgaTA	10391
497_1	77	6	72	29	TACAaatgtctattagGTT	10457
498_1	66	5	69	17	TGTAcAAatgtctatTAG	10460
499_1	27	10	20	4	AGCAtcacaattagTA	10535
500_1	31	10	25	5	CTAatgatagtgaGC	10548
501_1	21	7	30	8	AGCtaatgatagtGAA	10550
502_1	35	5	39	8	ATGCcttgacatatTA	10565
503_1	64	11	79	26	CTCAagattattgACAC	10623
504_2	25	4	83	32	ACctcaagattaTTGA	10626
504_1	94	7	22	6	ACctcaagattaTTGA	10626
505_1	31	6	34	10	AACctcaagattatTG	10627
506_1	55	6	62	17	CACAaacctcaagattaTT	10628
507_1	66	12	40	4	GTAActtaattagACCT	10667
508_1	78	5	80	10	AGTAActtaattagACC	10668
509_1	36	5	42	15	GTATgaggtggtaaAC	10688
510_1	40	4	48	22	AGGaaacagcagaAGTG	10723
511_1	27	7	13	6	GCacaacccagaggAA	10735
512_1	54	5	ND	ND	CAAGcacaacccagAG	10738
513_1	35	7	ND	ND	TTCaagcacaaccCAG	10740
514_1	49	6	52	15	AAttcaagcacaACCC	10742
515_1	72	4	106	49	TAATAattcaagcacaACC	10743
516_1	43	4	57	21	ACTAataattcaaGCAC	10747
517_1	37	3	60	12	ATAAtactaataattcAAGC	10749
518_1	9	3	6	1	TAgatttgtgagGTAA	11055
519_1	59	10	31	5	AGCCttaattctccAT	11091
520_1	41	4	34	9	AATGatctagagcCTTA	11100
521_1	34	6	34	7	CTAatgatctagaGCC	11103
522_1	52	6	52	17	ACTaatgatctaGAGC	11104
523_1	60	4	54	10	CATtaacatgttctTATT	11165
524_1	57	4	55	8	ACAAGtacattaacatGTTC	11170
525_1	53	6	44	5	TTACAagtacattaaCATG	11173
526_1	54	11	49	17	GCTTtattcatgtTTAT	11195

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
527_1	34	7	17	5	GCTttattcatgttTA	11196
528_1	11	2	21	4	AGAgctttattcatgtTT	11197
529_1	22	4	33	7	ATAAgagctttattCATG	11200
530_1	30	5	32	15	CATAagagctttaTTCA	11202
531_1	77	8	24	4	AGCAtaagagctTTAT	11205
532_1	8	3	15	6	TAGattgtttagtGCA	11228
533_1	4	2	10	2	GTagattgtttaGTGC	11229
534_1	41	6	33	11	GACAattctagtaGATT	11238
535_1	50	1	37	7	CTGacaattctaGTAG	11241
536_1	49	7	36	6	GCTGacaattctagTA	11242
537_1	59	2	42	11	AGgattaagatacgTA	11262
538_1	28	11	28	4	CAggattaagataCGT	11263
539_1	96	5	20	6	TCAggattaagataCG	11264
540_1	70	11	59	11	TTcaggattaagATAC	11265
541_1	53	5	28	4	AGGAagaaagtttgATTC	11308
542_1	92	13	59	12	TCAAggaagaaagtTTGA	11311
543_1	44	3	67	7	CTCAaggaagaaagTTTG	11312
544_1	43	4	32	4	TGCTcaaggaagaAAGT	11315
545_1	41	7	44	20	AATTatgctcaaggaAGA	11319
546_1	11	4	26	8	TAGGataccacattatGA	11389
547_1	25	4	26	12	CAtaatttattccattcCTC	11449
548_1	64	6	ND	ND	TGCAtaatttattcCAT	11454
549_1	48	17	49	7	ACTGcataatttatTCC	11456
550_1	91	10	92	15	CTAAactgcataattTATT	11458
551_1	85	8	38	9	ATaactaaactgCATA	11465
552_1	86	4	ND	ND	TTAttaataactaaaCTGC	11468
553_1	91	13	92	21	TAGTactattattaataaCT	11475
554_1	50	4	37	7	CATAactaaggacgTT	11493
555_1	41	5	30	7	TCataactaaggacGT	11494
556_1	80	7	55	13	CGTCataactaaggAC	11496
557_1	86	3	59	11	TCgtcataactaagGA	11497
558_1	51	9	33	12	ATcgtcataactAAGG	11498
559_1	91	6	65	26	GTtagtatcttacATT	11525
560_1	30	3	41	8	CTCtattgttagtATC	11532

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
561_1	59	8	18	6	AGTatagagttactGT	11567
562_1	65	11	41	11	TTCCtgggtgatactri	11644
563_1	57	13	45	13	GTTCCtgggtgatacTT	11645
564_1	57	15	30	7	TGttcctgggtgataCT	11646
565_1	17	4	35	4	ATAaacatgaatctCTCC	11801
566_1	16	3	30	4	CTTtataaacatgaaTCTC	11804
567_1	60	5	45	11	CTGtctttataaaCATG	11810
568_1	20	2	19	5	TTgttataaatctgTCTT	11820
569_1	68	9	44	4	TAAaatttattcttgGATA	11849
570_1	76	8	48	12	CTtaaatttattctTGGA	11851
571_1	62	5	66	5	CTTCTtaaatttattctTG	11853
572_1	28	4	44	10	TATGtttctcagtaaAG	11877
573_1	29	6	36	11	GAAAttatctttaaACCA	11947
574_1	74	6	34	7	CCCTtaaatttctaCA	11980
575_1	37	8	30	9	ACACTgctcttgtaCC	11995
576_1	45	14	27	6	TGAcaaacactgctCTT	12000
577_1	2	1	12	5	TACAtttattgggcTC	12081
578_1	65	14	39	9	GTacatttattggGCT	12082
579_1	34	4	53	12	TTGgtacatttatTGG	12085
580_1	41	7	35	6	CATGttgggtacattTAT	12088
581_1	11	4	12	5	AATCatgttggtacAT	12092
582_1	96	16	48	9	AAatcatgttggtacaCA	12093
583_1	71	15	42	13	GACAagtttgattAA	12132
584_1	46	34	39	6	AAgttccagatgCCTC	12197
585_1	37	26	28	12	GcttaatgttcagaTG	12201
586_1	75	8	43	12	CGTAcatagcttgaTG	12267
587_1	41	10	28	5	GTGaggaattaggaTA	12753
588_1	41	5	27	9	GTAacaatattggttTG	12780
589_1	67	10	37	7	GAAatattgtagaCTA	13151
590_1	97	10	80	12	TTGaaatattgtagAC	13153
591_1	64	10	47	9	AAgtctagtaattTGC	13217
592_1	84	7	60	9	GCTCagtagattatAA	13259
593_1	42	8	32	9	CATacactgttgcTAA	13296

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
594_1	101	6	79	17	ATGgtctcaaatcATT	13314
595_1	53	14	46	7	CAATgggtctcaaatCA	13316
596_1	47	6	36	6	TTCctattgattgaCT	13568
597_1	97	12	41	6	TTTCgttccacaacAC	13600
598_1	85	1	49	11	AGGaaccctactaaTCT	13702
599_1	56	3	34	7	TAAatggcaggaacCC	13710
600_1	15	4	24	8	GTAAatggcaggaaCC	13711
601_1	40	6	26	8	TTgtaaatggcagGAA	13713
602_1	59	12	26	6	TTatgagttaggCATG	13835
603_1	62	2	42	10	CCAggtgaaactttAA	13935
604_1	77	9	55	18	CCcttagtcagctCCT	13997
605_1	82	13	42	11	ACccttagtcagCTCC	13998
606_1	74	1	39	10	CACccttagtcagCTC	13999
607_1	76	9	30	8	TCTtctactaggCTCC	14091
608_1	82	5	50	13	CCtatctgtcatcATG	14178
609_1	82	1	48	12	TCctatctgtcatcAT	14179
610_1	41	6	50	13	GAGAagtgtagaaGC	14808
611_1	70	5	84	19	CATCcttgaagtttAG	14908
612_1	64	14	61	16	TAAaagatggctCCC	15046
613_1	85	2	51	14	CAAggcataataagAT	15053
614_1	47	1	35	10	CCaaggcataatAAGA	15054
615_1	74	8	53	11	TGatccaattctcaCC	15151
616_1	63	4	41	11	ATGatccaattctCAC	15152
617_1	46	7	42	9	CGCttcatcttcacCC	15260
618_1	104	4	15	4	TAtgacactgcaTCTT	15317
619_1	8	3	8	5	GTAtgacactgcaTCT	15318
620_1	21	3	27	10	TGtatgacactgCATC	15319
621_1	37	7	38	11	TTCTtctctgtaagTC	15363
622_1	49	7	36	11	TTctacagaggaACTA	15467
623_1	47	1	32	10	ACTacagttctacAGA	15474
624_1	78	8	69	6	TTCcacaggtaaaTG	15561
625_1	70	7	ND	ND	ATTAtttgaataatactCATT	15594
626_1	73	7	49	25	TGGGaggaaattatTTG	15606
627_1	80	5	64	11	TGACTcatcttaaaTG	15621

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
628_1	71	6	66	19	CTGactcatcttaaAT	15622
629_1	31	6	41	6	TTTactctgactcATC	15628
630_1	88	2	68	18	TATtggaggaattaTT	15642
631_1	53	2	27	6	GTAttggaggaattAT	15643
632_1	23	3	39	7	TGgtatacttctctaagTAT	15655
633_1	42	9	33	3	GATCctcttggtataCT	15666
634_1	38	1	30	16	CAgacaactctataCC	15689
635_1	10	2	19	3	AACAtcagacaacTCTA	15693
636_1	13	1	11	3	TAAcAtcagacaacTC	15695
637_1	14	2	27	2	TTTAacatcagacaACTC	15695
638_1	101	14	81	16	ATttaacatcagacAA	15698
639_1	14	1	17	1	CCtatttaacatcAGAC	15700
640_1	65	2	ND	ND	TCCctatttaacaTCA	15703
641_1	41	6	42	12	TCAAcgactattgGAAT	15737
642_1	37	2	29	5	CTTAtattctggcTAT	15850
643_1	31	7	35	4	ATCCttatattctgGC	15853
644_1	13	3	8	1	GATccttatattCTGG	15854
645_1	25	5	20	4	TGATccttatattCTG	15855
646_1	33	6	54	10	ATTGaaacttgATCCT	15864
647_1	43	3	27	6	ACTgtcattgaaACTT	15870
648_1	54	7	32	12	TCTtactgtcattgAA	15874
649_1	12	1	25	2	AGgatcttactgtCATT	15877
650_1	13	4	11	3	GCAaatcaactccATC	15896
651_1	10	5	16	3	GTGcaaatcaactCCA	15898
652_1	7	0	36	18	CAATtatttctttgTGC	15910
653_1	21	3	31	7	TGGcaacaattattTCTT	15915
654_1	75	9	73	24	GCTggcaacaatTATT	15919
655_1	21	6	39	6	ATCCatttctactgCC	15973
656_1	25	3	38	8	TAATatctattgataCTA	15988
657_1	14	2	11	5	TCaatagtgtagggCA	16093
658_1	11	4	10	3	TTCaatagtgtaggGC	16094
659_1	18	1	32	12	AGGTtaattaattcaATAG	16102
660_1	33	7	25	10	CATTtgaatccCTAG	16163

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines (Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).						
CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
660_2	64	14	31	8	CATttgtaatcccTAG	16163
661_1	48	6	34	6	ACAtttgtaatcccCTA	16164
662_2	29	6	23	5	AAcatttgtaatCCCT	16165
662_1	30	6	18	6	AACatttgtaatCCCT	16165
663_1	49	1	26	6	TAAatttcaagttCTG	16184
664_1	17	3	30	10	GTTtaaatttcaagTTCT	16185
665_1	22	7	40	9	CCAAGttttaaatttCAAG	16189
666_1	89	11	ND	ND	ACCCaagttttaaTTTC	16192
667_1	60	16	87	8	CATacagtgacccaagTTT	16199
668_1	65	9	50	12	ACatcccatacagTGA	16208
669_1	83	8	103	4	AGcacagctctaCATC	16219
670_1	80	9	150	36	ATAtagcacagcTCTA	16223
671_1	57	14	ND	ND	TCCatatagcacagCT	16226
672_1	53	10	106	8	ATTtccatatagCACA	16229
673_1	78	3	96	14	TTTAttccatataAGCA	16231
674_1	77	9	31	7	TTTatttccatataAGC	16232
675_1	32	6	ND	ND	AAGGagaggagatTATG	16409
676_1	32	5	24	6	AGTtcttggttagCT	16456
677_1	19	4	17	4	GAGttcttggttaGC	16457
678_1	14	3	25	3	ATTAattatccatCCAC	16590
679_1	11	2	20	6	ATCaattaattatcCATC	16593
680_1	31	5	40	11	AGAatcaattaattaTCC	16596
681_1	8	3	30	10	TGagataccgtgcaTG	16656
682_1	11	3	ND	ND	AAtgagataccgTGCA	16658
683_1	15	3	33	10	CTGtggttaggctaAT	16834
684_1	45	7	38	7	Aagagtaagggtctgtggri	16842
685_1	24	5	ND	ND	GATGggttaagagTAA	16854
686_1	11	2	ND	ND	AGCagatgggttaaGA	16858
687_1	ND	ND	51	7	TGtaaacatttgTAGC	16886
688_1	83	1	54	11	CCTgcttataaatgTA	16898
689_1	103	4	73	14	TGCCctgcttataaAT	16901
690_1	104	2	64	22	TCtcttagttcaaTA	16935
691_1	ND	ND	60	9	TGgtttctaactACAT	16980
692_1	ND	ND	94	22	AGtttggtttctaaCTA	16983

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
693_1	8	2	17	5	GAAtgaaacttgcCTG	17047
694_1	98	6	51	9	ATTatccttacatGAT	17173
695_1	48	4	18	4	GTaccaattatcCCT	17180
696_1	94	2	48	9	TGTaccaattatCCT	17181
697_1	31	5	42	13	TTgtaccaattaTCC	17182
698_1	41	4	39	6	TTTgtaccaattaTC	17183
699_1	63	0	28	12	AGCAgcaggttataTT	17197
700_1	99	6	43	12	TGGgaagtgtctGGG	17292
701_1	103	2	28	5	CTGgagagtataTA	17322
702_1	52	6	27	9	AATGctggattacgTC	17354
703_1	67	3	37	7	CAatgctggattaCGT	17355
704_1	36	10	80	12	TTgttcagaagtATCC	17625
705_1	19	9	47	9	GAtgatttgcctGGAG	17646
706_1	44	NA	60	9	GAAatcattcacaACC	17860
707_1	46	9	32	9	TTGtaacatctactTAC	17891
708_1	56	0	79	17	CATtaagcagcaagTT	17923
709_1	30	9	46	7	TTActagatgtgagCA	17942
710_1	29	4	36	6	TTtactagatgtgAGC	17943
711_1	41	13	41	6	GACcaagcaccttaCA	17971
712_1	36	19	49	11	AGAccaagcacctTAC	17972
713_1	30	6	34	7	ATgggttaaataAAGG	18052
714_1	70	2	24	8	TCaaccagagtattAA	18067
715_1	11	4	26	8	GTCaaccagagtatTA	18068
716_1	126	56	26	6	ATtgtaaagctgATAT	18135
717_1	73	1	42	10	CACataattgtaAAGC	18141
718_1	23	9	55	18	GAggtctgctattTAC	18274
719_1	50	1	42	11	TGtagattcaatgCCT	18404
720_1	79	3	39	10	CCtcattatactatGA	18456
721_1	27	6	30	8	CCttatgctatgacAC	18509
722_1	26	7	50	13	TCCCTtatgctatgaCA	18510
723_1	59	1	48	12	AAGatgtttaagtATA	18598
724_1	54	2	50	13	CTgattattaagATGT	18607
725_1	92	10	84	19	TGgaaaggtatgaaTT	18808

TABLE 10-continued

in vitro efficacy of anti-PD-L1 compounds in THP1 and KARPAS-299 cell lines
(Average from n = 3 experiments). PD-L1 mRNA levels are normalized to TBP in KARPAS-299 cells or ACTB in THP1 cells and shown as % of control (PBS treated cells).

CMP ID NO	KARPAS-299 cells 5 μ M CMP		THP1 cells 20 μ M CMP		Compound (CMP)	Start on SEQ ID NO 1
	% mRNA of control	sd	% mRNA of control	sd		
726_1	24	8	61	16	ACttgaatggcttgGA	18880
727_1	8	4	51	14	AACTtgaatggctTGG	18881
728_1	35	4	35	10	CAATgtgttactatTT	19004
729_1	36	9	53	11	ACAatgtgttactATT	19005
730_1	70	2	41	11	CATCtgcataataaGA	19063
731_1	38	NA	42	9	CCTAgagcaaatacTT	19223
732_1	102	15	15	4	CAGagttaataatAAG	19327
733_1	37	10	8	5	GTTCaagcacaacgAA	19493
734_1	13	1	38	11	AGggttcaagcacAAC	19496
735_1	49	NA	36	11	TGttggagacactgri	19677
736_1	48	NA	32	10	AAGgaggagttaggAC	19821
737_1	36	NA	64	11	CTATgccatttacgAT	19884
738_1	105	19	66	19	TcaaatgcagaattAG	19913
739_1	44	NA	41	6	AGtgacaatcaaATGC	19921
740_1	107	NA	68	18	AAgtgacaatcaaATG	19922
741_1	102	4	27	6	GTGTaccaagtaacAA	19978
742_1	110	10	30	16	TGGgatgttaaacTGA	20037

Example 2—Testing In Vitro Efficacy in a Dose Response Curve

[0459] A selection of oligonucleotides from Table 10 were tested in KARPAS-299 cells using half-log serial dilutions in PBS (50 μ M, 15.8 μ M, 5.0 μ M, 1.58 μ M, 0.5 μ M, 0.158 μ M, 0.05 μ M, to 0.0158 μ M oligonucleotide) in the in vitro

efficacy assay described in Example 1. IC 50 and max inhibition (% residual PD-L1 expression) was assessed for the oligonucleotides.

[0460] EC50 calculations were performed in GraphPad Prism6. The IC50 and maximum PD-L1 knock down level is shown in table 11 as % of control (PBS) treated cells.

TABLE 11

Max inhibition as % of saline and EC50 in KARPAS-299 cell line.

CMP ID NO	Max Inhibition (% residual PD-L1 expression; % of saline-treated) EC50 (μ M)				Compound CMP	Start on SEQ ID NO: 1
	Avg	SD	Avg	SD		
6_1	11	3.3	0.69	0.11	TCGCataagaatgaCT	371
8_1	29	1.7	0.06	0.01	CTGaacacacagtcGC	383
9_1	19	1.7	0.23	0.02	TCTgaacacacagtcCG	384
13_1	14	4.7	0.45	0.12	CTtacttagatgcTGC	495
41_1	10	1.8	0.19	0.02	TCAttagttaccCAA	822
42_1	17	1.3	0.19	0.02	TTcatttagttaCCCA	823

TABLE 11-continued

Max inhibition as % of saline and EC50 in KARPAS-299 cell line.							
CMP ID NO	Max Inhibition (% residual PD-L1 expression; % of saline-treated) EC50 (μ M)				Compound	CMP	Start on SEQ ID NO: 1
	Avg	SD	Avg	SD			
58_1	23	1.5	0.17	0.01	CCagagatatataTGC		909
77_1	24	2.4	0.16	0.02	AGTatcatagttcTCC		1075
92_1	12	2.4	0.25	0.03	AGattaagacagtTGA		1310
111_1	3	2.0	0.27	0.03	TGaatcccatatcCGA		1992
128_1	11	1.8	0.25	0.03	CTcatatcagggCAGT		2063
151_1	16	2.7	0.28	0.05	GTCatggattacaaCT		2324
164_1	19	1.6	0.15	0.01	TCTGtttatgtcacTG		2781
166_1	36	1.7	0.11	0.02	TGgtctgtttatGTCA		2784
169_1	10	1.6	0.22	0.02	TTcagcaaatTCGT		2995
171_1	12	2.0	0.21	0.02	TCTattgttaggtATC		3053
222_1	1	2.0	0.21	0.02	TGacttgaattgTGG		5467
233_1	1	4.3	0.89	0.17	TGGAatgcctaataTA		5591
245_1	4	2.0	0.17	0.02	TCggttatgttaTCAT		6470
246_1	7	2.1	0.25	0.03	CActttatctggTCGG		6482
250_1	0	2.5	0.23	0.03	CCacatataggtcCTT		6597
251_1	0	2.8	0.75	0.10	CAtattgctaccaTAC		6617
252_1	3	2.2	0.19	0.02	TCAattgctaccATA		6618
256_1	5	2.2	0.32	0.03	CAAtagtgagcCAG		6672
272_1	1	3.2	0.69	0.10	TACTgtagaacatgGC		7133
273_1	3	2.8	0.28	0.04	GCAAttcatttgaTCT		7239
287_1	1	1.4	0.13	0.01	ACAaataatggttaCTCT		7302
292_1	2	2.1	0.21	0.02	GCAtttgatatagAGA		7397
303_1	0	1.2	0.21	0.01	CAAgatgaatataTGCC		7551
314_1	3	2.1	0.39	0.04	GAgtttgattagCTG		7764
318_1	3	1.4	0.14	0.01	ACAggatatggaaGGG		7880
320_1	2	2.4	0.22	0.03	GAgtaattcaacAGG		7891
324_1	0	2.4	0.44	0.05	CAgcttactattaGGG		7906
336_1	0	2.5	0.21	0.03	GATGatttaattctagtCA		7984
342_1	1	2.2	0.12	0.01	CAGAttgatggttagTT		8030
343_1	4	1.8	0.11	0.01	CTcagattgatgGTAG		8032
344_1	0	0.9	0.12	0.01	GTTagccctcagaTTG		8039
345_1	0	2.3	0.36	0.04	TGtattgttagcCCTC		8045
346_1	1	2.1	0.22	0.02	ACTtgattgttAGCC		8048
349_1	4	2.9	0.21	0.03	ACAagtggtatctTCT		8228

TABLE 11-continued

Max inhibition as % of saline and EC50 in KARPAS-299 cell line.							
CMP ID NO	Max Inhibition (% residual PD-L1 expression; % of saline-treated)		EC50 (μ M)		Compound CMP	Start on SEQ ID NO: 1	
	Avg	SD	Avg	SD			
359_1	6	2.9	0.39	0.05	TTGAtgaggctaagTC	8395	
360_1	0	1.7	0.18	0.02	CCAggattatactaT	8439	
374_1	5	1.7	0.33	0.03	AAGatggattgggaGT	8775	
408_1	3	1.8	0.21	0.02	TTtgcataatggaGGTG	8966	
409_1	0	1.8	0.21	0.02	AAgtgaagtccaCAGC	8997	
415_1	0	1.4	0.23	0.02	AAttgagtgaatCCAA	9120	
417_1	7	0.9	0.15	0.01	GTGataattgagtGAA	9125	
424_1	6	3.2	0.19	0.03	CTcattgaaggtTCTG	9281	
429_1	5	2.5	0.48	0.05	CAAatagctttatCGG	9335	
430_1	1	2.7	0.68	0.09	CCaaatagctttATCG	9336	
458_1	0	4.1	0.35	0.07	TGgagtttatattcTAGG	9512	
464_1	0	4.1	0.56	0.10	TGCTccagtgaccCT	9755	
466_1	1	2.1	0.21	0.02	CTAattgtagtagtaCTC	9818	
474_1	0	2.4	0.27	0.03	GACacactcagatttcAG	9967	
490_1	0	1.9	0.29	0.03	TTacttaatttcttTGGA	10055	
493_1	3	1.8	0.20	0.02	CTTatgatataacTTA	10384	
512_1	0	3.3	0.63	0.10	GCacaaccagaggAA	10735	
519_1	5	1.5	0.15	0.01	TAgatttgtgagGTAA	11055	
529_1	0	2.7	0.24	0.03	AGAgctttatcatgtTT	11197	
533_1	6	1.5	0.14	0.01	TAGattgtttagtGCA	11228	
534_1	5	0.9	0.06	0.00	GTagattgtttaGTGC	11229	
547_1	1	1.6	0.26	0.02	TAGGataccacattatGA	11389	
566_1	0	3.0	0.40	0.06	ATAaacatgaatctCTCC	11801	
567_1	2	2.5	0.34	0.04	CTTtataaacatgaaTCTC	11804	
578_1	2	1.3	0.09	0.01	TACAtttattgggcTC	12081	
582_1	1	1.6	0.20	0.02	AATCatgttggtacAT	12092	
601_1	1	2.1	0.47	0.05	GTAAatggcaggaaCC	13711	
619_1	4	3.4	0.44	0.08	TAtgacactgcaTCTT	15317	
620_1	1	1.2	0.12	0.01	GTAtgacactgcaTCT	15318	

TABLE 11-continued

Max inhibition as % of saline and EC50 in KARPAS-299 cell line.								
CMP ID	NO	Max Inhibition (% residual PD-L1 expression; % of saline-treated) EC50 (μ M)				Compound	CMP	Start on SEQ ID NO: 1
		Avg	SD	Avg	SD			
636_1		0	1.3	0.19	0.01	AACAtcagacaacTCTA	15693	
638_1		0	2.2	0.36	0.04	TAACatcagacaacTC	15695	
637_1		0	2.1	0.21	0.02	TTTAacatcagacaACTC	15695	
640_1		2	3.3	0.42	0.06	CCtatttaacatcAGAC	15700	
645_1		1	2.9	0.34	0.04	GAtccttatattCTGG	15854	
650_1		0	2.4	0.24	0.03	AGgatcttactgtCATT	15877	
651_1		4	3.4	0.33	0.05	GCAaatcaactccATC	15896	
652_1		0	1.3	0.16	0.01	GTGcaaatcaactCCA	15898	
653_1		4	2.0	0.09	0.01	CAATtatttctttgTGC	15910	
658_1		3	1.6	0.32	0.02	TCaatagtgtaggCA	16093	
659_1		5	1.4	0.20	0.01	TTCaatagtgtaggGC	16094	
660_1		4	2.1	0.22	0.02	AGGTaattaattcaATAG	16102	
665_1		3	1.8	0.18	0.02	GTTtaatttcaagTTCT	16185	
678_1		3	2.1	0.43	0.04	GAgttcttgtgtaGC	16457	
679_1		0	3.5	0.31	0.05	ATTaattatccatCCAC	16590	
680_1		4	1.6	0.12	0.01	ATCaattaattatcCATC	16593	
682_1		3	2.4	0.27	0.03	TGagataccgtgcaTG	16656	
683_1		0	3.2	0.16	0.03	AAtgagataccgTGCA	16658	
684_1		2	2.3	0.25	0.03	CTGtggttaggctaAT	16834	
687_1		5	1.3	0.13	0.01	AGCagatgggtaaGA	16858	
694_1		0	1.7	0.16	0.02	GAAtgaaacttgcCTG	17047	
706_1		15	3.6	0.27	0.06	GAtgatttgcttGGAG	17646	
716_1		10	2.1	0.15	0.02	GTCaaccagagtatTA	18068	
728_1		5	1.2	0.09	0.01	AACttgaatggctTGG	18881	
733_1		0	12.7	8.01	3.62	CAGagttaataatAAG	19327	
734_1		0	14.6	3.49	2.39	GTTCaagcacaacgAA	19493	
735_1		0	2.5	0.30	0.04	AGggttcaagcacAAC	19496	

[0461] A selection of oligonucleotides from Table 6 were tested in THP-1 cells using 1:3 serial in water from 25 μ M to 0.004 μ M in the in vitro efficacy assay described in Example 1. IC 50 and max inhibition (Percent residual PD-L1 expression) was assessed for the oligonucleotides.

[0462] EC50 calculations were performed in GraphPad Prism6. The IC50 and maximum PD-L1 knock down level is shown in table 12 as % of control (PBS) treated cells.

TABLE 12

Max inhibition as % of saline and EC50 in THP1 cell line.							
CMP ID	NO	Max Inhibition (% residual PD-L1 expression; % of saline)		EC50 (μ M)		Compound	Start on SEQ ID
		Avg	SD	Avg	SD		
6_1	12	11.5	0.73	0.38	TCGCataagaatgaCT	371	
8_1	6	5.6	0.11	0.04	CTGaacacacagtcGC	383	
9_1	1	14.3	0.36	0.27	TCTgaacacacagtcGC	384	
13_1	2	12.4	0.49	0.31	CTtacttagatgctGC	495	
41_1	14	14.6	0.38	0.27	TCAtttagttaccCAA	822	
42_1	21	10.4	0.22	0.10	TTcatttagttaCCCA	823	
58_1	6	19.8	0.97	0.81	CCagagatatataTGC	909	
77_1	5	4.8	0.14	0.04	AGTatcatagttcTCC	1075	
92_1	0	12.9	0.57	0.39	AGattaagacagtcTGA	1310	
128_1	15	10.1	0.23	0.13	CTcatatcagggCAGT	2063	
151_1	9	14.4	0.18	0.15	GTCatggattacaaCT	2324	
164_1	16	22.0	0.57	0.60	TCTGtttatgtcacTG	2781	
166_1	13	11.9	0.17	0.11	TGgctctgtttatGTCA	2784	
169_1	0	9.3	0.22	0.11	TTcagcaaatatTCGT	2995	
171_1	11	12.9	0.28	0.20	TCTattgttaggtATC	3053	
222_1	16	19.7	0.68	0.64	TGacttgtaattgtGG	5467	
245_1	14	6.1	0.26	0.08	TCggttatgttaTCAT	6470	
246_1	28	7.3	0.10	0.20	CActttatctggTCGG	6482	
252_1	19	8.0	0.29	0.12	TCAattgctaccATA	6618	
272_1	3	9.7	0.25	0.14	TACTgtagaacatGTC	7133	
314_1	13	9.6	0.31	0.15	GAgtttgattagCTG	7764	
344_1	11	8.0	0.14	0.06	GTTagccctcagaTTG	8039	
349_1	12	12.5	0.18	0.14	ACAagtggatctTCT	8228	
415_1	11	9.6	0.26	0.12	AAAttgagtgaatCCAA	9120	
493_1	15	16.5	0.48	0.34	CTTatgatacaacTTA	10384	
512_1	43	14.1	0.31	0.68	GCacaacccagaggAA	10735	
519_1	9	12.2	0.45	0.26	TAgatttgtagGTAA	11055	
533_1	11	13.6	0.29	0.21	TAgattgttttagTGCA	11228	
534_1	9	6.5	0.09	0.03	GTagattgtttaGTGC	11229	

TABLE 12-continued

Max inhibition as % of saline and EC50 in THP1 cell line.								
CMP ID	NO	Max Inhibition (% residual PD-L1 expression; % of saline)		EC50 (μ M)		Compound	CMP	Start on SEQ ID NO: 1
		Avg	SD	Avg	SD			
582_1	0	12.3	0.33	0.23	AATCatgttggtacAT		12092	
619_1	8	10.4	0.32	0.18	TATgacactgcaTCTT		15317	
620_1	12	24.6	1.10	1.08	GTATgacactgcaTCT		15318	
638_1	2	5.4	0.00	0.00	TAAcAtcagacaacTC		15695	
645_1	20	29.6	1.10	1.50	GATccttatattCTGG		15854	
651_1	0	11.2	0.14	0.09	GCAaatcaactccATC		15896	
658_1	11	13.8	0.48	0.32	TCAatagtgtaggGCA		16093	
659_1	0	8.2	0.11	0.06	TTCaatagtgtaggGC		16094	
733_1	0	69.6	11.03	26.95	CAGagttaataatAAG		19327	
734_1	36	16.8	2.84	2.12	GTTCaagcacaacgAA		19493	

[0463] The results in table 7 and 8 are also shown in FIG. 2 in relation to their position where they target the PD-L1 pre mRNA of SEQ ID NO: 1.

[0464] From this it can be seen that almost all of the compounds have EC50 values below 1 μ M and a target knock down below 25% of the PD-L1 expression level in the control cells (treated with saline).

Example 3—In Vitro Potency and Efficacy and In Vivo PD-L1 Reduction in Poly(I:C) Induced Mice Using Naked and GalNAc Conjugated PD-L1 Antisense Oligonucleotides

[0465] Efficacy and potency testing was performed in an in vitro experiment in in dose-response studies in MCP-11 cells using the oligonucleotides in table 6. The same oligonucleotides as well as GalNAc conjugated versions (Table 8 CMP ID NO 755_2-765_2) were tested in vivo in poly(I:C) induced C57BL/6J female mice for their ability to reduce PD-L1 mRNA and protein expression

In Vitro Assay

[0466] MCP-11 cells (originally purchased from ATCC) suspended in DMEM (Sigma cat. no. D0819) supplemented with 10% horse serum, 2 mM L-glutamine, 0.025 mg/ml gentamicin and 1 mM sodium pyruvate were added at a density of 8000 cells/well to the oligonucleotides (10 μ l) in 96-well round bottom plates and cultured for 3 days in a final volume of 200 μ l/well in a humidified incubator at 37° C. with 5% CO₂. Oligonucleotides were screened in dose-range concentrations (50 μ M, 15.8 μ M, 5.0 μ M, 1.58 μ M, 0.5 μ M, 0.158 μ M, 0.05 μ M and 0.0158 μ M).

[0467] Total mRNA was extracted using the PureLink Pro 96 RNA Purification kit (Ambion), according to the manufacturer's instructions. cDNA was synthesized using M-MLT Reverse Transcriptase, random decamers RETROscript, RNase inhibitor (Ambion) and 100 mM dNTP set (Invitrogen, PCR Grade) according to the manufacturer's

instruction. For gene expressions analysis, qPCR was performed using TaqMan Fast Advanced Master Mix (2 \times) (Ambion) in a duplex set up with TaqMan primer assays for the PD-L1 (Thermo Fisher Scientific; FAM-MGB Mm00452054-m1) and Gusb (Thermo Fisher Scientific; VIC-MGB-PL Mm01197698-m1). The relative PD-L1 mRNA expression level is shown in table 9 as % of residual PD-L1 expression in % of PBS control samples (PBS-treated cells). EC50 calculations were performed in GraphPad Prism6. The EC50 and maximum PD-L1 knockdown level is shown in table 13 as % of control (PBS) cells.

In Vivo Assay

[0468] C57BL/6J female mice (20-23 g; 5 mice per group) were injected s.c. with 5 mg/kg unconjugated oligonucleotides to mouse PD-L1 or 2.8 mg/kg GalNAc-conjugated oligonucleotides to mouse PD-L1. Three days later, the mice were injected i.v. with 10 mg/kg poly(I:C) (LWM, Invivo-gen). The mice were sacrificed 5 h after poly(I:C) injection and liver samples were placed in RNA later (Thermo Fisher Scientific) for RNA extraction or frozen at dry ice for protein extraction.

[0469] Total mRNA was extracted from homogenized liver samples using the PureLink Pro 96 RNA Purification kit (Ambion), according to the manufacturer's instructions. cDNA was synthesized using M-MLT Reverse Transcriptase, random decamers RETROscript, RNase inhibitor (Ambion) and 100 mM dNTP set (Invitrogen, PCR Grade) according to the manufacturer's instruction. For gene expressions analysis, qPCR was performed using TaqMan® Fast Advanced Master Mix TaqMan Fast Advanced Master Mix (2 \times) (Ambion) in a duplex set up with TaqMan primer assays for the PD-L1 mRNA (Thermo Fisher Scientific; FAM-MGB Mm00452054-m1) and TBP (Thermo Fisher Scientific; VIC-MGB-PL Mm00446971_m1). The relative

PD-L1 mRNA expression level is shown in table 13 as % of control samples from mice injected with saline and poly(I:C).

[0470] Liver homogenates were prepared by homogenizing liver samples in 2 ml per 100 mg tissue T-PER® Tissue Protein Extraction Reagent (Thermo Fisher Scientific) mixed with 1× Halt Protease Inhibitor Cocktail, EDTA-Free (Thermo Fisher Scientific). Protein concentrations in liver homogenates were measured using Coomassie Plus (Bradford) Assay Reagent (Thermo Scientific) according to the manufacturer's instructions. Liver homogenates (40 µg protein) were separated on 4-12% Bis-Tris Plus polyacrylamide gels (Thermo Fisher Scientific) in 1×MOPS running buffer and transferred to nitrocellulose membranes using iBLOT Dry blotting system (Thermo Fisher Scientific) according to the manufacturer's instructions. Each blot was cut in to two parts horizontally at the 64 kDa band. Following blocking in TBS containing 5% skim milk and 0.05% Tween20, the

membranes were incubated overnight at 4° C. with rabbit monoclonal anti-vinculin (Abcam cat. no. ab129002) diluted 1:10000 (upper membranes) or goat polyclonal anti-mPD-L1 (R&D Systems cat. no. AF1019) diluted 1:1000 (lower membranes) in TBS containing 5% skim milk and 0.05% Tween20. The membranes were washed in TBS containing 0.05% Tween20 and exposed for 1 h at room temperature to HRP-conjugated swine anti-rabbit IgG (DAKO) diluted 1:3000 (upper membranes) or HRP-conjugated rabbit anti-goat IgG (DAKO) diluted 1:2000 in TBS containing 5% skim milk and 0.05% Tween20. Following washing of the membranes, the reactivity was detected using ECL select (Amersham GE Healthcare). For each group of mice treated with oligonucleotides, the intensity of the PD-L1 bands in relation to vinculin bands were evaluated by comparison with the PD-L1/vinculin band intensities of mice injected with saline and poly(I:C) (control). Results are shown in table 13, and westernblots with pairs of naked and conjugated oligonucleotides are shown in FIG. 9 A-E.

TABLE 13

In vitro and in vivo efficacy of oligonucleotides to mouse PD-L1						
CMP ID NO	Compound	CMP	Max Inhibition (% of PBS)	EC50 (µM)	PD-L1 mRNA (% of control)	PD-L1 protein (relative to control)
744_1	AGTttacattttcTGC		9.1	0.56	86	++
746_1	CACcttttaaaccCCA		5.0	0.46	181	nd
747_1	TCcTttataatcaCAC		4.4	0.52	104	++
748_1	ACGgtattttcacAGG		1.8	0.26	102	+++
749_1	GACactacaatgaGGA		7.6	1.21	104	nd
750_1	TGGtttttaggacTGT		12.4	0.74	84	nd
751_1	CGAcaaattctatCCT		9.9	0.69	112	nd
752_1	TGAtatacaatgcTAC		10.5	1.11	142	+++
753_1	TCGttgggtaaatTTA		5.7	0.53	116	+++
754_1	TGcTttataaatgGTG		5.2	0.35	98	nd
755_2	5'-GN2-C6-caAGTttacattttcTGC		nd	nd	58	+
757_2	5'-GN2-C6-caCACcttttaaaccCCA		nd	nd	62	nd
758_2	5'-GN2-C6-caTCcTttataatcaCAC		nd	nd	53	+
759_2	5'-GN2-C6-caACGgtattttcacAGG		nd	nd	66	+
760_2	5'-GN2-C6-caGACactacaatgaGGA		nd	nd	101	nd
761_2	5'-GN2-C6-caTGGtttttaggacTGT		nd	nd	99	nd
762_2	5'-GN2-C6-caCGAcaaattctatCCT		nd	nd	84	nd
763_2	5'-GN2-C6-caTGAtatacaatgcTAC		nd	nd	93	+++
764_2	5'-GN2-C6-caTCGttgggtaaatTTA		nd	nd	53	+
765_2	5'-GN2-C6-caTGcTttataaatgGTG		nd	nd	106	nd

+++ : similar to PD-L1/vinculin band intensity of control; ++ : weaker than PD-L1/vinculin band intensity of control; + : much weaker than PD-L1/vinculin band intensity of control; nd = not determined.

[0471] From the data in table 13 it can be seen that GalNAc conjugation of the oligonucleotides clearly improves the in vivo PD-L1 reduction. The reduction of mRNA generally correlates with a reduction in PD-L1 protein. Except for CMP ID NO: 754_1, a low in vitro EC50 value generally reflects a good in vivo PD-L1 mRNA reduction once the oligonucleotide is conjugated to GalNAc.

Example 4—In Vivo PK/PD in Sorted Hepatocytes and Non-Parenchymal Cells from poly(I:C) Induced Mice

[0472] The distribution of naked and GalNAc conjugated oligonucleotides as well as PD-L1 mRNA reduction was investigated in hepatocytes and non-parenchymal cells isolated from poly(I:C) induced mice.

[0473] C57BL/6J female mice (n=3 per group) were injected s.c. with 5 mg/kg unconjugated oligonucleotide (748_1) or 7 mg/kg GalNAc-conjugated oligonucleotides (759_2) targeting mouse PD-L1 mRNA. Two days later, the mice were injected i.p. with 15 mg/kg poly(I:C) (LWM, Invivogen). The mice were anesthetized 18-20 h after poly(I:C) injection and the liver was perfused at a flow rate of 7 ml per min through the vena cava using Hank's balanced salt solution containing 15 mM Hepes and 0.38 mM EGTA for 5 min followed by collagenase solution (Hank's balanced salt solution containing 0.17 mg/ml Collagenase type 2 (Worthington 4176), 0.03% BSA, 3.2 mM CaCl₂ and 1.6 g/l NaHCO₃) for 12 min. Following perfusion, the liver was removed and the liver capsule was opened, the liver suspension was filtered through 70 µm cell strainer using William E medium and an aliquot of the cell suspension (=mixed liver cells) was removed for later analysis. The rest of the cell suspension was centrifuged for 3 min at 50×g. The supernatant was collected for later purification of non-parenchymal cells. The pellet was resuspended in 25 ml William E medium (Sigma cat. no. W1878 complemented with 1× Pen/Strep, 2 mM L-glutamine and 10% FBS (ATCC #30-2030)), mixed with 25 ml William E medium containing 90% percoll and the hepatocytes were precipitated by centrifugation at 50×g for 10 min. Following 2× washing in William E medium, the precipitated hepatocytes were resuspended in Williams E medium. The supernatant containing non-parenchymal cells was centrifuged at 500×g 7 min and the cells were resuspended in 4 ml RPMI medium and centrifuged through two layers of percoll (25% and 50% percoll) at 1800×g for 30 min. Following collection of the non-parenchymal cells between the two percoll layers, the cells were washed and resuspended in RPMI medium.

[0474] Total mRNA was extracted from purified hepatocytes, non-parenchymal cells and total liver suspension (non-fractionated liver cells) using the PureLink Pro 96 RNA Purification kit (Ambion), according to the manufacturer's instructions. cDNA was synthesized using M-MLT Reverse Transcriptase, random decamers RETROscript, RNase inhibitor (Ambion) and 100 mM dNTP set (Invitrogen, PCR Grade) according to the manufacturer's instruction. For gene expressions analysis, qPCR was performed using TaqMan Fast Advanced Master Mix (2×) (Ambion) in a duplex set up with TaqMan primer assays for the PD-L1 (Thermo Fisher Scientific; FAM-MGB Mm00452054-m1) and TBP (Thermo Fisher Scientific; VIC-MGB-PL Mm00446971_m1). The relative PD-L1 mRNA expression level is shown in table 10 as % of control samples from mice injected with saline and poly(I:C).

[0475] Oligonucleotide content analysis was performed using ELISA employing a biotinylated capture probe with the sequence 5'-TACCGT-s-Bio-3' and a digoxigenin conjugated detection probe with the sequence 5'-DIG-C12-S1-CCTGTG-3'. The probes consisted of only LNA with a phosphodiester backbone. Liver samples (approximately 50 mg) were homogenized in 1.4 mL MagNa pure lysis buffer (Roche Cat. No 03604721001) in a 2 mL Eppendorf tube containing one 5 mm stainless steel bead. Samples were homogenized on Retsch MM400 homogenizer (Merck Eurolab) until a uniform lysate was obtained. The samples were incubated for 30 min at room temperature. Standards were generated by spiking the unconjugated antisense oligonucleotide compound (CMP ID NO 748_1) in defined concentrations into an untreated liver sample and processing them as the samples. Spike-in concentrations are chosen to match the expected sample oligo content (within ~10-fold).

[0476] The homogenized samples were diluted a minimum of 10 times in 5×SSCT buffer (750 mM NaCl, and 75 mM sodium citrate, containing 0.05% (v/v) Tween-20, pH 7.0) and a dilution series of 6 times 2 fold dilutions using capture-detection solution (35 nM capture probe and 35 nM detection probe in 5×SSCT buffer) were made and incubated for 30 min at room temperature. The samples were transferred to a 96 well streptavidin coated plate (Nunc Cat. No. 436014) with 100 µL in each well. The plates were incubated for 1 hour at room temperature with gentle agitation. Wash three times with 2×SSCT buffer and add 100 µL anti-DIG-AP Fab fragment (Roche Applied Science, Cat. No. 11 093 274 910) diluted 1:4000 in PBST (Phosphate buffered saline, containing 0.05% (v/v) Tween-20, pH 7.2, freshly made) was added to each well and incubated for 1 hour at room temperature under gentle agitation. Wash three times with 2×SSCT buffer and add 100 µL of alkaline phosphatase (AP) substrate solution (Blue Phos Substrate, KPL product code 50-88-00, freshly prepared). The intensity of the color was measured spectrophotometrically at 615 nm after 30 minutes incubation with gentle agitation. Raw data were exported from the readers (Gen5 2.0 software) to excel format and further analyzed in excel. Standard curves were generated using GraphPad Prism 6 software and a logistic 4PL regression model.

TABLE 14

PD-L1 expression and oligo content in total liver suspension, hepatocytes and non-parenchymal cells from poly(I:C) mice treated with unconjugated and GalNAc-conjugated oligonucleotides, n = 3.

Cell type	CMP ID	PD-L1 expression (% of saline-poly(I:C))		oligo content (ng/10 ⁵ cells)	
		Avg	SD	Avg	SD
Total liver	748_1	31	12.4	2.3	0.3
	759_2	28	5.3	8.3	1.1
Hepatocytes	748_1	33	8.0	5.1	3.7
	759_2	7	1.0	43.8	18.9
Non-parenchymal cells	748_1	31	10.1	2.2	0.7
	759_2	66	1.6	1.7	0.9

[0477] The results show that naked (CMP ID NO: 748_1) and conjugated (CMP ID NO: 759_2) oligonucleotide reduce PD-L1 mRNA equally well in total liver cells. In isolated hepatocytes, the effect of the conjugated oligonucleotide is almost 5 fold stronger than the effect of the naked

oligonucleotide, while naked oligonucleotides showed two fold stronger effect than GalNAc-conjugated oligonucleotides in non-parenchymal cells. In hepatocytes and non-parenchymal cells the reduction of PD-L1 mRNA expression correlates to some extent with the oligonucleotide content in these cell types.

Example 5—In Vivo PD-L1 Knock Down in AAV/HBV Mice Using Naked and GalNAc Conjugated PD-L1 Antisense Oligonucleotides

[0478] In the present study AAV/HBV mice were treated with naked or conjugated to GalNAc PD-L1 antisense oligonucleotides, and the PD-L1 mRNA expression and HBV gene expression was evaluated in the liver.

[0479] Female HLA-A2/DR1 mice 5-8 weeks old (5 animals pr. group) were pretreated at week -1 vehicle (saline), naked PD-L1 antisense oligonucleotides (CMP ID NO 752_1 at 5 mg/kg s.c.) and GalNAc PD-L1 antisense oligonucleotides (CMP ID NO 763_2 at 7 mg/kg s.c.), these doses correspond to equimolar concentrations of the oligonucleotides. The mice were transduced by 5×10^{10} vg AAV-HBV at week 0 (for further details see description AAV/ HBV mouse model in the Materials and Methods section). From W1 post AAV-HBV transduction to W4, mice received 4 additional s.c. injections of PD-L1 oligonucleotides or vehicle (saline solution), given one week apart.

[0480] Blood samples were taken one week before transduction and one week after each injection.

[0481] Mice were sacrificed two weeks after the last injections and their liver were removed following PBS perfusion. The liver was cut in smaller pieces and directly frozen.

[0482] To measure HBV gene expression, DNA was extracted from serum with Qiagen Biorobot using the QIAamp One for all nucleic acid kit, Cat.#965672, serum was diluted 1:20 dilution in PBS a total of 100 μ l was lysed in 200 μ l Buffer AL. DNA was eluted from the kit in 100 μ l.

[0483] For the Real-Time qPCR the TaqMan Gene Expression Master Mix (cat.#4369016, Applied Biosystems) was used together with a primer mix prepared by adding 1:1:0.5 of the following primers F3_core, R3_core, P3_core (Integrated DNA Technologies, all reconstituted at 100 μ M each)

Forward (F3_core):
 CTG TGC CTT GGG TGG CTT T (SEQ ID NO: 784)

Reverse (R3_core):
 AAG GAA AGA ACT CAG AAG GCA AAA (SEQ ID NO: 785)

Probe (P3_core):
 56-FAM-AGC TCC AAA/ZEN/TTC TTT ATA AGG GTC GAT CTC (SEQ ID NO: 786)

CAT G-3IABkFQ

[0484] A standard curve using HBV plasmid (Genotype D, GTD) was prepared using 10-fold dilutions starting with 1×10^9 copies/ μ l down to 1 copy/ μ l and used in 5 μ l per reaction.

[0485] For each reaction 10 μ l Gene Expression Master Mix, 4.5 μ l water, 0.5 μ l Primer mix and 5 μ l sample or standard was added and the qPCR was run.

[0486] For the analysis the copy number/ml/well was calculated using the standard curve. The results are shown in table 15.

[0487] PD-L1 mRNA expression was measured using qPCR.

[0488] mRNA was extracted from frozen liver pieces that were added to 2 ml tubes containing ceramic beads (Lysing Matrix D tubes, 116913500, mpbio) and 1 ml of Trizol.

[0489] The liver piece was homogenized using the Pre-cellys Tissue Disruptor. 200 μ l Chloroform was added to the homogenate, vortexed and centrifuged at 4° C. for 20 min at 10000 rpm. The RNA containing clear phase (around 500 μ l) was transferred into a fresh tube and the same volume of 70% EtOH was added. After mixing well the solution was transferred onto a RNeasy spin column and RNA was further extracted following the RNeasy Kit's manual RNeasy Mini Kit, cat.#74104, Qiagen (including the RNA digestion RNase-free DNase Set, cat.#79254). Elution in 50 μ l H₂O. The final RNA concentration was measured and adjusted to 100 ng/ μ l for all samples.

[0490] The qPCR was conducted on 7.5 μ l RNA using the Taqman RNA-to-ct 1-step Kit, cat.#4392938, Thermo Fisher according to the manufactures instructions. The primer mixed used contained PD-L1_1-3 (Primer number Mm00452054_m1, Mm03048247_m1 and Mm03048248_m1) and endogenous controls (ATCB Mm00607939_s1, CANX Mm00500330_m1, YWHAZ Mm03950126_s1 and GUSB Mm01197698_m1)

[0491] Data were analysed using the 2^{-ddct} method. The mean of all four endogenous controls was used to calculate dct values. The PD-L1 expression relative to mean of the endogenous controls and in % of saline

TABLE 15

PD-L1 mRNA expression and HBV DNA in AAV/HBV mice treated with unconjugated and GalNAc-conjugated oligonucleotides, n = 5.					
	CMP ID no	PD-L1 mRNA expression (% of saline)		HBV DNA expression (% of saline)	
		Avg	SD	Avg	SD
Naked	752_1	55	35	72	16
GalNAc conjugated	763_2	34	3	79	9

[0492] From these results it can be seen that both naked and GalNAc conjugated oligonucleotides are capable of reducing PD-L1 mRNA expression in the liver of an AAV/ HBV mouse, with the GalNAc conjugated oligonucleotide being somewhat better. Both oligonucleotides also resulted in some reduction in HBV DNA in the serum.

Example 6—In Vivo Effect on T Cell Response in AAV/HBV Mice

[0493] In the present study AAV/HBV mice from Pasteur were treated with an antibody or antisense oligonucleotides targeting PD-L1. The antisense oligonucleotides were either naked or conjugated to GalNAc. During the treatment the animals were immunized with a DNA vaccine against HBs and HBc antigens (see Materials and Methods section) to ensure efficient T cell priming by the antigen presenting cells. It was evaluated how the treatment affected the cell

population in liver and spleen, as well as the PD-L1 expression on these populations and whether a HBV specific T cell response could be identified.

Treatment Protocol:

[0494] Female HLA-A2/DR1 mice were treated according to the protocols below. The study was conducted in two separate sub-studies, with slight differences in the administration regimens as indicated in Table 16 and 17 below.

[0495] DNA vaccine and anti-PD-L1 antibody was administered as described in the materials and method section. The antisense oligonucleotides used were CMP ID NO 748_1 (naked) at 5 mg/kg and CMP ID NO: 759_2 (GalNAc conjugated) at 7 mg/kg, both where administered as subcutaneous injections (s.c.).

TABLE 16

AAV/HBV mouse treatment protocol with DNA vaccine and DNA vaccine + anti-PD-L1 antibody, 6 mice in each group			
Day	Vehicle (Group 10)	DNA vaccine (Group 11)	DNA vaccine + anti-PD-L1 Ab (Group 13)
0	AAV/HBV		
29*	Animal randomization		
34	Saline + Isotype	—	Ab
41	Saline + Isotype	—	Ab
48	Saline + Isotype	—	Ab
50	—	CaTx	CaTx
55*	PBS + Isotype	DNA	DNA + Ab
62	Saline + Isotype	—	Ab
69	PBS + Isotype	DNA	DNA + Ab
76*	Saline + Isotype	—	Ab
83	Saline + Isotype	—	Ab
97*	Sacrifice		

Isotype = mouse IgG control Ab,
CaTx = cardiotoxine,
DNA = DNA vaccine,
Ab = anti-PD-L1 Ab and
* = serum collection

TABLE 17

AAV/HBV mouse treatment protocol with DNA vaccine and DNA vaccine + naked or conjugated PD-L1 oligonucleotide (ASO), 7 mice in each group				
Day	Vehicle (Group 1)	DNA vaccine (Group 2)	DNA vaccine + GN-PDL-1 ASO (Group 7)	DNA vaccine + GN-PDL-1 ASO (Group 8)
0	AAV/HBV			
29*	Animal randomization			
39	Saline	Saline	ASO	GN-ASO
41	Saline	Saline	ASO	GN-ASO
46	Saline	Saline	ASO	GN-ASO
49	Saline	Saline	ASO	GN-ASO
53	Saline	Saline	ASO	GN-ASO
55	CaTx	CaTx	CaTx	CaTx
56	Saline	ASO	GN-ASO	GN-ASO
59	PBS + Saline	DNA + PBS	DNA	DNA
62*	Saline	Saline	ASO	GN-ASO
67	Saline	Saline	ASO	GN-ASO
70	Saline	Saline	ASO	GN-ASO
74	PBS + Saline	DNA + PBS	DNA	DNA
77	Saline	Saline	ASO	GN-ASO
81	Saline	Saline	ASO	GN-ASO
84*	Saline	Saline	ASO	GN-ASO
88	Saline	Saline	ASO	GN-ASO

TABLE 17-continued

AAV/HBV mouse treatment protocol with DNA vaccine and DNA vaccine + naked or conjugated PD-L1 oligonucleotide (ASO), 7 mice in each group				
Day	Vehicle (Group 1)	DNA vaccine (Group 2)	DNA vaccine + GN-PDL-1 ASO (Group 7)	DNA vaccine + GN-PDL-1 ASO (Group 8)
91	Saline	ASO	GN-ASO	GN-ASO
102	Sacrifice			

DNA = DNA vaccine,
CaTx = cardiotoxine,
Ab = anti-PD-L1 Ab,
ASO = naked PDL-1 oligonucleotide,
GN-ASO = GalNAc-PDL-1 oligonucleotide and
* = serum collection

[0496] At the time of sacrifice blood, spleen and liver mononuclear cells of each mouse from each group were collected and depleted of red blood cells (Lysing Buffer, BD biosciences, 555899). The liver mononuclear cells required a specific preparation as described in the materials and method section.

Cell Populations:

[0497] In the liver the cell population was analyzed by surface labeling on liver mononuclear cells (see materials and methods) using cytometry.

[0498] No significant changes were noticed in the frequencies of NK cells in the spleen and liver of treated mice compared to control groups (i.e. vehicle and DNA-immunized groups). Table 18 show that in the liver, groups treated with naked PD-L1 oligonucleotide (CMP ID NO 748_1) and GalNAc conjugated PD-L1 oligonucleotide (CMP ID NO: 759_2) had a significant increase in T cell numbers compared to either control groups (i.e. vehicle and DNA-immunized groups) also presented in FIG. 10 A. This increase was due to an increase in both CD4+ and CD8+ T cell populations (Table 18 and FIGS. 10B and 10C, respectively).

TABLE 18

T-cells in the liver following treatment in millions of cells						
	T-cells (millions)		CD4+ T-cells (millions)		CD8+ T-cells (millions)	
	Avg	Std	Avg	Std	Avg	Std
Vehicle (Group 1)	0.77	0.44	0.51	0.35	0.11	0.05
DNA vaccine (Group 2)	0.90	0.24	0.58	0.16	0.16	0.08
DNA vaccine + anti-PD-L1 Ab (Group 13)	1.98	0.90	1.40	0.81	0.41	0.23
Vehicle (Group 10)	1.73	0.87	1.13	0.55	0.40	0.25
DNA vaccine (Group 11)	1.27	0.97	0.79	0.58	0.32	0.32
DNA vaccine + PD-L1 ASO (Group 7)	3.78	1.31	2.46	0.72	0.79	0.39
DNA vaccine + GN-PD-L1 ASO (Group 8)	3.33	0.66	2.18	0.40	0.67	0.17

PD-L1 Expression:

[0499] The expression of PD-L1 protein was evaluated on macrophages, B and T cells from spleen and liver at time of sacrifice. The presence of PD-L1 antibody in the surface

labeling antibody mix (see materials and methods) allowed quantification of PD-L1 expressing cells by cytometry.

[0500] In spleen, no significant difference between the treatments was observed in the % of macrophages, B cells and CD4+ T cells expressing PD-L1. The % of the CD8+ T cells expressing PD-L1 was lower in mice treated with naked PD-L1 oligonucleotide (CMP ID NO 748_1) and GalNAc conjugated PD-L1 oligonucleotide (CMP ID NO: 759_2) when compared to the other treatments (data not shown).

[0501] In liver, PD-L1 was expressed mainly on CD8+ T cells with a mean frequency of 32% and 41% in the control groups (the two vehicle and DNA vaccination groups combined, respectively, FIG. 11A). Treatment with naked PD-L1 oligonucleotide or GalNAc PD-L1 oligonucleotide resulted in a decrease of the frequency of CD8+ T cells expressing PD-L1 (see table 19 FIG. 11A). Significant differences in the % of cells expressing PD-L1 were also noticed for B cells and CD4+ T-cells after ASO treatment, although these cell types express significantly less PD-L1 than the CD8+ T cells (see table 19 and FIGS. 11B and C). Treatment with anti-PD-L1 Ab, also resulted in an apparent decrease in the PD-L1 expression in all cell types. It is, however, possible that this decrease is due to partly blockage of the PD-L1 epitope by the anti-PD-L1 antibody used for treatment, so that the PD-L1 detection antibody in the surface labeling antibody mix is prevented from binding to PD-L1. Therefore what appears to be a PD-L1 down regulation by the anti-PD-L1 antibody used for treatment may be the result of epitope competition between the treatment antibody and the detection antibody.

TABLE 19

	% of liver cell population with PD-L1 expression					
	% of CD8+ T-cells		% of CD4+ T-cells		% of B-cells	
	Avg	Std	Avg	Std	Avg	Std
Vehicle (Group 10)	35.5	4.7	0.75	0.52	5.9	1.5
DNA vaccine (Group 11)	36.8	7.7	0.61	0.08	5.5	1.1
DNA vaccine + anti-PD-L1 Ab (Group 13)	18.6	12.3	0.33	0.10	2.9	1.7
Vehicle (Group 1)	28.5	11.5	0.64	0.21	5.9	1.7
DNA vaccine (Group 2)	44.9	14.4	1.43	0.69	8.7	3.1
DNA vaccine + PD-L1 ASO (Group 7)	9.6	2.4	0.37	0.21	2.9	0.8
DNA vaccine + GN-PD-L1 ASO (Group 8)	14.6	3.3	0.31	0.11	2.8	0.8

HBV Specific T Cell Response:

[0502] NK cells and CD4+ and CD8+ T cells producing pro-inflammatory cytokines were detected using the intracellular cytokine staining assays (see Materials and Methods section) detecting IFN γ and TNF α production.

[0503] In the spleen no NK cells and few CD4+ T cells secreting IFN γ - and TNF α were detectable (frequency <0.1%) at sacrifice. IFN γ -producing CD8+ T cells targeting the two HBV antigens were detected in mice treated with

naked PD-L1 oligonucleotide or GalNAc PD-L1 oligonucleotide as well as in mice from this study which received only DNA vaccine (data not shown).

[0504] In the livers of DNA-immunized HBV-carrier mice, no IFN γ -producing NK cells were detected at sacrifice, whereas IFN γ -secreting CD4+ T cells specific for Core or for S2+S were detected in the liver of a few DNA-immunized mice at a low frequency (<0.4%, data not shown). HBV S2+S-specific CD8+ T cells producing IFN γ were detected in the majority of DNA-immunized mice. The frequency of IFN γ -secreting CD8+ T cells increased in mice treated with combination of DNA vaccine and naked PD-L1 oligonucleotide or GalNAc PD-L1 oligonucleotide, whereas treatment with anti-PD-L1 antibody did not add any apparent additional effect to the DNA vaccination (FIG. 12). IFN γ -producing CD8+ T cells targeting the envelope and core antigens were detected in most DNA-immunized groups (except anti-PD-L1 antibody) (FIG. 12B). Most of the S2-S specific T cells produced both IFN γ and TNF α (FIG. 12C). The results are also shown in Table 20.

TABLE 20

	% of HBV antigen (S2-S or core) specific CD8+ T cells from total IFN γ or IFN γ + TNF α cell population					
	PreS2-S specific T cells (% of IFN γ cells)		Core specific T cells (% of IFN γ cells)		S2-S specific T cells (% of IFN γ + TNF α)	
	Avg	Std	Avg	Std	Avg	Std
Vehicle (Group 10)	0.15	0.37	0.18	0.43	0.00	0.00
DNA vaccine (Group 11)	1.48	1.10	0.47	0.53	0.42	1.02
DNA vaccine + anti-PDL-1 Ab	1.18	0.95	0	0	0.38	0.49
Vehicle (Group 1)	0.17	0.45	0.11	0.28	0.00	0.00
DNA vaccine (Group 2)	1.70	1.02	0.27	0.51	0.98	0.90
DNA vaccine + PDL-1 ASO	2.56	1.60	0.78	0.80	1.44	1.55
DNA vaccine + GN-PDL-1 ASO	3.83	2.18	0.68	1.16	2.62	1.62

Example 7—In Vivo Effect on HBV Antigen and HBV DNA in the Serum of AAV/HBV Mice

[0505] In the present study AAV/HBV mice from Shanghai (see Materials and Methods section) were treated with the GalNAc conjugated PD-L1 antisense oligonucleotide CMP ID NO 759_2.

[0506] It was evaluated how the treatment affected the HBe and HBs antigens and HBV DNA levels in the serum compared to vehicle treated animals.

Treatment Protocol:

[0507] Male C57BL/6 mice infected with recombinant adeno-associated virus (AAV) carrying the HBV genome (AAV/HBV) as described under the Shanghai model in the materials and method section were used in this study. The mice (6 mice pr. group) were injected once a week for 8 weeks with the antisense oligonucleotide CMP ID NO: 759_2 at 5 mg/kg or vehicle (saline) both where adminis-

tered as subcutaneous injections (s.c.). Blood samples were collected each week during treatment as well as 6 weeks post treatment. HBV DNA, HBsAg and HBeAg levels were measured in the serum samples as described below. The results for the first 10 weeks are shown in table 21 and in FIG. 13. The study was still ongoing at the time of filing the application therefore data for the remaining 4 weeks have not been obtained.

HBsAg and HBeAg Detection:

[0508] Serum HBsAg and HBeAg levels were determined in the serum of infected AAV-HBV mouse using the HBsAg chemoluminescence immunoassay (CLIA) and the HBeAg CLIA kit (Autobio diagnostics Co. Ltd., Zhengzhou, China, Cat. no. CL0310-2 and CL0312-2 respectively), according to the manufacturer's protocol. Briefly, 50 μ l of serum was transferred to the respective antibody coated microtiter plate and 50 μ l of enzyme conjugate reagent was added. The plate was incubated for 60 min on a shaker at room temperature before all wells were washed six times with washing buffer using an automatic washer. 25 μ l of substrate A and then 25 μ l of substrate B was added to each well. The plate was incubated for 10 min at RT before luminescence was measured using an Envision luminescence reader. HBsAg is

PrimeTime XL qPCR Primer/Probe (IDT) and 4.5 μ l distilled water in a 384 well plate and the PCR was performed using the following settings: UDG Incubation (2 min, 50° C.), Enzyme Activation (10 min, 95° C.) and PCR (40 cycles with 15 sec, 95° for Denaturing and 1 min, 60° C. for annealing and extension). DNA copy numbers were calculated from C_t values based on a HBV plasmid DNA standard curve by the ViiA7 software.

Sequences for TaqMan primers and probes (IDT):

Forward core primer (F3_core): (SEQ ID NO: 784)
 CTG TGC CTT GGG TGG CTT T
 Reverse primer (R3_core): (SEQ ID NO: 785)
 AAG GAA AGA ACT CAG AAG GCA AAA
 Taqman probe (P3_core): (SEQ ID NO: 786)
 56-FAM/AGC TCC AAA /ZEN/TTC TTT ATA AGG GTC GAT
 CTC CAT G/3IABkFQ.

TABLE 21

HBV-DNA, HBsAg and HBeAg levels in serum from AAV/HBV mice following treatment with GalNAc conjugated PD-L1 antisense oligonucleotide.												
Saline						CMP ID NO: 759_2 at 5 mg/kg						
Day	HBV-DNA		HBsAg		HBeAg		HBV-DNA		HBsAg		HBeAg	
	Avg	Std	Avg	Std	Avg	Std	Avg	Std	Avg	Std	Avg	Std
0	7.46	0.35	3.96	0.48	3.23	0.14	7.44	0.29	3.87	0.40	3.17	0.13
7	7.53	0.23	4.17	0.45	3.35	0.10	7.53	0.20	3.91	0.42	3.19	0.18
14	7.57	0.24	4.12	0.49	3.19	0.11	7.45	0.22	3.90	0.50	2.99	0.27
21	7.47	0.27	3.93	0.51	3.12	0.05	7.33	0.47	3.71	0.76	2.78	0.26
28	7.68	0.26	3.88	0.67	3.18	0.13	7.45	0.46	3.65	0.93	2.67	0.38
35	7.69	0.21	4.03	0.54	2.95	0.08	7.13	0.75	2.98	1.05	2.04	0.38
42	7.58	0.23	3.89	0.65	3.34	0.10	6.69	0.89	2.60	1.05	1.98	0.45
49	7.77	0.17	3.54	1.06	3.08	0.26	6.56	1.26	2.19	0.70	1.47	0.37
56	7.71	0.24	3.99	0.86	3.28	0.05	6.21	1.48	2.28	0.84	1.38	0.30
63	7.59	0.28	3.67	1.07	3.25	0.13	6.08	1.39	2.08	0.71	1.35	0.30

given in the unit IU/ml; where 1 ng HBsAg=1.14 IU. HBeAg is given in the unit NCU/ml serum. HBV DNA Extraction and qPCR:

[0509] Initially mice serum was diluted by a factor of 10 (1:10) with Phosphate buffered saline (PBS). DNA was extracted using the MagNA Pure 96 (Roche) robot. 50 μ l of the diluted serum was mixed in a processing cartridge with 200 μ l MagNA Pure 96 external lysis buffer (Roche, Cat. no. 06374913001) and incubated for 10 minutes. DNA was then extracted using the "MagNA Pure 96 DNA and Viral Nucleic Acid Small Volume Kit" (Roche, Cat. no. 06543588001) and the "Viral NA Plasma SV external lysis 2.0" protocol. DNA elution volume was 50 μ l.

[0510] Quantification of extracted HBV DNA was performed using a Taqman qPCR machine (ViiA7, life technologies). Each DNA sample was tested in duplicate in the PCR. 5 μ l of DNA sample was added to 15 μ l of PCR mastermix containing 10 μ l TaqMan Gene Expression Master Mix (Applied Biosystems, Cat. no. 4369016), 0.5 μ l

[0511] From this study it can be seen that GalNAc conjugated PD-L1 antisense oligonucleotide CMP NO 759_2 has a significant effect on the reduction of HBV-DNA, HBsAg and HBeAg levels in serum after 6 weeks of treatment, and effect that is sustained for at least 2 weeks after the treatment has ended.

Example 8—In Vitro PD-L1 Knock Down in Human Primary Hepatocytes Using GalNAc Conjugated PD-L1 Oligonucleotides

[0512] The ability of GalNAc conjugated PD-L1 antisense oligonucleotide compounds to reduce the PD-L1 transcript in primary human hepatocytes was investigated using genomics.

Cell Culture

[0513] Cryopreserved human hepatocytes were suspended in WME supplemented with 10% fetal calf serum, penicillin

(100 U/ml), streptomycin (0.1 mg/ml) and L-glutamine (0.292 mg/ml) at a density of approx. 5×10^6 cells/ml and seeded into collagen-coated 24-well plates (Becton Dickinson A G, Allschwil, Switzerland) at a density of 2×10^5 cells/well. Cells were pre-cultured for 4 h allowing for attachment to cell culture plates before start of treatment with oligonucleotides at a final concentration of 100 μ M. The oligonucleotides used are shown in table 21 and table 8, vehicle was PBS. Seeding medium was replaced by 315 μ l of serum free WME (supplemented with penicillin (100 U/ml), streptomycin (0.1 mg/ml), L-glutamine (0.292 mg/ml)) and 35 μ l of 1 mM oligonucleotide stock solutions in PBS were added to the cell culture and left on the cells for 24 hours or 66 hours.

Library Preparation

[0514] Transcript expression profiling was performed using Illumina Stranded mRNA chemistry on the Illumina sequencing platform with a sequencing strategy of 2x51 bp paired end reads and a minimum read depth of 30M per specimen (Q squared EA). Cells were lysed in the wells by adding 350 μ l of Qiagen RLT buffer and were accessioned in a randomization scheme.

[0515] mRNA was purified using the Qiagen RNeasy Mini Kit. mRNA was quantitated and integrity was assessed using an Agilent Bioanalyzer. Upon initial quality assessment of the isolated RNA, it was observed that all samples met the input quality metric of 100 ng with RIN scores >7.0.

[0516] Sequencing libraries were generated for all samples using the Illumina TruSeq Stranded mRNA Library Preparation, starting with 100 ng of total RNA. Final cDNA libraries were analyzed for size distribution and using an Agilent Bioanalyzer (DNA 1000 kit), quantitated by qPCR (KAPA Library Quant Kit) and normalized to 2 nM in preparation for sequencing. The Standard Cluster Generation Kit v5 was used to bind the cDNA libraries to the flow cell surface and the cBot isothermally to amplify the attached cDNA constructs up to clonal clusters of ~1000 copies each. The DNA sequence was determined by sequencing-by-synthesis technology using the TruSeq SBS Kit.

Data Processing

[0517] Illumina paired-end sequencing reads of length 2x51 bp were mapped on the human reference genome hg19 using the GSNAP short read alignment program. SAM-format alignments were converted into sorted alignment BAM-format files using the SAMTOOLS program. Gene read counts were estimated for PD-L1 based on the exon annotation from NCBI RefSeq, specified by the corresponding GTF file for hg19. A normalization step accounting for the different library size of each sample was applied using the DESeq2 R package.

[0518] The reduction in PD-L1 transcript after incubation with GalNAc conjugated PD-L1 antisense oligonucleotide compounds are shown in table 22.

TABLE 22

PD-L1 transcript reduction in human primary hepatocytes following treatment with GalNAc conjugated oligonucleotides, n = 4		
Compound	PD-L1 expression level 24 h (library size adjusted counts)	PD-L1 expression level 66 h (library size adjusted counts)
Vehicle	259	156
	159	168
	192	136
	202	211
	7	7
767_2	11	14
	22	9
	28	15
	16	13
766_2	15	10
	17	11
	29	13
769_2	15	21
	18	18
	25	18
768_2	26	25
	41	25
	27	48
	31	25
	34	22
770_2	21	16
	44	62
	67	51
	38	63

[0519] All five GalNAc conjugated antisense compounds showed significant PD-L1 transcript reduction after 24 and 66 hour incubation when compared to samples treated with vehicle.

Example 9—EC50 of Conjugated and Naked PD-L1 Antisense Oligonucleotides in HBV Infected ASGPR-HepaRG Cells

[0520] The potency of two naked and the equivalent GalNAc conjugated PD-L1 antisense oligonucleotides were compared in HBV infected ASGPR-HepaRG cells.

Cell Line

[0521] HepaRG cells (Biopredic International, Saint-Gregoire, France) were cultured in Williams E medium (supplemented with 10% HepaRG growth supplement (Biopredic)). From this cell line a HepaRG cell line stably overexpressing human ASGPR1 and ASGPR2 was generated using a lentiviral method. Proliferating HepaRG cells were transduced at MOI 300 with a lentivirus produced on demand by Sirion biotech (CLV-CMV-ASGPR1-T2a_ASGPR2-IRES-Puro) coding for Human ASGPR1 and 2 under the control of a CMV promoter and a puromycin resistance gene. Transduced cells were selected for 11 days with 1 μ g/ml puromycin and then maintained in the same concentration of antibiotic to ensure stable expression of the transgenes. ASGPR1/2 overexpression was confirmed both at mRNA level by RT-qPCR (ASGPR1: 8560 fold vs non-transduced, ASGPR2: 2389 fold vs non transduced), and at protein level by flow cytometry analysis.

[0522] The cells were differentiated using 1.8% DMSO for at least 2 weeks before infection. HBV genotype D was derived from HepG2.2.15 cell culture supernatant and was concentrated using PEG precipitation. To evaluate activity of test compounds against HBV, differentiated ASGPR-

HepaRG cells in 96 well plates were infected with HBV at an MOI of 20 to 30 for 20 h, before the cells were washed 4 times with PBS to remove the HBV inoculum.

Oligonucleotide Potency

[0523] The following oligonucleotides

Naked PD-L1 ASO	Equivalent GalNAc conjugated PD-L1 ASO
CPM ID NO: 640_1	CPM ID NO: 768_2
CPM ID NO: 466_1	CPM ID NO: 769_2

were added to the HBV infected ASGPR-HepaRG cells on day 7 and day 10 post infection using serial dilutions from 25 μM to 0.4 nM (1:4 dilutions in PBS). Cells were harvested on day 13 post infection.

[0524] Total mRNA was extracted using the MagNA Pure 96 Cellular RNA Large Volume Kit on the MagNA Pure 96 System (Roche Diagnostics) according to the manufacturer's instructions. For gene expression analysis, RT-qPCR was performed as described in Example 5.

[0525] Data were analysed using the 2^{-ddct} method. ActinB was used as the endogenous control to calculate dct values. The PD-L1 expression is relative to the endogenous controls and to the saline vehicle.

[0526] EC50 calculations were performed in GraphPad Prism6 and is shown in table 23.

TABLE 23

EC50 in ASGPR-HepaRG HBV infected cells, n = 4.	
CMP ID NO	EC50 (μM)
640_1	2.25
768_2	0.10
466_1	5.82
769_2	0.13

[0527] These data clearly shows that GalNAc conjugation of the PD-L1 antisense oligonucleotides improves the EC50 values significantly.

Example 10—Stimulation T Cell Function in PBMCs Derived from Chronic HBV Patients

[0528] It was investigated whether naked PD-L1 antisense compounds could increase the T cells function of chronically infected HBV (CHB) patients after ex-vivo HBV antigen stimulation of the peripheral blood mononuclear cells (PBMCs).

[0529] Frozen PBMCs from three chronic HBV infected patients were thawed and seeded at a density of 200,000 cells/well in 100 μl medium (RPMI1640+GlutaMax+8% Human Serum+25 mM Hepes+1% PenStrep). The next day, cells were stimulated with 1 μM PepMix HBV Large Envelope Protein or 1 μM PepMix HBV Core Protein (see table 9) with or without 5 μM of CMP ID NO: 466_1 or CMP ID NO: 640_1 in 100 μl medium containing 100 μg/ml IL-12 and 5 ng/ml IL-7 (Concanavalin stimulation was only applied at day 8). Four days later PD-L1 antisense oligonucleotide treatment was renewed with medium containing 50 IU IL-2. At day 8 after the first stimulation the cells were re-stimulated with PepMix or 5 μg/ml Concanavalin A plus PD-L1 antisense oligonucleotide for 24 h. For the last 5 h of the stimulation, 0.1 μl Brefeldin A, 0.1 μl Monensin and 3 μl anti-human CD-107 (APC) were added.

[0530] After 24 h the cells were washed with Stain Buffer (PBS+1% BSA+0.09% Sodium Azide+EDTA) and surface staining was applied for 30 min at 4° C. [anti-human CD3 (BV 605), anti-human CD4 (FITC), anti-human CD8 (BV711), anti-human PDL1 (BV421), anti-human PD1 (PerCP-Cy5.5) and Live and Dead stain (BV510) (BD Biosciences)]. Cells were fixed in BD Fixation Buffer for 15 min at 4° C. The next morning, cells were permeabilized with BD Perm/Wash Buffer for 15 min at 4° C. and intracellular staining was done for 30 min at 4° C. [anti-human INFγ (PE)]. After washing in Perm/Wash Buffer cells were dissolved in 250 μl stain buffer.

[0531] FACS measurement was performed on a BD Fortessa (BD Biosciences). For the analysis, the whole cell population was first gated on live cells (Live and Death stain, BV510), and then on CD3+ (BV605) cells. The CD3+ cells were then graphed as CD107a+ (APC) vs IFNγ+ (PE).

[0532] The results are shown in table 24.

TABLE 24

	Effect of PD-L1 ASO treatment on CD3+ T cell from PBMCs isolated from three chronically HBV infected patients.								
	No antigen stimulation			Envelope antigen			Core antigen		
	Saline	CMP 466_1	CMP 640_1	Saline	CMP 466_1	CMP 640_1	Saline	CMP 466_1	CMP 640_1
INFγ-/	1.16	4.95	4.81	4.7	9.12	8.62	3.84	9.66	7.31
CD107+	2.7	3.59	2.74	2.57	3.69	3.2	3.25	3.34	2.92
	3	3.87	3.98	4.59	12.5	10.9	9.23	6.11	6.88
INFγ+/	0.12	1.03	1.15	3.19	17.3	18.9	2.38	15.1	5.75
CD107+	0.49	3.12	1.75	2.73	7	5.34	1.63	2.35	1.9
	0.24	1.13	1.5	1.6	8.16	3.06	1.68	1.9	1.91
INFγ+/	0.33	1.43	1.08	5.11	7.74	9.47	3.14	7.76	2.83
CD107-	0.61	2.9	2.26	7.84	5.79	5.78	2.33	2.82	2.95
	0.17	1.57	1.72	1.22	2.58	0.99	0.1	0.61	1.04

[0533] From these data it can be seen that the antigen stimulation by itself is capable of inducing T cell activation (increase % of CD3+ cells expressing INF γ and/or CD107a) in the PBMCs of CHB patients (n=3). The addition of

PD-L1 antisense oligonucleotide CMP 466_1 or 640_1 resulted in an additional increase of CD3+ T cell response. This increase was mainly observed in the HBV envelop stimulated group.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 786

<210> SEQ ID NO 1

<211> LENGTH: 20064

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

```

ggcgcaacgc tgagcagctg gcgctgccg cgcggcccca gttctgcgca gttcccgag    60
gctccgcacc agcccgctt ctgtccgctt gcaggtaggg agcgttgctc ctcccggggt    120
gcccacggcc cagtatctct ggctagctcg ctgggcactt taggacggag ggtctctaca    180
ccctttcttt gggatggaga gaggagaagg gaaaggaac gcgatggtct agggggcagt    240
agagccaatt acctgttggg gttaataaga acaggcaatg catctggcct tcctccaggc    300
gcgattcagt tttgctctaa aaataattta tacctctaaa aataaataag ataggtagta    360
taggataggt agtcattctt atgcgactgt gtgttcagaa tatagetctg atgctaggct    420
ggaggctctg acacgggtcc aagtcaccg ccagctgctt gctagtaaca tgacttgtgt    480
aagttatccc agctgcagca tctaagtaag tctcttctg cgctaagcag gtccaggatc    540
cctgaacgga atttatcttgc tctgtccatt ctgagaaccc aaaggagtcc taaaagagga    600
atggaggagc ctaagaataa aaatagtata ataaaacatt tcttagacac attgacctg    660
gcctatgtca aagttcagtc tgggtttgtc ttataacaca aggagtataa gtaccattgt    720
tctacctctt ttttaatac ttgaaaaaaa tttactgtgg atgcttttct atgaattaaa    780
taaccttcta aaaaatgttt tcattgtctc attcgattag attgggtaac taaatgaaat    840
taattcctca ctgttgggta taaaggttat ttacagtgtt tctgtcttag ccattcactg    900
aactcattgc atatatatct ctggaatatt gctgattggt tccttcaagt aaacttagaa    960
gtgtaactac ttagtcaaag agcctgaata ttttaaaggc cttttgaaga aaactgaaaa   1020
tgctttccag aaaggatgta tcagttgaca atgacagtcg tcaacagtat ttaaggagaa   1080
ctatgatact ctgaagaaaa acctagcctt tctcagtaaa agtaggtagg cagaggccac   1140
atgacagcag ttagagtgtg gtcttcaagg aagtcacaga aatactgtgg ggaattgaaa   1200
ccccatgtgg aaaatgtaca agagtgtctc agtgtgactg agaaggaggt tgggcatggg   1260
gtttcatgga gtttaataaa gtttggctac ttagtagagg ttaataaat caactgtctt   1320
aatctttgat cctacttaag aatttttttt ttgtttttgt agagatgggg ctcttggtat   1380
gttgccaggc ctgttctcga actcctagcc tcaggcgatc ctccctctc aggctccaga   1440
agtccctgga ttactggcgg gagccaccat gcaggcctct tgctcctact tttgagaaag   1500
gaagtttaac cggttttttt tgtctttttt tttttttttt tgagacagag tctcactctg   1560
ttgcccatgc tggagtgcag tgggtgcaatc tcagctcact gcctcccggg ttcaagtgat   1620
tctcctgctt cagcctcccg agtagctggg actacaggca cctgccacca cggccagcta   1680
atttttgtat ttttagtaga aatggggttt caccatattg gccaggctga tctcgaactc   1740
ctgacctcag gtgatccgcc tgcctcggcc tccc aaagtg ctgggattac aggcattgagc   1800

```

-continued

cactgctcct	ggctgcttaa	ctttttctct	atctcatcct	cctacceatc	ctacccttgg	1860
aagatagaga	agtagtatta	gttccatagt	gttatactgg	gcttccccca	gggacaaacc	1920
cacttccccca	acctgaatga	gccatcactt	cttccccagt	ttacatttca	ttgctcttta	1980
aatgtctcca	ttcggatag	ggaattcaca	tatggtcata	attcttacct	gaagaagatg	2040
tcagtctctc	tctcttagac	caactgocct	gatatgaggt	ttagaggtta	aagaacatgt	2100
gtgtatttac	atgatctttg	tattctgcct	tttcgctcct	cactaatgac	agctgcaccc	2160
caaggaaatg	gagctgtgga	agagaggggt	tgataagaaa	ttaagtaaat	attggatcta	2220
atccatcacc	ctccaggaag	cctttattac	tcctaaaaat	ttcaaccaa	ttcattaaag	2280
gacaagaact	ccaccagagt	aggccataaa	cattggcaaa	attagttgta	atccatgact	2340
agatttaatg	tccctttggt	ttattcccat	atgggtataa	tgctttgctt	ggcattaggg	2400
gtattttaag	ttttctctg	cctagtaagt	gaatttgtgt	ttataataca	ataatcataa	2460
aatatcacat	taatatttta	taactgtaca	gttataaaat	attttataag	taatatttat	2520
attttataag	taatatttta	taactgtaca	gttaactctg	gccaaggaa	aagatagtct	2580
gatagatgct	gcagcccat	tttagcaaat	gtgacctcac	aggcctgaat	gccatcgcta	2640
ttccacatct	acaggataga	cggaaaggaa	agaaataaaa	aaataggta	ctaacactgg	2700
caagaggatg	atgactcatg	ttatttcaat	taaccttttt	atcttttaac	atgaaggact	2760
catacagggt	gataagaaac	cagtgcata	aacagaccaa	aaaatgatca	gatctttcaa	2820
attagcaaaa	aaataatatt	ttttaacaa	tgggtgaaaa	tacagtgtaa	cagtaccaat	2880
tatcaacatg	tgttgagaac	cagaaaaatg	ttcttttct	ttgatcagca	acactatttg	2940
ggaaaatcta	tcctcagggc	ctagcctggg	gccctggcac	acagtaggca	ctcaacgaat	3000
atgtgctgaa	cacacaaata	cttatgatat	tttaaaaaat	tggcaacaat	ctgataccta	3060
acaatagagg	gattaaatat	tatggaactg	ttaaataaga	tgcttatgaa	taccatgcag	3120
taagatgggc	aatatttatg	ccataagctt	taatgaaaca	aatgggtatt	aatgtatga	3180
taaggttata	aattactttt	taaaagatta	cagggaaaaa	aattgaaaga	tatacactga	3240
aatgtttttt	gctcacagtg	gtgacaaggt	ttctcagcac	tggcactggt	gacgttttag	3300
gctgtatgtc	tttctgtggg	gaggtggccc	tgtgcaactg	agggtgtttg	gcagcactct	3360
tggcctctgc	ccctagatag	caatagcagt	cctccctcaa	ccagcccaat	tttgacaacc	3420
aaaaatgttt	ccaggcatca	ccagatgctc	cctgggtgag	agtgatgaaa	tagtagggga	3480
ttttcccctt	cttttcttat	tttctgtaat	tccattatat	tactttaata	ataaagaaaa	3540
aaacataaaa	aataaacgaa	tgttattatt	ctacgtcagt	ttggatgttt	ggactccatt	3600
ttgggtttct	ttccattata	tcacttggtc	tgctaaacat	tctacggttt	ggtaagggtga	3660
agtgatcat	gaaattttgg	ttttattttt	ttcctgatac	taaaaataaa	acattctttc	3720
acttggaat	ttggacacag	aacaccaaaa	aaaatocata	atctcatctc	tctttttctg	3780
tcttttccct	ccttttttcc	ctttaaaaa	aataaagagt	gaaacctacc	tgttctccct	3840
ctaatttaat	tcctaaatat	aatcactgtc	aatatcttgg	acatttctctg	tgtctaaca	3900
cacacacaca	cttttttttt	tcagcaaaag	tggatttctg	ctacatgtag	tgttctgcaa	3960
cttactttct	atgtgtttac	aaaatcagta	catgtacata	tgctgaattc	agtccttaat	4020
ggtattatat	tttgtgaata	tacaaaaatt	tgtttaacca	cttagacaat	ctaggatatt	4080

-continued

ctcagtttgc	tgttatgagc	aatgctcttc	ctttacatat	acagacatat	atatatatat	4140
gtgtgtgtgt	gtgtttttgt	tttagtagga	tagatttcta	ggagagggtg	aaaggcttta	4200
tgacatccgc	atttacgatt	gtaataggaa	gtatcaaagt	gccccctaaa	gaaaaaaatc	4260
ctcccattag	tgggtaagaa	agcctatttg	ttcatatctt	cacaaacact	aaatattaga	4320
aatattttaca	attgtgggtca	agctcataag	tgaaaatggt	atttcatatc	ttatattttt	4380
tattgtgaga	ttgaacatct	ttcatatggt	tacatgtcac	ctgtatttct	tattctctga	4440
actatatggt	atgacctttc	actttttttc	ctcatgggtt	atgtgtagtt	tgtatagttg	4500
tcttattgat	tgtaggagc	tatttatata	ttaggaacat	taatctctcg	tcttatatat	4560
acgtggcatc	gattagttga	tcatttgtga	gttcatgtct	gtatacaaaag	attggagagg	4620
cactaagagg	gaaaacttac	ctctttctta	tcaaagtgtg	taaatatatg	tataacagaa	4680
gagggagaaa	atattaataa	atgcacagat	tggctgaaat	agagtataaa	tcttttactc	4740
ccctacttca	acataaaactg	caaaaggaga	gtgacttttc	tttcaactcg	acttccgtat	4800
tctctcatgct	taaaatagtg	cctagcacag	aagaggtgct	caatcagtgt	ttgctaacg	4860
aaataattag	tcacatttca	agcaggatga	ctaaatgaag	aatagaatct	aggcagatac	4920
tctggaagag	tggctgtgag	tcattcatat	cttagtatga	attagtcaaa	tccaactctc	4980
tccccttccc	actccccact	gtagtagaaa	gaatctgttt	attgagagaa	tagatttata	5040
attagaata	agtgagaggg	gcagaagagg	agattttgaa	ggatggcacc	tgaaggagga	5100
ctagcatggc	tgagacagtg	aagtggagc	cttgaatagc	taaagggtaa	gatgaaagta	5160
tttagctgta	gggggaaaaa	gcattgacag	gttgaaaaag	taaaagtcag	attctccttg	5220
ctctgaaatt	ttgtacaggg	caggttctac	taggtatggt	acaatgcaga	aaaaacatga	5280
aataattgag	aggaatttgg	tgcaatatta	tcttcttggc	ttcttttgag	tgggcagatt	5340
tttttcacgg	cctgtaacta	taataaattt	gaaacttctc	atcttttagt	aacttttttc	5400
acttaagttt	atgtggctgt	gggcaatgga	atgaagatat	tgaacttcca	attccctggt	5460
gggtttccac	aattacaagt	caatcatgac	tgggtattag	aagactattt	cagttagaac	5520
caccaagtcc	catattgtca	tattgtatgt	ttaattatta	agtgaagcag	tcttcttttc	5580
gtgttttcca	taattagggc	attccagaaa	gatgaggata	tttgctgtct	ttatattcat	5640
gacctactgg	catttctgta	acggtaagac	accaaactct	tccattaggt	tctatatttt	5700
aaatatttta	accatgagtt	taaaactaaa	atgatcattt	aaaatgcatg	caattttctt	5760
atagagagaa	cattctattc	tttctctctc	ttacacaat	ggcaaagtct	tctttctact	5820
ttacgcaatg	ataaagttac	ctgtgtcatt	ttgtaaaaat	atagagaata	tagacaaatt	5880
gaaagacaca	aaataatcta	ttaccattt	cccaggggta	actactgaaa	atatctgggg	5940
aaatggcctg	tatgtataca	tttatttgtt	tgccttcaac	aaggccaaga	tcctttgatc	6000
tttcagtctt	ggttgctctg	tgacatgcct	ttcctgatga	ggatacttta	aggaagaatt	6060
gtaagataca	tggaaaatgt	caggctaaca	cagtactggc	atcaccctgt	gctctttcct	6120
gaactccata	ccaatgtact	tcttgccaga	aaactgatca	aaagtttagg	gaagtaaaaa	6180
gagatgactg	ttagaatcta	ccattccctc	tatgtaggaa	gcaaataggt	gtcctgtcaa	6240
aggacattct	ggggatgtct	acatgaaacc	aagtctccct	ggttgtaagg	actccatctc	6300
catataatat	ttatacagta	atatatgttt	ataaattgtg	ggggcaactt	gtttagctaa	6360

-continued

ttttattatt	ctgctattgg	gacactgtgt	ctcagcatga	gatatagtgt	cccaaaacat	6420
atltcaagcc	cattggataa	aatatgtggt	tagcaagttc	ttaaataata	tgataacata	6480
accgaccaga	taaagtgatt	tataaacgct	gtgccaatth	tgtaaatggt	tcgaggaatt	6540
ttcccttttc	tgaagattgt	ccttctttct	tttttagcatt	tactgtcacg	gttccaagg	6600
acctatatgt	ggtagagtat	ggtagcaata	tgacaattga	atgcaaatcc	ccagtagaaa	6660
aacaattaga	cctggctgca	ctaattgtct	attgggaaat	ggaggataag	aacattattc	6720
aatttgtgca	tggagaggaa	gacctgaagg	ttcagcatag	tagctacaga	cagagggccc	6780
ggctgttgaa	ggaccagctc	tccttgggaa	atgctgcact	tcagatcaca	gatgtgaaat	6840
tgcaggatgc	agggggttac	cgtgcatga	tcagctatgg	tggtgccgac	tacaagcgaa	6900
ttactgtgaa	agtcaatggt	aagaattatt	atagatgaga	ggcctgatct	ttattgaaaa	6960
catattccaa	gtgttgaa	cttttcattc	ttgtaagtcc	atacttattt	tcaaacagaa	7020
cagcatagtc	tgttcattca	ttcattcaat	tcattgaattc	atccacataa	ttatccaatt	7080
tcttgagcac	ctatttgata	gtcactggaa	atccagagac	aaacaacaca	gagccatggt	7140
ctacagtatg	tacagttttc	caaaaagaat	ttctagtctt	tactttttta	ttacaaatgg	7200
aatacgtata	cttgcaaaata	atccagatac	tgtggaagag	atcaaatgaa	ttgcaaaaagt	7260
gtccctctc	ccttcaccac	tatctcccat	ggcatgcaga	gagagtaacc	attatttgtg	7320
tgtccctcca	gaaatttttt	tattcaacta	ctattttttt	atltttattag	gtccgtcagt	7380
tttccctttt	tgagcctctc	tatatcaaat	gcaataaat	atattcagaa	caaacccac	7440
tgtaaggttc	acattaaaaa	agacttgaag	tcaccctatg	aagacaaaaa	ataatcacat	7500
taagtgtgaa	agaacctatt	cttccagtac	aggataagcc	atacttactg	ggcatatatt	7560
catcttgaaa	atctatactg	atgttgtctt	ggggaattga	aaaggaacta	ggagtgttag	7620
ttcctcggta	ttgaccacaca	gttatgttat	caggtoactt	gagttcaaag	ttttgtgttg	7680
gcactagcta	agtaaaggaa	aacacctctg	ctttcattgt	tgagtttcac	agaattgaga	7740
gctgaaagga	tcccaggcag	gagcagctaa	tccaaactcc	cacaaagaac	aaaaatcccc	7800
cagaggatct	tctgttctta	tatttccctgc	aatggcgtcc	ctgtcatatc	ccacaatggc	7860
ctccctgcca	tttggatata	ccttccatat	cctgttgaaa	ttactcccta	atagtaagct	7920
gaaatctgcc	cctctagtgt	tagtcttggg	attatttcat	ttacatgatg	accttttaat	7980
atltgactag	aattaaatca	tctccccttg	gtccttccat	tcctgggcta	actaccatca	8040
atctgagggc	taacaatata	agtagaaaaa	gtatacattt	gtcactgatc	actgatcaat	8100
tattaatcaa	tgatcactga	taactataaa	ctcaaaaaa	aatcatgtg	gggattaaga	8160
gaaatgtatc	agttttatgt	tgtatttctg	gtccctgata	ctggctcagg	taatgccact	8220
attgtcaaga	agataccact	tgtaaagtag	atlttaatttt	cattatattt	taccatagtc	8280
ttctccattc	atgacatctc	ttgagatggt	gtggtttata	ctttcagttt	ttctccagtc	8340
catccgcaaa	tatcaggcat	ctactgtggt	ccaagatatt	aaagaaatca	tcagtactta	8400
gcctcatcaa	cagcattgct	agatctggga	tggaaaggaa	gagtataatc	ctggcagtca	8460
ggaagaaggc	agcataaagt	ataagtttct	gcttccaaaa	aaggtctctc	atcagcctgt	8520
agggagtgtg	tagggaaggg	acagctgtcc	ttgtagtagg	gaagggtttt	atltcaggtcg	8580
tctgggtccc	ataatatccc	ttgtgtatct	gcagtctcct	ttgccatgga	tcaacacaat	8640

-continued

aggaaatcct	ccggcactga	tggtttttcc	aagggggagt	tcttctgga	gcaaagcaaa	8700
tgaccaacca	ggtttgagga	cctgatttgt	ttgacaattc	cattttgtat	tgtaaattac	8760
ttaattggca	ttctactocc	aatccatcct	gtcattttgca	tacagtgggt	ttgggattga	8820
gttcagctat	accaaagtc	tgaaccttct	gcacttagaa	caaggcaacc	accaagcttc	8880
acttgactg	aggcogtgc	tccaatggaa	atgaggcagc	tggcttgca	gagcttccca	8940
actcagggaa	gtagaactcc	tgagtcacct	ccatatgcaa	atgatttcac	agtaatgctg	9000
ttgaacttca	cttcccatca	cagcaaatgt	gtggtaacat	agcttcccca	caggagttta	9060
ctcaccatgg	tattttaaag	gtgaaacatt	tcaaaactga	aatttgaaag	aatttagttt	9120
tggattcact	caattatcac	tatcacttcg	ggtgttattg	cacctttcct	gtttgtgagt	9180
ttaaagtcca	gactctcagg	ccactaactt	tcaattaaaa	gtgttttct	ttaatcgctg	9240
aacctaacag	cagggaaaac	gaaatgttca	ttcagacttt	cagaaccttc	aatgagatta	9300
ggcagctgaa	agatcaaagt	gttgcatagt	tgteccgata	aagctatttg	gatcatatgg	9360
accaaactga	ctgctgtcat	tccccacca	ccccatctct	ccccaaaatt	cccagcctg	9420
tttaagtgtt	ctctgtagca	tttatctcta	tctagtatat	tgtgtagcat	atcatatcat	9480
acttttctgt	tttgtttatt	gtctctctcc	tcttagaata	taaactccac	aagcacaaa	9540
at ttgggcct	gttttataat	attgttgcac	ccccagggcc	tgatatacag	cagagtgggtg	9600
gtacgaaaag	agcacacaaa	aaaatatttg	ttgagtcaat	gaatgaatga	tttctcaaa	9660
taggattagc	ctaaaatttt	ggaacatga	acagatttgg	atatgtgaaa	at ttatttcc	9720
agactgttca	tcaggaactg	ttagcagctt	ctaaagggta	cactggagca	gcagtagtaa	9780
aaggaggaag	aggagcagct	ctgctactgc	tactatcgag	tactactaca	attagcactt	9840
gcttattctg	tgtgttaggc	cctgtactga	acactctgtc	taaattagtt	catttctctc	9900
tggaaatgac	tctagggggt	aagtgttca	tcatgtaaga	tgagtatttt	tcacattttg	9960
ttgtgtctga	aatctgagtg	tgtctttcaa	tgatggaatc	tttgattcca	tgataagtg	10020
tattattccc	at tttaagga	tgaggaaact	gaggtccaaa	gaaattaagt	aatttgccca	10080
aattcaccca	gcctagaaaa	tgataaagct	agttctaaac	ccaagcagat	tagctctgaa	10140
gtctgggccc	ttaataacca	ctttttattg	cctatatattg	tacctctggg	gtacgtatca	10200
agttatatgt	tgacttcaaa	actatcatga	ccttttcttg	gttttgattg	tccaacatta	10260
gtatagtgtt	ctgggtctgc	aaaaattttg	attactcatc	tcatctgtaa	aacattttga	10320
actcgtgtgt	ttgtgcatgc	acatttgtgt	gtaattataa	aaattttact	ttctgttaat	10380
atataagttg	tatcataaga	aactgocgtt	tttgaagagc	aaaaaaagg	tgaatgttac	10440
cagttacatc	tggttcaacc	taatagacat	ttgtacaaaa	acagacattt	taagaggttg	10500
aaataaaaat	ttaataaaca	atattttcag	tttttactaa	ttgtgatgct	tcactatcat	10560
tagctaatat	gtcaaggcat	aatatacctt	agggtgaact	ttatcattaa	caaagggtga	10620
tgggtgcaat	aatcttgagg	tttgtgtttt	tttatataac	actgocagggt	ctaattaagt	10680
acttactgtt	taccacctca	tacagtggcc	gataaaaaag	gtcacttctg	ctgtttcctc	10740
tgggttgtgc	ttgaattatt	agtattatct	tcagtcctca	gtttctttgt	gggaaacttt	10800
ttaattagtt	gtttaatttt	gtaagatgg	tagtttagtc	aaaattagat	aagagaattt	10860
gaaaatccgt	agctacccca	aagcaacctc	cacataagaa	ctattatttt	tgtgttttga	10920

-continued

aatcataatt	ttattgattt	ccagtgtttc	cactggtagt	ggtttcattg	atataggagt	10980
atcaaaacat	cactcattat	ttatttcagt	ttcatttgat	cctagccggt	ttgtattaac	11040
tctctgtgaa	gaaattacct	cacaaatcta	ttgctgtcct	tggtaaagga	atggagaatt	11100
aaggctctag	atcattagtg	gttacctat	agtattagaa	gtaaaaaaaa	gattatacca	11160
acaaaaaag	aacatgtaa	tgtacttgta	atgaataaac	atgaataaag	ctcttatgct	11220
atataggtag	actaaacaat	ctactagaat	tgctagcaaa	ctacgtatct	taatcctgaa	11280
agggccccaa	accaatgatc	taaaattgaa	tcaaactttc	ttccttgagc	ataattactt	11340
aatgattta	ttaaaatagc	cagcatttaa	aagcttaaaa	tgtaaatatc	ataatgtggt	11400
atcctagata	gcaccccaga	acagaaaaag	gatattaggg	aaaaactgga	ggaatggaat	11460
aaattatgca	gtttagttat	taataatgta	ctaacgtcct	tagttatgac	gattgtacca	11520
tggtaatgta	agatactaac	aatagaggaa	accgggtaag	gagtatacag	taactctata	11580
ctatctttgc	aacttttttg	taaatttaaa	acttctaaaa	taaagaacaa	atttaaacat	11640
taaaaagtat	caccaggaac	atatatcact	gtttacagat	gaaatactat	gtattttcat	11700
atctaatttc	tgatcattga	cttcaaatca	gaaaagtgaa	tgacacctca	aaatcagggt	11760
ttctgtttac	tgaagtctaa	gaaaagaaag	cataccagct	ggagagattc	atgtttataa	11820
agacagattt	ataacaacaa	aaataaaata	tccaagaata	aatttaagaa	gaagcacttt	11880
actgagaaac	atatgaaaac	ctgaacaaat	ggagagggat	attttgtatt	tgaatagaaa	11940
gacttctggg	ttaagataa	ttctctttaa	attatttttt	gtagaaattt	aaggggtaca	12000
agagcagtg	tgccacatgg	atatattaca	tagtggtgaa	gtctgggggt	ttagtgtaaa	12060
ttaatcttta	cattttgttt	gagcccaata	aatgtaccaa	catgattttt	atagaaagat	12120
agtcattcct	attaatccaa	acttgtocca	actttgaatt	gaattgagge	agagctagca	12180
gggtttcccc	acggctgagg	catctgaaca	ttaagcatat	ccctctgaga	accagcctgc	12240
attgatactc	tttctaattg	ggacagcacc	aagctatgta	cgtagttctg	tgctcagcaa	12300
aagccctgac	ttctttttgt	ttatgtocca	gccccataca	acaaaaatcaa	ccaaagaatt	12360
ttggttgtgg	atccagtcac	ctctgaacat	gaactgacat	gtcaggctga	gggctacccc	12420
aaggccgaag	tcactctggac	aagcagtgac	catcaagtcc	tgagtggtaa	gaccaccacc	12480
accaattcca	agagagagga	gaagcttttc	aatgtgacca	gcacactgag	aatcaacaca	12540
acaactaatg	agattttcta	ctgcactttt	aggagattag	atcctgagga	aaaccataca	12600
gctgaattgg	tcaccccagg	taatattctg	aatgtgtcca	ttaaaatag	tctaactactg	12660
tccccatgca	cctagcatga	tgctctgcta	tcatagtcac	tcagtgattg	ttgaataaat	12720
gaatgaatga	ataacactat	gtttacaaaa	tatatcctaa	ttcctcacct	ccattcattcc	12780
aaacatatt	gttacttaat	aaacattcag	cagatattta	tggaatatac	cttttgttcc	12840
atgcattgta	gtactcattg	gatacacata	gaataataag	actcagttca	cactcttcag	12900
gaaacagata	aaaaactaag	aaacaacaa	aaaacaggca	atccaacacc	atgtgggaaa	12960
tgctttcata	gccgggaaac	ctgggggaata	cctgagagga	atactcaatt	caggccttgt	13020
ttcaggaatc	caaatcctgg	cacatcagag	ctgcttcctc	ctttccaggg	tggaaggaaa	13080
taaatggaac	atatttttct	atcttatgcc	aaacatgagg	gaccttttct	ccccggtgcc	13140
tctcccaagg	tagtctacaa	tatttcaact	ctagcagtc	gcttagtgca	tagaacatga	13200

-continued

ggctgtgtgt	ccctgggcaa	attactagac	ttctgtgtgc	ttcactttcc	ctgtaggatt	13260
ataatctact	gagcaagctt	attgtaaggg	tcagattagc	aacagtgtat	gaaaatgatt	13320
tgagaccatt	gcctgcacaa	attcaactat	ttttttttat	ctcactactc	tacagaagta	13380
ggtaggggtg	gagacagagt	ctgatgagag	gctcagaatg	tgaaagaaag	tgaggcgagt	13440
gagcatgata	tttaataata	acacaaagat	attctgagaa	gagctgctca	ctgccccctc	13500
ccccaataca	tgttgatagg	aaaatgccac	gtacttcagc	aaaaacaact	gaaaaattag	13560
atagaaaagt	caatcaatag	gaaaagataa	tccaggacgg	tgttgtgaac	agaaagaggg	13620
ggaaaaaact	ttagaaaaat	atggggatgc	tcttactggg	gtacgagtcc	tcaggtattg	13680
aactggcttt	cagtaaaagc	tagattagtg	ggttctctgc	atttacaagc	tgttttatga	13740
caacttactt	gttgggtggc	ctacagtaac	tcacctaaact	gcactgagtc	tgtttcctca	13800
tctgtaaatt	ggggatTTTT	ttttaaatac	ctggcatgcc	taactcataa	agttgttctg	13860
aaactgaaat	aaaacatacg	tgaacaggca	ttgtaaactg	taagttacgg	aaaaagctgg	13920
ctgttgtgtg	gtctttaaag	ttcacctggg	gtagtcaaag	atggatcatg	ggtctcagtg	13980
gagagctgag	ccaggcgagga	gctgactaag	ggtgagaggt	gggagttagc	agcctctgaa	14040
catctgtgta	ccatgggacc	ccctttctct	ctgcatggta	ccccagacaa	ggagcctagt	14100
aagagatact	aatggcttgt	tgtccagaga	tgttcaaact	gcagagaaag	ataagacaac	14160
aagcattggc	ctccaatcat	gatgacagat	aggaggaggt	gggagctcct	tagcagtgct	14220
ggttggcctt	ccatgttcta	ctgtgggcca	tctctgccat	gtactgtagg	ctactagctt	14280
ctatattaaa	gaatgcaaga	ggggccagga	gcbgaggctc	atgcctgtaa	tctcagcact	14340
ttgggaggcc	aaggtgggca	gatcacttga	ggtcaggagt	ttgtgaccag	cctggccaac	14400
atggtgaaac	tctgccttta	ctaaaaatat	aaaaattagc	tgggtgtggt	ggtgtgcacc	14460
tgtaatccca	gctactcggg	agactgaggc	acaagaattg	cttgaacctg	ggaggcggaa	14520
gttgcagtga	gcccagattg	cgccactgca	ctccaccctg	ggcaacagag	aaagactctg	14580
cctcaaaaaa	aaaaaaaaaa	agcaagagga	agtgaataa	tcaaggccgc	catttaatat	14640
tgagcagcca	ctccatgtgg	tactgtgcaa	gcacattata	aatattagcc	tcacaagaaa	14700
tgtattagca	tttgtatttt	gtacactygt	taagtatctt	gccaagacc	tcaaaactgg	14760
ttaagggcag	cagaatttag	ccccagcacc	accttttcaa	agcctgggct	tctcacactt	14820
ctccatgctg	ttcccatttt	aacacaggta	tctcgccatt	ccagccactc	aaactttggc	14880
atttaagaaa	attatcctaa	agctaaacta	aacttcaagg	atgaccattc	tcttgacccc	14940
ttcccataca	aattttatct	ttagtcagtt	tgttttcggt	ttgttttgtt	tttcagaact	15000
acctctggca	catcctccaa	atgaaaggac	tcacttggtg	attctgggag	ccatcttatt	15060
atgccttggt	gtagcactga	cattcatctt	ccgtttaaga	aaaggtagta	tttccttaat	15120
tgcagtggtc	tccactgggg	gtgaggaagg	ggtgagaatt	ggatcatggc	tgcaaggaaa	15180
cccgaactta	cctctgcaag	gtgggtgcaaa	ggcattccac	tgttcaacag	caattatatt	15240
gaagctgagt	gggatcactg	ggtgaagatg	aagcgtaagg	ggtgaggggc	aggagaaatg	15300
gtatggatgg	aggtagaaga	tgcaagtgtca	tacagttttt	ttctatcatg	aaaataacca	15360
cagacttaca	gaagagaaag	agctaaaatg	cccgtcattt	tcagttgcat	tttagtcttg	15420
cattagttgc	aaccagctgg	tttctgggta	ccctaagtaa	taaaaatagt	tcctctgtag	15480

-continued

aactgtagta	tgtttaccat	agagtatttt	gcaaaatfff	tggttagagga	tgttacataa	15540
tttgcattgtg	ttcattttctc	cattttacctg	tggaacaat	taaaatccag	gaaaatgagt	15600
atattcaaat	aatttctctc	catttaagat	gagtcagagt	aaataattcc	tccaatactt	15660
agagaagtat	accaagagat	ccagtgatgg	tatagagttg	tctgatgtta	aatagggag	15720
tagaatatgg	aaggggatc	caatagtcgt	tgaaaaatc	cccataacc	cttaccatggg	15780
ggaaagttagt	gttaactgag	agagttagaga	taagctgttt	ccaaaaatta	tattcttaac	15840
aggactgaga	tagccagaat	ataaggatca	agtttcaatg	acagtaagat	cctgagatgg	15900
agttgatttg	cacaaagaaa	taattgttgc	cagcatgcat	tttgaatatt	tctctggaaa	15960
aaaagattag	ttggcagtag	aaatggatag	aaatcaatag	atattaaaa	acctcagaat	16020
ttggttcatc	tctgggaaaa	gatgaaaaat	aaaagtgtat	actcctcaag	aacatctagg	16080
atcaaaagca	tgtgccctac	actattgaat	taattaacct	cataagttgg	gacctgtgga	16140
ataaggatgt	ccaccagact	tcttagggat	tacaaatggt	tcacagaact	tgaaatttaa	16200
acttgggtca	ctgtatggga	tgtagagctg	tgctatatgg	aaataaaaat	gatttctttt	16260
tctcaaggga	gaatgatgga	tgtgaaaaaa	tgtggcatcc	aagatacaaa	ctcaaagaag	16320
caaagtggta	agaatatcag	aaggaattgg	gaagtaaaag	tcaaaggaaa	caaaaagcta	16380
aagcaataac	aaagagaaat	ccatcagtca	taatctctc	tccttttaa	gaatgctggt	16440
tcccccttgc	ctcacagcta	acacaagaac	tctccaccg	tctgaggagg	tttaggagca	16500
gggaagggga	aggagtccg	ttcatttgc	aatcttctgt	tgccctgcac	cctagcagct	16560
ccttgcagca	ggggacaagg	atgacttagg	tgatggata	attaattgat	tctaaaaat	16620
tgtgtgtcag	tattgtaata	ctatgttaat	tgccaccatgc	acggtatctc	atttaatccc	16680
ccacccttg	ccattaccaa	agagagagag	agagagagag	agagaaatac	tagaatttat	16740
cctcatfita	cagtagagaa	aacagagggt	caagaagata	atgtaaagtg	cccaagaaca	16800
cacagctgat	cacaaaaatc	aagcttgggg	gccattagcc	taaccacaga	cccttactct	16860
taaccatct	gcttcaatcc	atfittgctac	aaatgtttac	atfittataagc	agggcagaaa	16920
aacctcatcc	aggttattga	actaagaaga	aagttatatt	aaggtttcta	atfittfita	16980
tgtagttaga	aacaaactt	aacaatgagc	ccaagtttaa	agcagtctaa	ttaacctgga	17040
caagctcagg	caagtttcat	tctgtggccc	atagcatcat	ctgtgttgta	aagctaagta	17100
gcaaatgttg	tttgggtcat	gctgggggac	aagccatccc	aatttgcctca	ggactgaggg	17160
gttttccagg	atatcatgta	aggataattg	ggtacaaata	taacctgctg	ctttctctca	17220
tttcaaatf	atcatttate	atatcagcaa	ctatgagtta	tgfittfittat	tagatfittctt	17280
gttactfitt	ccccagacca	cttcccatga	aattaatata	ctattatcac	tctccagata	17340
cacatttggga	ggagacgtaa	tccagcattg	gaacttctga	tcttcaagca	gggattctca	17400
acctgtggtt	taggggttca	tggggctga	gcgtgacaag	aggaaggaat	gggcccgtgg	17460
gatgcaggca	atgtgggact	taaaaggccc	aagcactgaa	aatggaaacct	ggcgaaaagca	17520
gaggaggaga	atgaagaaag	atggagtcaa	acagggagcc	tggaggggaga	ccttgatact	17580
ttcaaatgcc	tgaggggctc	atcgacgct	gtgacagggga	gaaaggatac	ttctgaacaa	17640
ggagcctcca	agcaaatcat	ccattgctca	tcttaggaag	acgggttgag	aatccctaat	17700
ttgagggtca	gttctctcag	aagtgcctt	tgccctccact	caatgcctca	atfittgtttc	17760

-continued

tgcatgactg	agagtctcag	tgttggaaacg	ggacagtatt	tatgtatgag	tttttcctat	17820
ttattttgag	tctgtgaggt	cttcttgca	tgtgagtg	ggtgtgaatg	atttcttttg	17880
aagatatatt	gtagtagatg	ttacaatttt	gtcgccaaac	taaacttgct	gcttaatgat	17940
ttgctcacat	ctagtaaaac	atggagtatt	tgtaagggtc	ttggtctcct	ctataactac	18000
aagtatacat	tggaagcata	aagatcaaac	cgttggttgc	ataggatgct	acctttat	18060
aaccattaa	tactctggtt	gacctaatct	tattctcaga	cctcaaggtg	ctgtgcagta	18120
tctgttccat	ttaaataca	gctttacaat	tatgtggtag	cctacacaca	taatctcatt	18180
tcacgctgt	aaccacctg	ttgtgataac	cactattatt	ttacctcgc	tacagctgag	18240
gaagcaaaa	gattaagtaa	cttgcccaaa	ccagtaaata	gcagacctca	gactgccacc	18300
cactgtcctt	ttataatata	atttacagct	atattttact	ttaagcaatt	cttttattca	18360
aaaaccattt	attaagtgcc	cttgcaatat	caatcgctgt	gccaggcatt	gaatctacag	18420
atgtgagcaa	gacaaagtac	ctgtcctcaa	ggagctcata	gtataatgag	gagattaaca	18480
agaaaatgta	ttattacaat	ttagtccagt	gtcatagcat	aaggatgatg	cgaggggaaa	18540
acccgagcag	tgttgccaag	aggaggaaa	aggccaatgt	ggtctgggac	ggttgat	18600
acttaaacat	cttaataatc	agagtaattt	tcatttaca	agagaggtcg	gtacttaaaa	18660
taaccctgaa	aaataacact	ggaattcctt	ttctagcatt	atatttattc	ctgatttgc	18720
tttgccatat	aatctaagc	ttgtttatat	agtgtctggt	attgtttaac	agttctgtct	18780
tttctattta	aatgccacta	aattttaaat	tcataccttt	ccatgattca	aaattcaaaa	18840
gatcccatgg	gagatggttg	gaaaatctcc	acttcacct	ccaagccatt	caagtctcct	18900
ttccagaagc	aactgctact	gcctttcatt	catatgttct	tctaaagata	gtctacattt	18960
ggaaatgat	gttaaaagca	cgtattttta	aaattttttt	cctaaatagt	aacacattgt	19020
atgtctgctg	tgtactttgc	tatttttatt	tatttttagtg	tttcttatat	agcagatgga	19080
atgaatttga	agtcccagg	gctgaggatc	catgccttct	ttgtttctaa	gttatctttc	19140
ccatagcttt	tcattatcct	tcatatgatc	cagtatatgt	taaataatgct	ctacatatac	19200
atthagacaa	ccaccatttg	ttaagtattt	gctctaggac	agagtttgga	ttgtttatg	19260
ttgtctcaaa	aggagacca	tgggctctcc	agggtgcact	gagtcaatct	agtcctaaaa	19320
agcaatctta	ttattaactc	tgtatgacag	aatcatgtct	ggaacttttg	ttttctgctt	19380
tctgtcaagt	ataaacttca	ctttgatgct	gtacttgcaa	aatcacattt	tctttctgga	19440
aattccggca	gtgtaccttg	actgctagct	acctgtgcc	agaaaagcct	cattcgttgt	19500
gcttgaacc	ttgaatgcca	ccagctgtca	tcactacaca	gccctcctaa	gaggcttct	19560
ggaggtttgc	agattcagat	gccctgggag	atcccagagt	ttcctttccc	tcttggecat	19620
attctggtgt	caatgacaag	gagtaccttg	gctttgccac	atgtcaaggc	tgaagaaaca	19680
gtgtctccaa	cagagctcct	tgtgttatct	gtttgtacat	gtgcatttgt	acagtaattg	19740
gtgtgacagt	gttcttttg	tgaattacag	gcaagaattg	tggtgagca	aggcacatag	19800
tctactcagt	ctattcctaa	gtcctaactc	ctccttgg	tggttgattt	gtaaggcact	19860
ttatcccttt	tgtctcatgt	ttcatcgtaa	atggcatagg	cagagatgat	acctaattct	19920
gcatttgatt	gtcacttttt	gtacctgcat	taatttaata	aaatattcct	atttattttg	19980
ttacttggtg	caccagcatg	tccattttct	tgtttatttt	gtgtttaata	aaatgttcag	20040

-continued

tttaacatcc cagtggagaa agtt 20064

<210> SEQ ID NO 2

<211> LENGTH: 20261

<212> TYPE: DNA

<213> ORGANISM: macaca fascicularis

<400> SEQUENCE: 2

gtaaaatcaa ggtgcgttca gatggtggct tgttgtaaat ttctgtttat attaataaca 60
taccaaatgt ggatttgttt taactctcgg aactctttcc ggtgaaaacc tcatttacia 120
gaaaactgga ctgacagggt tcactttctg tttcatttct atacatagct ttattcctag 180
gacaccaaca ccaactcgta cccaaactga aagcttcccc gattccgccc aaggtcagga 240
aagtccaatg ccgggcaaac tggatttget gccttgcgca gaggtgggcg ggaccccgcc 300
tccgggcccg gcgccaagtt gagcagctgg cacgcctcgc gaagccccag tcctgaagcc 360
ccagtcctgc gctgcttccc gaggetccgc accagccgcg cttctctctg cctgcaggta 420
gggagcgttg ttctccgca ggtgcccacg gccagcctc tctggctaac tcgctgggca 480
ccttaggacg gaggatctct acacccttcc tttgggatgg agagaggagg agggaaaggg 540
aaggcgatgg tctagggggc agtagagcca attacctgtt ggggttaata agaacaggca 600
atgcatctgg gcttcccca ggcgcaattc agttttgctc taaaaataat ttatacctct 660
aaaaataaat aagggtggga gtataggata ggtagtcatc cttatgcgac cgtgtgttca 720
gaatatagct ctgatgctag gctggaagtc tggacacggg tcctagtcca ccgtcagctg 780
cttgctagta atatgacttg tgtaagtcac ccagctgca gcagataagt aagtctcttc 840
ctgcgctaag cacgtccagg acccctgaac ggaatttatt tgctctgtcc attctgaaaa 900
cccaaaggag tcctaaaaga ggaatggagg agcctaagaa taaaaatagt ataataaaac 960
atctcttaga catgttgacc ttggcctatg tcaaagttca gtctgggttt gtcttataac 1020
ataaggagta aaagtaccat tgttctacct ctttttttaa tacttgaaaa aaaatttact 1080
gtagatgctt ttctattaat taaataacct tctaaaaaat gtttttagtg ctgcattcga 1140
ttaggttggg taactaaatg aaattaattc ctcactgttg ggtataaagg ttatttacag 1200
tggttctgtc tttagctatc actgaacatc attacataga tatctctgga atattgctga 1260
ttgtttccgt caataaaact agaagtgtaa ctacttagtc aaagagactg aatattttaa 1320
aggcattttg aagaaaactg aaaatgcttt ccagaaagga tgtatcagtt gacaatgatg 1380
gttgcaaca gtatttaagg agaactatga tactctgaag aaaaacttag cctttctcag 1440
tagaagcagg taggcagagg ccacatgaca gcagttagag tgtggctctc aaggaagtca 1500
cagaaatact gtggggaatt gaaaccccaa gtggaaaatg tacaagagtg tctcagtgtg 1560
actgagaagg aggttgggct tggggtttaa cttagaat tttttctttt tcttttggtg 1620
agatagggct tttgttatgt taccaggct ggtcttgaac tcctagcctc aggcgatcct 1680
cccgcctcag gctgcagaag tcctgggatt actggccgga gccaccatgc aggcctcttg 1740
ctcctacttt tgagaaagga agcttaacct tttttttttg tttgtttgtt tttgtttttt 1800
gttttttttg agacgagtct cactctgttg cccaagctgg agtgcagtgg tgccatctca 1860
gctcacggca acctctgctc cctgggttca agtgattctc ctgcctcagc ctcccagta 1920
gctgggacta caggcaccca ccaccagcc cggctaattt ttgtattttt agtagagatg 1980

-continued

gggtttcacc atattggtca ggctgatctc gaactcctga ctcaggtgat ccacctgcct	2040
cagcctccca aagtgctggg attacaggcg tgagccaccg cgcttggeca cttgactttt	2100
tctctatctc ttccttctac ccatectacc cttggaagat agagaagtaa tctcagttcc	2160
atcgtgttat actgggcttc ccccaggac aaaccactt cccaacctg aatgagccat	2220
cacttottec ccagtttaca tttcattgct ctttgaatgt ctccgttcgg atatgggaat	2280
tcacatgtgg tcataattct tacctgaaga agactgacgt cttcttctct tagaccaact	2340
gccctgatgt gaggtttaga ggttaaagaa catgtgtgta tttacatgat ctttgtatc	2400
tgccttttcc tccctcacta atgacagctg aacccaagg aaatagagct gtggaggaga	2460
gggtttgatg agaaagtagg taaatattgg atctaataca tcatcttcca ggaacctcc	2520
attacttcta aaaatttcaa ccaaatctgt taaaggacaa gaactccacc agagtagggc	2580
cataaacatt ggcaaaatta gttgtaactc atgactagat ttaatgtccc tttgttttat	2640
tcacatatgg ttataatgct ttgcttgga ttaggggtat ttttaagttt cttctgcta	2700
gtaagtgtat ttgtgcttat aatacaataa ttataaata tcacattaat attttatac	2760
tgtacagtta actctggccc aaggaaaaga tagtccggtg gatgctgcag cctgattttg	2820
tatctaacc tggaagagg ataatgactc atgttatttc acttaccctt tttatctttt	2880
aacatgaagg gctcatatag gtcaataaga aaccagtgat ataacagac caaaaaatga	2940
tcagatcttt cacattagca aaaaaaata ttttttaaac aatacccaac tgggtgaaaa	3000
tacagtgtaa cagtacaaa tatcaacatg tgtcaagaac cagaaaaatg tttgtttct	3060
ttgatcagca aactatttg aggaaatcta tctcagggc ctacgctggg gcctggcaca	3120
cagtaggcac tgaacaaata tttgctgaac acacacatac ttatgatatt tttaaaattg	3180
gcaacaatcc aatacccaat aatagaggaa ttaaatatta tagaactgtt caataagatg	3240
cttacgaata tcatgcagta agatgggcaa tatttatatc ataagcttaa atgaaacaaa	3300
tgggtattaa aggtatggta aggttataaa ttacttttta agagattaaa gggaaaagac	3360
tgaaagatat aactgaaat gctcacagtg gtgacaaggt tcccagcct tggcactatt	3420
gacattttgg gctatgtctt tgctgtggga ggctggcctg tgctctgcag gaggtttggc	3480
agcactcttg gttctacccc ctgatagca gtagcaaccc tccctcaacc agcccaattt	3540
tgacaaccaa aatgtttcc aggcacacc agattctccc tgggtgagag tgatgaaaca	3600
gtaggtgatt tccccttct tttctcattt tctgtaattt tgccacatta cgtaataat	3660
aaggaaaaaa cataaaaaat agatgaattt attattctac ctcagtttgg atgtttggac	3720
tccccttggg ggttctttcc attatatcac ttggtctgct aaacagtcta tggtttggca	3780
aggtgaaatg attcatgaaa ttttgttttt attttttacc tgatactaaa agtaaaacat	3840
tcattcgctt gaaaatttgg acacagaaca ccaaaaaaaa tccataatct catctctctt	3900
tttctgtctt ttccttctt ttttcccttt aaaaacaaga gtgaaaacct accggttctc	3960
cctccaattt aattcctaaa tataatcact gttaacatct tggacatttc ctgtgtctaa	4020
acacacatac tcaacttttc ttttttttag caaaaagtgg atttctgcta catgtagtgt	4080
tccgcaactt cctacatggt tacaaaatca gtacatttac atatgctgaa ttcagtcctt	4140
aatggtatta tatttttga atatacaaaa atttatttaa ccaactagac aatctaagat	4200
attctcagtt tgctgttatg agcaatgctc ttcctttaca tatacatata tatgtgtgtg	4260

-continued

tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	ttttagtagg	atagatttct	aggagagggc	4320
gaaatgtcat	atgacatcca	catttacaat	tgtaatagga	agtatcaaag	tgccccctaa	4380
aaaaaaaaat	tcctccatt	agtgtgtgag	aaagcctatt	tgttcatatc	ttcacaaca	4440
ctaaatatta	gaaatattta	caattgtgtt	caagctaaga	agtgaaaaat	ggtatttcat	4500
atcttataat	ttttgtgtg	agattgaaca	tatttccat	gtttacatgt	cacctgtatt	4560
tcttattctc	tgaactatac	gttatgacct	ttcacttatt	ttcctcatgg	gttatgtgta	4620
gtttgtgtag	ttgtcttatt	gattgttagg	agctatttat	atattaggaa	cattaatctc	4680
ctgtcttata	tgtatgtggc	attgattagt	tgatcatttg	tgagtccatg	tctgtataca	4740
aagattagag	aggcagtaag	agggaaaact	tacctcttc	ttatcaaagt	ttgtaaatat	4800
atgtataaca	gaagagagag	aaaacattaa	taaagtctga	aataaagtat	aaatttttta	4860
ctccactact	tcaacataaa	ctacaaaagg	agagtgactt	ttctttcatg	ctgacttcca	4920
tattccccat	gcctaaaata	gtgcctagca	cagaagaggt	gctcaatcag	tgtttgctaa	4980
atgaaagaat	tagtaacatt	tcaagcagga	tgactaaatg	aagaatagaa	tctaggcaga	5040
tactctggaa	gagtgactgt	gagtcattca	tggtcttgg	atgaattagt	caaatccagc	5100
tttctccct	tcccactccc	cactgttagt	agaataatct	gtttattgag	agaatagatt	5160
tataatttag	aataagaggg	gcagaagagg	agattttgaa	ggatggcacc	tgaaggagga	5220
ctagcatggc	tgagatagtg	aagtggaaat	cttgaaaagc	taaagggtaa	gatgaaagta	5280
tttagccgta	gggggaaaaa	gcattgacag	gttgaaaatg	taaaagtcag	attctccttg	5340
ctttgaaatt	ttgtacaggg	caggttctac	taggtatgtt	acaatgcaga	aaaaacatga	5400
aatagttgag	aggaatttgg	tgaatatta	tcttctggc	ttctttgag	tgagcagatt	5460
tttttcaggg	cctgtaacta	taataaattt	gaaacttctc	atcttttagt	aaactttttc	5520
acttaagttt	atgtggctgt	gggcaatgga	atgaaggat	tgaacttctc	attccctgct	5580
gggtttccac	aattacaagt	caatcatgac	tggttattag	aagactattt	caattagaac	5640
caccaagtcc	cataatgtca	tattgtgtgt	ttaattatta	agtaaagcag	tcttcttttt	5700
gtgttttcca	taattagcac	attccagaaa	gatgaggata	tttgotgtct	ttatattcac	5760
gatctactgg	catttctgta	atggtaagac	accaaactct	tccattaggt	tctatatttt	5820
aaatatttta	accatgagtt	taaaactaaa	atgataattt	aaaatgcatg	caattttctt	5880
atagagagaa	tattctcttc	ttctctctac	ttacacaaat	gacaaagtct	ttcttctgct	5940
ttacacaatg	ataaagtctc	ctgtgtcatt	gtgtaaaaat	atagagaata	tagacaaatt	6000
gaaagacaca	aaataatcta	ttaccattt	cccagggta	actactgaaa	atatctgggg	6060
aaatggcctg	tatgtatata	tttatttgtt	tgttttcaac	aaggccagga	tctttcaatc	6120
tttcaatctt	ggttgctctg	tgacatgcct	ttcctgatga	gaatactcta	aggaagaatt	6180
gtaggataca	tggaaaatgt	cagggttaaca	cagtactggc	accaccctgc	ggctctttct	6240
gaactccata	ccaatgtact	tcttgccaga	aaactgatca	aaagtttagg	gaagtaaaaa	6300
gagatgttag	aatctacat	ttcctctatg	taggaagcaa	atagggttcc	agtaaaagga	6360
cattctgggg	atgtctacat	gaaaccaagt	ctcctgggtg	taagtaactcc	atctccatat	6420
aatatttcta	cagtaatata	tgtttataaa	ttgtgggggc	aacttgttta	gctaatttta	6480
ttattctgtt	attgggacac	tatgtctctg	catgagacat	agtgccccaa	aacatatttc	6540

-continued

aagcccatg gataaaatat gtatttagca agttcttaaa tataatgata acataactga 6600
ccagataagg tgatttttaa atgctgtgcc aactttataa atgttttgag gaattttccc 6660
ttttctgaag gttattcttc tttcttttta gcatttactg tcacggttcc caaggaccta 6720
tatgtgtag agtatggcag caatatgaca attgaatgca aattcccagt agaaaaaaa 6780
ttagacctga cttcactaat tgtctattgg gaaatggagg ataagaacat tattcaattt 6840
gtgcatggag aggaagacct gaaggttcag catagtaact acagacagag ggcccagctg 6900
ttgaaggacc agctctccct gggaaatgct gcacttcgga tcacagatgt gaaattgcag 6960
gatgcagggg tttaccgctg catgatcagc tatggtggtg ccgactacaa gcggattacc 7020
gtgaaagtca atggttaagaa ttattataga tgagaggcct gatctttata gaaaacatat 7080
tctaagtgtt gaagactttt cattcttata agtccatact tttttcaaa cagaatagca 7140
tagtctcttc attcattcat tcagttcatg aattcattca cgtaagtctc caattagcat 7200
ttcttgagca cctatatgat agtcattgga aatccagaga caacacagag ccatgttcta 7260
cggatgtac agttttccaa aaataattcc tagtctttac tttttatta taaatgtaat 7320
acataactt gcaaaagatt cagatactat ggaagagatc aatgaattg caaaagtgtc 7380
cctctccct tcaccactat ctcccatgag ataaccaaga gacactccaa gagagtaacc 7440
attatttggt tgtccctcca gaacctttt tattcaacta ccattttttt attttattag 7500
gtctgtcagt tttcttttt tgagcctctc tatatcaaat gctaataaat atattcagat 7560
caaaacccac tgtaaggttc atattaataa agacttgaag tctccctatg aagacaaaaa 7620
ataatcatat taagtgtaaa agaacttatt cttccagtag agtataaact atactcactg 7680
ggcatatatt catcttgaag atctatactg atgtgtctt ggggaattga agaggaacta 7740
ggagtgtcaa ttctgggaa ctgaccocaca gttatgtcat caggtcactt gagttogaag 7800
ttttgtgttg gcactagcta agtaaaaggaa aacacctctg ctttcaattg tgagtttcat 7860
agaattgaga gctgaaagga tcccaggcag gagcgactaa tccaaactcc cacaagaac 7920
aaaaatcccc cagaggatct tctgttcata tatttctgc agtggcatcc ctgtcatatc 7980
ccacaatggc atccctgcca tttgactcc ccttccatat cctgttgaaa ttaactcccta 8040
atagtaagct gaaatctgcc cctctagttg tagttttgga attatttcat ttccatgatg 8100
accttttaat atttgactag aattaaatca tctcccttg gtatttccat tctggacta 8160
actaccatca atctgagggc taacaatata agtagaaaa gtctacactt gtcattgatc 8220
actgatcaat gattaatcaa tgatcactga taattataaa ctcaaaaaa aatcatgta 8280
gggattaaga gaaatgtatc agttttatgt tgtatttctg gtcctgatt ctggctcaaa 8340
taatgctact attgtcaaga agatctcact tgtaaagtag atttaatttt cattatattt 8400
taccatgtgc ttctccatc acggcatttc ttgagatgtt gtggtttata ctttcagttt 8460
ttctccagtc catcagcaaa tatcaggcat ctactgtgtt ccaagatatt aaagaaatca 8520
tcatgactta gcctcatcaa cagcattgct agatctggga tggaaaagaa gagtataatc 8580
ctggcagtc ggaagaaggc tgcataaagt ataagtttct gcttccaaag aagatctctc 8640
atcagcctgt agggagtgt tagggagggg acagctgtcc ttgtagtagc aaagggtttt 8700
attcaggtca tctgggctcc ataatatccc ttgtgtatct gcagtctcct ttgcatgga 8760
tcaacacaat aggaaatctt ccggcactga tggtttttcc aagggggagt tcttcaggga 8820

-continued

gcaaagcaaa tgaccaacca ggtttgagga cctgatttga caattccatt ttgtatttta 8880
aattagttaa tttgcattct agtccaatc catcttgca tttgcagaca gtggttttgg 8940
ggttgagttg agctatacca aaagtctgaa ccttctgcac ttagaacaag gaaggcaacc 9000
accaagcttc acttgcaactg aggcagtgtc tccaatggaa acgaggtagc tggtctgcag 9060
aagctttcca actcagggaa gtagaactcc tgagtcacct ccatatgcaa ataatttcac 9120
agtactgctg ttgaacttca cttcccatca cagcaaatgt gtggtaacat agctttgcca 9180
caggagttta ctcaccatgg gattttaaag gtgaaacatt tcaaaactga aatttgaaag 9240
aatttagttt tggattcact caattatcat gatcactttg ggtgttattg cacctttcat 9300
gtttgtgagt ttaataacca gactctcagg cctctaactt tcaattaaaa gtgtttttct 9360
ttaatcactg aacctaatag tagggaaaac gaaatgttca ttcagacttt caggaccttc 9420
aatgagatga ggcagctgaa agatcaaaagt gttgcatagt tatcccagta aagctatttg 9480
gatcgtatgg accagatcaa ctgctgtcat tccccaccaa ccccatcttt ccccaaaatt 9540
cccagccctg ttaagtgtt ctctgtagca tttatctcta tctagtatat tgtgtagcat 9600
atcatatcat acttttctat tttgtttatt gtctctctcc tccctagaata taaactccac 9660
aagcacagag atttgggtct gttttttaat attgttgtat ccccagggtt tgacgtaaag 9720
cagagtggta gtatgacaaa agcacacaaa aaaatatttg ttgagtcaat gaatgaatga 9780
tttctcaaaa taggattagc ctaaaatttt ggaaacatga acagacttgg atatatgaaa 9840
atttatttcc aaaactgttc atcaggaact gttagcacct tctaagggtt aactgaagc 9900
agcagtagta aaaggaggag gaggagaagc agctctgcta ctactattat cgagtactac 9960
tacaactatc gagtactact acaactatcg agtactacta caattagcac ttgcttattc 10020
tgtgtgtagt gtctgtact gaacattctg cctaaattag ttcatttctc cctggaaatg 10080
actctgtggg gtaggtgctt catcatgtaa gatgagtatt tttcacactt cactgtctct 10140
gaaatctgag tgtgtcttcc aatgatggaa tctttgattt catgataagt ggtattattc 10200
ccattttaag gatgaggaaa ctgggggtcca aagaaattaa gtaatttgc caaattcacc 10260
tagcctcgta aatgataaag ctagtcttaa atccaagcag attggctctg aagtctgggc 10320
ccttaataac cacttattgc ctgtatttgc acctctgggt tatgtatcaa gttatatatt 10380
ggcttcaaaa ctatcatgac cttttcttga ttttgattgt tcaatattag tatagtgttc 10440
tagatctagt agaccagggg tctgcaaaaa attttgatta ctcacctcat ctgtaaaaca 10500
ttttaaactt gtgtgtctgt gcaggcaccat ttgtgtgtaa ttataaaaaa tttactatct 10560
attaatatat aggttgtagc gtaagaaaaa ttgccatttt tgaagagcaa aaaaggttga 10620
atattaccag tttcatctgg ttcaacctaa tagacatttg taaaaaaca gacattttaa 10680
gaggatgaaa taaaaattta ataacaata ttttcaattt ttactaattg tgacgttca 10740
ctattgttag ctaatatgtc aaggcatgat ataccttagg gtggaattta tcattaacaa 10800
aggtggatag tgtcaataat cttgaggttt gtgttttttt atataaact gtgaggtcta 10860
attaagtact taattgttta caacctcata cagtcgcaa taataagtgt cacttctgct 10920
gttccctctg ggtgtgctt gaattattag tattatcttc aatcctcagt ttctttgtgg 10980
aaaacttttt aattagttgt ttaattttgt aagatggta gtttagtcaa aattagataa 11040
gagaatctga aatccataa ttaccccaaa gcaaccact cataagaact attatttttg 11100

-continued

tgttttgaaa tcataatfff attgatttcc agtgtttcca ctggtagtgg ttccattgat 11160
gtaggagat caaaacatca ctaattatff atttcagttt tgtttgatcc tagctgtfff 11220
gtgtaactt tgaagaaatt acatcacaga tctattgttg tccttggtaa aggaatggag 11280
agttaaggct ctagatcatt agtggttatg ctgtagtatt aggagtaaaa aaaaagatta 11340
tatcaacaaa ataagaacat gttaatgtac ttgtaataga taaacatgaa taaagctcct 11400
atgctatata gatgcactga acaatctact agaattgtca gcaaacggta tcttaatcct 11460
aaaagggtcc caaaccaatg atctaaaatt gaatcaaaact ttcttccttg agcataatta 11520
tttaagtgat ttattaaatf agccagcatt taaaagctta aaatataagt atcataatgt 11580
ggatccctag atagatccca gaacagagaa aggatattag ggaaaaactg gaggaatgga 11640
ataaattatg cagtttagtt attaataatg tactaatgtc cttagttatg accattgtac 11700
catggtaaag taagatacta acaatagagg aaattgggta aggggtatat gtaactctat 11760
actatccttg caatfttttt gtaaatftta aacttctaaa ataaagaaca aatftgaaca 11820
ttaaaaagtg tccccaggaa catgtatcac tgtttacaga tgaaacagta tgtatfttta 11880
tatctaattt ctgatcattg gcttcaaatc agaaaagtga atgacacatc aagatcaggf 11940
tttctgttta ctaataaagf tctaagaaaa caaagcatac cagctggaga gattcatgtt 12000
tataaagaca gatttataac aacaaaaata aaatatccaa gaataaattt aagaagaaat 12060
agggcactat gtaaaaagta tagcactftta ctgagaaaaa tatgaaaacc tgaatacatg 12120
gagagaggta ttttatatft gaatagaaag attgctggft taaagataat tctctfttaa 12180
ttftttftgt agaaatftta gaggtacaag agcagttftg tcacacggat atattacata 12240
gtggtgaagt ctggggtftt agtgtaaatf aatctfttaca tfttgtftga gcccataaa 12300
tgtaccaaca tgatftftat agcaagatag tcatctctat taacccaaac ftgtcccaac 12360
fttgaactga actgaggcag agctagcagg tgttcccac tgcctgaggca tctgaacatt 12420
aagcgtatcc ctctgagaac cagcctgcatt tgatcctctt tctaatgtag acagcatcaa 12480
gctatataat tagttctgtg ctccagcaaaa gccctgactt cftttftgctt atgtcctage 12540
tccatacaac aaaatcaacc aaagaatftt ggttgtcgat ccagtcacct ctgaacatga 12600
actaacatgt caggctgagg gctaccccaa ggcgaagtc atfttgacaa gcagtgacca 12660
tcaagtctg agtggtaaga ccaccaccac caattccaag agagaggaga agctftftaa 12720
tgtgaccagc aactgagaa tcaacacaac agctaattgag atfttctact gcattfttag 12780
gagattagat cctgaggaaa accatacagc tgaattggtc atcccaggta atattctgaa 12840
tgtgtccatt aaaatatgtc taactctgtc ccttagcacc tagtatgatg tctgcctatc 12900
atagtcattc agtgtftgtt gaataaatga attaatgaat aacattatat ftacaaaatg 12960
tatcctaatt cctcacttcc attcatccaa atcatattgt tacttaataa acattcacca 13020
aatatfttatt gaatatgcct ftgttccat gcattgtagt actcattftga cacacataga 13080
ataataagac tcaagttcac actcttcagg aaacagataa aaaacaaatg aacaaacaaa 13140
aaacaggcaa tccaatacca tgtgggaaat gctftcatac catgtgggaa acctggggga 13200
atacctgaga ggaatattca attcaggcca tgttccagga atccaaatcc tggcacatca 13260
gagccgcctc cttcttacta gggfttctgt ggcaggaaat aaatggaacg tattfttcta 13320
tcttatgcca aacaggaggg accctfttctc cctgtgcct ctcccaaggf agtctacaat 13380

-continued

atttcaacgc tagcagctctg tttagtgcac aggacatgag gctgtgtatc cctgggcaaa	13440
ttgctacact tctgtgtgct tcactttctc tgtaggatta taacctactg agcaaggta	13500
ttgtgggggt caaattagca acagtgtatg aaaatgattt gagaccagtg cctgcacaaa	13560
ttcaactatt tttttttatc tcactactct atagaagtag gtaggatggg agacagagtc	13620
tgatgggagg ctcagaatgt gaaagtaagt gaggtgagtg agcatgatat ttcataataa	13680
cacaaagata ctctgagaag agcttctcac ttccccgcc cccaatagat gttgacagga	13740
aatgccatg tacttcagca aaaacagctg aaaaattaga cataaaagtc aatcaatagg	13800
aaaagataat ccaggatggg cttgtgaaca gaaagagga aaaaaaagt ttagaaaatg	13860
atggggatgc tcttactggg gtatgagtcc tcaggatctc aactggcttt cagaaaaagc	13920
tagactagtg ggttcctgcc atttaaaagc tgtttatga caacttactt gttgggtggc	13980
ctacagtaac tcacttaact gtgctgagtc tgtttcctca tctgtaaatt ggggattttt	14040
taaaataact ggcattgccta actcataaag ttgttctgaa actgaaataa aacatatatg	14100
aacaggcatt gtaaactgta agttacgaa aaagctggct gttgttgtgt ctttaaagct	14160
tcacctgggt agttagagat ggatcatggg tctcagtga gagctgagcc aggcaggagc	14220
tgactaaggg taagaggtgg gagttagcaa tctctgaaca tctgtgtgcc atgggacccc	14280
ttttcctcct gcatggtacc ccagacaagg agcctagtaa gagatactaa tgacttgttg	14340
tccagagatg ttcaaactgc agagaaagat aagacaacaa gcattggcct ccaatcatga	14400
tgacagatag gaggaggtgg gagctcctta gcagtgtgg ttggttttcc atgttctact	14460
gtgggccatc tctgccatgt actgtaggct actaacttct atattaaaa atgcaagagg	14520
ggccgggagt ggaggctcat gcctgtaate tcagcacttt gggaggccaa ggtgggcaga	14580
tcacttgagg tcaggagttt gtaaccagcc tggccaacat ggtgaatctc tgccctact	14640
aaaaatacaa aaattagcca gatgtgggtg cgtgcacccg taatcccagc tactcgggaa	14700
gctgaggcac gagaattgct tgaacctggg aggcggaggt tgcagtgagc caagattgtg	14760
ccactgcctt ccagcctggg caacagagaa agactttgcc tcaaaaaata ataaataaat	14820
aaataaataa ataaataaat aaatggaagt gaaataatca aggccaccat ttaatactga	14880
gtagccactc catgtgttac tgtgctaagc acattataaa atattagcct cacaagaaat	14940
gtattagcat ttgtattttg tacactggtt aagtatcttg cccaagacct caaaactggt	15000
taaggggcag cagaatttaa cccagcgcc accttttcaa agtctgggct tcttacctt	15060
ctccatgctg ttcccatttt aacagatgta tctcgccatt ccagccactc aaactttggc	15120
atttaagaaa attatcctaa agctaaacta aacttcaagg atgactatct tcttgatgac	15180
cccttcccat caaaatttta tctttagta gtttgttttt gttttgtttt gtttttcaga	15240
actacctctg gcgcttctc caaatgaaag gactcacttg gtaattctgg gagccatctt	15300
tttactcctt ggtgtagcac tgacattcat cttctattta agaaaaggta gtatttctt	15360
aattgcagtg gtctccactg gggatgagga gggggtgaga attggatcga tcatggctgc	15420
aaggaaacct gacttaacct ctgcaggggt gtgcaaaggc attccactat tcaacagtaa	15480
ttatattgaa gctgcatggg atcactgggt gaagatgagg tgtaaggggt gagggacagg	15540
agaatgggta tggatggagg tagaagatgc agtgcatac aattttttc tatcatgaaa	15600
ataaccacag acttactgta aagaaggagc taaaatgcct gtcattttca gttgcatttt	15660

-continued

agttttgcat tagttgcacc cagctgggtt ctgggtactc taagtaataa aaatagttcc	15720
tctgtagaac tgtagtattt tcaccataga gtattttgta aaattattgg tagaggatgt	15780
tacataatth gcatgtgttc ctttctccat ttacctgtgg gaacaattaa aatccaggaa	15840
aatgagtata ttcaaataat ttctcccat ttatgatgat tcagagtaaa taattcctct	15900
gatacttaga gaagtatacc aagagatcca gtgattgtat agagttgtct gatgttaaat	15960
agggaaagtag aatatggaag ggaattccaa tagtcgttga aaaattcccc acaaccctt	16020
acatggggga aagtgggtt aactgagata gtagagataa gctgttacca aaaattatgt	16080
tcttaacagg attgagatag ccagaatata aggatcaagt ttcaatgaca gtaagatcct	16140
gagatgcagt tgatttgac aaagaaataa ttggtgccag cttgcatttt gaatatttct	16200
ctggaaaaag agattagtgt gcagtagaaa tgaatagaaa tcaatagata ttaaaatacc	16260
tcagaatttg attcatctct gggaaaagat gaaaaataa agtgtatagt cctcaagaaa	16320
atctgggatc aaaagcatgg gccttaccct attgaattaa ttaacctcag aagttgggaa	16380
ctgtggaata aggatgtcca ccagacttcc tagggattac aaatgttca tagaacttga	16440
aatttaaact tgggtcactg tatgggatgt agagctgtgc tatatggaaa taaaaatgat	16500
ttctttttct caaggagaa tgatggatat gaaaaatgt ggcattcgag ttacaaactc	16560
aaagaagcaa cgtggtgaaga atatcagaag gaattgggaa gtagaaggca aaggaaaca	16620
aaagctaaag caataacaaa gagaaatcca ttagtcataa tctcctctcc ttttaagaa	16680
tgctggttcc cctttgctc acaactaata caagaacttc tccaccatct caggaagttt	16740
agggatggcc ttcaagagta gagagtaggg agcagctctg tggagagagg agaggagcag	16800
ggaaggggaa ggagtcagct tctctttgct aatctgttgc cctgcacctc agcagctccc	16860
tgacgagggg gacaaggttg acttaggttg atggataatt aattgattct aaaaatttgt	16920
gtgtcagtat tgtatattgt aatactatgt taactgcgcc atgcacggtc tctcatttaa	16980
tcccccccc cttgccatta ccaaaaagag agagagaaaa atactagaat tctcctcatt	17040
ttacagtaga gaaaaacagag ggtcaagaag ataaagtaa gtgcccaaga acacacaact	17100
gatcacaat atcaagcttg ggtccatta gcctaaccac agacccttac tcttaacca	17160
tctgcttcaa tccattttgc tacaatgtt tacatttata tgcagggcag aaaagtctca	17220
tccagtttat tgaactaaga agaaagtat attaagggtt ctaatttttt ttaatgtagt	17280
tagaaaccaa acttaacaat gagcccaagt ttaaagcagt ctaattaact tgacaagctc	17340
aggcaagttt cattctgtgg cctgtagcat catctgttgc gtaaagctaa gtagcaaatg	17400
ttatttgggt catcctgggg ggaagtcac cccaatttgc tcaagactga ggggttttct	17460
aggatatcat gtaagataa ttgggtacaa atataacctg cttctttctc tcatttcaaa	17520
tttatcattt atcatctcag caactatgag ttatgttttt tattagattt cttgttactt	17580
tttccccaga ccgctcccca tgaattaat atactattat cactctccag atacacaatt	17640
ggaggagacg taatccagca ttggaacttc tgatcttcaa gcagggatc tcagcctgtg	17700
gtttgggggt tcgctcagggc tgagcatgac cagaggaatg aatgggcccg tgggatgcat	17760
gcagtatggg acttaaaagg cccaagcact gaaaatggaa cctggcgaaa gcagaggagg	17820
agaatgaaga aaaatggagt tgaacaggga gcgtggaggg agaccttgat actttcaaat	17880
gcctgagggg ctcatcgggtg catgtgacag ggagaaagga tacttctgaa caaggagcct	17940

-continued

ccaagcaaat catccactgc tcactcttagg aaaacgggtt gagaatccct aatttgaggg 18000
tcagttcctg cagaagtgcc ctttgctccc actcaatgcc tcaatttggt ttctgcgtga 18060
ctgaggggtcc cagtgttggg acagtatatta tgtatgagat tttcctatth attttgagtc 18120
tgtgaggtct tcttgtcatg ggagtggtgt tgtgaatgat ttcttttgaa gatataattgt 18180
agtagatggt acaattttgt cgccaaacta aacttgatgc ttaatgactt gctcacatct 18240
agtaaacat ggagtatttg taagggtgct ggtctcctct ataactacaa gtacacattg 18300
gaagcataaa gatcaaaccc ttgatttgta taggatgtca cctttattta acccattaat 18360
actctgattg acttaactctt attctcagac ctcaagtgtc tgtgcagtat ctgttcatt 18420
taaataatcag ctttataatt atgtgttacc atacacacat aatctccttt catcgtctga 18480
accaccctgt tgtgatgacc actattatth taccattgt acagctgagg aagcaaacag 18540
attaagtaac ttgccaaaac cagtaaatag cagagctcag actgccccc actgtccttt 18600
tataatacaa tttacagcta tttttactt taagcaatc atttattcaa aaccattta 18660
ttaagtgtcc ttgcaatata aatcactgta ccaggcattg aatctacaga tgtgagcaag 18720
agaaagtacc tgcctcaag gagcttgagg tataataagg agattaataa gaaaatata 18780
tattacaatc tagtccagtg tcatagcata aggatgatgt gaggagaaaa gctgagcagt 18840
gttgccaaga ggaggaaata ggccaatgtg gtctgggaca gttgaatgta ttaaacatc 18900
ttaataatca aagtaatttt catttaciaa gagaagtcag tacttaaaat aaccctgaaa 18960
aataacactg gaattccttt tctagcatta tattttccc tgatttgctt ttgccataca 19020
atctaattgt tgtttatata gtgtctgata ttgtttaaca gttctgtctt ttctattcaa 19080
atgctattaa attttaaat cataccttc catgattcaa aatc0aaaag atcccatggg 19140
agatggtttg aaaatctoca ctctactc caagccatc aagtttctt tccagaagca 19200
actgctactg ccttttatth atatgttctt ct0aaagatg tctacatttg gaaatgatg 19260
ttaaagcat atatttttaa attttttcc ct0aatagta acacattata tgtctgctgt 19320
gcactttgct atttttatth attgtagtgt ttcttatgta gcagatggaa tgaatttgaa 19380
gctccaagg gtcaggacac atgccttctt tgtttctaag ttatctttcc catagctttt 19440
cataatcttt catatgattt agtacatggt aaatatgtgc tacatataca tttagacaac 19500
cagcatttgt taagtatttg ctctaggact gagtttggtt ttatgtttgc tcaaaaggag 19560
accatgggc tctccagggt gcactgagtc aatctagtc taaaagcaa tcttattatt 19620
aactctgtat gacagaatca tatctggaac ttttgtttcc tgctttctgt caagtataaa 19680
cttcaacttg atgtgtact tgcaaaatca cattttcttt ctggaaatc cagtagtgta 19740
ccttgactgc tagttaccct gtgccagaaa agcctcattc gttgtgcttg aacccttaa 19800
tgccaccagc tgtcatcact acacaggcct cctaagaggc ttctggagg ttttgagatt 19860
cagatgcct gagagatccc agagtttctt ttccctcttg gccacattct ggtgtcagtg 19920
acaaggaata ccttcgcttt gccaccgtc aaggttgaag aaacagcgtc tccaacagag 19980
ctccttgtgt tatctgtttg tacatgtgca tttgtacagt aatttgtgtg acagtgttct 20040
ttgtgtgaat tacaggcaag aactgtggct gagcaaggca catagtctac tcagtctatt 20100
cctaactcct ccttttggtg ttggatttgt aaggcacttt atcccttttg tctcatgttt 20160
catcgtaaat ggcataggca gagatgatata ctaattctgc atttgattgt cactttttgt 20220

-continued

acctgcatta atttaataaaa atataccttat ttattttgtt a 20261

<210> SEQ ID NO 3
<211> LENGTH: 20340
<212> TYPE: DNA
<213> ORGANISM: macaca fascicularis
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (1658)..(1881)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2742)..(2745)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2747)..(2747)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2749)..(2749)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (4764)..(4802)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (8775)..(8778)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (8980)..(8984)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9161)..(9293)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9344)..(9348)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9840)..(9874)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (9958)..(9973)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10437)..(10452)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10603)..(10603)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10830)..(10830)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (10989)..(11006)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (11105)..(11122)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (11457)..(11457)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:

-continued

```

<221> NAME/KEY: misc_feature
<222> LOCATION: (13710)..(13710)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14015)..(14049)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14518)..(14585)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14689)..(14699)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14707)..(14767)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (14837)..(14865)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (15703)..(15741)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (17403)..(17415)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (19122)..(19135)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 3

ctgaaagctt ccccgattcc gccgaaggtc aggaaagtcc aatgccgggc aaactggatt      60
tgctgccttg cgcagagggtg ggcgggaccc cgcctccggg cggggcgcca agttgagcag      120
ctggcacgcc tcgcaagcc ccagtcctga agccccagtc ctgctgctgt tcccgaggct      180
cgcaccagc cgcgcttctc tctgctgca ggtagggagc gttgttctc cgcaggtgcc      240
cacggcccag catctctggc taactcgtg ggcaccttag gacggaggat ctctacacce      300
tttctttggg atggagagag gaggagggaa agggaaggcg atggtctagg gggcagtaga      360
gccaattacc tgttgggggtt aataagaaca ggcaatgcat ctgggcttcc tccagcgcaa      420
ttcagttttg ctctaaaaat aatttatacc tctaaaaata aataaggttg gtagtatagg      480
ataggtagtc attcttatgc gaccgtgtgt tcagaatata gctctgatgc taggctggaa      540
gtctggacac gggtcctagt ccaccgtcag ctgcttgcta gtaatatgac ttgtgtaagt      600
catcccagct gcagcagata agtaagtctc ttcctgctgt aagcacgtcc aggaccctg      660
aacggaatth atttgctctg tccattctga aaacccaaag gagtccctaaa agaggaatgg      720
aggagcctaa gaataaaaat agtataataa aacatttctt agacaggttg accttggcct      780
atgtcaaagt tcagtcctggg tttgtcttat aacataagga gtaaaagtac cattgttcta      840
cctctttttt taatacttga aaaaaaattt actgtagatg cttttctatt aattaataa      900
ccttctaaaa aatgttttta gtgctgcatt cgattaggtt ggataactaa atgaaattaa      960
ttcctcactg ttgggtataa aggttattha cagtggttct gtcttagcta ttcactgaac     1020
atcattacat agatattctt ggaatattgc tgattgttcc cgtaataaaa cttagaagtg     1080
taactactta gtcaaagaga ctgaatattt taaaggcatt ttgaagaaaa ctgaaaatgc     1140

```

-continued

tttccagaaa	ggatgtatca	gttgacaatg	atggttgta	acagtattta	aggagaacta	1200
tgatactctg	aagaaaaact	tagcctttct	cagtagaagc	aggtaggcag	aggccacatg	1260
acagcagtta	gagtgtgggc	ttcaaggaag	tcacagaaat	actgtgggga	attgaaacct	1320
caagtggaaa	atgtacaaga	gtgtctcagt	gtgactgaga	aggaggttgg	gcttgggggt	1380
taacttaaga	atTTTTTctt	tctTTTTgtg	gagatagggc	TTTTgtatg	ttaccaggc	1440
tggctctgaa	ctcctagcct	caggcgatcc	tcccgcctca	ggctgcagaa	gtcctgggat	1500
tactggccgg	agccaccatg	caggcctctt	gctcctactt	ttgagaaagg	aagcttaacc	1560
TTTTTTTT	gTTTgtttt	gTTTTTgtt	TTTTTgtag	acgagtctca	ctctgttgcc	1620
caagctggag	tgcagtggg	ccatctcagc	tcacagcnnn	nnnnnnnnnn	nnnnnnnnnn	1680
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1740
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1800
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	1860
nnnnnnnnnn	nnnnnnnnnn	ngactTTTT	tctatctctt	cctctaccc	atcctacct	1920
tggaagatag	agaagtaata	tcagttccat	cgtgttatac	tgggcttccc	ccagggacaa	1980
accacttcc	ccaacctgaa	tgagccatca	cttcttcccc	agtttacatt	tcattgctct	2040
ttgaatgtct	ccgttcggat	atgggaattc	acatgtgggc	ataattctta	cctgaagaag	2100
actgacgtct	tctctcttta	gaccaactgc	cctgatgtga	ggTTtagagg	ttaaagaaca	2160
tgtgtgtatt	tacatgatct	ttgtattctg	cctttctgct	cctcactaat	gacagctgaa	2220
cccccaaggaa	atagagctgt	ggaggagagg	gTTTgatgag	aaagtaggta	aatattggat	2280
ctaateccatc	atcttccagg	aaacctccat	tacttctaaa	aatttcaacc	aaattcgtta	2340
aaggacaaga	actccaccag	agtagggcca	taaacattgg	caaaattagt	tgtaatctat	2400
gactagattt	aatgtccott	tgttttattc	acatatgggt	ataatgcttt	gcttgggaatt	2460
aggggtattt	taagttttct	tctgcctagt	aagtgtattt	gtgcttataa	tacaataatt	2520
ataaaatatac	acattaatat	tttataactg	tacagttaac	tctggcccaa	ggaaaagata	2580
gtccggtaga	tgtctcagcc	tgatTTTgta	tctaaccctg	gcaagaggat	aatgactcat	2640
gttatttccac	ttaccctttt	tatcttttaa	catgaagggc	tcatataggt	caataagaaa	2700
ccagtgatat	aaacagacca	aaaaatgatc	agatctttca	cnnnnanana	aaaaaaatat	2760
TTTTaaacaa	tacccaactg	ggtgaaaata	caatgtaaca	gtaccaaata	tcaacatgtg	2820
tcaagaacca	gaaaaatggt	tgttttcttt	gatcagcaac	actatttgag	gaaatctatc	2880
ctcagggcct	agcctggggc	ctggcacaca	gtaggcactg	aacaaatatt	tgtctgaacac	2940
acacatactt	atgatatttt	taaaattggc	aacaatccaa	tacccaataa	tagaggaatt	3000
aaatattata	gaactgttca	ataagatgct	tacgaatatac	atgcagtaag	atgggcaata	3060
tttatatcat	aagcttaaat	gaaacaaatg	ggtatttaaag	gtatggtaag	gTTataaatt	3120
actttttaag	agattaaagg	gaaaagactg	aaagatatat	actgaaatgc	tcacagtggt	3180
gacaaggttc	cccagccttg	gcactattga	cattttgggc	tatgtctttg	ctgtggggagg	3240
ctggcctgtg	ctctgcagga	ggtttggcag	cactcttggg	ttctaccctt	agatagcagt	3300
agcaaccctc	cctcaaccag	cccaattttg	acaacaaaaa	atgtttccag	gcatcaccag	3360
attctccctg	ggtgagagtg	atgaaacagt	aggtgatTTT	ccccttcttt	tctcattttc	3420

-continued

tgtaatttg tcacattacg ttaataataa ggaaaaaaca taaaaaatag atgaatttat	3480
tattctacct cagtttgat gtttgactc cctttggggg ttctttccat tatatcactt	3540
ggtctgctaa acagtctatg gtttgcaag gtgaaatgat tcatgaaatt ttgtttttat	3600
tttttacctg atactaaaag taaaacattc attcgttga aaatttggac acagaacacc	3660
aaaaaaaaac cataatctca tctctctttt tctgtctttt ccttctcttt ttccctttaa	3720
aaacaagagt gaaaaacctac cggttctccc tccaatttaa ttccataata taatcactgt	3780
taacatcttg gacatttctt gtgtctaaac acacatactc actttttctt ttttttagca	3840
aaaagtggat ttctgctaca tgtagtgttc cgcaacttcc tacatgttta caaaatcagt	3900
acatttacct acgctgaatt cagtccttaa tggattata ttttgtgaat ataacaaat	3960
ttatttaacc acttagacaa tctaagatat tctcagtttg ctgttatgag caatgctctt	4020
cctttacata tacatatata tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtt	4080
ttagtaggat agatttctag gagagggcga aatgtcatat gacatccaca tttacaattg	4140
taataggaag tatcaaagtg cccctaaaa aaaaaattc ctcccattag tgtgtgagaa	4200
agcctatttg ttcatatctt cacaaacct aaatattaga aatatttaca attgtgttca	4260
agctaagaag tgaaaaatgg tatttcatat cttataattt ttgttgtgag attgaacata	4320
tttctatgt ttacatgtca cctgtatttc ttattctctg aactatacgt tatgacctt	4380
cacttatttt cctcatgggt tatgtgtagt ttgtgtagt gtcttattga ttgttaggag	4440
ctatttatat attaggaaca ttaatctcct gtcttatatg tatgtggcat tgattagtgt	4500
atcatttvtg agttcatgtc tgtatacaaa gattagagag gcagtaagag ggaaaactta	4560
cctctttctt atcaaagttt gtaaatatat gtataacaga agagagagaa aacattaata	4620
aatgtgaaa taaagtataa atttttactc cactacttca acataaacta caaaaggaga	4680
gtgacttttc tttcatgtg acttccatat tcccctgcc taaaatagtg cctagcacag	4740
aagaggtgct caatcagtgt ttgnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnnnnn	4800
nnaaatgaag aatagaatct aggagatac tctggaagag tgactgtgag tcattcatgg	4860
tcttggtag aattagtcaa atccagctt ctcccctcc cactcccac tgttagtaga	4920
ataatctgtt tattgagaga atagatttat aatttagaat aagaggggca gaagaggaga	4980
ttttgaagga tggcacctga aggaggacta gcatggctga gatagtgaag tggaaagtctt	5040
ggaaagctaa aggtaagat gaaagtattt agccgtaggg ggaaaaagca ttgacagggt	5100
ggaaatgtaa aagtcagatt ctccctgtct tgaaattttg tacagggcag gttctactag	5160
gtatgttaca atgcagaaaa aacatgaaat agttgagagg aatttgggtga aatattatct	5220
tccctgcttc ttttgagtga gcagattttt ttcagggcct gtaactataa taaatttgaa	5280
acttctcatc ttttagtaac ttttttcaact taagtttatg tggctgtggg caatggaatg	5340
aaggtattga acttctatt cctgtctggg tttccacaat tacaagtcaa tcatgactgg	5400
ttattagaag actatttcaa ttagaaccac caagtccat aatgtcatat tgtgtgttta	5460
attattaagt aaagcagtct tctttttgtg ttttccataa ttagcacatt ccagaaagat	5520
gaggatattt gctgtcttta tattcacgat ctactggcat ttgctgaatg gtaagacacc	5580
aaatccttcc attaggttct atattttaaa tattttaacc atgagtttaa aactaaaatg	5640
ataatttaaa atgcatgcaa ttttcttata gagagaatat tctcttctt cttctacttt	5700

-continued

acacaatgac	aaagtctttc	tctgcttta	cacaatgata	aagctccctg	tgctattgtg	5760
taaaaatata	gagaatatag	acaattgaa	agacacaaaa	taatctatta	cccatttccc	5820
agggttaact	actgaaaata	tctggggaaa	tggectgtat	gtatatat	attgtttgt	5880
tttcaacaag	gccaggatct	ttcaatctt	caatcttgg	tgctctgtga	catgccttc	5940
ctgatgagaa	tactctaagg	aagaattgta	ggatacatgg	aaaatgtcag	ggtaacacag	6000
tactggcacc	accctgcggt	cctttctgaa	ctccatacca	atgtacttct	tgccagaaaa	6060
ctgatcaaaa	gtttagggaa	gtaaaaagag	atgttagaat	ctaccattcc	ctctatgtag	6120
gaagcaata	gggtgccagt	caaaggacat	tctggggatg	tctacatgaa	accaagtctc	6180
ctggttgtaa	gtactccatc	tccatataat	atctctacag	taatatatgt	ttataaattg	6240
tgggggcaac	ttgtttagct	aattttatta	ttctgttatt	gggacactat	gtctctgcat	6300
gagacatagt	gtcccaaac	atatttcaag	cccattggat	aaaatgtgta	tttagcaagt	6360
tcttaaatat	aatgataaca	taactgacca	gataagggtg	tttttaaatg	ctgtgccaac	6420
tttataaatg	ttttgaggaa	ttttccctt	tctgaaggtt	attcttcttt	ctttttagca	6480
tttactgtca	cggttcccaa	ggacctatat	gtggttagagt	atggcagcaa	tatgacaatt	6540
gaatgcaaat	tcccagtaga	aaaacaatta	gacctgactt	cactaattgt	ctattgggaa	6600
atggaggata	agaacattat	tcaatttgtg	catggagagg	aagacctgaa	ggttcagcat	6660
agtaactaca	gacagagggc	ccagctgttg	aaggaccagc	tctccctggg	aaatgctgca	6720
cttcggatca	cagatgtgaa	attgcaggat	gcaggggttt	accgctgcat	gatcagctat	6780
gggtgtgccc	actacaagcg	gattaccgtg	aaagtcaatg	gtaagaatta	ttatagatga	6840
gaggcctgat	ctttatagaa	aacatattct	aagtgttgaa	gacttttcat	tcttataagt	6900
ccatacttat	tttcaaacag	aatagcatag	tctcttcatt	cattcattca	gttcatgaat	6960
tcattcacgt	aagtctccaa	ttagcatttc	ttgagccct	atatgatagt	cattggaaat	7020
ccagagacaa	cacagagcca	tgttctacgg	tatgtacagt	tttccaaaaa	taattcctag	7080
tctttacttt	tttattataa	atgtaataca	tatacttgca	aagaattcag	atactatgga	7140
agagatcaaa	tgaattgcaa	aagtgtccct	cctcccttca	ccactatctc	ccatgagata	7200
accaagagac	actccaagag	agtaaccatt	atgtgtgtgt	ccctccagaa	ccttttttat	7260
tcaactacca	tttttttatt	ttattaggtc	tgctcagttt	ccttttttga	gcctctctat	7320
atcaaatgct	aataaatata	ttcagatcaa	accccactgt	aaggttcata	ttaaaaaaga	7380
cttgaagtct	ccctatgaag	acaaaaaata	atcatattaa	gtgtaaaaga	acttattctt	7440
ccagtacagt	ataaactata	ctcactgggc	atatattcat	cttgaaaatc	tatactgatg	7500
ttgtcttggg	gaattgaaga	ggaactagga	gtgtcaattc	ctgggaactg	accacagtt	7560
atgtcatcag	gtcacttgag	ttcgaagttt	tgtgttagca	ctagctaagt	aaaggaaaac	7620
acctctgctt	tcattgttga	gtttcataga	attgagagct	gaaaggatcc	caggcaggag	7680
cgactaatcc	aaactcccac	aaagaacaaa	aatccccag	aggatcttct	gttcatatat	7740
ttcctgcagt	ggcatcccctg	tcatatccca	caatggcatc	cctgccattt	ggactcccct	7800
tccatatcct	gttgaaatta	ctccctaata	gtaagctgaa	atctgcccct	ctagttgtag	7860
ttttggaatt	atctcatttc	catgatgacc	ttttaatatt	tgactagaat	taaatcatct	7920
ccccttggtg	ttccatttcc	tggactaact	accatcaatc	tgagggctaa	caatacaagt	7980

-continued

agaaaaagtc	tacacttgtc	attgatcact	gatcaatgat	taatcaatga	tcaactgataa	8040
ttataaactc	aaaaacaaaa	tcactgtaggg	attaagagaa	atgtatcagt	tttatgttgt	8100
atctctggtc	cctgattctg	gctcaaaata	tgctactatt	gtcaagaaga	tatcacttgt	8160
aaagtagatt	taattttcat	tatattttac	catgtgcttc	tccattcact	gcatttcttg	8220
agatgttggtg	gtttataact	tcagtttttc	tccagtcact	cagcaaatat	caggcatcta	8280
ctgtgttcca	agatattaaa	gaaatcatca	tgacttagcc	tcatcaacag	cattgctaga	8340
tctgggatgg	aaaagaagag	tataatcctg	gcagtcagga	agaaggctgc	ataaagtata	8400
agtttctgct	tccaaagaag	atctctcatc	agcctgtagg	gagtgtatag	ggaggggaca	8460
gctgtccttg	tagtagcaaa	gggttttatt	caggtcatct	gggtccata	atatcccttg	8520
tgatctgca	gtctcctttg	ccatggatca	acacaatagg	aaatcttccg	gactgatgg	8580
tttttccaag	ggggagtctc	tcaggagca	aagcaaatga	ccaaccagg	ttgaggacct	8640
gatttgacaa	ttccattttg	tattttaaat	tagttaattt	gcattctagt	cccaatccat	8700
cttgtcattt	gcagacagtg	gttttgggtg	tgagttgagc	tataccaaaa	gtctgaacct	8760
tctgcactta	gaacnnnaa	ggcaaccacc	aagcttcact	tgactgagg	cagtgtctcc	8820
aatggaaaag	aggtagctgg	cttgacagaag	ctttccaact	cagggaaagta	gaactcctga	8880
gtcacctcca	tatgcaata	atctcacagt	actgctgttg	aacttcactt	cccatcacag	8940
caaatgtgtg	gtaacatagc	tttgccacag	gagtttactn	nnnccatgg	gattttaaag	9000
gtgaaacatt	tcaaaactga	aatttgaaag	aatttagttt	tggattcact	caattatcat	9060
gatcactttg	ggtgttattg	cacctttcat	gtttgtgagt	ttaaatacca	gactctcagg	9120
cctctaactt	tcaattaa	gtgtttttct	ttaatcactg	nnnnnnnnnn	nnnnnnnnnn	9180
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	9240
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnctgtcat	9300
tccccaccaa	ccccatcttt	ccccaaaatt	cccagccctg	ttttnnnngt	ttttctttaa	9360
tcaactgaacc	taatagtagg	gaaaacgaaa	tgttcattca	gactttcagg	acettcaatg	9420
agatgaggca	gctgaaagat	caaagtagtt	gcatagttat	cccagtaaag	ctatttggat	9480
cgatggacc	agatcaactg	ctgtcattcc	ccaccaacc	catctttccc	caaaattccc	9540
agccctgttt	aagtgttctc	tgtagcattt	atctctatct	agtatattgt	gtagcatatc	9600
atatcatact	tttctatttt	gtttattgtc	tctctctccc	tagaatataa	actccacaag	9660
cacagagatt	tgggtctgtt	ttttaatatt	gttgtatccc	cagggttga	cgtaaagcag	9720
agtgttagta	tgacaaaagc	acacaaaaaa	tatttgttga	gtcaatgaat	gaatgatttc	9780
ctcaaatagg	attagcctaa	aatttggaaa	catgaacaga	cttggatata	tgaaaatttn	9840
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnttctaa	agggtacact	gaagcagcag	9900
tagtaaaagg	aggaggagga	gaagcagctc	tgctactact	attatcgagt	actactannn	9960
nnnnnnnnnn	nnnctacaac	tatcgagtac	tactacaatt	agcacttgc	tattctgtgt	10020
gttaggtcct	gtactgaaca	tctgcctaa	attagttcat	ttctcctgg	aatgactct	10080
gtgggtagg	tgcttcatca	tgtaagatga	gtatttttca	cacttcactg	tctctgaaat	10140
ctgagtggtg	ctttcaatga	tggaaatctt	gatttcatga	taagtggat	tattcccatt	10200
ttaaggatga	ggaaaactggg	gtccaaagaa	attaagtaat	ttgccaaat	tcacctagcc	10260

-continued

tcgtaaatga	taaagctagt	tctaaatcca	agcagattgg	ctctgaagtc	tgggccctta	10320
ataaccactt	attgcctgta	tttgcacctc	tggtgtatgt	atcaagtat	atattggctt	10380
caaaactatc	atgacctttt	cttgattttg	attgttcaat	attagtatag	tgttctnnnn	10440
nnnnnnnnn	nngggctctg	aaaaatttt	gattactcac	ctcatctgta	aaacatttta	10500
aacttgctg	tctgtgcagg	cacattttg	tgtaattata	aaaaatttac	tatctattaa	10560
tatatagggt	gtaccgtaag	aaaaattgcc	atTTTTgaag	agncaaaaa	ggttgaatat	10620
taccagtttc	atctgggtca	acctaataga	catttgta	aaaacagaca	ttttaagagg	10680
atgaaataaa	aatttaataa	acaatatttt	caatttttac	taattgtgac	gcttcactat	10740
tgtagctaa	tatgtcaagg	catgatatac	cttaggggtg	aatttatcat	taacaagggt	10800
ggatagtgtc	aataatcttg	aggtttgtn	TTTTtata	aacctgtga	ggtctaatta	10860
agtactta	tgTTTacaac	ctcatacagt	cgccaataat	aagtgtcact	tctgctgttt	10920
cctctgggtt	gtgcttgaat	tattagtatt	atcttcaatc	ctcagtttct	ttgtgaaaa	10980
ctTTTaan	nnnnnnnnn	nnnnnaaga	tggttagttt	agTcaaaatt	agataagaga	11040
atctgaaat	ccataattac	cccaaagcaa	cccactcata	agaactatta	TTTTTgtgt	11100
ttggnnnnn	nnnnnnnnn	nntttccagt	gtttccactg	gtagtggttt	cattgatgta	11160
ggagtatcaa	aacatcacta	attatttatt	tcagttttgt	ttgatcctag	ctgTTTTgtg	11220
ttaactttga	agaaattaca	tcacagatct	attgtgtcc	ttggtaaagg	aatggagagt	11280
taaggctcta	gatcattagt	ggttatgctg	tagtattagg	agTaaaaaaa	agattatatac	11340
aacaaaataa	gaacatgtta	atgtacttgt	aatagataaa	catgaataaa	gctcttatgc	11400
tatatagatg	cactgaacaa	tctactagaa	ttgtcagcaa	acggtatctt	aatcctnaaa	11460
agggtcccaa	accaatgatc	taaaattgaa	tcaaacttcc	ttccttgagc	ataattattt	11520
aagtgattta	ttaaaatagc	cagcatttaa	aagcttaaaa	tataagtatc	ataatgtgggt	11580
atcctagata	gatcccagaa	cagagaaagg	atattagga	aaaactggag	gaatggaata	11640
aattatgcag	tttagttatt	aataatgtac	taatgtcctt	agttatgacc	attgtaccat	11700
ggtaaagtaa	gatactaaca	atagaggaaa	ttgggtaagg	ggtatatgta	actctatact	11760
atctttgcaa	TTTTTTgtgta	aattTaaaac	ttctaaaata	aagaacaaat	ttgaacatta	11820
aaaagtgtcg	ccaggaacat	gtatcactgt	ttacagatga	aacagtatgt	atTTTTatata	11880
ctaatttctg	atcattggct	tcaaatcaga	aaagtgaatg	acacatcaag	atcaggTTTT	11940
ctgTTTacta	aataaagtct	aagaaaacaa	agcataccag	ctggagagat	tcagtTTTat	12000
aaagacagat	ttataacaac	aaaataaaat	atccaagaat	aaatttaaga	agaaataggg	12060
cactatgtaa	aaagtatagc	actttactga	gaaacatatg	aaaacctgaa	tacatggaga	12120
gaggTatttt	atatttgaat	agaagattg	ctggTTTaaa	gataattctc	TTTTaaatttt	12180
TTTTgttaga	aatttaagag	gtacaagagc	agTTTTgtca	cacggatata	ttacatagtg	12240
gtgaagtctg	gggtTTtagt	gTaaattaat	ctttacattt	tgTTTgagcc	caataaatgt	12300
accaacatga	TTTTtatagc	aagatagtca	ttcctattaa	cccaaaactg	tcccaacttt	12360
gaactgaact	gaggcagagc	tagcagggtg	tccccactgc	tgaggcatct	gaacattaag	12420
cgtatccctc	tgagaaccag	cctgcattga	tctcttttct	aatgtagaca	gcatcaagct	12480
atatactag	ttctgtgctc	agcaaaagcc	ctgacttctt	tttgcttatg	tcctagctcc	12540

-continued

atacaacaaa	atcaacccaaa	gaattttggg	tgctgatcca	gtcacctctg	aacatgaact	12600
aacatgtcag	gctgagggct	accccaaggc	cgaagtcatt	tggacaagca	gtgaccatca	12660
agtctgagt	ggtaagaacca	ccaccaccaa	ttccaagaga	gaggagaagc	ttttaaatgt	12720
gaccagcaca	ctgagaatca	acacaacagc	taatgagatt	ttctactgca	tttttaggag	12780
attagatcct	gaggaaaacc	atacagctga	attggctcgc	ccaggtaata	ttctgaatgt	12840
gtccattaaa	atatgtctaa	cactgtcccc	tagcacctag	tatgatgtct	gcctatcata	12900
gtcattcagt	gtttgttgaa	taaatagaat	aatgaataac	attatattta	caaaatgtat	12960
cctaattcct	cacttccatt	catccaaatc	atattgttac	ttaataaaca	ttcaccaaat	13020
athtattgaa	tatgcctttt	gttccatgca	ttgtagtact	catttgacac	acatagaata	13080
ataagactca	cgttcacact	cttcaggaaa	cagataaaaa	acaaatgaac	aaacaaaaaa	13140
caggcaatcc	aataccatgt	gggaaatgct	ttcatacat	gtgggaaacc	tgggggaata	13200
cctgagagga	atattcaatt	caggccatgt	ttcaggaatc	caaatcctgg	cacatcagag	13260
ccgcctcctt	cttactaggg	tttctgtggc	aggaaataaa	tggaaactgt	tttctctct	13320
tatgccaaac	aggagggacc	ctttctcccc	tgtgcctctc	ccaaggtagt	ctacaatatt	13380
tcaacgctag	cagtctgttt	agtgcacagg	acatgaggct	gtgtatccct	gggcaaatgt	13440
ctacacttct	gtgtgcttca	ctttctctgt	aggattataa	cctactgagc	aaggttattg	13500
tgggggtcaa	attagcaaca	gtgtatgaaa	atgatttgag	accagtgcct	gcacaaattc	13560
aactattttt	ttttatctca	ctactctata	gaagttagta	ggatgggaga	cagagtctga	13620
tgggaggctc	agaatgtgaa	agtaagttag	gtgagttagc	atgatatttc	atataaacac	13680
aaagatactc	tgagaagagc	ttctcacttn	ccccgcccc	aatagatggt	gacaggaaaa	13740
tgccacgtac	ttcagcaaaa	acagctgaaa	aattagacat	aaaagtcaat	caataggaaa	13800
agataatcca	ggatggtctt	gtgaacagaa	agaggaaaaa	aaaagttag	aaaatgatgg	13860
ggatgctctt	actgggtgat	gagtcctcag	gtattcaact	ggctttcaga	aaaagctaga	13920
ctagtggggt	cctgccattt	aaaagctggt	ttatgacaac	ttacttggtg	ggtggcctac	13980
agtaactcac	ttaactgtgc	tgagtctggt	tcctnnnnnn	nnnnnnnnnn	nnnnnnnnnn	14040
nnnnnnnnna	tgccctaactc	ataaagtgtg	tctgaaactg	aaataaaaca	tatatgaaca	14100
ggcattgtaa	actgtaagtt	acggaaaaag	ctggctggtg	ttgtgtcttt	aaagcttcac	14160
ctgggtagtt	agagatggat	catgggtctc	agtggagagc	tgagccaggc	aggagctgac	14220
taagggtaa	agggtgggaa	tagcaatctc	tgaacatctg	tgtgccatgg	gaccctttt	14280
cctctctgat	ggtagccccag	acaaggagcc	tagtaagaga	tactaatgac	ttgttgtcca	14340
gagatgttca	aactgcagag	aaagataaga	caacaagcat	tggcctccaa	tcgatgatgac	14400
agatagagga	ggtagggagct	ccttagcagt	gctggttggg	tttccatggt	ctactgtggg	14460
ccatctctgc	catgtactgt	aggctactaa	cttctatatt	aaaaaatgca	agaggggnnn	14520
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	14580
nnnnntcagg	agtttgtaac	cagcctggcc	aacatggtga	atctctgcct	ctactaaaaa	14640
tacaaaaatt	agccagatgt	ggtggcgtgc	acccgtaatc	ccagctacnn	nnnnnnnnna	14700
ggcacgnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	14760
nnnnnnnagc	atgggcaaca	gagaaagact	ttgcctcaaa	aataaataaa	aaataaataa	14820

-continued

ataaataaat	aaataannnn	nnnnnnnnnn	nnnnnnnnnn	nnnnncattt	aatactgagt	14880
agccactcca	tgtggtactg	tgtaagcac	attataaaat	attagcctca	caagaaatgt	14940
attagcattt	gtattttgta	cactggtaa	gtatcttgc	caagacctca	aaactggta	15000
aggggcagca	gaatttaacc	ccagcgccac	cttttcaaag	tctgggcttc	ttacacttct	15060
ccatgctgtt	cccattttaa	cagatgtatc	tcgccattcc	agccactcaa	actttggcat	15120
ttaagaaat	tatectaaag	ctaaactaaa	cttcaaggat	gactattctc	ctcatgacce	15180
cttcccatca	aaattttatc	tttagtcagt	ttgttttgt	tttgtttgt	tttcagaac	15240
tacctctggc	gcttcctcca	aatgaaagga	ctcacttggg	aattctggga	gccatctttt	15300
tactccttgg	tgtagcactg	acattcatct	tctatttaag	aaaaggtagt	atttccttaa	15360
ttgcagtggg	ctccactggg	gatgaggagg	gggtgagaat	tggatcgatc	atggctgcaa	15420
ggaaacctga	cttaacctct	gcagggtggg	gcaaaggcat	tccactattc	aacagtaatt	15480
atattgaaagc	tgcattggat	cactgggtga	agatgggggtg	taaggggtga	gggacaggag	15540
aatgggatag	gatggaggta	gaagatgcag	tgatcataca	tttttttcta	tcatagaaat	15600
aaccacagac	ttactgtaaa	gaaggagcta	aaatgcctgt	cattttcagt	tgcattttag	15660
ttttgcatta	gttgaccoca	gctggtttct	gggtactcta	acnnnnnnnn	nnnnnnnnnn	15720
nnnnnnnnnn	nnnnnnnnnn	nccatagagt	attttgtaaa	attattggca	gaggatgtac	15780
ataatttgca	tgtgttccct	tctccattta	cctgtgggaa	caattaaat	ccaggaaat	15840
gagtatatct	aaataatttc	ctcccattta	tgatgattca	gagtaataaa	ttcctctgat	15900
acttagagaa	gtataccaag	agatccagtg	attgtataga	gttgtctgat	gttaaatagg	15960
gaagtagaat	atggaaggga	ttccaatagt	cgttgaaaaa	ttcccacaa	ccccttacat	16020
gggggaaagt	gggtgttaact	gagatagtag	agataagctg	ttacaaaaa	ttatgttctt	16080
aacaggattg	agatagccag	aatataagga	tcaagtttca	atgacagtaa	gatcctgaga	16140
tgcagttgat	ttgcacaaag	aaataattgt	tgccagcttg	cattttgaaat	atttctctgg	16200
aaaaagagat	tagttggcag	tagaaatgaa	tagaaatcaa	tagatattaa	aatacctcag	16260
aatttgattc	atctctggga	aaagatgaaa	aataaaagtg	tatagtcctc	aagaaaatct	16320
gggatcaaaa	gcattggcct	taccctattg	aattaattaa	cctcagaagt	tggaactgt	16380
ggaataagga	tgtccaccag	acttctagg	gattacaaat	gtttcataga	acttgaaatt	16440
taaaactggg	tcactgtatg	ggatgtagag	ctgtgctata	tggaataaaa	aatgatttct	16500
ttttctcaag	ggagaatgat	ggatagaaa	aaatgtggca	ttcgagttac	aaactcaaag	16560
aagcaacgtg	gtaagaatat	cagaaggat	tgggaagtag	aaggcaagg	aaacaaaaag	16620
ctaaagcaat	aacaaagaga	aatccattag	tcataatctc	ctctcctttt	aaagaatgct	16680
ggttcccctt	tgccctcaaa	ctaatacaag	aacttctcca	ccatctcagg	aagtttaggg	16740
atggccttca	agagtagaga	gtaggagca	gctctgtgga	gagaggagag	gagcagggaa	16800
ggggaaggag	tcagcttctc	tttgetaatc	tggtgcccctg	caccctagca	gctcccctgca	16860
gcaggggaca	aggttgactt	agtgatggg	ataattaatt	gattctaaaa	tattgtgtgt	16920
cagtattgta	tattgtaata	ctatgttaac	tgcccatg	acggatctc	atttaatccc	16980
ccacccttg	ccattaccaa	aaagagagag	agaaaaatc	tagaattatc	ctcattttac	17040
agtagagaaa	acagagggtc	aagaagataa	agtaaagtgc	ccaagaacac	acaactgatc	17100

-continued

acaaatatca agcttgggggt ccattagcct aaccacagac ccttactctt aacctatctg	17160
cttcaatcca ttttgctaca aatgtttaca ttatatgcag ggcagaaaag tctcatccag	17220
tttattgaac taagaagaaa gttatattaa ggtgtctaata tttttttaat gtagttagaa	17280
acaaaactta acaatgagcc caagtttaa gcagtcata taacttgaca agctcaggca	17340
agtttcatct tgtggcctgt agcatcatct gtggtgtaaa gctaagtagc aaatgttatt	17400
tgnnnnnnnn nnnnngtca tctgggggg aaagtcaccc caatttgctc aagactgagg	17460
ggtttttcag gatcatcatg aaggataatt gggtaacaa ataacctgct tctttctctc	17520
atttcaaatt tatcatttat catctcagca actatgagtt atgtttttta ttagatttct	17580
tgttactttt tccccagacc gctccccatg aaattaatat actattatca ctctccagat	17640
acacaattgg aggagacgta atccagcatt ggaacttctg atcttcaagc agggattctc	17700
agcctgtggt ttgggggttc gtcagggtcg agcatgacca gaggaatgaa tgggcccgtg	17760
ggatgcatgc agtatgggac ttaaaaggcc caagcactga aaatggaacc tggcgaaagc	17820
agaggaggag aatgaagaaa aatggagttg aacagggagc gtggaggag accttgatac	17880
tttcaaatgc ctgaggggct catcggtgca tgtgacaggg agaaaggata cttctgaaca	17940
aggagcctcc aagcaaatca tccactgctc atcttaggaa aacgggttga gaatccctaa	18000
tttgagggtc agttcctgca gaagtgcctt ttgcctccac tcaatgcctc aatttgttt	18060
ctgctgact gagggtecca gtgttgaac agtatttatg tatgagattt tcctatttat	18120
tttgagtctg tgaggcttc ttgtcattgg agtgtggtg tgaatgattt cttttgaaga	18180
tatattgtag tagatgttac aattttgtcg ccaaaactaaa cttgatgctt aatgacttgc	18240
tcacatctag taaaacatgg agtatttga aggtgcttgg tctcctctat aactacaagt	18300
acacattgga agcataaaga tcaaacggtt gatttgtata ggatgtcacc tttatttaac	18360
ccattaatac tctgattgac ttaatcttat tctcagacct caagtgtctg tgcagtatct	18420
gttccattta aatatcagct ttataattat gtggtacat acacacataa tctcctttca	18480
tcgctgtaac caccctgttg tgatgaacc tattatttta cccattgtac agctgaggaa	18540
gaaaacagat taagtaactt gccaaaacca gtaaatagca gagctcagac tgccaccac	18600
tgtcctttta taatacaatt tacagctata ttttacttta agcaattcat ttattcaaaa	18660
ccatttatt aagtgcctt gcaatatcaa tcaactgtacc aggcattgaa tctacagatg	18720
tgagcaagag aaagtacctg tcctcaagga gcttgagta taataaggag attaataaga	18780
aaatatatta ttacaatcta gtcagatgct atagcataag gatgatgtga ggagaaaagc	18840
tgagcagtg tgccaagagg aggaaatagg ccaatgtggt ctgggacagt tgaatgtatt	18900
taaacatctt aataatcaaa gtaattttca tttacaaga gaagtcagta cttaaaataa	18960
cctgaaaaa taacactgga atccttttc tagcattata tttatcctg atttgcttt	19020
gccatacaat ctaatgcttg tttatatagt gtctgatatt gtttaacagt tctgtcttt	19080
ctattcaatg ctattaattt taaattcata cctttccatg annnnnnnnn nnnnngatcc	19140
catgggagat ggtttgaaaa tctccacttc atcctccaag ccattcaagt ttcctttcca	19200
gaagcaactg ctactgcctt ttattcatat gttcttctaa agatagtcta ctttggaaa	19260
tgtatgttaa aagcatatat ttttaattt ttttccctaa atagtaacac attatatgct	19320
tgctgtgcac tttgctatth ttatttattg tagtgtttct tatgtagcag atggaatgaa	19380

-continued

```

tttgaagctc ccaaaggcca ggacacatgc cttctttggt tetaagttat ctttcccata 19440
gcttttcata atctttcata tgatttagta catgttaaat atgtgctaca tatacattta 19500
gacaaccagc atttgtaag tatttgctct aggactgagt ttggatttat gtttgctcaa 19560
aaggagacc atgggctctc cagggcgac tgagtcaatc tagtccataa aagcaatctt 19620
attattaact ctgtatgaca gaatcatatc tggaaactttt gttttctgct ttctgtcaag 19680
tataaacttc actttgatgc tgtacttgca aaatcacatt ttctttctgg aaattccagt 19740
agtgtactct gactgctagt taccctgtgc cagaaaagcc tcattcgttg tgcttgaacc 19800
ctttaatgcc accagctgtc atcactacac aggcctccta agaggcttcc tggaggtttt 19860
gagattcaga tgccctgaga gatcccagag ttctctttcc ctcttgcca cattctggtg 19920
tcagtgacaa ggaatacctt cgctttgcca cccgtcaagg ttgaagaac agcgtctcca 19980
acagagctcc ttgtgtatc tgtttgtaca tgtgcatttg tacagtaatt tgtgtgacag 20040
tgctctttgt gtgaattaca ggaagaact gtggctgagc aaggcacata gtctactcag 20100
tctattccta actcctcctt ttgggttgg atttgtaagg cactttatcc cttttgtctc 20160
atgtttcatc gtaaatggca taggcagaga tgatatctaa ttctgcattt gattgtcact 20220
ttttgtacct gcattaatth aataaaatat ccttatttat tttgttactt ggtacaccag 20280
catgtccatt ttctgtttha ttttgtgtt cataaaatgc ttagtttaac atcccgggtg 20340

```

<210> SEQ ID NO 4

<211> LENGTH: 20641

<212> TYPE: DNA

<213> ORGANISM: mus musculus

<400> SEQUENCE: 4

```

gcctcatgcc aggetgcact tgcacgtcgc gggccagtct cctcgcctgc aggtaagga 60
gcatcttctc gcggaatccg cttgcagggc actttaaga gccagaatcc ctagaccttt 120
ttaggacgga gaagggaacc ggttctctgg gaaagttaag aactcagaat ccgcagtttt 180
gtgtgtttat ggatcttggt ggttaggtagc tgggtcagaa gagatgaatt aattggtcct 240
agcgcgactt gactgtttgc tagcaatgac tgggtcttcc cacttgaagc atctccggag 300
gtcccttctc ctgtcgaggt ctaggatgct ggagcttaag attttcattc tatctgccc 360
gagaacctaa aggatttttg gaagaaaatg tcccacacag ttcttagata cagtgcacta 420
ggctatgta aagtttaggt tggggtgtc ataagaggtg aaagtacaat attctatctt 480
tttttaaaaa taaattatta caggtgcttt cctatgaatt acttagccag tttttttta 540
attgctatat tccattgtgc tgggttatta aagggcatca ctctcccact gaggaatgca 600
caggttagta atagtgcctt actagctcag tcatccactg accatctgtg tatgtgactg 660
tctggaatat ggctaggat ttcattaga taaactctta tatgtataag tacttcatta 720
tgtttgagtg tctgaaaggc ctttgtgtag aaaaaaaaa aacaacaacc tgagaataca 780
ttccagaaag tatccgcagc tgatgatgat agtgaccaag cgggtgttaa ggagaacttt 840
atacagggaa aatattcacc tttcccagct gagcatcata gataggaaga catgatagtg 900
gttatatgct gctctaagga gggatggaga agggatggat ttgagcacag ggttcaggat 960
catttgatag aatttgaaaa ctgggtaaat tttcactctt ttgagaaagg aagtttgcat 1020
ctgcttcccc tcccccccc aggcactctt cccccccca tcccccccg tgccccccc 1080

```

-continued

ccccatggga agataaagaa gtggcgttcc aagatcttca tctggacttc cctggggaca	1140
aacctatttc cccatcttga atgagcgtca cttctttact ttaaactctg ttctgtgaaa	1200
ggctctcagc tcttgtctgg gaatttgtga aaggttacag tttcttgccg gagggagggga	1260
gaaggtgacc ctggactctt agcccatgta agaggtgcag gtttagaggt caaaggccat	1320
gctgatttac atggctcctg aatttcccct tttgatctac tgctcacacc tgcacctga	1380
gagccagggga ggggaggata tgatactgaa gaaggtgact atcagaccca acctatcacc	1440
tttcagactt tatactaagc tttaaagcag actcataagc aatagataac tgttccaact	1500
gagctgcca tcaacgtagg aaaaattagg tacagtcttc agtggatc atgtacctca	1560
ttgtgactgt ctagtactcg gcttgccat ttctcccagg gcctcattgc aacagtcaact	1620
gtgtcctcac aggcctggat gtcacctgc ctcactctgt tgggcagatg aactggagag	1680
atatgattaa taatgagtca tttgattttg ctctttttgt aaatgtcctt ggtttggttt	1740
ggtttgttta tttttgttt tgttgtgtt gtttgtttt attttcatgc tcttgttgtt	1800
gtttgagaca gagtctcact atgtagocca ggctagcctc tccccagc ctctcagatg	1860
ctgttgcatc tgcccctttc taacatcaat gattcataat aatcagcaag aaggctatga	1920
ccttaacagt caaaaataagt aatcaggtaa ttattgagag ctaaatattt atttaaaaa	1980
atcaagttgc atttttcaag aattgaatgg ggggatctaa aaagtaatgt ttgtgctgca	2040
caaagatgta gtggtatcag ttgccatagt ctttctcctt agatccgcag atctccttag	2100
ggaaatctat aattcaagcc taaacttga cctggtacac aactggtact cgcccaaca	2160
ttggccaagc acacacatat ttgtgactct gaaaaaaggg acaacacata acagcaaagg	2220
cgctccgtgt taggggctg ttaaatataa gacttgggga aattatgcca taatcttaca	2280
ttttaaaaat ggctattaca tgtgtgagac aacgggggct ggagagatac ctacagaggta	2340
ctaggcacac atatggcaag cagatgtaca agcaggcaaa acattcttaa aaaacaaaa	2400
caaaacccca aaacagatct ctttctatat tatttatatg gggttctgcc tgcgtgtaca	2460
cctgaagggc agaggagagc accaggtctc ataggtgggt ggttgaagc taccatattg	2520
ttgctaggaa ttaaactcag gactttggtg agagcagcca gtgctcttaa cctctgagcc	2580
atccctccag tcccagacaa aacactctta cacataaaat aaatcaatct ttaaaagtgt	2640
agaggaaaat ggctgaacag aaactattga cagacatgct gagagtggtc accgtttctc	2700
cagcttgcca ctggtggtgc tgtaggccat ctcagtgtct gtcacctgg ggcggggcgg	2760
ggggcgggag ggggggaagg cggcagggca gggctctggc agcatctcgg gcctctattt	2820
catcacatca gtaacagctc tccttcgtcc caagcaagct ttggcaacca aataaatatg	2880
ttagccaata ttaccaaacg gtccctagag gagaatgtgt gtaatgtgcc tacattcgtt	2940
tttataacaa caccaacaat atccaacat aaaaataaac tgaatggtc actctacctc	3000
agtgacaacg tctgagctcc gtttcagggt cctcacaag aaattcgata ggtgtaatga	3060
tttatttttc ctaataagta aaatgattat tcaactcattt gaaaattgga cacacacaca	3120
aaaaaatgaa gaaaaattt gctatttcat ctctcctttt ctatctcttt ccctttaaaa	3180
aaagtataaa tgtgggctaa agagatggct cagcagttaa gagcactggc tgctcttccg	3240
gaggtactga gttcaaacctg caccaaccac atgggtggctc acaacctct gtaatggat	3300
ctgatgcctt cttctggtgt gtctagagac agtgacagtg tactcacata cataaaataa	3360

-continued

gtaaaaaaaaa aaaaaacaaa actttttttt aagtataaat gtgtaagaac ttacctgtct	3420
tccctataaa agccacaatt acctttgcag ataatcactg tcaggcagtg tcttcaagag	3480
aagtgggggtt gttctacgac acaagaatat ttttgttat atactacct ctaagctcct	3540
tcctacttct ctgcaaacct atccccctg catatactga aatctatccg tcacggattt	3600
ttgagtatac acagttatcc gtcacgggat tttgagtata cacagtttta ttagctaata	3660
catgggggat ttcaagctg ggactggtt tggtgtgtc atctctgtta catatgactt	3720
atattttcta agatgaattt ccaagacagg aatagagaga tcatacgaca tgcacagtta	3780
aagttttaag agattacaaa attgaccttt aagaagctat acaatttcac atcctttcca	3840
ggaaaggtea agaaatccct gtatcttcac taatgctacc tatgaggagt ctgtaatttt	3900
ggtagagcag aaggtccaaa tggtatcaca gatcctccat ggactttctt atcgagagcg	3960
ttctttccgc ttttattgat tacccttga gctatgtgag actctcatcc gtcttctct	4020
tgaccgatgt atagttttct cactgagttc agaggctagg atgcagaage cgtcctcgtc	4080
agctttatc acctttcaga ttgactgtga atgagcacac aggtcagaga gacggtaagg	4140
gaagacctac tctccatga acgttgtaaa catgcgaata acacagaagc agaaaatgta	4200
aactattaga ctggctggaa tgtagcgtc acctttgagc ccactccttt agacaccggt	4260
ttcatggaag aatggctcct gtttcccacc tgctgcttca gcagtgcctc aaatagtgc	4320
agattcagag gagatactca gtgtttgccc agtgaattag gaaagtgtc agcggagggg	4380
acactagcat tcagacatcc agacctaga gtaaccgggc cagatggaag tctccttct	4440
tcccatagct gttaccactg tactgtcttt actggggaaa agatttatca tgtggaatag	4500
gtgcgaggca gaggtgagat tttaatgggg aggaagcatt gaaaagtga agtgaatatt	4560
ggatgctctt tgctttgaag ctttgcttaa agcaggtttt agctttcaaa tacgtttcaa	4620
tgttgaaaga acgcatgata catatggagg ggggcctggg gggggtcctt ggctgagttt	4680
gaatgtacat taacaatctg gggggctaata aactcaatgt aaagctgctg atcccatcat	4740
actgacttct tccacttgg ttctacatgg ctttgagtta caaaatgaaa gcattgaatt	4800
ttgaactgtt cagctgtgtt tccacacttg caaatcgggt gttggccagc cctcagaatt	4860
gcttcagtta cagctggctc gctctctct tccagactgg cttttagggc ttatgtatat	4920
atgagaagga cacatttact agtgtctcct tgctctgcta ttgaaattaa gcagacctct	4980
ctgtgtttcc cgttactaga tagttcccaa aacatgagga tatttgctgg catttatctc	5040
acagcctgct gtcacttgc acggggtaag tcaccaaact ttttcagtgg gttctatatt	5100
ttcaatattt tagctatgaa ttaaaaatgg aagtaatttg tgggggtgtg atgtgtgtgt	5160
atatgtgtgt gtagaggggg gctctgtgt atgtgcagtt gctaggcaca cataaagcgt	5220
tcataggaca acctagagct tagtctctc cttctacctt gtttgagaca aggtctctta	5280
tttgtgttac attgctgagt cctgtagttc ggctagctca gaacctcctg ggggctctcc	5340
tgctccacc tcccagtcca ctgagattgt aggcacatgc tactgcacct ggcttctacc	5400
tggtctctgg ggatttgaac ttgggtccat gggctacaca gcaagtcggt tacttactgg	5460
gcaatcactc catcccctaa gataattata aggaatatac cttgcttacc caaacacatt	5520
ctcattctcc tttgccataa ataagttact tggcaaatat attgtatgta tttttaataa	5580
ataaataaaa tcttaaaaat aaataaaatt atttgtgaag acaaaaaaaaa taagttactt	5640

-continued

ggaaaggatg aaggaaaata ctggagcttt ggggtgtggt tagtagtaga acacttggt	5700
gatgtaaaa aaaagcccta ggtgcaatcc caacaccaga aacaaatgaa ggaatgaaca	5760
acaaccgccc ccccccca ggggatgaat ataaaaatat caggtaatac agaactaaca	5820
ggtgatccgt ttcctatgaa taactactga acattcccag ggaggtggcc cactgataat	5880
atatttttat ttattgggtc cttttaaaca agactgggaa tatattatct agcttgcac	5940
accaccacca ccccccccc cgcgccatg aagttatttc aaagaagaat tttagtgtc	6000
atgtgatcc ctaaataaaa tgatagtaac cttttaccga ggttttcaga tgtgtttgga	6060
ggagttttct gtcttctgag ggtgtgtcct ctttctttt cagcgtttac tatcacggct	6120
ccaaaggact tgtacgtggt ggagtatgc agcaacgca cgatggagtg cagattccct	6180
gtagaacggg agctggacct gcttgcgta gtggtgtact gggaaaagga agatgagcaa	6240
gtgattcagt ttgtggcagg agaggaggac ctttaagcctc agcacagcaa cttcaggggg	6300
agagcctcgc tgccaaaagga ccagcttttg aagggaaatg ctgcccctca gatcacagac	6360
gtcaagctgc aggacgcagg cgtttactgc tgcataatca gctacgggtg tgcggactac	6420
aagcgaatca cgctgaaagt caatgtaag aattaccctg gatggggaag gcttcatccg	6480
tatttaaaac agctccctaa tgttgagagc tcttcattct tgagagtctg caccgacttc	6540
tcacagaaca acagcagcct gttcttctcg ctgctttgtt cattcgtctg ttcacacact	6600
tcaccagtga aaaagcctag cactgtgtgt ttgatagtaa cttgagattc agtaccagat	6660
aatactcagc catgctttgc agtcagtacc atgatcttc aaagggtgaaa tgccagggtg	6720
ttgtttctta tcataaatgc aatataat atattacata gatgtataga tataactgtg	6780
taacatgcaa taagatataa tatgcatata tttcatataa cataatgtat aatataat	6840
gtataataat atatactaca atatatagtt atatgcatag ttatatattg catttatgat	6900
aaaaagcaaa cacctggcat ttcacttttg caagcttttt gaattacttg taaatatata	6960
tacatgcaaa catacataca cacacatgtt tttttacaag taatttgaat gtcgatgaaa	7020
gaaatagaat cataaaaatg tccctcctcc ctaactacca tcttctaagc ataaatatac	7080
agtaactact atttgtacat cctccatga ctttttgatt ggattactgt ttatattdaa	7140
tctatcaggc ttagcacatt tcttctcct tgaatacctc catacaaaat tcaatgtgtg	7200
tttatatata tatgtatata tatagttata tcatatcata tatcatacaa agttttatat	7260
atgtatacat atataaacac acatatctac acatacatc acatttttta tatatataca	7320
caatatataa tgtatatgtg tgtgtgtgtg catatacctc tatatctatc tatctatcta	7380
tctatctatc tatctatcta tctatctatc tatagcttct actgtaaggg tcacttttta	7440
aaaaattaag gttaatctat gaaggatgag aagtgaagat ctttaagtga gaagaagccg	7500
ttcttcaca gagatggtac aggctacact cagcaggcat gcattcattt tcagggcctg	7560
catctctggg agtctgagg aggaactatg agtgaagtt cctgggtaac gagccacaga	7620
aatgtcatca ggtcccttga gttcacgggt ctgggttggga actaactaag ggaaggaaaa	7680
caccttgcta accaccctg ctttcaactgt tgggttgcac agacctgaga gcttcaactca	7740
tcgcaggcgt gcacacagcc agcccagttg cccaccagga ctggaaatcc ccaaggetct	7800
cctcttcaca tacctcccac agtgggtgcc ctccaatcag gtccccttctg tggctctgcg	7860
aaacttcacc ttgatggaca ctgagccgaa ccccgctctc tccaggcaga cgttgcagat	7920

-continued

ggtctgcctg	ctccttttcg	gttttcataa	taactttaa	actatttggc	tagaatcaga	7980
tagtctcctt	cgatcttttt	actcctaaac	tagtgtgaag	ctcaatatta	tacataggaa	8040
aaattcacat	tcctcataag	ggatcacggc	agttattaac	gcaatcttat	gtagagatta	8100
ggaaaaatgt	gtccattoga	cagtttatta	atgggtctgt	gatgggtggg	cgcttagagc	8160
ttatgaagat	gccacttgcc	ttatttcggg	gcttggtctt	aacttccatt	accttttact	8220
tacaattctt	catttgtgac	actcatgaaa	ggagactcgg	gatatggttg	ttaatatctt	8280
gagcagctgt	tagtacatca	gcaaatatga	ggctcctggt	tggttccaag	atttttaaag	8340
acattgtgaa	gctggaaggc	catgagcagt	caaagtgtct	ggacctgggg	cactggaagg	8400
agctcaaggc	gggcagtcag	gaagaaggga	gcagggtgta	agcctctgtg	acaagaggtc	8460
tctcatggct	tgtaggaggt	aggtgactct	ggtaaggagg	aatttactct	agattatgtg	8520
ctcagtgata	tctctgatac	caaagacaat	cttttgagc	gcacggcttc	tccacggagg	8580
gacctgtgat	gcgcaaaagc	tggtatocaa	gcagtcttga	aggcctgctt	gactattttg	8640
ttttcttaca	gaaatcacta	cgtcgatatt	ttactcccag	ttcaccttgc	catttgcattg	8700
cacgttagct	ggctagggc	aagagtctga	accttgggtg	tggctcaaat	ctgtaatctc	8760
agctatgtgg	gaagctgagg	caggagaatc	gcgcaattag	gacttgtctg	agctacgaac	8820
atatagcagg	ttcaagagca	gcctgggcaa	tttgcaaga	tccgttctca	aagacataca	8880
tacatacata	tatttggcaa	gatccgttct	caaagacata	catacataca	tacatttggc	8940
aagatccgtt	ctcaaagaca	tacatacatg	catgcatgca	taaatacatg	tataaatgaa	9000
tataaaatta	aaataggaac	aggactgagg	acatgccag	tgatgtacag	gaccctggtt	9060
tcagtttcta	gcaccatggg	cgctggcatg	caaaagcttt	ccatgtcaag	gaagtagaac	9120
tcctgaattc	tgtgctatgc	aaatgacttc	acagcaagggt	tccttcccat	cactgcaagt	9180
gtgtgggtgt	gaagcagccc	tacagggagt	tcactcgcca	tggggtttta	aaggatgaatt	9240
atttcaaac	tgaatctga	aagagtgtag	ttttggatta	actcagtttt	tattatctct	9300
ttggataatg	ttctaccttc	aaaggtttac	agaagaccct	caggcatcag	gcttttaatt	9360
gaaaaatatt	cagctttaat	cactgacctc	aatatcagaa	aagaatgaag	tgtccattta	9420
gtagtctctg	gaccgtagat	ggcattaagc	agctgtaaga	aacacgctca	tcacatgggt	9480
caacaattaa	ggattgccoat	gggtgcacccg	atccccagc	tctgtttaa	ccttttctct	9540
gtcatctatg	cctatctaag	atgtctcagc	atatcatgct	tattgtctct	ttccttctct	9600
tgaacacaag	ctctaggggt	aggggctttg	gtcagtttta	ttgttgacc	tggttgccct	9660
gacgtattat	gaaggggagc	tgttaataaga	aaagaaaacc	gtgtttgttg	atggaatggg	9720
ttaaaaaaa	attagcttaa	aatgtatgct	atacgaacgg	gcatgaatct	gggagatttt	9780
agactgttcc	ttgtgagccg	taggaacttt	cttgtttctg	tgttcacagt	cctccgcagc	9840
tgtgctcatg	gtcctccaca	tctgcctaac	aacagcaggg	gtagatgtta	taattaacac	9900
tcacagaaca	cctgatatgt	gagagggtgt	gccctgggct	tcttgtctcat	atgaattcat	9960
ttcatcttta	acataactct	tcgggggagg	cacttgccca	tgaccatggc	ttgttttctt	10020
tcctatcgac	tatctttcaa	atcggaatgt	gtctttccct	aggtgacatc	tcagattcaa	10080
tgttacacag	cactgctgtg	cccattttca	ggcattaaaa	atgcgatccg	cctaaattcc	10140
accccataa	aattatgcag	ccagggtcgg	aacccaacta	gcccattctct	aaaaatctat	10200

-continued

gcccttccta gcctcgcttt gttgcctgtc tttgtacctc tggagtggtt atcaaggaaac 10260
agaatggcctt taaacatgat ttgaactttt cctgggtttt gatcacagca gtaacagagt 10320
gttctagaga taagccagag gtttgaaaac aaacagaact tgtctttgag gtgttataaa 10380
catgtgtgtg attataaagg atatatctgg tgccaatagg tatagcttat attataagaa 10440
atggccattg tgaagatcag aaggagataa ctcaactgatt tcagggtggt gattcaatct 10500
aacacatgat atattctgaa actgtacaaa aaagatattc aaaagaagaa acacatggaa 10560
caaagagtat atggaaatc tgacaactca gaatcagtgt atgttaagat gaagtccatg 10620
attaacaaat ggagatggtc gcagtcattc tgaagcttat tttagccaat gctttatcac 10680
atccaactca atctctggtt ttttttttcc agatggatct tcccattttt aattaacctt 10740
atcatgatag cccctagtaa ggcagtctct gacatttctt ttcttttttt ttatagctta 10800
tgtttctttt tttaaaaatt tttttactac atattttctt caattacatt tccaatgcta 10860
tccccaaaagt ccccccatacc ctctctcccc actcccctac ccacccactc ccactttttg 10920
gccctggggt tcccctgtac tgggggatat aaagtctgcg tgtccaatgg gcctctcttt 10980
ccagtgatgg cctactaggc catcttttga tacatatgca gcttgagtca agagctccgg 11040
ggtaactggt agttcatagt gttgttccac ctatagggtt gcagatccct ttagttcctt 11100
gggtgcttcc tctagcttct ccattgggag ccctgtgatc catccaatag ctgactgtga 11160
gcateccatt ctgtgtttgc taggtcccgg ccaagtctca caagagacag ctatttcagg 11220
gtcctttcag catatgcttg ctagtgtatg caatgggtgc atcgtttgga ggctaattat 11280
gggatggctc cctggatatg gcagctctca aatgggtccat ccttttgtct cagctccaaa 11340
ctttgtctct gtaactcctt tcaatctctg tttttaatgt ccgaaaatga ctggtaacct 11400
cactgcttac atttcccttt gctttgtgtt gaattgtgag ctttatcttt gatctggagt 11460
ttctttaaga agactttgta atgtgcttat ttttaagat ggtgaattca attaaagata 11520
gacaagaggg acgggtctgt atttcatctg gttagagtgt tacctgccat tcatgaagt 11580
ctggttcgat ccccggcaca gcatagaacc acatcggtg gcaactcagt tgctgtgac 11640
cccagcactc aggagctaga ggcaggttac ctttgactac acagcaagtt caaggctagc 11700
ctggtctaca tgcaactcct cctcaaaggg aaaacaaaac aaaaatagac aggagaattg 11760
gaaacatcca tagaaacca aatgatgaa c aatagactcc cctcttctctg tgtcagacat 11820
tcagactcag tgacagccgt caccgtttat gaggcagtac tgattttaca gatcctagag 11880
caagcgtgca caattctggt gtttctctcc tgcgtcctca cacacacgct caccttaggg 11940
acggaggcag cggaggctca gtcagtttca gacgaatcca ctcatcagct gctcaccatg 12000
gtcttctagg tgaagcagaa ctctccttcc atcagcaccg gtgaaaaaca aaagtggaaa 12060
gcagatattt cactccgaat gctttatcat tggcagtgat ttcaaattta aaccactaat 12120
ttcccagaag aattagggtca cgggccatgt ggcattagac cctattgtgg tgacattatt 12180
tctgatgtg cctatttaat aatgatagat ggtctcatct ttatttagtt ggtcttgaat 12240
gtgataaata caagactggg caagtgttca tcaaagctgt tacttgaat tgtaattata 12300
cctattttgt tgggtggtgt ttttcttggg tcatggacaa ccaaacacat tacggctttg 12360
ctttgtctta gctactctgt gtaagttcc tgtgaaaata ccgtattaca gtgctcttat 12420
tacatcttgg gtaatgaagt agtcacctaa gccctatcc tgggctctct atggctcact 12480

-continued

aaagaatcgt	aagttggata	atgattgctg	aagaaataga	tatgttttat	ttacattgag	12540
gtagaaagac	ctgtggtttc	taggtaacag	tttacttaac	ttagttgcta	catctagttt	12600
gcactcagta	aacacctgg	tgtggttttt	acaacaacaa	ggttgttctc	gaagcccaaa	12660
catggcccag	atttgaatag	aagacctgag	gcagactaac	actcactccc	tgctgccaaa	12720
gtagcagagc	cggggacata	tttctccaat	agccagcccg	agttgatgct	ctttgtaagc	12780
agacaccaca	aagccacacg	gctagcccta	agatgggaga	gccctgacct	ctctttgctt	12840
ctgacctagc	cccataccgc	aaaatcaacc	agagaatttc	cgtggatcca	gccacttctg	12900
agcatgaact	aatatgtcag	gccgaggggt	atccagaagc	tgaggtaatc	tggaacaaac	12960
gtgaccacca	accctgagtg	gggaagagaa	gtgtcaccac	ttcccggaca	gaggggatgc	13020
ttctcaatgt	gaccagcagt	ctgaggggtc	acgccacagc	gaatgatggt	ttctactgta	13080
cgttttggag	atcacagcca	gggcaaaaac	acacagcggg	gctgatcatc	ccaggtgagt	13140
tgccaaactc	gtccccggat	tctagcacg	atggccatcc	gccatagtca	tttagcagta	13200
gttgcccgag	tgtatgaata	catgaaactt	acattggcta	gacgtattct	agttcctctt	13260
tctcttgctg	gcaagccata	atgctacttg	gtcaaacctc	agcaagaatt	aagtgtttgc	13320
tcttgacaga	cagtatgtta	gtcattgagt	atctgtgggt	ggataggaca	taagttactc	13380
tgctccagga	aacaggtgac	agtcgcatgt	aggagatgct	cttgtaactt	gggcaccacg	13440
ggcaacgtga	gagcaagcct	atgcttcagg	aatgtaaacc	tttgtcacat	caaagctgcc	13500
ctcttccctc	ccgggctgct	gtagttagaa	gcaaatgcat	tgcccttttt	tgtatcttat	13560
attcaacagg	aagaatcctt	tcttcccata	ctcctcttca	gggcattccc	tgatacttca	13620
actccaggaa	gtctgcctgt	gcatagaaca	cgaggctgat	gcctatgggc	aaccgactag	13680
ctgggttgta	actcaccagg	ccagggcatt	gtagggatag	aatgagctgc	acgaaaatga	13740
ttgtaggaaa	atcgtttgag	aattcagctg	tctttaaata	tcatttacct	tacagaaata	13800
gggccacagg	agacagtttg	gtgagaggct	cagagcatta	tatgaatatg	aaccagagg	13860
tactcactct	gaggaggggt	gcttctgct	ccatcgacac	ccctttccca	atgtatgtca	13920
acagtacatt	gatgtctaga	gatagctctg	tgaagtttag	agaagatata	taaaactaca	13980
ttaaaaagtc	aaccaatgat	aaaaatgaag	cccaggatgg	gcgtggagcc	aaaaggagca	14040
cacaagtttg	gaaaaatgta	aaataaaaag	gaagacactc	taactagaat	tggaactttc	14100
cataaaagct	atattgttgg	tttctacca	ttaaatgttt	tatggggctg	gagacgttgt	14160
agctcagttg	ggagagtact	tgccatgcat	ccacaatgct	ctgaccccag	cgccatataa	14220
acgtatatag	ggctcaccta	tagtctaaac	actttgggtg	tggaagccgg	agggtcagtt	14280
caaggtcatc	ctcagcttca	tagcaagttc	aaggccagta	tggactgact	acaagagacc	14340
ctgcctcaaa	gacaaaacaa	gcaaacatca	tcataataaa	acagcaaaaa	gctgttctct	14400
ggccatttct	ttgtaggaca	tctggagta	acttaaccac	tctgagtgtc	tcttctcatc	14460
tgtaacttgg	gttcatagtg	ggaccaata	ggagctgagt	tacaacagga	gatggaagtt	14520
agcaatctca	gagcatccca	gagccctggg	accatttttt	ctctttctca	aaactccagg	14580
cagagaaaca	gggagatggt	aatgactgga	gtgcccaga	gtctcagaca	tggaagaaac	14640
acaacccgca	ctggctcaca	tttgtgggag	acagaagcgg	cttagcagtg	ccccgctttc	14700
ccatgttcgg	gagttggcct	tccacaccaa	gtcagccatt	actgtctata	ttaatgagtg	14760

-continued

cacaaggaag	ttactgcact	aaggttacca	tttaatattg	cagtcacttt	ctgtggcaac	14820
atgtcacagg	cctggagttc	ttctctgtgc	tgctcccagt	ttcttaggag	atctgtcttc	14880
ttcttccaac	ccttacctgg	acattaactt	tcagtgatta	agattaccct	aagaccaaac	14940
tatatttcag	gagtcacat	tcccctgact	atggcgcagc	aaagccttac	cttccatcag	15000
cttctcttta	tccttttcca	gaactgctcg	caacacatcc	tccacagaac	aggactcact	15060
gggtgcttct	gggatccatc	ctgttgctcc	tcattgtagt	gtccacggtc	ctctctctct	15120
tgagaaaaaca	aggtatttcc	tccattgctg	tactgctgc	agggaaagtgc	atgagggctc	15180
cttcaccatt	gccttgagca	ggcagtgcca	gagatggtag	caccctgaca	agaacagacc	15240
cacatcacag	ggcgtcttac	actgcacgct	agctgaacct	caccaggaaa	cactgacttg	15300
aaagtgctg	ccctccattc	cctgggcttg	ctttcagtta	cacagagtaa	gttttaacag	15360
tgactctggt	gtactgagtc	ttccttaagt	cctgttcaca	ttgttctct	gcgacatctc	15420
ctaccttgga	gctcgggtgt	ggaccctgtt	gtaatatgaa	gaggtatcag	ttggacaagg	15480
gcgtagggaa	gctaaaagac	ttagctttca	aggcgtggg	gagggggagg	gcattgtgag	15540
gttccctgtt	cagcggttca	gagtaaagct	gggcagcaca	caagtttaga	caacaaggaa	15600
gatgctctaa	ctgggggttg	aggtcaatgg	tgacaggata	ggtagcaatg	gaggctaaaag	15660
aagaaagcca	taaggtttct	ttctacagac	tctgaagaca	gagcactgtg	gtgcctattg	15720
gtctcaggtg	aactcaagtc	ttgtgttct	tacaccacct	attgagctgg	gttctggata	15780
ccctaagtgg	aaaaaacact	ctgtctaaaa	agagctgtgg	catctttacc	acaaagcact	15840
tttttttttt	gcaagatttc	tgaagacgaa	atgacacagt	ttttaaata	atttccatat	15900
atattattca	gtacttacc	ataagaatga	ctgaaatcta	ggaaatgaa	tatattcaaa	15960
taatgccttc	ctattgtaaa	gtgacttaga	gtaaaacttt	tcaccaata	ctttgaaatg	16020
cataccaagt	gagccaatga	tgcatggact	tgtgtgaagc	caaatgggga	aatagaatat	16080
gggaggggaa	atcaatcatc	agagaggaat	tcccacac	ccttttgag	ggcgcgtgta	16140
tgggaaaagt	gttgtaactg	ggcggtagc	gaccagctgc	ttccaaagaa	taagccctga	16200
gcagaaccaa	gagggttgcc	agggtgtgaa	gattaagctt	cagagacaca	tctggcttag	16260
ggctagccta	ggacttgcac	aggaccgcag	ttgttgccta	atggcatctg	ggatgattgg	16320
ctgaggatga	ggaaagcaga	gagtcagtta	ggtgtaagc	tagctcagga	tgtgggacgt	16380
ttctgaggg	agggtggaag	acaaagtaga	cagtcctaaa	aaccatctga	gaatgaaagt	16440
atgtacccta	aattgttgaa	taattaactt	tgccgcgtgg	gatctggaat	aaggaagttc	16500
acgggctaaa	agcctggtga	ttaggggatt	gatcgggtgc	tcctaaaaac	cttaagttga	16560
aaatcgagtc	cctgtgggtt	gtagtagcat	cttgctataa	ggaattaaga	ttgatttctt	16620
cttctttagt	gagaatgcta	gatgtggaga	aatgtggcgt	tgaagataca	agctcaaaaa	16680
accgaaatgg	taagtgtgag	taacgaggga	ggggcaagcc	gagggaaatga	gtgggacaga	16740
gcagccaagc	agggtcctgc	aagggtgca	gttccagcgc	tctgtaggct	gaggcagggg	16800
gatagggagt	tccaggccag	caaccacaca	gccccaaaca	aacaaacaaa	acaaaaaaca	16860
aagcaaaagg	aagagcagaa	aaagctactg	ttaccaacaa	gagacatact	ttagccgtga	16920
tctctctctc	ttccaaaagga	agctgtttgt	ggggctgct	ggttctctg	cctaaggatc	16980
gccacatctg	agaaaactct	gggtttgctg	ctgcgggtgc	tgtgtggtag	ccctgcaacc	17040

-continued

agggacgctg ttgacttatt tgaatgggca tttgattaag caaatgattc tgctgtgtgg	17100
ttagctgtta actgtttcat gtgtatgata tggcatttca tttcatcatc ctgccccaa	17160
tcagataaat atgagaatca tctccattgt atagtaggga aaacagggct gagaagataa	17220
tgcgagggtgc ctaagaacac acagacttgc taccacagac gtccgttctt tgctagggtgc	17280
ttcaatctat gctgctacta atgtctgtat ttataagagt agaaaactct gcccgggcgt	17340
tggtggccca cgcctttaat cccagcactc gggaggcaga ggtagtcgga tttctgagtt	17400
tgaggccagc ctggtctaca gagtgagttc caggacagcc aggctacaca gagaaacct	17460
gtctcgaaaa aaatcaaaaa agaaaaaga acaagaaaac tctaactgaa ctatcttcta	17520
gtaaattaca gtgtgttcta attcatttta gtgtgttag aaaccaaaca gtaaggccag	17580
gcagaactaa agtggtttgc ctaacttggg cagacccaag caggttccct cctgtacatt	17640
accatttatt ctgctgagtc accctgagga accggcctgg cttgctcaag actgaggatt	17700
tctcagccat gaacactttc cattttaaaa ctagggcagt cccggacaag caaggatggt	17760
tagtcatcct tcatcatgta agggtagtca gacataggta gtatctgtct ctgtcttacg	17820
gcaacgttac tatctgtctc agcaaacatc ccatttgttt atcttacata tcatacgttt	17880
cccccccaca tattccttgc cctgtgaaa ttattatact atgatcactc tccagataca	17940
caattcgagg agacgtaagc agtgttgaac cctctgatcg tcgattggca gcttgtggtc	18000
tgtgaaagaa agggcccatg ggacatgagt ccaaagactc aagatggaac ctgagggaga	18060
gaaccaagaa agtgttggga gaggagcctg gaacaacgga catttttttc agggagacac	18120
tgctaagcaa gttgccatc agtctcttg ggaatggat tgagggttcc tggcttagca	18180
gctggtcctt gcacagtgc ctttctctc gctcagtgcc gggatgagag atggagtcat	18240
gagtggtgaa gaataagtgc cttctattta ttttgagtct gtgtgttctc actttgggca	18300
tgtaattatg actggtgaat tctgacgaca tgatagatct taagatgtag tcaccaaact	18360
caactgctgc ttagcatcct ccgtaactac tgatacaagc agggaacaca gaggtcacct	18420
gcttggtttg acaggctctt gctgtctgac tcaaataatc tttatttttc agtctcaag	18480
gctcttcgat agcagttgtt ctgtatcagc cttatagggt tcaggtatag cactcaacat	18540
ctcatctcat tacaatagca accctcatca ccatagcaac agctaacctc tgttatcctc	18600
acttcatagc caggaagctg agcagctaag tcaactgccc acagagtatc agctctcaga	18660
tttctgttct tcagccactg tccttccagg atagaatttg tcgttaagaa attaattdaa	18720
aaactgatta ttgagttagca ttgtatatca atcacaacat gccttgtgca ctgtgctggc	18780
ctctgagcat aaagatgtac gccggagtac cggtcggaca tgtttatgtg tgttaatac	18840
tcagagaaat gttcattaac aaggagcttg catttttagag aactggaaa gtaactccag	18900
ttcattgtct agcattacat ttacctcatt tgctatcctt gccatacagt ctcttgttct	18960
ccatgaagtg tcatgaatct tgttgaatag ttcttttatt ttttaaatgt ttctatttaa	19020
atgatattga catctgaggc gatagctcag ttggtaaaac cctttcctca caagtgtgaa	19080
accctgagtc ttatccttag aaccacata aaaaacagtt gcgtatgttt gtgcatgctt	19140
ttgatcccag cactagggag gcagaggcag gcagatcctg agctctcatt gaccaccag	19200
cctagcctac atggtttagct ccaggcctac aggagctggc agagcctgaa aaacgatgcc	19260
tagacacaca cacacacaca cacacacaca cacacacaca cacacacat gtactcatag	19320

-continued

```

acctaagtgc accctcctac acatgcacac acatacaatt caaacacaaa tcaacagggg 19380
attgtctcag aatgggtccc aagacaaaaga agaagaaaaa caccaaacca gctctattcc 19440
ctcagcctat cctctctact ccttctctaga agcaactact attgtttttg tatataaatt 19500
taccacaacga cagttaatat gtagaatata tattaagtg tctgtcaata tatattatct 19560
ctttctttct ttcttctctt ctttctttct ttcttctctt ctttctttct ttcttctctt 19620
ctttcttctt tccttctctt ctttcttctt tccttctctt ctttctttct ttcttctctt 19680
ttttctgtct atctgtaoct aaatgggtgc tcaactatgca ttttctgtgc tcttcgccct 19740
ttttatttaa tgtatggata tttatgctgc ttccagaatg gatctaaagc tctttgtttc 19800
taggttttct ccccatcctt tctaggcctc tctcacactg tctaggccag acaccatgct 19860
tgctgcctga atctgtagac accatttata aagcacgtac tcaccgagtt tgtatttggc 19920
ttgttctgtg tctgattaaa gggagaccat gagtccccag ggtacactga gttaccccag 19980
taccaagggg gagecctgtt tgtgtctcca tggcagaagc aggccctggag ccattttgtt 20040
ttcttctctg acttctctca aacacagacg cctcacttgc tcattacagg ttctcctttg 20100
ggaatgtcag cattgctcct tgactgctgg ctgccctgga aggagcccat tagctctgtg 20160
tgagcccttg acagctactg cctctcctta ccacaggggc ctetaagata ctggttaacta 20220
gaggtcctga ggatctgtgt tctctggggg gaggaaagga ggaggaacc agaactttct 20280
tacagtttct cttgttctgt cacatgtcaa gactgaagga acaggctggg ctacgtagtg 20340
agatcctgtc tcaaaggaaa gacgagcata gccgaacccc cgggtggaacc cctctgttta 20400
cctgttcaca caagcttatt gatgagtctc atgttaatgt cttgtttgta tgaagttaa 20460
gaaaatatcg ggttgggcaa cacattctat ttattcattt tatttgaat cttaatgcca 20520
tctcatggtg ttggattggt gtggcacttt attcttttgt gttgtgtata accataaatt 20580
ttattttgca tcagattgtc aatgtattgc attaatata taaatatttt tatttattaa 20640
a

```

20641

```

<210> SEQ ID NO 5
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

```

<400> SEQUENCE: 5

taattgctc tactgc

16

```

<210> SEQ ID NO 6
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

```

<400> SEQUENCE: 6

tcgcataaga atgact

16

```

<210> SEQ ID NO 7
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

```

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 7

tgaacacaca gtcgca 16

<210> SEQ ID NO 8
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 8

ctgaacacac agtcgc 16

<210> SEQ ID NO 9
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 9

tctgaacaca cagtcg 16

<210> SEQ ID NO 10
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 10

ttctgaacac acagtc 16

<210> SEQ ID NO 11
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 11

acaagtcatg ttacta 16

<210> SEQ ID NO 12
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 12

acacaagtca tgttac 16

<210> SEQ ID NO 13
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 13

-continued

cttacttaga tgctgc 16

<210> SEQ ID NO 14
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 14

acttacttag atgctg 16

<210> SEQ ID NO 15
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 15

gacttactta gatgct 16

<210> SEQ ID NO 16
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 16

agacttactt agatgc 16

<210> SEQ ID NO 17
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 17

gcaggaagag acttac 16

<210> SEQ ID NO 18
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 18

aataaattcc gttcagg 17

<210> SEQ ID NO 19
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 19

gcaaataaat tccggt 16

<210> SEQ ID NO 20

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 20

agcaataaaa ttccgt 16

<210> SEQ ID NO 21
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 21

cagagcaaat aaattcc 17

<210> SEQ ID NO 22
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 22

tggacagagc aaataaat 18

<210> SEQ ID NO 23
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 23

atggacagag caaata 16

<210> SEQ ID NO 24
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 24

cagaatggac agagca 16

<210> SEQ ID NO 25
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 25

ttctcagaat ggacag 16

<210> SEQ ID NO 26
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 26

ctgaactttg acatag 16

<210> SEQ ID NO 27
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 27

aagacaaaacc cagactga 18

<210> SEQ ID NO 28
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 28

tataagacaa acccagac 18

<210> SEQ ID NO 29
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 29

ttataagaca aaccgaga 18

<210> SEQ ID NO 30
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 30

tgttataaga caaaccc 17

<210> SEQ ID NO 31
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 31

tagaacaatg gtacttt 17

<210> SEQ ID NO 32
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 32

-continued

gtagaacaat ggtact 16

<210> SEQ ID NO 33
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 33

aggtagaaca atggta 16

<210> SEQ ID NO 34
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 34

aagaggtaga acaatgg 17

<210> SEQ ID NO 35
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 35

gcatccacag taaatt 16

<210> SEQ ID NO 36
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 36

gaaggttatt taattc 16

<210> SEQ ID NO 37
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 37

ctaatcgaat gcagca 16

<210> SEQ ID NO 38
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 38

taccaatct aatcga 16

<210> SEQ ID NO 39

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 39

tagttacca atctaa 16

<210> SEQ ID NO 40
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 40

catttagtta cccaat 16

<210> SEQ ID NO 41
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 41

tcatttagtt acccaa 16

<210> SEQ ID NO 42
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 42

ttcatttagt taccca 16

<210> SEQ ID NO 43
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 43

gaattaatth catttagt 18

<210> SEQ ID NO 44
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 44

cagtgaggaa ttaattt 17

<210> SEQ ID NO 45
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 45

ccaacagtga ggaatt 16

<210> SEQ ID NO 46
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 46

cccaacagtg aggaat 16

<210> SEQ ID NO 47
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 47

tatacccaac agtgagg 17

<210> SEQ ID NO 48
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 48

ttatacccaa cagtgag 17

<210> SEQ ID NO 49
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 49

tttataccca acagtga 17

<210> SEQ ID NO 50
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 50

cctttatacc caacag 16

<210> SEQ ID NO 51
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 51

-continued

taacctttat acccaa 16

<210> SEQ ID NO 52
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 52

aataaccttt ataccca 17

<210> SEQ ID NO 53
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 53

gtaaataacc tttata 16

<210> SEQ ID NO 54
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 54

actgtaaata acctttat 18

<210> SEQ ID NO 55
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 55

atatatatgc aatgag 16

<210> SEQ ID NO 56
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 56

agatatatat gcaatg 16

<210> SEQ ID NO 57
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 57

gagatatata tgcaat 16

<210> SEQ ID NO 58

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 58

ccagagatat atatgc 16

<210> SEQ ID NO 59
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 59

caatattcca gagatat 17

<210> SEQ ID NO 60
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 60

gcaatattcc agagata 17

<210> SEQ ID NO 61
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 61

agcaatattc cagagat 17

<210> SEQ ID NO 62
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 62

cagcaatatt ccagag 16

<210> SEQ ID NO 63
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 63

aatcagcaat attccag 17

<210> SEQ ID NO 64
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 64
acaatcagca atattcc 17

<210> SEQ ID NO 65
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 65
actaagtagt tacacttct 19

<210> SEQ ID NO 66
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 66
ctaagtagtt acacttc 17

<210> SEQ ID NO 67
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 67
gactaagtag ttacactt 18

<210> SEQ ID NO 68
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 68
tgactaagta gttaca 16

<210> SEQ ID NO 69
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 69
ctttgactaa gtagtta 17

<210> SEQ ID NO 70
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 70

-continued

ctctttgact aagtag 16

<210> SEQ ID NO 71
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 71

gctctttgac taagta 16

<210> SEQ ID NO 72
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 72

ccttaaatac tgttgac 17

<210> SEQ ID NO 73
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 73

cttaaatact gttgac 16

<210> SEQ ID NO 74
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 74

tccttaaata ctggtg 16

<210> SEQ ID NO 75
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 75

tctccttaaa tactggt 17

<210> SEQ ID NO 76
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 76

tatcatagtt ctcctt 16

<210> SEQ ID NO 77

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 77

agtatcatag ttctcc 16

<210> SEQ ID NO 78
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 78

gagtatcata gttctc 16

<210> SEQ ID NO 79
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 79

agagtatcat agttct 16

<210> SEQ ID NO 80
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 80

cagagtatca tagttc 16

<210> SEQ ID NO 81
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 81

ttcagagtat catagt 16

<210> SEQ ID NO 82
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 82

cttcagagta tcatag 16

<210> SEQ ID NO 83
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 83

ttcttcagag tatcata 17

<210> SEQ ID NO 84
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 84

tttcttcaga gtatcat 17

<210> SEQ ID NO 85
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 85

gagaaaggct aagttt 16

<210> SEQ ID NO 86
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 86

gacactcttg tacatt 16

<210> SEQ ID NO 87
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 87

tgagacactc ttgtaca 17

<210> SEQ ID NO 88
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 88

tgagacactc ttgtac 16

<210> SEQ ID NO 89
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 89

-continued

ctttattaaa ctccat 16

<210> SEQ ID NO 90
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 90

accaaacttt attaaa 16

<210> SEQ ID NO 91
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 91

aaacctctac taagtg 16

<210> SEQ ID NO 92
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 92

agattaagac agttga 16

<210> SEQ ID NO 93
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 93

aagtaggagc aagaggc 17

<210> SEQ ID NO 94
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 94

aaagtaggag caagagg 17

<210> SEQ ID NO 95
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 95

gttaagcagc caggag 16

<210> SEQ ID NO 96

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 96

agggtaggat gggtag 16

<210> SEQ ID NO 97
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 97

aaggtagga tgggta 16

<210> SEQ ID NO 98
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 98

caaggtagg atgggt 16

<210> SEQ ID NO 99
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 99

ccaaggtag gatggg 16

<210> SEQ ID NO 100
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 100

tccaaggta ggatgg 16

<210> SEQ ID NO 101
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 101

cttccaagg taggat 16

<210> SEQ ID NO 102
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 102

atcttccaag ggtagga 17

<210> SEQ ID NO 103
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 103

agaagtgatg gctcatt 17

<210> SEQ ID NO 104
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 104

aagaagtgat ggctcat 17

<210> SEQ ID NO 105
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 105

gaagaagtga tggtca 17

<210> SEQ ID NO 106
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 106

atgaaatgta aactggg 17

<210> SEQ ID NO 107
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 107

caatgaaatg taaactgg 18

<210> SEQ ID NO 108
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 108

-continued

gcaatgaaat gtaaactg 18

<210> SEQ ID NO 109
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 109

agcaatgaaa tgtaaact 18

<210> SEQ ID NO 110
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 110

gagcaatgaa atgtaaac 18

<210> SEQ ID NO 111
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 111

tgaattccca tatccga 17

<210> SEQ ID NO 112
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 112

agaattatga ccatat 16

<210> SEQ ID NO 113
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 113

aggtaagaat tatgacc 17

<210> SEQ ID NO 114
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 114

tcaggtaaga attatgac 18

<210> SEQ ID NO 115

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 115

cttcaggtaa gaattatg 18

<210> SEQ ID NO 116
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 116

tcttcaggta agaatta 17

<210> SEQ ID NO 117
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 117

cttcttcagg taagaat 17

<210> SEQ ID NO 118
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 118

tcttcttcag gtaagaa 17

<210> SEQ ID NO 119
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 119

tcttcttcag gtaaga 16

<210> SEQ ID NO 120
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 120

tggtctaaga gaagaag 17

<210> SEQ ID NO 121
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 121

g ttggtctaa gagaag 16

<210> SEQ ID NO 122
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 122

ag ttggtcta agagaa 16

<210> SEQ ID NO 123
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 123

ca gttggtct aagagaa 17

<210> SEQ ID NO 124
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 124

gc agttggtc taagagaa 18

<210> SEQ ID NO 125
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 125

ca gttggtct aagaga 16

<210> SEQ ID NO 126
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 126

gc agttggtc taagaga 17

<210> SEQ ID NO 127
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 127

-continued

gcagttggtc taagag 16

<210> SEQ ID NO 128
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 128

ctcatatcag ggcagt 16

<210> SEQ ID NO 129
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 129

cacacatggt ctttaac 17

<210> SEQ ID NO 130
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 130

taaatacaca catgttct 18

<210> SEQ ID NO 131
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 131

gtaaatacac acatgttc 18

<210> SEQ ID NO 132
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 132

tgtaaataca cacatggt 18

<210> SEQ ID NO 133
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 133

gatcatgtaa atacacac 18

<210> SEQ ID NO 134

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 134

agatcatgta aatacaca 18

<210> SEQ ID NO 135
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 135

caaagatcat gtaaatacac 20

<210> SEQ ID NO 136
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 136

acaaagatca tgtaaataca 20

<210> SEQ ID NO 137
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 137

gaatacaaaag atcatgta 18

<210> SEQ ID NO 138
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 138

agaatacaaaa gatcatgt 18

<210> SEQ ID NO 139
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 139

cagaatacaaa agatcatg 18

<210> SEQ ID NO 140
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 140

gcagaataca aagatca 17

<210> SEQ ID NO 141
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 141

aggcagaata caaagat 17

<210> SEQ ID NO 142
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 142

aaggcagaat acaaaga 17

<210> SEQ ID NO 143
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 143

attagtgagg gacgaa 16

<210> SEQ ID NO 144
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 144

cattagtgag ggacga 16

<210> SEQ ID NO 145
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 145

gagggtgatg gattag 16

<210> SEQ ID NO 146
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 146

-continued

ttaggagtaa taaagg 16

<210> SEQ ID NO 147
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 147

ttaatgaatt tggttg 16

<210> SEQ ID NO 148
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 148

ctttaatgaa tttggt 16

<210> SEQ ID NO 149
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 149

catggattac aactaa 16

<210> SEQ ID NO 150
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 150

tcatggatta caacta 16

<210> SEQ ID NO 151
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 151

gtcatggatt acaact 16

<210> SEQ ID NO 152
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 152

cattaaatct agtcat 16

<210> SEQ ID NO 153

-continued

<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 153

gacattaaat ctagtca 17

<210> SEQ ID NO 154
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 154

agggacatta aatcta 16

<210> SEQ ID NO 155
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 155

caaagcatta taacca 16

<210> SEQ ID NO 156
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 156

acttactagg cagaag 16

<210> SEQ ID NO 157
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 157

cagagttaac tgtaca 16

<210> SEQ ID NO 158
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 158

ccagagttaa ctgtac 16

<210> SEQ ID NO 159
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 159
gccagagtta actgta 16

<210> SEQ ID NO 160
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 160
tgggccagag ttaact 16

<210> SEQ ID NO 161
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 161
cagcatctat cagact 16

<210> SEQ ID NO 162
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 162
tgaaataaca tgagtcac 18

<210> SEQ ID NO 163
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 163
gtgaaataac atgagtc 17

<210> SEQ ID NO 164
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 164
tctgtttatg tcaactg 16

<210> SEQ ID NO 165
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 165

-continued

gtctgtttat gtcact 16

<210> SEQ ID NO 166
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 166

tggtctgttt atgtca 16

<210> SEQ ID NO 167
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 167

ttggtctgtt tatgtc 16

<210> SEQ ID NO 168
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 168

tcaccattg tttaaa 16

<210> SEQ ID NO 169
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 169

ttcagcaaat attcgt 16

<210> SEQ ID NO 170
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 170

gtgtgttcag caaatat 17

<210> SEQ ID NO 171
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 171

tctattgtta ggtatc 16

<210> SEQ ID NO 172

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 172

attgccatc ttactg 16

<210> SEQ ID NO 173
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 173

tattgccat cttact 16

<210> SEQ ID NO 174
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 174

aaatattgcc catctt 16

<210> SEQ ID NO 175
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 175

ataaccttat cataca 16

<210> SEQ ID NO 176
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 176

tataacctta tcatatc 16

<210> SEQ ID NO 177
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 177

ttataacctt atcata 16

<210> SEQ ID NO 178
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 178

tttataacct tatcat 16

<210> SEQ ID NO 179
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 179

actgctattg ctatct 16

<210> SEQ ID NO 180
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 180

aggactgcta ttgcta 16

<210> SEQ ID NO 181
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 181

gaggactgct attgct 16

<210> SEQ ID NO 182
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 182

acgtagaata ataaca 16

<210> SEQ ID NO 183
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 183

ccaagtgata taatgg 16

<210> SEQ ID NO 184
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 184

-continued

ttagcagacc aagtga 16

<210> SEQ ID NO 185
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 185

gtttagcaga ccaagt 16

<210> SEQ ID NO 186
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 186

tgacagtgat tatatt 16

<210> SEQ ID NO 187
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 187

tgtccaagat attgac 16

<210> SEQ ID NO 188
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 188

gaatadccta gattgt 16

<210> SEQ ID NO 189
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 189

caaactgaga atatcc 16

<210> SEQ ID NO 190
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 190

gcaaactgag aatatc 16

<210> SEQ ID NO 191

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 191

tcctattaca atcgta 16

<210> SEQ ID NO 192
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 192

ttcctattac aatcgt 16

<210> SEQ ID NO 193
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 193

actaatggga ggattt 16

<210> SEQ ID NO 194
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 194

tagttcagag aataag 16

<210> SEQ ID NO 195
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 195

taacatatag ttcaga 16

<210> SEQ ID NO 196
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 196

ataacatata gttcag 16

<210> SEQ ID NO 197
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 197
cataacatat agttca 16

<210> SEQ ID NO 198
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 198
tcataacata tagttc 16

<210> SEQ ID NO 199
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 199
tagctcctaa caatca 16

<210> SEQ ID NO 200
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 200
ctccaatctt tgtata 16

<210> SEQ ID NO 201
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 201
tctccaatct ttgtat 16

<210> SEQ ID NO 202
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 202
tctatttcag ccaatc 16

<210> SEQ ID NO 203
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 203

-continued

cggaagtcag agtgaa 16

<210> SEQ ID NO 204
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 204

ttaagcatga ggaata 16

<210> SEQ ID NO 205
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 205

tgattgagca cctctt 16

<210> SEQ ID NO 206
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 206

gactaattat ttcggt 16

<210> SEQ ID NO 207
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 207

tgactaatta ttcggt 16

<210> SEQ ID NO 208
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 208

gtgactaatt atttcg 16

<210> SEQ ID NO 209
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 209

ctgcttgaaa tgtgac 16

<210> SEQ ID NO 210

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 210

cctgcttgaa atgtga 16

<210> SEQ ID NO 211
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 211

atcctgcttg aaatgt 16

<210> SEQ ID NO 212
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 212

attataaatc tattct 16

<210> SEQ ID NO 213
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 213

gctaaatact ttcac 16

<210> SEQ ID NO 214
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 214

cattgtaaca taccta 16

<210> SEQ ID NO 215
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 215

gcattgtaac atacct 16

<210> SEQ ID NO 216
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 216

taatattgca ccaaat 16

<210> SEQ ID NO 217
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 217

gataatattg caccaa 16

<210> SEQ ID NO 218
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 218

agataatatt gcacca 16

<210> SEQ ID NO 219
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 219

gccagaaga taatat 16

<210> SEQ ID NO 220
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 220

cacagccaca taaact 16

<210> SEQ ID NO 221
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 221

ttgtaattgt ggaaac 16

<210> SEQ ID NO 222
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 222

-continued

tgacttgtaa ttgtgg 16

<210> SEQ ID NO 223
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 223

tctaactgaa atagtc 16

<210> SEQ ID NO 224
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 224

gtggttctaa ctgaaa 16

<210> SEQ ID NO 225
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 225

caatatggga cttggt 16

<210> SEQ ID NO 226
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 226

atgacaatat gggact 16

<210> SEQ ID NO 227
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 227

tatgacaata tgggac 16

<210> SEQ ID NO 228
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 228

atatgacaat atggga 16

<210> SEQ ID NO 229

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 229

cttcacttaa taatta 16

<210> SEQ ID NO 230
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 230

ctgcttcact taataa 16

<210> SEQ ID NO 231
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 231

aagactgctt cactta 16

<210> SEQ ID NO 232
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 232

gaatgcccta attatg 16

<210> SEQ ID NO 233
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 233

tggaatgccc taatta 16

<210> SEQ ID NO 234
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 234

gcaaagcca gtaggt 16

<210> SEQ ID NO 235
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 235

ctaataagaag gatttg 16

<210> SEQ ID NO 236
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 236

aatatagaac ctaatg 16

<210> SEQ ID NO 237
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 237

gaaagaatag aatggt 16

<210> SEQ ID NO 238
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 238

atgggtaata gattat 16

<210> SEQ ID NO 239
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 239

gaaagagcac aggggtg 16

<210> SEQ ID NO 240
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 240

ctacatagag ggaatg 16

<210> SEQ ID NO 241
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 241

-continued

gcttcctaca tagagg 16

<210> SEQ ID NO 242
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 242

tgcttcctac atagag 16

<210> SEQ ID NO 243
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 243

tgggcttgaa atatgt 16

<210> SEQ ID NO 244
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 244

cattatattt aagaac 16

<210> SEQ ID NO 245
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 245

tcggttatgt tatcat 16

<210> SEQ ID NO 246
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 246

cactttatct ggtcgg 16

<210> SEQ ID NO 247
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 247

aaattggcac agcggt 16

<210> SEQ ID NO 248

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 248

accgtgacag taaatg 16

<210> SEQ ID NO 249
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 249

tgggaaccgt gacagta 17

<210> SEQ ID NO 250
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 250

ccacatatag gtcctt 16

<210> SEQ ID NO 251
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 251

catattgcta ccatag 16

<210> SEQ ID NO 252
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 252

tcatattgct accata 16

<210> SEQ ID NO 253
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 253

caattgtcat attgct 16

<210> SEQ ID NO 254
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 254

cattcaattg tcatattg 18

<210> SEQ ID NO 255
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 255

tttctactgg gaatttg 17

<210> SEQ ID NO 256
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 256

caattagtgc agccag 16

<210> SEQ ID NO 257
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 257

gaataatggtt cttatcc 17

<210> SEQ ID NO 258
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 258

cacaaattga ataatgttct 20

<210> SEQ ID NO 259
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 259

catgcacaaa ttgaataat 19

<210> SEQ ID NO 260
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 260

-continued

atcctgcaat ttcacat 17

<210> SEQ ID NO 261
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 261

ccaccatagc tgatca 16

<210> SEQ ID NO 262
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 262

accacatag ctgatca 17

<210> SEQ ID NO 263
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 263

caccaccata gctgatc 17

<210> SEQ ID NO 264
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 264

tagtcggcac caccat 16

<210> SEQ ID NO 265
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 265

cttgtagtcg gcaccac 17

<210> SEQ ID NO 266
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 266

cttgtagtcg gcacca 16

<210> SEQ ID NO 267

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 267

cgctttagt cggcac 16

<210> SEQ ID NO 268
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 268

tcaataaaga tcaggc 16

<210> SEQ ID NO 269
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 269

tggacttaca agaatg 16

<210> SEQ ID NO 270
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 270

atggacttac aagaat 16

<210> SEQ ID NO 271
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 271

gctcaagaaa ttggat 16

<210> SEQ ID NO 272
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 272

tactgtagaa catggc 16

<210> SEQ ID NO 273
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 273

gcaattcatt tgatct 16

<210> SEQ ID NO 274
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 274

tgaaggagg aggacac 18

<210> SEQ ID NO 275
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 275

agtggtgaag ggaggag 17

<210> SEQ ID NO 276
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 276

tagtggtgaa gggaggag 18

<210> SEQ ID NO 277
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 277

atagtgtga agggaggag 19

<210> SEQ ID NO 278
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 278

tagtggtgaa gggagga 17

<210> SEQ ID NO 279
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 279

-continued

atagtgtga agggagga 18

<210> SEQ ID NO 280
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 280

tagtggtgaa gggagg 16

<210> SEQ ID NO 281
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 281

atagtgtga agggagg 17

<210> SEQ ID NO 282
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 282

gatagtgtg aaggagg 18

<210> SEQ ID NO 283
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 283

atagtgtga agggag 16

<210> SEQ ID NO 284
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 284

gatagtgtg aaggag 17

<210> SEQ ID NO 285
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 285

gagatagtgg tgaagg 16

<210> SEQ ID NO 286

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 286

catgggagat agtggt 16

<210> SEQ ID NO 287
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 287

acaaataatg gttactct 18

<210> SEQ ID NO 288
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 288

acacacaaat aatggtta 18

<210> SEQ ID NO 289
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 289

gaggacaca caaataat 18

<210> SEQ ID NO 290
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 290

atatagagag gctcaa 16

<210> SEQ ID NO 291
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 291

ttgatataga gaggct 16

<210> SEQ ID NO 292
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 292
gcatttgata tagaga 16

<210> SEQ ID NO 293
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 293
tttgattg atatag 16

<210> SEQ ID NO 294
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 294
ctggaagaat aggttc 16

<210> SEQ ID NO 295
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 295
actggaagaa taggtt 16

<210> SEQ ID NO 296
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 296
tactggaaga ataggt 16

<210> SEQ ID NO 297
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 297
tggcttatcc tgtact 16

<210> SEQ ID NO 298
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 298

-continued

atggcttatac ctgtac 16

<210> SEQ ID NO 299
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 299

tatggcttat cctgta 16

<210> SEQ ID NO 300
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 300

gtatggctta tcctgt 16

<210> SEQ ID NO 301
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 301

atgaatatat gcccgat 17

<210> SEQ ID NO 302
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 302

gatgaatata tgccca 16

<210> SEQ ID NO 303
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 303

caagatgaat atatgcc 17

<210> SEQ ID NO 304
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 304

gacaacatca gtataga 17

<210> SEQ ID NO 305

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 305

caagacaaca tcagta 16

<210> SEQ ID NO 306
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 306

cactcctagt tccttt 16

<210> SEQ ID NO 307
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 307

aacactccta gttcct 16

<210> SEQ ID NO 308
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 308

taacactcct agttcc 16

<210> SEQ ID NO 309
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 309

ctaacactcc tagttc 16

<210> SEQ ID NO 310
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 310

tgataacata actgtg 16

<210> SEQ ID NO 311
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 311
ctgataacat aactgt 16

<210> SEQ ID NO 312
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 312
tttgaactca agtgac 16

<210> SEQ ID NO 313
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 313
tcctttactt agctag 16

<210> SEQ ID NO 314
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 314
gagtttggat tagctg 16

<210> SEQ ID NO 315
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 315
tgggatatga cagggg 16

<210> SEQ ID NO 316
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 316
tgtgggatat gacagg 16

<210> SEQ ID NO 317
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 317

-continued

atatggaagg gatatc 16

<210> SEQ ID NO 318
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 318

acaggatatg gaaggg 16

<210> SEQ ID NO 319
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 319

attcaacag gatatgg 17

<210> SEQ ID NO 320
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 320

gagtaatttc aacagg 16

<210> SEQ ID NO 321
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 321

agggagtaat ttcaaca 17

<210> SEQ ID NO 322
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 322

attagggagt aatttca 17

<210> SEQ ID NO 323
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 323

cttactatta gggagt 16

<210> SEQ ID NO 324

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 324

cagcttacta ttaggg 16

<210> SEQ ID NO 325
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 325

tcagcttact attagg 16

<210> SEQ ID NO 326
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 326

atctcagctt actattag 18

<210> SEQ ID NO 327
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 327

ttcagcttac tattag 16

<210> SEQ ID NO 328
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 328

cagatttcag cttact 16

<210> SEQ ID NO 329
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 329

gactacaact agaggg 16

<210> SEQ ID NO 330
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 330

agactacaac tagagg 16

<210> SEQ ID NO 331
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 331

aagactacaa ctagag 16

<210> SEQ ID NO 332
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 332

atgatttaat tctagtcaaa 20

<210> SEQ ID NO 333
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 333

tttaattcta gtcaaa 16

<210> SEQ ID NO 334
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 334

gatttaattc tagtca 16

<210> SEQ ID NO 335
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 335

atgatttaat tctagtca 18

<210> SEQ ID NO 336
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 336

-continued

gatgatttaa ttctagtca 19

<210> SEQ ID NO 337
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 337

gatttaattc tagtca 16

<210> SEQ ID NO 338
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 338

gatgatttaa ttctagtc 18

<210> SEQ ID NO 339
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 339

tgatttaatt ctagtc 16

<210> SEQ ID NO 340
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 340

gagatgattt aattcta 17

<210> SEQ ID NO 341
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 341

gagatgattt aattct 16

<210> SEQ ID NO 342
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 342

cagattgatg gtagtt 16

<210> SEQ ID NO 343

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 343

ctcagattga tggtag 16

<210> SEQ ID NO 344
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 344

gtagccctc agattg 16

<210> SEQ ID NO 345
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 345

tgtattgtta gccctc 16

<210> SEQ ID NO 346
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 346

acttgattg ttagcc 16

<210> SEQ ID NO 347
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 347

agccagtatc agggac 16

<210> SEQ ID NO 348
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 348

ttgacaatag tggcat 16

<210> SEQ ID NO 349
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 349
acaagtggta tcttct 16

<210> SEQ ID NO 350
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 350
aatctacttt acaagt 16

<210> SEQ ID NO 351
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 351
cacagtagat gcctgata 18

<210> SEQ ID NO 352
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 352
gaacacagta gatgcc 16

<210> SEQ ID NO 353
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 353
cttggaacac agtagat 17

<210> SEQ ID NO 354
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 354
atatcttgga acacag 16

<210> SEQ ID NO 355
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 355

-continued

tctttaatat cttggaac 18

<210> SEQ ID NO 356
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 356

tgatttcttt aatatcttg 19

<210> SEQ ID NO 357
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 357

tgatgatttc ttaataatc 19

<210> SEQ ID NO 358
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 358

aggctaagtc atgatg 16

<210> SEQ ID NO 359
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 359

ttgatgaggc taagtc 16

<210> SEQ ID NO 360
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 360

ccaggattat actctt 16

<210> SEQ ID NO 361
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 361

gccaggatta tactct 16

<210> SEQ ID NO 362

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 362

ctgccaggat tatact 16

<210> SEQ ID NO 363
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 363

cagaaactta tactttatg 19

<210> SEQ ID NO 364
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 364

aagcagaaac ttatact 17

<210> SEQ ID NO 365
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 365

gaagcagaaa cttatact 18

<210> SEQ ID NO 366
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 366

tggaagcaga aacttatact 20

<210> SEQ ID NO 367
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 367

tggaagcaga aacttatac 19

<210> SEQ ID NO 368
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 368
aagcagaaac ttatac 16

<210> SEQ ID NO 369
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 369
tggaagcaga aacttata 18

<210> SEQ ID NO 370
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 370
aagggatatt atggag 16

<210> SEQ ID NO 371
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 371
tgccggaaga tttcct 16

<210> SEQ ID NO 372
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 372
atggattggg agtaga 16

<210> SEQ ID NO 373
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 373
agatggattg ggagta 16

<210> SEQ ID NO 374
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 374

-continued

aagatggatt gggagt 16

<210> SEQ ID NO 375
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 375

acaagatgga ttggga 16

<210> SEQ ID NO 376
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 376

agaaggttca gacttt 16

<210> SEQ ID NO 377
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 377

gcagaaggtt cagact 16

<210> SEQ ID NO 378
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 378

tgcagaaggt tcagac 16

<210> SEQ ID NO 379
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 379

agtcagaag gttcag 16

<210> SEQ ID NO 380
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 380

aagtcagaa ggttca 16

<210> SEQ ID NO 381

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 381

taagtcaga aggttc 16

<210> SEQ ID NO 382
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 382

tctaagtgca gaaggt 16

<210> SEQ ID NO 383
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 383

ctcaggagtt ctacttc 17

<210> SEQ ID NO 384
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 384

ctcaggagtt ctactt 16

<210> SEQ ID NO 385
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 385

atggaggtga ctcaggag 18

<210> SEQ ID NO 386
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 386

atggaggtga ctcagga 17

<210> SEQ ID NO 387
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 387
atggaggtga ctcagg 16

<210> SEQ ID NO 388
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 388
tatggaggtg actcagg 17

<210> SEQ ID NO 389
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 389
atatggaggt gactcagg 18

<210> SEQ ID NO 390
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 390
tatggaggtg actcag 16

<210> SEQ ID NO 391
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 391
atatggaggt gactcag 17

<210> SEQ ID NO 392
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 392
catatggagg tgactcag 18

<210> SEQ ID NO 393
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 393

-continued

atatggaggt gactca 16

<210> SEQ ID NO 394
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 394

catatggagg tgactca 17

<210> SEQ ID NO 395
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 395

catatggagg tgactc 16

<210> SEQ ID NO 396
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 396

gcatatggag gtgactc 17

<210> SEQ ID NO 397
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 397

tgcatatgga ggtgactc 18

<210> SEQ ID NO 398
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 398

ttgcatatgg aggtgactc 19

<210> SEQ ID NO 399
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 399

tttgcatatg gaggtgactc 20

<210> SEQ ID NO 400

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 400

gcatatggag gtgact 16

<210> SEQ ID NO 401
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 401

tgcatatgga ggtgact 17

<210> SEQ ID NO 402
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 402

ttgcatatgg aggtgact 18

<210> SEQ ID NO 403
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 403

tttgcataatg gaggtgact 19

<210> SEQ ID NO 404
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 404

tgcatatgga ggtgac 16

<210> SEQ ID NO 405
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 405

ttgcatatgg aggtgac 17

<210> SEQ ID NO 406
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 406
tttgcata_ggaggtgac 18

<210> SEQ ID NO 407
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 407
tttgcata_ggaggtga 17

<210> SEQ ID NO 408
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 408
tttgcata_ggaggtg 16

<210> SEQ ID NO 409
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 409
aagtgaagtt caacagc 17

<210> SEQ ID NO 410
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 410
tgggaagtga agttca 16

<210> SEQ ID NO 411
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 411
atgggaagtg aagttc 16

<210> SEQ ID NO 412
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 412

-continued

gatgggaagt gaagtt 16

<210> SEQ ID NO 413
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 413

ctgtgatggg aagtgaa 17

<210> SEQ ID NO 414
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 414

attgagtgaa tccaaa 16

<210> SEQ ID NO 415
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 415

aattgagtga atccaa 16

<210> SEQ ID NO 416
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 416

gataattgag tgaatcc 17

<210> SEQ ID NO 417
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 417

gtgataattg agtgaa 16

<210> SEQ ID NO 418
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 418

aagaaagggtg caataa 16

<210> SEQ ID NO 419

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 419

caagaaaggt gcaata 16

<210> SEQ ID NO 420
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 420

acaagaaagg tgcaat 16

<210> SEQ ID NO 421
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 421

atttaaactc acaaac 16

<210> SEQ ID NO 422
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 422

ctgtaggtt cagcga 16

<210> SEQ ID NO 423
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 423

tctgaatgaa catttcg 17

<210> SEQ ID NO 424
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 424

ctcattgaag gttctg 16

<210> SEQ ID NO 425
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 425
ctaattctcat tgaagg 16

<210> SEQ ID NO 426
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 426
cctaattctca ttgaag 16

<210> SEQ ID NO 427
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 427
actttgatct ttcagc 16

<210> SEQ ID NO 428
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 428
actatgcaac actttg 16

<210> SEQ ID NO 429
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 429
caaatagctt tatcgg 16

<210> SEQ ID NO 430
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 430
ccaaatagct ttatcg 16

<210> SEQ ID NO 431
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 431

-continued

tccaaatagc tttatc 16

<210> SEQ ID NO 432
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 432

gatccaaata gcttta 16

<210> SEQ ID NO 433
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 433

atgatccaaa tagctt 16

<210> SEQ ID NO 434
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 434

tatgatccaa atagct 16

<210> SEQ ID NO 435
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 435

taaacagggc tgggaat 17

<210> SEQ ID NO 436
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 436

acttaaacag ggctgg 16

<210> SEQ ID NO 437
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 437

acacttaaac agggct 16

<210> SEQ ID NO 438

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 438

gaacacttaa acaggg 16

<210> SEQ ID NO 439
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 439

agagaacact taaacag 17

<210> SEQ ID NO 440
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 440

ctacagagaa cactta 16

<210> SEQ ID NO 441
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 441

atgctacaga gaacact 17

<210> SEQ ID NO 442
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 442

ataaatgcta cagagaaca 19

<210> SEQ ID NO 443
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 443

agataaatgc tacagaga 18

<210> SEQ ID NO 444
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 444
tagagataaa tgctaca 17

<210> SEQ ID NO 445
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 445
tagatagaga taaatgct 18

<210> SEQ ID NO 446
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 446
caatatacta gatagaga 18

<210> SEQ ID NO 447
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 447
tacacaatat actagatag 19

<210> SEQ ID NO 448
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 448
ctacacaata tactag 16

<210> SEQ ID NO 449
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 449
gctacacaat atacta 16

<210> SEQ ID NO 450
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 450

-continued

atatgctaca caatatac 18

<210> SEQ ID NO 451
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 451

tgatagctca cacaat 16

<210> SEQ ID NO 452
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 452

atgatatgat atgctac 17

<210> SEQ ID NO 453
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 453

gaggagagag acaataaa 18

<210> SEQ ID NO 454
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 454

ctaggaggag agagaca 17

<210> SEQ ID NO 455
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 455

tattctagga ggagaga 17

<210> SEQ ID NO 456
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 456

ttatattcta ggaggag 17

<210> SEQ ID NO 457

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 457

gtttatattc taggag 16

<210> SEQ ID NO 458
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 458

tggagtattat attctagg 18

<210> SEQ ID NO 459
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 459

cgtaccacca ctctgc 16

<210> SEQ ID NO 460
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 460

tgaggaaatc attcattc 18

<210> SEQ ID NO 461
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 461

tttgaggaaa tcattcat 18

<210> SEQ ID NO 462
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 462

aggctaattcc tattttg 16

<210> SEQ ID NO 463
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 463

ttaggctaa tcctat 16

<210> SEQ ID NO 464
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 464

tgctccagtg tacctt 16

<210> SEQ ID NO 465
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 465

tagtagtact cgatag 16

<210> SEQ ID NO 466
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 466

ctaattgtag tagtactc 18

<210> SEQ ID NO 467
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 467

tgctaattgt agtagt 16

<210> SEQ ID NO 468
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 468

agtgctaatt gtagta 16

<210> SEQ ID NO 469
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 469

-continued

gcaagtgcta attgta 16

<210> SEQ ID NO 470
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 470

gaggaaatga actaattta 19

<210> SEQ ID NO 471
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 471

caggaggaaa tgaacta 17

<210> SEQ ID NO 472
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 472

ccctagagtc atttcc 16

<210> SEQ ID NO 473
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 473

atcttcatg atgaagc 17

<210> SEQ ID NO 474
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 474

gacacactca gatttcag 18

<210> SEQ ID NO 475
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 475

agacacactc agatttcag 19

<210> SEQ ID NO 476

-continued

<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 476

aagacacact cagatttcag 20

<210> SEQ ID NO 477
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 477

agacacactc agatttca 18

<210> SEQ ID NO 478
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 478

aagacacact cagatttca 19

<210> SEQ ID NO 479
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 479

aaagacacac tcagatttca 20

<210> SEQ ID NO 480
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 480

gaaagacaca ctcagatttc 20

<210> SEQ ID NO 481
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 481

aagacacact cagatttc 18

<210> SEQ ID NO 482
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 482
aaagacacac tcagatttc 19

<210> SEQ ID NO 483
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 483
tgaaagacac actcagattt 20

<210> SEQ ID NO 484
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 484
tgaaagacac actcagatt 19

<210> SEQ ID NO 485
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 485
tgaaagacac actcagat 18

<210> SEQ ID NO 486
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 486
attgaaagac acactca 17

<210> SEQ ID NO 487
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 487
tcattgaaag acacact 17

<210> SEQ ID NO 488
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 488

-continued

ttccatcatt gaaaga 16

<210> SEQ ID NO 489
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 489

ataataccac ttatcat 17

<210> SEQ ID NO 490
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 490

ttacttaatt tctttgga 18

<210> SEQ ID NO 491
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 491

ttagaactag ctttatca 18

<210> SEQ ID NO 492
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 492

gaggtacaaa tatagg 16

<210> SEQ ID NO 493
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 493

cttatgatac aactta 16

<210> SEQ ID NO 494
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 494

tcttatgata caactt 16

<210> SEQ ID NO 495

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 495

ttcttatgat acaact 16

<210> SEQ ID NO 496
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 496

cagtttctta tgatag 16

<210> SEQ ID NO 497
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 497

gcagtttctt atgata 16

<210> SEQ ID NO 498
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 498

tacaaatgtc tattaggtt 19

<210> SEQ ID NO 499
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 499

tgtacaaaatg tctattag 18

<210> SEQ ID NO 500
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 500

agcatcaciaa ttagta 16

<210> SEQ ID NO 501
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 501

ctaatgatag tgaagc 16

<210> SEQ ID NO 502
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 502

agctaatgat agtgaa 16

<210> SEQ ID NO 503
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 503

atgccttgac atatta 16

<210> SEQ ID NO 504
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 504

ctcaagatta ttgacac 17

<210> SEQ ID NO 505
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 505

acctcaagat tattga 16

<210> SEQ ID NO 506
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 506

aacctcaaga ttattg 16

<210> SEQ ID NO 507
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 507

-continued

cacaaacctc aagattatt 19

<210> SEQ ID NO 508
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 508

gtacttaatt agacct 16

<210> SEQ ID NO 509
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 509

agtacttaat tagacc 16

<210> SEQ ID NO 510
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 510

gtatgagggtg gtaaac 16

<210> SEQ ID NO 511
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 511

aggaaacagc agaagtg 17

<210> SEQ ID NO 512
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 512

gcacaacca gagga 16

<210> SEQ ID NO 513
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 513

caagcacaac ccagag 16

<210> SEQ ID NO 514

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 514

ttcaagcaca acccag 16

<210> SEQ ID NO 515
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 515

aattcaagca caacc 16

<210> SEQ ID NO 516
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 516

taataattca agcacaacc 19

<210> SEQ ID NO 517
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 517

actaataatt caagcac 17

<210> SEQ ID NO 518
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 518

ataatactaa taattcaagc 20

<210> SEQ ID NO 519
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 519

tagatttggtg aggtaa 16

<210> SEQ ID NO 520
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 520

agccttaatt ctccat 16

<210> SEQ ID NO 521
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 521

aatgatctag agcctta 17

<210> SEQ ID NO 522
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 522

ctaatgatct agagcc 16

<210> SEQ ID NO 523
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 523

actaatgatc tagagc 16

<210> SEQ ID NO 524
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 524

cattaacatg ttcttatt 18

<210> SEQ ID NO 525
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 525

acaagtacat taacatgttc 20

<210> SEQ ID NO 526
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 526

-continued

ttacaagtac attaacatg 19

<210> SEQ ID NO 527
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 527

gctttattca tgtttat 17

<210> SEQ ID NO 528
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 528

gctttattca tgttta 16

<210> SEQ ID NO 529
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 529

agagctttat tcatgttt 18

<210> SEQ ID NO 530
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 530

ataagagctt tattcatg 18

<210> SEQ ID NO 531
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 531

cataagagct ttattca 17

<210> SEQ ID NO 532
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 532

agcataagag ctttat 16

<210> SEQ ID NO 533

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 533

tagattgttt agtgca 16

<210> SEQ ID NO 534
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 534

gtagattggt tagtgc 16

<210> SEQ ID NO 535
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 535

gacaattcta gtagatt 17

<210> SEQ ID NO 536
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 536

ctgacaattc tagtag 16

<210> SEQ ID NO 537
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 537

gctgacaatt ctagta 16

<210> SEQ ID NO 538
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 538

aggattaaga tacgta 16

<210> SEQ ID NO 539
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 539
caggattaag atacgt 16

<210> SEQ ID NO 540
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 540
tcaggattaa gatacg 16

<210> SEQ ID NO 541
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 541
ttcaggatta agatac 16

<210> SEQ ID NO 542
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 542
aggaagaaag tttgattc 18

<210> SEQ ID NO 543
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 543
tcaaggaaga aagtttga 18

<210> SEQ ID NO 544
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 544
ctcaaggaag aaagtttg 18

<210> SEQ ID NO 545
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 545

-continued

tgctcaagga agaaagt 17

<210> SEQ ID NO 546
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 546

aattatgctc aaggaaga 18

<210> SEQ ID NO 547
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 547

taggatacca cattatga 18

<210> SEQ ID NO 548
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 548

cataatttat tccattcctc 20

<210> SEQ ID NO 549
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 549

tgcataattt attccat 17

<210> SEQ ID NO 550
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 550

actgcataat ttattcc 17

<210> SEQ ID NO 551
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 551

ctaaactgca taatttatt 19

<210> SEQ ID NO 552

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 552

ataactaaac tgcata 16

<210> SEQ ID NO 553
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 553

ttattaataa ctaaactgc 19

<210> SEQ ID NO 554
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 554

tagtacatta ttaataact 19

<210> SEQ ID NO 555
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 555

cataactaag gacggt 16

<210> SEQ ID NO 556
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 556

tcataactaa ggacgt 16

<210> SEQ ID NO 557
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 557

cgtcataact aaggac 16

<210> SEQ ID NO 558
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 558

tcgtcataac taagga 16

<210> SEQ ID NO 559
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 559

atcgtcataa ctaagg 16

<210> SEQ ID NO 560
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 560

gttagtatct tacatt 16

<210> SEQ ID NO 561
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 561

ctctattggt agtatac 16

<210> SEQ ID NO 562
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 562

agtatagagt tactgt 16

<210> SEQ ID NO 563
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 563

ttcctggtga tacttt 16

<210> SEQ ID NO 564
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 564

-continued

gttcctggtg atactt 16

<210> SEQ ID NO 565
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 565

tgttcctggt gatact 16

<210> SEQ ID NO 566
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 566

ataaacatga atctctcc 18

<210> SEQ ID NO 567
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 567

ctttataaac atgaatctc 19

<210> SEQ ID NO 568
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 568

ctgtctttat aaacatg 17

<210> SEQ ID NO 569
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 569

ttggtataaaa tctgtctt 18

<210> SEQ ID NO 570
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 570

ttaaatttat tcttgata 19

<210> SEQ ID NO 571

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 571

cttaaattta ttcttgga 18

<210> SEQ ID NO 572
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 572

cttcttaaat ttattcttg 19

<210> SEQ ID NO 573
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 573

tatgtttctc agtaaag 17

<210> SEQ ID NO 574
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 574

gaattatctt taaacca 17

<210> SEQ ID NO 575
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 575

cccttaaatt tctaca 16

<210> SEQ ID NO 576
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 576

acaactgctct tgtacc 16

<210> SEQ ID NO 577
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 577
tgacaacact gctctt 16

<210> SEQ ID NO 578
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 578
tacatttatt gggctc 16

<210> SEQ ID NO 579
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 579
gtacatttat tgggct 16

<210> SEQ ID NO 580
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 580
ttggtacatt tattgg 16

<210> SEQ ID NO 581
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 581
catgttgga catttat 17

<210> SEQ ID NO 582
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 582
aatcatgttg gtacat 16

<210> SEQ ID NO 583
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 583

-continued

aaatcatggt ggtaca 16

<210> SEQ ID NO 584
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 584

gacaagtttg gattaa 16

<210> SEQ ID NO 585
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 585

aatgttcaga tgcctc 16

<210> SEQ ID NO 586
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 586

gcttaatggt cagatg 16

<210> SEQ ID NO 587
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 587

cgtacatagc ttgatg 16

<210> SEQ ID NO 588
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 588

gtgaggaatt aggata 16

<210> SEQ ID NO 589
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 589

gtaacaatat ggtttg 16

<210> SEQ ID NO 590

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 590

gaaatattgt agacta 16

<210> SEQ ID NO 591
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 591

ttgaaatatt gtagac 16

<210> SEQ ID NO 592
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 592

aagtctagta atttgc 16

<210> SEQ ID NO 593
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 593

gctcagtaga ttataa 16

<210> SEQ ID NO 594
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 594

catacactgt tgctaa 16

<210> SEQ ID NO 595
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 595

atggtctcaa atcatt 16

<210> SEQ ID NO 596
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 596
caatggtctc aaatca 16

<210> SEQ ID NO 597
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 597
ttcctattga ttgact 16

<210> SEQ ID NO 598
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 598
tttctgttca caacac 16

<210> SEQ ID NO 599
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 599
aggaaccac taatct 16

<210> SEQ ID NO 600
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 600
taaatggcag gaacc 16

<210> SEQ ID NO 601
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 601
gtaaatggca ggaacc 16

<210> SEQ ID NO 602
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 602

-continued

ttgtaaatgg caggaa 16

<210> SEQ ID NO 603
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 603

ttatgagtta ggcatg 16

<210> SEQ ID NO 604
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 604

ccagtgaaa ctttaa 16

<210> SEQ ID NO 605
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 605

cccttagtca gctcct 16

<210> SEQ ID NO 606
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 606

acccttagtc agctcc 16

<210> SEQ ID NO 607
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 607

cacccttagt cagctc 16

<210> SEQ ID NO 608
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 608

tctcttacta ggctcc 16

<210> SEQ ID NO 609

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 609

cctatctgtc atcatg 16

<210> SEQ ID NO 610
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 610

tcctatctgt catcat 16

<210> SEQ ID NO 611
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 611

gagaagtgag agaagc 16

<210> SEQ ID NO 612
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 612

catcctgaa gtttag 16

<210> SEQ ID NO 613
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 613

taataagatg gctccc 16

<210> SEQ ID NO 614
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 614

caaggcataa taagat 16

<210> SEQ ID NO 615
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 615

ccaaggcata ataaga 16

<210> SEQ ID NO 616
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 616

tgatccaatt ctcacc 16

<210> SEQ ID NO 617
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 617

atgatccaat tctcac 16

<210> SEQ ID NO 618
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 618

cgcttcatct tcaccc 16

<210> SEQ ID NO 619
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 619

tatgacactg catctt 16

<210> SEQ ID NO 620
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 620

gtatgacact gcatct 16

<210> SEQ ID NO 621
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 621

-continued

tgtatgacac tgcac 16

<210> SEQ ID NO 622
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 622

ttctcttctg taagtc 16

<210> SEQ ID NO 623
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 623

ttctacagag gaacta 16

<210> SEQ ID NO 624
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 624

actacagttc tacaga 16

<210> SEQ ID NO 625
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 625

ttcccacagg taaatg 16

<210> SEQ ID NO 626
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 626

attatttgaa tatactcatt 20

<210> SEQ ID NO 627
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 627

tgggaggaaa ttatttg 17

<210> SEQ ID NO 628

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 628

tgactcatct taaatg 16

<210> SEQ ID NO 629
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 629

ctgactcatc ttaaat 16

<210> SEQ ID NO 630
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 630

tttactctga ctcatc 16

<210> SEQ ID NO 631
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 631

tattggagga attatt 16

<210> SEQ ID NO 632
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 632

gtattggagg aattat 16

<210> SEQ ID NO 633
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 633

tggatactt ctctaagtat 20

<210> SEQ ID NO 634
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 634
gatctcttgg tatact 16

<210> SEQ ID NO 635
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 635
cagacaactc tatacc 16

<210> SEQ ID NO 636
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 636
aacatcagac aactcta 17

<210> SEQ ID NO 637
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 637
tttaacatca gacaactc 18

<210> SEQ ID NO 638
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 638
taacatcaga caactc 16

<210> SEQ ID NO 639
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 639
atttaacatc agacaa 16

<210> SEQ ID NO 640
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 640

-continued

cctatttaac atcagac 17

<210> SEQ ID NO 641
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 641

tccctattta acatca 16

<210> SEQ ID NO 642
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 642

tcaacgacta ttggaat 17

<210> SEQ ID NO 643
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 643

cttatattct ggctat 16

<210> SEQ ID NO 644
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 644

atccttatat tctggc 16

<210> SEQ ID NO 645
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 645

gatccttata ttctgg 16

<210> SEQ ID NO 646
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 646

tgatccttat attctg 16

<210> SEQ ID NO 647

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 647

attgaaactt gatcct 16

<210> SEQ ID NO 648
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 648

actgtcattg aaactt 16

<210> SEQ ID NO 649
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 649

tcttactgtc attgaa 16

<210> SEQ ID NO 650
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 650

aggatccttac tgcatt 17

<210> SEQ ID NO 651
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 651

gcaaatcaac tccatc 16

<210> SEQ ID NO 652
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 652

gtgcaaatca actcca 16

<210> SEQ ID NO 653
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 653

caattatttc tttgtgc 17

<210> SEQ ID NO 654
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 654

tggcaacaat tatttctt 18

<210> SEQ ID NO 655
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 655

gctggcaaca attatt 16

<210> SEQ ID NO 656
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 656

atccatttct actgcc 16

<210> SEQ ID NO 657
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 657

taatattctat tgatttcta 19

<210> SEQ ID NO 658
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 658

tcaatagtgt agggca 16

<210> SEQ ID NO 659
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 659

-continued

ttcaatagtg tagggc 16

<210> SEQ ID NO 660
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 660

aggttaatta attcaatag 19

<210> SEQ ID NO 661
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 661

catttgtaat ccctag 16

<210> SEQ ID NO 662
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 662

acatttgtaa tcccta 16

<210> SEQ ID NO 663
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 663

aacatttgta atccct 16

<210> SEQ ID NO 664
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 664

taaatttcaa gttctg 16

<210> SEQ ID NO 665
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 665

gtttaaattt caagttct 18

<210> SEQ ID NO 666

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 666

ccaagttaa atttcaag 18

<210> SEQ ID NO 667
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 667

accaagttt aaatttc 17

<210> SEQ ID NO 668
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 668

catacagtga cccaagttt 19

<210> SEQ ID NO 669
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 669

acatcccata cagtga 16

<210> SEQ ID NO 670
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 670

agcacagctc tacatc 16

<210> SEQ ID NO 671
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 671

atatagcaca gctcta 16

<210> SEQ ID NO 672
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 672
tccatatagc acagct 16

<210> SEQ ID NO 673
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 673
atttccatat agcaca 16

<210> SEQ ID NO 674
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 674
tttatttcca ttagca 17

<210> SEQ ID NO 675
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 675
tttatttcca ttagc 16

<210> SEQ ID NO 676
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 676
aaggagagga gattatg 17

<210> SEQ ID NO 677
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 677
agttcttggtg ttagct 16

<210> SEQ ID NO 678
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 678

-continued

gagttcttgt gttagc 16

<210> SEQ ID NO 679
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 679

attaattatc catccac 17

<210> SEQ ID NO 680
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 680

atcaattaat tatccatc 18

<210> SEQ ID NO 681
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 681

agaatcaatt aattatcc 18

<210> SEQ ID NO 682
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 682

tgagataccg tgcacg 16

<210> SEQ ID NO 683
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 683

aatgagatag cgtgca 16

<210> SEQ ID NO 684
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 684

ctgtggtag gctaat 16

<210> SEQ ID NO 685

-continued

<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 685

aagagtaagg gtctgtggtt 20

<210> SEQ ID NO 686
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 686

gatgggtaa gagtaa 16

<210> SEQ ID NO 687
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 687

agcagatggg ttaaga 16

<210> SEQ ID NO 688
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 688

tgtaaacatt tgtagc 16

<210> SEQ ID NO 689
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 689

cctgcttata aatgta 16

<210> SEQ ID NO 690
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 690

tgccctgctt ataaat 16

<210> SEQ ID NO 691
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 691

tcttcttagt tcaata 16

<210> SEQ ID NO 692
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 692

tggtttctaa ctacat 16

<210> SEQ ID NO 693
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 693

agtttggttt ctaacta 17

<210> SEQ ID NO 694
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 694

gaatgaaact tgcttg 16

<210> SEQ ID NO 695
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 695

attatcctta catgat 16

<210> SEQ ID NO 696
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 696

gtaccaatt atcctt 16

<210> SEQ ID NO 697
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 697

-continued

tgtacccaat taccct 16

<210> SEQ ID NO 698
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 698

ttgtacccaa ttatcc 16

<210> SEQ ID NO 699
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 699

tttgtaccca attatc 16

<210> SEQ ID NO 700
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 700

agcagcaggt tatatt 16

<210> SEQ ID NO 701
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 701

tgggaagtgg tctggg 16

<210> SEQ ID NO 702
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 702

ctggagagtg ataata 16

<210> SEQ ID NO 703
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 703

aatgctggat tacgtc 16

<210> SEQ ID NO 704

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 704

caatgctgga ttacgt 16

<210> SEQ ID NO 705
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 705

ttgttcagaa gtatcc 16

<210> SEQ ID NO 706
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 706

gatgatttgc ttggag 16

<210> SEQ ID NO 707
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 707

gaaatcattc acaacc 16

<210> SEQ ID NO 708
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 708

ttgtaacatc tactac 16

<210> SEQ ID NO 709
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 709

cattaagcag caagtt 16

<210> SEQ ID NO 710
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 710
ttactagatg tgagca 16

<210> SEQ ID NO 711
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 711
tttactagat gtgagc 16

<210> SEQ ID NO 712
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 712
gaccaagcac cttaca 16

<210> SEQ ID NO 713
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 713
agaccaagca ccttac 16

<210> SEQ ID NO 714
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 714
atgggttaaa taaagg 16

<210> SEQ ID NO 715
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 715
tcaaccagag tatta 16

<210> SEQ ID NO 716
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 716

-continued

gtcaaccaga gtatta 16

<210> SEQ ID NO 717
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 717

attgtaaagc tgatat 16

<210> SEQ ID NO 718
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 718

cacataattg taaagc 16

<210> SEQ ID NO 719
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 719

gaggtctgct atttac 16

<210> SEQ ID NO 720
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 720

tgtagattca atgcct 16

<210> SEQ ID NO 721
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 721

cctcattata ctatga 16

<210> SEQ ID NO 722
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 722

ccttatgcta tgacac 16

<210> SEQ ID NO 723

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 723

tccttatgct atgaca 16

<210> SEQ ID NO 724
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 724

aagatgttta agtata 16

<210> SEQ ID NO 725
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 725

ctgattatta agatgt 16

<210> SEQ ID NO 726
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 726

tggaaggta tgaatt 16

<210> SEQ ID NO 727
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 727

acttgaatgg cttgga 16

<210> SEQ ID NO 728
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 728

aacttgaatg gcttgg 16

<210> SEQ ID NO 729
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 729
caatgtgtta ctattt 16

<210> SEQ ID NO 730
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 730
acaatgtggtt actatt 16

<210> SEQ ID NO 731
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 731
catctgctat ataaga 16

<210> SEQ ID NO 732
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 732
cctagagcaa atactt 16

<210> SEQ ID NO 733
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 733
cagagttaat aataag 16

<210> SEQ ID NO 734
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 734
gttcaagcac aacgaa 16

<210> SEQ ID NO 735
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif
<400> SEQUENCE: 735

-continued

agggttcaag cacaac 16

<210> SEQ ID NO 736
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 736

tgttggagac actggt 16

<210> SEQ ID NO 737
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 737

aaggaggagt taggac 16

<210> SEQ ID NO 738
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 738

ctatgccatt tacgat 16

<210> SEQ ID NO 739
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 739

tcaaatgcag aattag 16

<210> SEQ ID NO 740
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 740

agtgacaatc aatgac 16

<210> SEQ ID NO 741
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 741

aagtgacaat caaatg 16

<210> SEQ ID NO 742

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 742

gtgtaccaag taacaa 16

<210> SEQ ID NO 743
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 743

tgggatgtta aactga 16

<210> SEQ ID NO 744
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 744

agtttacatt ttctgc 16

<210> SEQ ID NO 745
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 745

tatgtgaaga ggagag 16

<210> SEQ ID NO 746
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 746

cacctttaa acccca 16

<210> SEQ ID NO 747
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 747

tcctttataa tcacac 16

<210> SEQ ID NO 748
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 748

acggtatttt cacagg 16

<210> SEQ ID NO 749
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 749

gacactacaa tgagga 16

<210> SEQ ID NO 750
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 750

tggttttttag gactgt 16

<210> SEQ ID NO 751
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 751

cgacaaattc taccct 16

<210> SEQ ID NO 752
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 752

tgatatacaa tgctac 16

<210> SEQ ID NO 753
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 753

tcggtgggta aattta 16

<210> SEQ ID NO 754
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 754

-continued

tgctttataa atggtg 16

<210> SEQ ID NO 755
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 755

caagtttaca ttttctgc 18

<210> SEQ ID NO 756
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 756

catatgtgaa gaggagag 18

<210> SEQ ID NO 757
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 757

cacctttaa acccca 16

<210> SEQ ID NO 758
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 758

catcctttat aatcacac 18

<210> SEQ ID NO 759
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 759

caacggtatt ttcacagg 18

<210> SEQ ID NO 760
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 760

cagacactac aatgagga 18

<210> SEQ ID NO 761

-continued

<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 761

catggttttt aggactgt 18

<210> SEQ ID NO 762
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 762

cacgacaaat tctatcct 18

<210> SEQ ID NO 763
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 763

catgatatac aatgctac 18

<210> SEQ ID NO 764
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 764

catcgttggg taaattta 18

<210> SEQ ID NO 765
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 765

catgctttat aaatggtg 18

<210> SEQ ID NO 766
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 766

caacaaataa tggttactct 20

<210> SEQ ID NO 767
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 767

cacagattga tggtagtt 18

<210> SEQ ID NO 768
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 768

cacctattta acatcagac 19

<210> SEQ ID NO 769
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 769

cactaattgt agtagtactc 20

<210> SEQ ID NO 770
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 770

caataaacat gaatctctcc 20

<210> SEQ ID NO 771
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotide motif

<400> SEQUENCE: 771

tgatttaatt ctagtca 17

<210> SEQ ID NO 772
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Target sequence

<400> SEQUENCE: 772

gcagtagagc caatta 16

<210> SEQ ID NO 773
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 773

-continued

Phe Leu Pro Ser Asp Phe Phe Pro Ser Val
1 5 10

<210> SEQ ID NO 774
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 774

Gly Arg Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp
1 5 10 15

<210> SEQ ID NO 775
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 775

Thr Thr Phe His Gln Thr Leu Gln Asp Pro Arg Val Arg Gly Leu
1 5 10 15

<210> SEQ ID NO 776
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 776

Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser
1 5 10 15

<210> SEQ ID NO 777
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 777

Phe Leu Leu Thr Arg Ile Leu Thr Ile
1 5

<210> SEQ ID NO 778
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 778

Thr Ser Leu Asn Phe Leu Gly Gly Thr Thr Val Cys Leu Gly Gln
1 5 10 15

<210> SEQ ID NO 779
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: HBV epitope

-continued

<400> SEQUENCE: 779

Phe Leu Gly Gly Thr Thr Val Cys Leu
1 5

<210> SEQ ID NO 780

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 780

Trp Leu Ser Leu Leu Val Pro Phe Val
1 5

<210> SEQ ID NO 781

<211> LENGTH: 21

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 781

Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr
1 5 10 15

Val Trp Leu Ser Val
20

<210> SEQ ID NO 782

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 782

Gly Leu Ser Pro Thr Val Trp Leu Ser Val
1 5 10

<210> SEQ ID NO 783

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: HBV epitope

<400> SEQUENCE: 783

Ser Ile Leu Ser Pro Phe Leu Pro Leu Leu
1 5 10

<210> SEQ ID NO 784

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial

<220> FEATURE:

<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 784

ctgtgccttg ggtggcttt

19

<210> SEQ ID NO 785

<211> LENGTH: 24

<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 785

aaggaagaa gtcagaaggc aaaa

24

<210> SEQ ID NO 786
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 786

ttctttataa gggtcgatgt ccatg

25

1. An antisense oligonucleotide conjugate comprising:
 - a. an oligonucleotide (Region A) comprising a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 90% complementarity to a PD-L1 target nucleic acid; and
 - b. at least one asialoglycoprotein receptor targeting conjugate moiety (Region C) covalently attached to the oligonucleotide in a).
2. The oligonucleotide conjugate of claim 1, wherein the contiguous nucleotide sequence is complementary to a target nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2 and/or SEQ ID NO: 3.
3. The oligonucleotide conjugate of claim 1, wherein the contiguous nucleotide sequence is complementary to a subsequence of the target nucleic acid, wherein the subsequence is selected from the group consisting of position 371-3068, 5467-12107 and 15317-19511 on SEQ ID NO: 1
4. The oligonucleotide conjugate of claim 1, wherein the contiguous nucleotide sequence is complementary to a subsequence of the target nucleic acid, wherein the subsequence is selected from the group consisting of A221, A360, A180, A160 and A269.
5. The oligonucleotide conjugate of claim 1 wherein the oligonucleotide comprises a sequence selected from SEQ ID NO: 466, 640, 342, 287 and 566.
6. The oligonucleotide conjugate of claim 1, wherein the contiguous nucleotide sequence comprises one or more modified nucleosides, such as one or more 2' sugar modified nucleosides.
7. The oligonucleotide conjugate of claim 6, wherein the one or more 2' sugar modified nucleoside is independently selected from the group consisting of 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA, 2'-amino-DNA, 2'-fluoro-DNA, arabino nucleic acid (ANA), 2'-fluoro-ANA and LNA nucleosides.
8. The oligonucleotide conjugate of claim 6, wherein the all the modified nucleosides are LNA nucleosides.
9. The oligonucleotide conjugate of claim 7, wherein the contiguous nucleotide sequence comprises at least one modified internucleoside linkage, such as at least one phosphorothioate internucleoside linkage.
10. The oligonucleotide conjugate of claim 1, wherein the oligonucleotide is a gapmer.
11. The oligonucleotide conjugate of claim 10, wherein the gapmer has formula 5'-D'-F-G-F'-3' or 5'-F-G-F'-D''-3',

where region F and F' independently comprise 1-7 modified nucleosides, G is a region between 6 and 16 nucleosides which are capable of recruiting RNaseH and region D' or D'' is optional and comprise 0-5 phosphodiester linked nucleosides.

12. The oligonucleotide conjugate of claim 1, wherein the asialoglycoprotein receptor targeting conjugate moiety comprises at least one carbohydrate moiety selected from group consisting of galactose, galactosamine, N-formyl-galactosamine, N-acetylgalactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine and N-isobutanoyl-galactosamine.
13. The oligonucleotide conjugate of claim 1, wherein the asialoglycoprotein receptor targeting conjugate moiety is mono-valent, di-valent, tri-valent or tetra-valent.
14. The oligonucleotide conjugate of claim 1, wherein the asialoglycoprotein receptor targeting conjugate moiety is a tri-valent N-acetylgalactosamine (GalNAc) moiety.
15. The oligonucleotide conjugate of claim 1, wherein the asialoglycoprotein receptor targeting conjugate moiety is the trivalent GalNAc moiety in FIG. 3.
16. The oligonucleotide conjugate of claim 1, wherein the oligonucleotide conjugate is selected from CMP ID NO: 766_2, 767_2, 768_2, 769_2 and 770_2.
17. An antisense oligonucleotide comprising an oligonucleotide or a contiguous nucleotide sequence according to claim 1.
18. A pharmaceutical composition comprising the oligonucleotide conjugate claim 1 and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.
19. An in vivo or in vitro method for modulating PD-L1 expression in a target cell which is expressing PD-L1, said method comprising administering an oligonucleotide conjugate of claim 1 in an effective amount to said cell.
20. A method for treating a disease comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide conjugate of claim 1 to a subject suffering from or susceptible to the disease.
21. The method of claim 20, wherein the disease is selected from viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis; and liver cancer or metastases in the liver.

22. A method for restoration of immune response against a virus or parasite comprising administering a therapeutically or prophylactically effective amount of an oligonucleotide conjugate of claim 1 to a subject infected with a virus or parasite.

23. The method of claim 22, wherein the restoration of the immune response is an increase in the liver of CD8+ T cells specific to one or more HBV antigens when compared to a control.

* * * * *